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ABSTRACT 
 
Using a comparative methodology the thesis analyses the patentability of 
pharmaceutical and related inventions in the UK and South Africa. The viewpoint 
adopted is that of the industry actors, who are engaged in the conception through to 
the commercialisation of inventions, although this perspective is measured against the 
concerns of wider stakeholders. 
 
            Drawing, in particular, on the classical justifications of the patent system, the 
research identifies the attributes of an optimal patentability standard which can be 
adjusted as technology and the legislative landscape changes. Framing an optimal 
patentability benchmark as one that both promote and protect the invention, the thesis 
considers the elements that ground the judicial patentability decision-making process. 
As pharmaceutical patenting tends to be an emotive and contentious area, the 
interplay between the international and respective domestic patentability frameworks 
is also evaluated in its impact on the inventor within the pharmaceutical chain. 
 
            The research then turns to investigate four individual patentability limbs as 
applied in the two jurisdictions. The definition of the invention and excluded subject 
matter is evaluated in mapping out the pharmaceutical activity and the associated 
research output that falls within patentable subject matter. The novelty, non-
obviousness and industrial application limbs to patentability are then examined, 
giving particular attention to the tests used by the courts in evaluating whether an 
invention meets the requisite criteria. The argument is made that the courts in 
interpreting patentability must apply principles advancing the purpose of the patent 
system in arriving at decisions. A systematic and robust approach is advanced that 
improves repeatability and precision in arriving at patentability decisions whilst 
preventing subjective application of the criteria. It is suggested that the application of 
the tests whilst aligning with the rationale and policy of the patent system, have to 
make sense to the scientist working in inventive pharmaceutical activities.  
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CHAPTER ONE 
 
INTRODUCTION 
 
1.1 The purpose of the study 
 
1.1.1 The general purpose of the study 
 
The aim of this study is to comparatively examine the patentability of pharmaceutical 
inventions as applied in South Africa and the United Kingdom with the view of 
making reform proposals where optimal patentability standards are not accomplished. 
The thesis suggests that optimal patentability standards are those that have 
characteristics which are simultaneously compatible with the needs of industry and 
the dictates of public policy. 
 
In order for inventions to qualify for legal protection there is a threshold that they 
must attain before they receive patent protection. This legal threshold is evaluated by 
establishing whether an invention has a series of elements known as limbs to 
patentability. However, on one level these elements have been generally 
misunderstood by the public. On another level, these patentability limbs have proven 
to be difficult to apply in practice, which over time has resulted in numerous patent 
disputes and strained policy debates on current and future appropriate patentability 
standards. 
 
One of the ways of eliminating the difficulties in patentability disputes is to have 
clearly set standards, known to potential patentees and other third parties, which the 
courts would use in deciding patentability cases. Ideally, these standards would be the 
tests that are used in approving patent applications.
1
 In this thesis the legal tests and 
the doctrines behind these standards are analyzed, which would ultimately be used by 
tribunals and courts in assessing whether or not an invention is indeed patentable. 
                                                             
1 The lack of consistency between patent offices and courts decisions has been referred to as ‗the 
notorious difference between the standards applied by the Patent Office and the courts‘: Graham v. 
John Deere Co. 383 U.S. 1, 18(1966). Bessen J. and Meurer M. ‗Lessons for patent policy from 
empirical research on patent litigation‘ (2005) Lewis and Clark Law Review, p.1-27, discuss how this 
gap can be manipulated by patentees and competitors and recommends some performance efficiency 
improvements for Patent Offices. 
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The current general limbs to patentability that are studied within the scope of this 
thesis are that the invention should be new, non-obvious, capable of industrial 
application and be of non-excluded subject matter. These patentability limbs 
developed over years and the tests for assessing their presence are constantly being 
refined and optimized by the judiciary and legislature in both jurisdictions. At the 
same time, globalization, international trade and the necessity of reciprocity of patent 
protection has added a further layer of difficulty in determining appropriate and 
applicable local standards. 
 
Throughout this thesis the doctrine of patentability, and its relevance and application 
in the balanced and appropriate patent protection of inventions, will be analyzed and 
evaluated and compared between the two jurisdictions. The thesis seeks to establish 
whether the patentability standards allow invention and innovation and offers 
adequate protection for inventions.
2
 This is the equilibrium point that is considered to 
be the optimal patentability standard in this thesis. Although the patentability doctrine 
is well established, on the contrary the approach to patentability evaluation is rather 
modest because many cases where the patentability standards are in issue are settled 
before they reach the courts.
3
 This is compounded by the restraint of the courts to 
answer wider patentability questions before them
4
 or simply too few judicial 
interpretation of the concept.
5
 
 
                                                             
2
 The distinction and legal consequence thereof, between invention and innovation ‗which is the putting 
of new ideas into effect‘ will be analysed in chapter 4 on subject-matter excluded from patentability: 
Kingston W. ‗Patent protection for modern technologies‘ (1997) Intellectual Property Quarterly, 
p.350-369, p.352. 
3 Licensing and cross-licensing is the strategic mechanism that is usually used in commercializing 
patents or to settle patent disputes: Soyama D. ‗Strategic determinants of decisions not to settle patent 
litigation‘ (2003) Strategic Management Journal, p.17-38. Lanjouw J.O. and Schankerman M. 
‗Enforcing intellectual property rights‘ (2001) NBER working paper N.8656, found that up to ninety-
five percent of initiated patent suits are settled before trial. 
4 The courts have been hesitant in going beyond facts of cases before them when they would be within 
their capacity to do so. There is the opposing view that unprecedented judicial theorising often dangers 
the narrow fact-based resolution of cases before the courts from which case law develops. King 
generally elaborates a balanced framework of practical reasoning within which courts impart 
predictability of decisions with some judicial restraint principles: King J.A. ‗Institutional approaches to 
judicial restraint‘ (2008) Oxford Journal of Legal Studies, p.409-441. 
5 The UK and South Africa have less patenting activity compared to some of the notable patent offices: 
Garg K.C. ‗Inter-country comparison of patenting activity‘ (1997) World Patent Information, p.37-39. 
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Furthermore, with South Africa being a non-examining authority of granted patents 
under the domestic patent grant route, the doctrine is obscured only to receive focus 
when a dispute arises.
6
 The non-examination of South African patents does not detract 
from the comparative nature of the study as substantive examination is implied and 
incorporated into the South African system. For example, in the correction of errors in 
patent applications before grant, if ‗it appears to the Registrar that the correction 
would materially alter the scope of the document‘7 he or she may institute 
proceedings to prevent the change, revealing that substantive examination does occur. 
Moreover, South Africa has a significant number of patents granted under the Patent 
Cooperation Treaty
8
 (PCT) route where limited substantive examination occurs.
9
 
Moreover, it is the validity of the granted patent under the patentability conditions that 
is under scrutiny in this thesis rather than the means or procedural process for the 
grant. 
 
There has been a trend in most jurisdictions toward considered modernizing and 
harmonization of the approach toward patentability standards and the recognition that 
the doctrine has a far-reaching role to fulfill within the legal and regulatory 
framework. The emergence of a more modern approach to the doctrine also 
manifested beyond the legal environment and infiltrates the scientific, economic and 
commercial world in dimensions previously unanticipated. That is to say the doctrine 
is well-founded in law but has vital and expanded connotations for and increased 
interaction with other fields in today‘s knowledge society. 
 
The resultant wider stakeholder base from the expansion of the patentability doctrine 
has an increasingly crucial role to play in attaining the optimal patentability 
standard.
10
 Therefore the doctrine of patentability has to be placed in a context so that 
                                                             
6 Patent Act 1978, s.34 does not provide for the substantive examination of patent applications, with 
examination only to formalities according to Patent Regulation 1978, R.41.  
7 Patents Act 1978, s.50(4). 
8 International applications under the PCT were inserted as Chapter VA by s.38 of Act no.38 of 1997 
into the Patents Act 1978. 
9 It is a limited examination because the search report is not binding on the eventual grant or rejection 
of an application in view of the report under the South African Patents Act, section 43C(c) electing the 
South African Patent Office as the elected Office. 
10 Activities of pharmaceutical firms have to respond to multiple stakeholders: Kennedy C.R., Harris H. 
and Lord M. ‗Integrating public policy and public affairs in a pharmaceutical marketing program: The 
AIDS pandemic‘ (2004) Journal of Public Policy and Marketing, p.128-139. Pharmaceutical policy 
making, besides organised actors, has to include even the lay public: Traulsen J.M. and Almarsdottir 
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it encompasses all extremities of knowledge generation and commercialization, from 
local to global inventions and cumulative to groundbreaking technologies in a fair and 
consistent manner.
11
 International or a country‘s external obligations and prerequisites 
for global trade have caused the necessity of establishing a balance between the local 
patenting standards and international standards. In light of these developments, the 
purpose of this study is to propose that both countries actively set out their model for 
what would be a workable patentability standard which meets their developmental 
and economic needs under both domestic and international patent law.
12
 The 
overarching reality is that the local patentee with a valuable invention can no longer 
simply rely on a local patent that is not in tune with international benchmarks. 
 
 
1.1.2 Specific purpose of the study 
 
1.1.2.1 The law under focus 
 
As intellectual property (IP) law is a rapidly developing area of law,
13
 a study aimed 
at all stakeholders in the patenting industries is important. Although patent law is 
territorial, the stakeholders transcend national boundaries as inventive and innovative 
activities have tended to filter across jurisdictional boundaries. The patentability 
standards have to protect inventions by these stakeholders, both internally and 
externally. 
 
                                                                                                                                                                              
A.B. ‗Pharmaceutical policy and the lay public‘ (2005) Pharmacy World and Science, p.273-277, also 
noting at p.275, that the matrix of stakeholders has diverse interests, for instance, patient groups as the 
ultimate beneficiary of the ensuing invented pharmaceuticals can have different interests from patient 
activist groups and public health advocacy groups even though these frequently coincide. 
11 Vaver D. ‗Reforming intellectual property law: an obvious and not-so-obvious agenda: the Stephen 
Stewart Lecture for 2008‘ (2009) Intellectual Property Quarterly, p.143-161, suggests overhauling of 
IP laws to make the system clear, just and efficient in order to gain public respect and acceptance. 
Ngcobo S. ‗Sustaining public confidence in the judiciary: An essential condition for realising the 
judicial role‘ (2011) South African Law Journal, p.5-17, has noted that ‗public confidence is necessary 
for the effective performance of judicial functions.‘ 
12 For instance, there have been rather volatile negotiations for the establishment of an international 
patentability standard under the Substantive Patent Law Treaty (SPLT), where both South Africa and 
the UK expressed their desire to be party to such a treaty and have made various contributions to what 
they perceive would be the ideal standard; for example, generally in WIPO document SCP/11/6, 
specifically para.40. 
13 Soetendorp R. ‗Intellectual property education- in the law school and beyond‘ (2005) Intellectual 
Property Quarterly, p.82-110, p.90. 
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Patentability standards remain at the centre of patenting systems for the protection of 
those inventions. The levels of patentability standards set determine whether the 
patenting system is effective or not in protecting industry‘s valuable inventions. A 
deeper understanding of patentability standards is pivotal at the research and 
development (R&D) stage if the patenting route is contemplated by scientists or 
industrialists. The standards determine the appropriate inventions that will pass the 
threshold for patentable inventions at the patent application stage.
14
 It is this standard 
that will determine if the patent system is not burdened with low quality patents that 
under scrutiny have little to offer as an improvement in the state of the art.
15
 As such, 
the patentability standards have a direct bearing on the quality of patents. Wagner 
states that ‗[p]atent quality is the capacity of a granted patent to meet (or exceed) the 
statutory standards of patentability…Thus, a ―low quality‖ patent is one granted for 
an invention which does not meet these standards.‘16 The disadvantage of South 
Africa‘s non-examination of applications in allowing the existence of patents falling 
below this benchmark has been acknowledged.
17
 Of the jurisdictions under study, it is 
only the UK that has patentability case law developed from the application stage. 
                                                             
14 Based on the premise that ‗inconsistent assessments regarding identical information during the grant 
and the challenge phase is not desirable in any circumstances‘, it has been shown empirically, in a 
sample of biotechnology patent applications, that the EPO‘s patentability decision making on patent 
quality during the grant and opposition phases was inconsistent even though the patentability decisions 
were made based on identical information throughout the application process: Burke P.F. and Reitzig 
‗Measuring patent assessment quality- Analyzing the degree and kind of (in)consistency in patent 
offices‘ decision making‘ (2007) Research Policy, p.1404-1430, p.1425. 
15 Patent Offices profess that they are burdened with unsustainable workloads; suggested solutions 
range from simple increased number of examiners, including the contracting of examination to other 
offices or even private companies, to radical mechanisms for bidding and auctioning of substantive 
examination slots, see Katopis C.J. ‗Perfect happiness?: Game theory as a tool for enhancing patent 
quality‘ (2008) Yale Journal of Law and Technology, p.360-404. 
16
 Wagner R.P. ‗Understanding patent-quality mechanisms‘ (2009) University of Pennsylvania Law 
Review, p.2135-2173, p.2138. Some define patent quality by a two-fold means:- the legal quality 
created by the patent‘s reliability as an enforceable property right or sustainability when challenged and 
additionally, as the techno-economic quality created by the patent‘s underlying invention or 
technological ‗merit‘ : Thomas J. ‗The responsibility of the rulemaker: Comparative approaches to 
patent administration reform‘ (2002) Berkeley Technology Law Review, p.728-761. 
17 WIPO, Study of patents and the public domain (2012) Committee on Development and Intellectual 
Property, WIPO Publication Geneva, CDIP/8/INF/3Rev2. The South African Court of Appeal in 
Bateman Equipment Ltd v The Wren Group (case480/97), rejecting any impeding formalistic approach 
to amending claims or enquiry into reasons for doing so, has put it this way: ‗The nature and object of 
amendment proceedings must be seen in the context of our patent system as a whole. Ours is a non-
examining country and an alleged inventor is entitled to a patent for his supposed invention without 
having to satisfy anyone of its merit or validity. He does not have to give any reasons for his choice of 
wording. Should he sue for infringement, he has no duty to assist the alleged infringer in establishing 
whether his monopoly is valid or not. Why should he be saddled with a burden if he wished to reduce 
the scope of his protection in an attempt to render the patent valid, while in obtaining or enforcing a 
monopoly he bears no similar burden? As much as it is in the public interest that persons with inventive 
 16 
Granting of a patent is not in itself an end of the relevance of patentability standards. 
These standards become significant when validity is disputed in infringement 
proceedings.
18
 The standards against which infringement is measured necessarily have 
to be exacting in nature.
19
 In addition, effective patent enforcement revolves around 
the exacting patentability standards, as allegations are usually made that the patent 
being enforced falls below the required standards, thus reverting back to the question 
of whether protection should have been granted in the first place.
20
 In both the UK 
and South Africa, the case law on patentability has mainly developed in the context of 
enforcement and infringement of patents and this is usually accompanied by 
revocation counter-action.
21
 For the respective countries under comparison the thesis 
focuses mainly on the ground that the granted patent was not patentable under Patents 
Act 1977, s.72(1)(a) and Patents Act 1978, s.61(1)(c). 
 
It is in light of these considerable consequences that rigorous patentability standards 
and the assessment methods of patentability validity are suggested as necessary in this 
thesis. Judging these qualities has tended to be an elusive concept, both for the 
layperson and legal scholars, as usually evidenced by polarised debates of seemingly 
simple patentability concepts, not only in patent offices and courts,
22
 but also in 
international trading and law-making forums. An overarching observation is that 
developed and developing countries put differing emphasis on these standards, yet 
                                                                                                                                                                              
minds should be encouraged to give the results of their efforts to the public in exchange for the grant of 
a patent, it is in public interest that patents should be rectified or validated by way of amendment.‘ 
18 Scholars assert that caution is to be exercised  in the interpretation of patent litigation statistics as 
these are complex and are underlined by multiple reasons and the policy that could be derived 
therefrom is not straightforward because ‗patent suits probably constitute a small and uncharacteristic 
subset, drawn from the set of all patent disputes. Certainly, patent trials constitute a small and 
uncharacteristic subset of filed patent suits‘: Bessen/Meuer, fn.1, p.4. 
19
 For divergent perspective, Dent C. ‗To see patents as devices of uncertain (but contingent) quality: A 
Foucaultain perspective‘ (2007) Intellectual Property Quarterly, p.148-163, argues that the system can 
never eliminate uncertainty and stakeholder-contingent aspects because of the variable perspectives and 
action, founded on patentability requirements, that can be taken by each stakeholder within the system. 
20 For instance, in making the distinction between what should be a discovery and invention, 
pharmaceutical companies are accused of patenting developing world products as a result of ‗the 
glaring fallacy and inherently biased Western perception that, because significant financial resources 
have been invested in refining the original material, scientific trials and chemical analysis, the product 
has been improved and should be regarded as novel‘ and are subsequently sold with the exclusion of 
the original holders of the knowledge: Stenton G. ‗Biopiracy within the pharmaceutical industry: a 
stark illustration of how abusive, manipulative and perverse the patenting process can be towards 
countries of the South‘ (2004) European Intellectual Property Review, p.17-26, p.19. 
21 Respectively under Patents Act 1977, s.72 and Patents Act 1978, s.61 and revocation counter-claim 
according to Patents Act 1977, s.74(1) and Patents Act 1978, s.65(4). 
22 For example, as is sometimes the case with EPO granted patents, Occlutech GmbH v AGA Medical 
Corporation [2010] EWCA Civ 702 resulted in different judicial decisions in the European Patent 
Convention (EPC) Contracting States, of the same patent litigated under the same instrument. 
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there is a consensus point that would have to be reached for the system to adequately 
function in reality. In this study the approaches and tests as used by the courts in the 
two jurisdictions to determine patentability are examined. Views held by patent 
examiners and administrators are also analysed to suggest ways to bring them in line 
with what the courts would ultimately interpret as statutorily correct. The views held 
by legal scholars and other commentators
23
 who are outside of the confines of the 
administration of the patent system are also analysed
24
 for assistance in the definition 
and interpretation of the patentability concept. Suggestions are made on how these 
requirements could be improved, especially under the convenience notion of 
harmonising patenting laws over time.  
 
1.1.2.2 The science under focus 
 
An examination is made of whether these standards are perceived to help industry in 
encouraging and protecting their inventions and innovations in the UK and South 
Africa. The inventors are important stakeholders to the patent system. They not only 
include the parties that seek the patent, but they include competitors and third parties. 
It has even been suggested that the inventors‘ interests in a balanced patentability 
standard as third parties is more than when they are applicants.
25
  
                                                             
23 Braun A. ‗Professors and judges in Italy: It takes two to tango‘ (2006) Oxford Journal of Legal 
Studies, p.665-681, p.666-670, although acknowledging that the situation has changed, concedes that 
formerly, comparative lawyers identified the role of academic scholars in the judicial law-making 
process to be the major difference between civil and common law jurisdictions, with English judges 
giving lower esteem and regard to academic scholarship than in other European jurisdictions. UK 
judicial reasoning has been shown to be increasingly receptive of and influenced by academic 
discourse: Duxbury N. Jurists and judges: an essay on influence (2001) Oxford: Hart Publishing, 
chapter 5. Legal scholarship is no longer confined to academics, for example, members of the judiciary 
have not been hesitant to comment on wider issues outside of their judicial roles, for instance in giving 
lectures or in journal scholarship, for example, Jacob LJ in Jacob R. ‗Patents and Pharmaceuticals–a 
Paper given on 29th November 2008 at the Presentation of the Directorate-General of Competition‘s 
Preliminary Report of the Pharma-sector inquiry‘, November 2008, at 
http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/jacob.pdf or Lord Hoffmann ‗Claim 
construction‘ (2006) The CIPA Journal, p.727-731. 
24 The influence of institutional mandates or curtailments behind academic writings by authors 
associated with institutions is raised for instance when Johnson reviews the book by Gervais, formerly 
a World Trade Organization (WTO) legal adviser, and comments that he can now write freely on the 
intricacies to TRIPS Agreement conclusion as he is now free of the shackles of WTO: Johnson P. ‗The 
TRIPS Agreement: Drafting history and analysis‘ (2009) European Intellectual Property Review, 
p.441. 
25 EPO President Benoît Battistelli ‗How Can Europe Be a Key Player at Global Level in the Patent 
Field? What is the Role of the EPO?‟, 8 November 2011, London: UCL, suggesting that competitors 
still benefit from being third parties in patent grant when the standards are optimally set. 
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The focus of this thesis, on the general level, is on the rapidly advancing fields based 
on chemical inventions as opposed to the more mechanical fields,
26
 as these are the 
fields that tend to rapidly change without giving the legislature opportunity to 
prescribe new rules.
27
 This is a broad field of technology characterised by the 
chemistry of manipulation, isolation and reaction of atoms and compounds; from 
identification, isolations and reactions of the pharmaceutical compounds to complex 
micro and macro building of compounds and complex structures in biotechnology, 
genetic engineering, nanotechnology and other associated technologies.
28
 That is not 
to mean there will be total avoidance of other areas of science and technology because 
the process of inventing is usually inextricably interlinked with other fields; for 
example, these processes are usually automated and computer-implemented.
29
  
 
To further demarcate the parameters of the study, there is particular reference to 
pharmaceutical inventions as a subset of the broader science of chemistry.
30
 To this 
end, the view held is that pharmaceutical invention generally refers to a ‗process or 
substance used in the diagnosis or treatment of diseases or other medical conditions in 
humans or animals, including processes or substances used in medical research.‘31 
This sector is complemented by other related fields of technology, for example 
                                                             
26 Another classification that has been used is referring to the former as unpredictable arts and the latter 
as predictable arts: Seymore S.B. ‗Rethinking novelty in patent law‘ (2011) Duke Law Review, p.919-
976, p.929. It has been said that ‗a technology classified as pharmaceutical will also be within either 
the chemistry or biotechnology areas‘ although biotechnology has only recently developed into a 
distinct field separate from the chemistry field: Allison J.R. and Lemley M.A. ‗Who is patenting? An 
empirical exploration of patent prosecution‘ (2000) Vanderbilt Law Review, p.2099-2174, p.2110.  
27
 There is acknowledgement that the laws have to be flexible enough keep up with technological 
developments in some fields: Lord Irvine of Lairg ‗The law: An engine of trade‘(2001) Modern Law 
Review, p.333-349. 
28 Generally class A and C, under the International Patent Classification system, established under the 
1971 Strasbourg Agreement Concerning the International Patent Classification. 
29 IFPMA, ‗Encouraging pharmaceutical R&D in developing countries‘ (2003) International Federation 
of Pharmaceutical Manufacturers Associations, Geneva, p.13-14. 
30 WIPO usually reports patent filings technology groupings with chemistry as a core group with 
subgroups in pharmaceuticals, biotechnology, etc, for example, 
http://www.wipo.int/export/sites/www/ipstats/en/statistics/patents/xls/wipo_pat_filings_technology.xls. 
Dutfield G., ‗The pharmaceutical industry, the evolution of patent law and the public interest: A brief 
history‘, in Westkamp G. (ed) Emerging issues in intellectual property: Trade, technology and market 
freedom: Essays in honor of Herchel Smith (2007) Cheltenham: Edward Elgar Publishing Limited, 
reviews and examines how chemistry was central to the origin and evolution of the pharmaceutical 
industry and patent law development. 
31 Allison J.R. and Lemley M.A. ‗Who is patenting? An empirical exploration of patent prosecution‘ 
(2000) Vanderbilt Law Review, p.2099-2174, p.2110. 
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biotechnology, pharmacogenetics and other types of technology upon which its 
innovative R&D techniques are embedded.
32
 
 
There are at least four main routes by which new pharmaceutical products are 
developed and brought into the public sphere. The four general sources of 
pharmaceutical inventions, which can either be stand-alone or integrated depending 
on a particular R&D programme,
33
 are natural products, existing drugs, computer 
model screenings and the identification of the physiological mechanism of the 
disease.
34
 Each poses its own set of contentious issues and consequences within the 
patenting regime, which will be addressed throughout the thesis, but will be outlined 
here.  
 
Firstly, natural products give the oldest source of new medicines as biologically active 
natural compounds serve as chemical leads that are refined by scientists to give more 
specifically acting pharmacological compounds.
35
 In fact there have been estimates 
                                                             
32 Laird noted that many small biotechnology firms are often called such, yet this is a misnomer since 
these are frequently technically involved in small-molecule chemistry rather than biotechnological 
work: Laird T. ‗In praise of emerging pharmaceutical companies‘ (2006) Organic Process Research & 
Development, p.685-686. The biotechnology-based products market is dominated by 
biopharmaceuticals and are predicted to increase their market share (Bostyn S.J.R. Patenting DNA 
sequences (polynucleotides) and scope of protection in the European Union: an evaluation, 2004, 
European Communities, Brussels, p.6) although some have doubted the potential to deliver adequate 
innovative pharmaceutical in view of the heightened expectations from biotechnology and the ensuing 
policy aligned to this overestimation (Nightingale P. and Martin P. ‗The myth of the biotech 
revolution‘ (2002) Trends in Biotechnology, p.564-569). Also, pharmacogenomics, the use of genomic 
information to inform or predict pharmaceutical activity and response, has been hailed as presenting 
radical change in the pharmaceutical R&D process (Bostyn S.J.R. Patenting DNA sequences 
(polynucleotides) and scope of protection in the European Union: an evaluation, 2004, European 
Communities, Brussels, p.6) with some cautioning the potential of pharmacogenomics to deliver 
innovative pharmaceuticals, depending on how it is eventually absorbed into clinical practice: (Cook J., 
Hunter G. and Vernon J.A. ‗The future costs, risks and rewards of drug development: The economics 
of Pharmacogenomics‘ (2009) Pharmacoeconomics p.355-363). 
33 Ohlmeyer M. and Zhou M. ‗Integration of small molecule drug discovery in academic biomedical 
research‘(2010) Mount Sinai Journal of Medicine, p.350-357, describes mechanisms to integrate small-
molecule academic research in the discovery process in ways that incorporate the other sources of new 
pharmaceuticals. The importance of process inventions that brings about these products is examined in 
section 4.2. 
34 Ganellin C.R. and Roberts S. M. Medicinal chemistry: The role of organic chemistry in drug 
research (1993) London: Academic Press, p.122. 
35 Ibid, p.122. Turner D.M. ‗Natural products source material use in the pharmaceutical industry: the 
Glaxo experience‘ (1996) Journal of Ethnopharmacology, p.39-44. Schmitt E.K, Moore C.M., Krastel 
P. and Petersen F. ‗Natural products as catalysts for innovation: a pharmaceutical industry perspective‘ 
(2011) Current Opinion in Chemical Biology, p.497–504. South Africa, with abundant natural 
resources, has expressed the desire to protect natural products from inappropriate exploitation but the 
resulting protection frameworks are criticised as excessively bureaucratic, stifling innovation and 
commercialisation of South African-sourced natural products: Van Wyk B.E. ‗The potential of South 
African plants in the development of new medicinal products‘ (2011) South African Journal of Botany, 
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that up to half of medical prescription have been for pharmaceuticals derived from 
natural substances.
36
 The issue to address is how far the patentability laws and tests 
properly demarcate patentable subject matter, in terms of, inter alia, excluded subject 
matter, prior art or requisite contribution by the inventor to what will constitute a 
patentable invention. Secondly, in recent decades there has been a diminishing 
discovery of radical new drugs, with many more new drugs resembling the old.
37
 The 
patent justification as an incentive for inventing has as a result become doubtful as 
more new drugs are seen as simple variants of the old. Thirdly, the screening of 
chemical models by computational or mathematical methods is a modern approach to 
pharmaceutical design
38
 although ‗there is still a strong element of speculations in 
drug design and considerable uncertainty in achieving success.‘39 As a result only a 
small proportion of drug models become useful synthetic therapeutic agents in 
practice.
40
 The issue raised in this instance is how the patentability requirements 
address mere scientific speculation posited as actual advance in the state of the art. 
Fourthly, the physiological mechanism route to new pharmaceuticals entails the in-
depth investigation of the target disease pathways so as to find cures.
41
 However there 
have been accusations that ‗the target diseases selected for study in the 
pharmacological industry are generally those prevalent in western society.‘42 
                                                                                                                                                                              
p.812-829; Myburgh A.F. ‗Legal developments in the protection of plant-related traditional knowledge: 
An intellectual property lawyer's perspective of the international and South African legal framework‘ 
(2011) South African Journal of Botany, p.844-849. 
36 Eiland, M.L. Patenting traditional medicine (2008) Munich: Munich Intellectual Property Law 
Center; Bull A.T. and Stach J.E.M. ‗Marine actinobacteria: New opportunities for natural product 
search and discovery‘ (2004) Trends in Microbiology, p.491-509. Some authors have reviewed the 
intense use of plant-based products in South African pharmaceutical R&D: Rybicki E.P., et al, ‗Plant-
made therapeutics: An emerging platform in South Africa‘ (2012) Biotechnology Advances, p.449-459. 
37 Abbott F.A. and Graham D.G. Global pharmaceutical policy: Ensuring medicines for tomorrow‟s 
world (2009) Cheltenham: Edward Elgar Publishing Limited, p.64-65. 
38
 Kapetanovic I.M. ‗Computer-aided drug discovery and development (CADDD): In silico-chemico-
biological approach‘ (2008) Chemico-Biological Interactions, p.165–176. Other computer-related 
fields or tools of pharmaceutical discovery, for instance bio-informatics will be explored in chapter 
four. 
39 Ganellin/Roberts, fn.31, p.138.  
40 Scholars have demonstrated that out of five million molecules screened by these models combined, 
only three to six lead to clinical studies and only one is eventually approved, Cloutier L.M. and Sirois 
S. ‗Measurement of innovation and intellectual property: Challenging process‘, in Castle D. The role of 
intellectual property in biotechnology innovation (2009) Cheltenham: Edward Elgar Publishing 
Limited, p.206. 
41 Croston G.E. ‗Functional cell-based uHTS in chemical genomic drug discovery‘ (2002) Trends  in 
Biotechnology, p.110-115; Patric G.L. Introduction to medicinal chemistry, 4th ed (2009) Oxford: 
Oxford University Press, p.187-196. Debouck C. and Metcalf B. ‗The impact of genomics on drug 
discovery‘ (2000) Annual Review of Pharmacology Toxicology, p.193–208 illustrates the genomic 
approaches to drug discovery used at SmithKline Beecham for instance. 
42 Ganellin/Roberts, fn.34, p.128. Although there are challenges in pharmaceutical development, these 
are addressed for instance through public-private partnerships of scientists in academia and industry 
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Therefore the patent system is perceived as biased towards the needs of developed 
nations in the health sector and also generally in technologies which foster 
development only prominently in developed countries. 
 
It is apparent from the simplistic inventive process outlined above that a study 
focusing on pharmaceuticals is warranted as it also encompasses patenting principles 
germane to other technologies.
43
 Moreover, the pharmaceutical industry deserves 
closer examination as it exhibits unique qualities evoking questions of the suitability 
of the patents system to protect these inventions. The pharmaceutical industry claims 
that the risks and costs of bringing the inventions to the market are exorbitant and 
could not be possible without the patent.
44
 Because of the demands and needs of 
society, stringent safety studies alone for potential drugs can take more than three 
years and it typically takes ten to fifteen years to invent and develop a new marketable 
pharmaceutical.
45
 The inadequacy of the patent grant to reward the efforts of 
inventors could, as a result, have devastating effects on the pharmaceutical enterprise. 
This research considers how appropriate patentability requirements could contribute 
to addressing those concerns in a way that is appreciative of the reality of industry. 
 
1.1.2.3 The stakeholder under focus 
 
It is also intended that the study simplifies the judging of whether an inventive idea 
                                                                                                                                                                              
and has introduced multifunctional drug design strategies which have already reported some novel and 
validated molecular targets for the neglected tropical diseases: Cavalli A., and Bolognesi M.L. 
‗Neglected tropical diseases: Multi-target-directed ligands in the search for novel lead candidates 
against Trypanosoma and Leishmania‘ (2009 ) Journal of Medicinal Chemistry, p.7339-7359. 
43 Miller H.I. ‗The impact of new technology on regulation by the FDA: Recombinant DNA 
technology‘ (1981) Food, Drug, Cosmetic Law Journal, p.348-353, p.348 notes that technology 
development in one area may give rise to advancement in very diverse technological classes. 
44IFPMA ‗Encouraging pharmaceutical R&D in developing countries‘, 2003 International Federation 
of Pharmaceutical Manufacturers Associations, Geneva, p.12 and Festel G., Schicker A. and Boutellier 
R. ‗Performance improvement in pharmaceutical R&D through new outsourcing models‘ (2010) 
Journal of Business Chemistry, p.83-96. 
45 Ganellin/Roberts, fn.34, p.139. The Treatment Action Campaign (TAC), a company at the forefront 
of the campaign for access to medicine for HIV\AIDS patients has for instance taken to court firms 
selling medicines of disputed efficacy and not having undergone robust clinical and safety standards: 
Treatment Action Campaign and another v Rath and  Others [2008] ZAWCHC 34. Political support by 
Government and Cabinet of clinical trials of veridine, a compound developed by medical research 
scientists and claimed to halt the development of HIV into AIDS turned out to be misdirected in light 
of the subsequently discovered toxicity of the compound: Nattrass N. ‗AIDS and the scientific 
governance of medicine in post-apartheid South Africa‘ (2008) African Affairs, p.157-176. A turning 
point in the approval of new pharmaceuticals, which introduced rigorous preclinical safety evaluations, 
was with the thalidomide crisis: Avorn J. ‗Teaching clinicians about drugs-50 years later, whose job is 
it?‘ The New England Journal of Medicine, p.1185-1187. 
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will meet patentability requirements, especially by industry players themselves before 
seeking legal counsel. There has been much reliance on the business communities for 
technological innovations in the past.
46
 This self-assessment is important, given the 
rate of emergence of new technologies and their multi-disciplinary nature, which at 
times requires an understanding of the underlying rationale and policy for the set 
patentability standards in order to make informed patentability decisions. 
 
The skill to discern whether inventions are patentable or not, and indeed whether 
patenting is a viable option is important for the inventor to learn for themselves or be 
competent in. This applies on a continuum from the small one-time inventor to large-
scale multinational routine R&D entities.
47
 The inventors are the ones who, in most 
cases, have intimate knowledge of their activities and business, their short-term and 
long-term R&D and competitive strategies and other financial considerations,
48
 which 
they may not easily translate, if at all possible, to patent practitioners‘ briefings when 
contemplating patenting.
49
 Indeed patent attorney firms have admitted to giving 
infringement advice on what they viewed as lost-cause-cases, only to have them being 
successful and what they thought had guaranteed chances of success eventually 
failing.
50
 Patent filing practitioners may not necessarily be biased toward unnecessary 
                                                             
46 Ginburg D.H. ‗Antitrust, uncertainty, and technological innovation‘ (1979) Antitrust Bulletin, p.635-
686, p.642. 
47 It has been observed that the discovery pipeline in large pharmaceutical firms has become depleted 
and that ‗micropharma – academia-originated biotech start-up companies that are efficient, innovative, 
product-focused and small (having less than 25, and frequently less than 10 employees)‘, is filling this 
crucial pharmaceutical R&D gap: Barden C.J. and Weaver D.F. ‗The rise of micropharma‘ (2010) 
Drug Discovery Today, p.84-87, p.85. As a comparison, the South African pharmaceutical industry is 
noted to comprise about two-thirds of the UK pharmaceutical industry, both in terms of the total 
number of pharmaceutical establishments and also the number of pharmaceutical establishments that 
have less than ten employees: p.80-81: Barnes Reports: 2012 Worldwide Pharmaceutical Preparation 
Manufacturing Industry (2011) Barnes and Co., available at www.researchandmarkets.com/reports. 
48 Although R&D is important for generating new inventions, however, given that not all R&D 
intensive firms patent their inventive outcomes, there have been multiple factors identified that affect 
industry‘s patenting propensity for instance whether R&D is internal or external to the firm, the size 
and age of the firm, simplicity or complexity of the invention and the codifiability of the knowledge: 
Perez-Luno A. and Valle-Cabrera R. ‗How does the combination of R&D and types of knowledge 
matter for patent propensity?‘ (2011) Journal of Engineering and Technology Management, p.33-48. 
Commentators suggest that from an industry perspective, the ‗patent-trade secret decision‘ is more 
complex in chemical based industries than in mechanical industries: Munson D.C. ‗The patent-trade 
secret decision: An industry perspective‘ (1996) Journal of the Patent and Trademark Office Society, 
p.689-715, p.698-700. 
49 Dent, fn.19, p.157 claims that the translation process of the essence of the invention is inherently not 
perfect. 
50 Simmons and Simmons Report to EC Pharmaceutical Sector Enquiry, at p.6-7, 
http://ec.europa.eu/competition/consultations/2009_pharma/simmons_simmons.pdf. The quality of IP 
advice has at times been doubted: Phillips J. ‗Good business, shame about the lawyering‘ (2010) 
Journal of Intellectual Property Law and Practice, p.129. 
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and indiscriminate patent application filing for patentable inventions,
51
 but by virtue 
of their filing specialism, may functionally be compromised towards general patenting 
without utmost regard for other available protection mechanisms.
52
 The response to a 
report that legal fees are disproportionately high,
53
 by some legal practitioners 
conceding that there exists bias toward high predicable success cases
54
 exacerbates 
these concerns. Indeed some commentators have equated the patent system to a 
lottery where the value in patents is related to predicted success of infringement 
litigation.
55
  
 
 
1.2 The importance the research 
 
The relevance of patentability standards has been called into question in recent years. 
Accusations range from their allowing into existence of patented inventions that add 
nothing to the public fund of knowledge to actually preventing societal progress, 
particularly in pharmaceuticals.
56
 In view of the aforementioned effect of patentability 
standards, improvement suggestions for a more effective domestic protection are 
made for the respective jurisdictions. This is in line with continual reforms that were 
necessitated by limited understanding of the patent system by domestic industrialists, 
                                                             
51 Empirical studies show that patents are not and should not exclusively be obtained in areas perceived 
as ‗high technology‘: Allison J.R. and Lemley M.A. ‗Who is patenting? An empirical exploration of 
patent prosecution‘ (2000) Vanderbilt Law Review, p.2099-2174. 
52 Vaver suggests there could be a bias towards patents by practitioners: Vaver D. ‗Some agnostic 
observations on intellectual property‘ (1990) Intellectual Property Journal, p.125-153, at p.140-141. 
53 Lord Jackson Review of Civil Litigation Costs, http://www.judiciary.gov.uk/about_judiciary/cost-
review/jan2010/final-report-140110.pdf. Commentators, explaining increases in rates of patent 
litigation have stated that ‗in the presence of a court system that allows parties to drive up each other‘s 
costs and treats patent holders preferentially, patents are a valuable instrument for the extortion of 
payments - irrespective of their ultimate validity status‘: Harhoff D. ‗Challenges affecting the use and 
enforcement of intellectual property rights‘, in UKIPO ‗The economic value of intellectual property: 
An agenda for policy relevant research‘ (2009) Newport: Intellectual Property Office, p.111. 
54 http://news.bbc.co.uk/1/hi/uk/8459897.stm. 
55 Katopis C.J. ‗Perfect happiness?: Game theory as a tool for enhancing patent quality‘ (2008) Yale 
Journal of Law and Technology, p.360-404, p.387-388; Also, Brunel, an engineer testifying before 
1829 Parliamentary Select Committee on Letters Patent, stated ‗I think that patents are like lottery 
offices, where people run with great expectations, and enter any thing almost‘: Ford P. and Ford G. 
British Parliamentary Papers: Report from Commissioners and from Select Committees on letters 
patent with proceedings minutes of evidence, appendices and indices, Inventions- General 1 (1968) 
Shannon: Irish University Press, Law Relative to Patents for Inventions, 1829 (332) Vol III, Select 
Committee (hereafter, 1829 Select Committee) and 1851 (486) Vol XVIII (hereafter, 1851 Select 
Committee), p.5. 
56 For instance, Adusei P. ‗Regulatory diversity as key to the ‗myth‘ of drug patenting in Sub-Sahara‘ 
(2010) Journal of African Law, p.26-50, asserting that the basis for sustaining the patent system is one 
of deception and myth for developing countries. 
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high rate of new technology emergence, high rate of patent litigation and associated 
expense. The patent administrators have reiterated the importance of patents in 
innovation and that if industrialists understood patents they would have clearly 
vigorously utilised them.
57
 Patents and IP generally has become the very survival tool 
in this knowledge economy, where ‗[t]he movement of material goods is now much 
less important than flows of information and knowledge.‘58  It is said that ‗in the 
commercial and business world, the development of new tactics and new strategies 
for deployment of IPRs for commercial advantage has been identified as the next 
corporate challenge on the battlefields of the knowledge economy.‘59  
 
At the same time the thesis makes suggestions that allow for the coexistence of the 
respective domestic patent systems in the global context, as without this any perfect 
local patenting system could easily be circumvented and made ineffective if there is 
no reciprocate protection from other jurisdictions. It is anticipated that the study could 
ease the divide between developing and developed countries, in terms of the necessity 
and use of the system. As the principal justification of IPRs is economic, without 
proper understanding of the substantive and policy considerations, it is not a far-
fetched notion that developing countries would essentially insist on a conspiracy by 
world powers to re-colonise and monopolise development through patents.
60
 
 
Another area of importance and a source of contention is that the patentability 
standards have a direct bearing on invention and innovation in the health sector.
61
 
With inappropriate standards there would be the loss of potential R&D for new drugs, 
                                                             
57
 Innovation report: Competing in the global economy, December 2003, Department of Trade and 
Industry, UK. 
58 May C. A global political economy of intellectual property rights: The new enclosures (2000) 
London: Routledge, p.2.  
59 Soetendorp, fn.13, p.84. 
60  Patenting alliances between developed nation governments, the academia and pharmaceutical and 
biotechnology firms are said to have unfairly extracted from and controlled developing countries‘ 
potential wealth from natural resources: Ostergard R., Tubin M. and Altman J. ‗Stealing from the past: 
globalisation, strategic formation and the use of indigenous intellectual property in the biotechnology 
industry‘ (2001) Third World Quarterly, p.643-656. Also, Rahmatian A. ‗Neo-colonial aspects of 
global intellectual property‘ (2009) Journal of World Intellectual Property, p.40-74. It is acknowledged 
in this thesis that the North-South divide that is commonly used when patenting issues are dealt with is 
a rather loose historical grouping of different patenting systems between the wealthy and poor nations, 
but that does not exempt countries from possessing elements from either groups or being leaders in 
certain patenting sectors while lagging in other sectors. 
61 Kettle H.E. ‗Using intellectual property regimes to meet global health R&D needs‘ (2003) Journal of 
World Intellectual Property, p.655-683. 
 25 
and thus exacerbating neglected tropical disease drugs and shunning of orphan drugs, 
a phenomenon whereby rare medical conditions necessitates R&D of special and 
specific pharmaceutical agents.
62
 According to Roin, when the patentability limbs are 
perceived to make no concessions for the development costs of pharmaceuticals by 
the weak effective patent protection they offer, this leads the pharmaceutical firms to 
screen and discard those that attract weak patent protection.
63
 The obtaining of 
regulatory and marketing approval for one successful chemical entity represents costs 
in excess of a hundred million dollars for the US and European markets,
64
 which in 
itself is prohibitively high to be to be compounded with standards perceived as 
inadequate for inventing. The thesis seeks to suggest what is a balanced patentability 
standard for these needs. 
 
 
1.3 Research methods, sources and approach 
 
1.3.1 The comparative method 
 
Intuitively, a comparative legal study entails a comparison of a legal system with a 
foreign one,
65
 but does not reveal the necessary methodological rigors to qualify as 
such. There are arguments for a strict and rigid approach on one hand and a flexible 
one on the other hand.
66
  In its essence ‗[c]omparative law denotes a method of study 
and research, or is a technique…used for a variety of practical or scholarly 
purposes…the investigation of legal rules and procedures not of one system but in 
harness with the examination of the equivalent rules in at least another system.‘67 It is 
                                                             
62 Hemphill T.A. ‗Extraordinary pricing of orphan drug: Is it a socially responsible strategy for the U.S. 
pharmaceutical industry?‘ (2010) Journal of Business Ethics, p.225-242, p.226-227. 
63 Roin B.N. ‗Unpatentable drugs and the standards of patentability‘ (2009) Texas Law Review, p.503-
570. 
64 Scherer F.M. ‗Pharmaceutical industry and world intellectual property standard‘ (2000) Vanderbilt 
Law Review, p.2245-2254, p.2246, whilst other less conservative estimates suggesting costs of over 1.7 
billion dollars, with only one in three products recouping those investments made, Abbott/Graham, 
fn.37, p.66. 
65 Saidov A. Kh. Comparative Law (2003) London: Wildy: Simmonds & Hill, p.22-23 asserts that 
study of foreign law is only a foundation and precursor to comparative law although these concepts do 
overlap. 
66 Watson A. Legal transplants: An approach to comparative law, 2nd ed, (1993) Athens: University of 
Georgia Press p.17-18, makes the case that systematic and detailed knowledge of the systems 
compared may not be necessary in some comparative endeavours.   
67 Ibid, p.1-2. 
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asserted here that the exact form of method adopted for the comparative activity is 
predicated therefore on the purpose for the comparison. 
 
The categories of the comparative branch of law have been identified and divided in 
various contexts into three broad groups:- descriptive, which is the inventory of past 
and present rules either at an elemental or holistic level; historical, desiring to 
establish a universal history, which may sometimes be obscure, predicting the 
development of legal institutions; and the jurisprudential, seeking to establish ‗the 
common trunk on which present national doctrines of law are destined to graft 
themselves as a result of both the development of the study of law as a social science, 
and of the awakening of an international legal consciousness.‘68 The view held in this 
thesis is that these are non-exclusive of each other and can be used in combination in 
furtherance to the purposes of the comparative enterprise. 
  
The comparative law method has many purposes and justifications. The comparative 
method has been used inter alia:- 
 
1. ‗[t]o contribute toward knowledge of the social world through the study of 
its legal aspects.‘69 It is in this purpose that legal scholars have sought to 
analyze how the law has been applied in society and the resultant shaping of 
society that could be expected from similar principles. ‗The prime virtue of 
comparative law‘, writes Watson, is in its informative insight into the 
development of law and ‗by means of it we should be able to isolate the 
factors which have led to real innovation in a particular society.‘70 
2. To enhance one‘s knowledge and understanding of one‘s legal system.71 
The comparing of ones own system with another, one can have an objective 
and enlightened view of their own system. 
3. To ‗harmonize or unify areas of law on a transnational basis to promote 
trade and economic activity across borders…‘ which can in turn give insight 
                                                             
68 Ibid, p.3. 
69 Cotterrell R. Law, culture and society: Legal ideas in the mirror of social theory (2006) Hampshire: 
Ashgate Publishing Limited, p.130. 
70 Watson, fn.66, p.16. 
71 Cotterrell, fn.69, p.130. 
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into the ‗power of legal cultures, for example, as barriers to harmonization of 
law.‘72 
 
In light of these, the thesis adopts the comparative law method with the aims: 
 
1. To elucidate and improve understanding of the legal and attendant social 
developments in the two jurisdictions‘ patentability standards. 
2.  To suggest improvements of the respective jurisdictions‘ legal systems in 
the area of patentability standards in light of unique developments in the other 
jurisdiction. 
3. Ultimately, to contribute to the harmonization of the law of patents in 
relation to attainment of appropriate and optimal standards in a globalised 
society. 
  
This is a thesis on substantive patentability law, but the influence of some significant 
socioeconomic factors will be acknowledged. But as Cotterrell
73
 points out that 
‗comparists tend to distrust broad social or legal theory that might purport to offer 
matrices for the widest legal and social comparisons‘, the thesis adopts an approach 
that cautions against an indiscriminate clouding of substantive rules with 
socioeconomic issues, solutions of which may lie in other areas of law and 
governance. That is to say, the thesis is not a socioeconomic ignorant approach, but it 
cautions against using socioeconomic issues, prevalent in the pharmaceutical industry, 
to compromise the substantive rules. 
 
Since the basic principles that underpin the doctrine of patentability standards in 
South African law have a large influence from English law,
74
 the initial part of the 
research for this thesis involves an historical analysis of how patentability developed 
through the centuries from its English roots. Thus the UK is an archetypal type model 
                                                             
72 Ibid. 
73 Ibid, p.127, emphasis added. Authors indeed suggest the need to understand technological change in 
relation to broader societal perspectives: Elzen B., Enserink B. and Smit W.A. ‗Socio-Technical 
Networks: How a technology studies approach may help to solve problems related to technical 
change‘(1996) Social Studies of Science, p.95-141. 
74 Cameron E. ‗Legal chauvinism, executive-mindedness and justice- L.C. Steyn‘s impact on South 
African Law‘ (1982) South African Law Journal, p.38-75, explaining the significance of English law in 
South Africa, much against repudiation attempts by Roman-Dutch law purists. 
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in the historical context. This section of the thesis is important for establishing the 
principles that now underlie both the English and South African justifications for the 
patenting system and the patentability standards. Due to the fact that the aim of the 
thesis is not principally historical, this part of the thesis will not consist of an 
exhaustive historical analysis of the entire spectrum of the development of the 
patenting concept but will introduce the periods that have remnant patentability 
principles and justifications that are still operative in the modern law of the two 
jurisdictions or have a philosophical and theoretical impact on its future. Indeed, 
Watson asserts that to avoid an arbitrary and non-systematic approach to comparative 
law there has to exist a relationship between the systems compared although the exact 
boundaries of such relationship cannot always be identified or defined in all areas or 
in all historical periods.
75
 
 
The bulk of the thesis is a comparative analysis of the contemporary substantive 
patentability standards in South Africa and the UK as representative of developing 
and developed countries, respectively under the N-S groupings. Although there are 
exceptions, South Africa can be considered representative as it is a middle-income 
country
76
 as a number of other developing countries belonging to similar trading 
blocs
77
 or international IP forums
78
 or the Commonwealth.
79
 Indeed, South Africa is 
ranked comparably within the same group as other African developing countries when 
using a composite index of technology capacity incorporating patents and scientific 
publications,
80
 or under the Global Competitiveness Index.
81
 Grouping countries with 
similar characteristics in one variable does not eliminate disparities in other variables. 
                                                             
75 Watson, fn.66, p.7-8. 
76
 According to the World Bank Development indicators. 
77 Kahn M. and Reddy B.D. ‗Science and technology in South Africa: Regional innovation hub or 
passive consumer?‘ Why South Africa matters‘ Daedalus: Journal of the American Academy of Arts 
and Sciences, p.205-234. 
78 Park W.G. (2008) ‗International Patent Protection, 1960–2005‘ (2008) Research Policy, p.761–766. 
79 Wadlow C. ‗The British Empire patent 1901 - 1923: the ―global‖ patent that never was‘ (2006) 
Intellectual Property Quarterly, p.311-346, examines the historical attempts to create a Commonwealth 
supra-patent. 
80 Archibugi D. and Coco A. ‗A new indicator of technological capabilities for developed and 
developing countries‘ (2004) World Development, p.629-654. Indeed South Africa has multiple R&D 
development partnership with fellow SADC countries: Konde V., Kapoor S. and Thorsteinsdottir H. 
‗Promoting an African Renaissance? South Africa‘s health biotechnology collaboration with Sub-
Saharan African countries‘, in Thorsteinsdottir H. South-South collaborations in health biotechnology: 
Growing partnerships amongst developing countries (2012) New Delhi: International Development 
Research Centre. 
81 Global Competitive Index 2013–2014, http://www3.weforum.org/docs/GCR2013-
14/GCR_CountryHighlights_2013-2014.pdf, p16-19. 
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More importantly, South Africa belongs in the same common law family of laws as 
the other members, which allows the extrapolation of conclusions to the other 
members of the group.
82
 The UK could be generally considered representative of the 
European Patent Convention (EPC) Contracting States as they have an obligation to 
interpret patentability in a harmonized way.
83
 
 
The thesis in this section therefore suggests a move away from the blanket emulation 
of UK standards,
84
 and adopts an approach that views the UK and South Africa as 
broadly representative of advanced and emerging countries in the quest for a standard 
that can be sustained in globalised environments. There is reference to other 
jurisdictions as although the UK and South Africa have commendable patenting 
activity, it is less than what other countries have accomplished.
85
 Moreover, pragmatic 
patentability standards have to be in line with other jurisdictions due globalization and 
general harmonization and convergence.
86
 It is at the same time necessary to remain 
true to the basic principles of the South African and British common law in 
conducting this exercise, or the proposed reforms would make no sense in the context 
                                                             
82 Epstein L. and King G. ‗The rules of inference‘ (2002) University of Chicago Law Review, p.1-133, 
address the proper ways of making inferences of observed results to other jurisdictions, whilst Phillips 
J. ‗Why history matters‘ (2010) Vitoria University of Wellington Law Review, p.293-316, argues that 
even within a set of seemingly similar common law jurisdictions or legal doctrines, the law is 
contingent and shaped by unique circumstances and context. 
83 Moreover, and distinct from EPC membership, there is bound to be a more unified development of 
the law within EU members as a result of the incoming unified patent regime. See ww.unified-patent-
court.org. Established by two Regulations is the Unitary Patent, which is the first piece of the EU 
patent package, entered into force on 20 January 2013 and which will be applicable from 1 January 
2014 or the date of the entry into force of the Agreement on a Unified Patent Court, whichever is later, 
and the Agreement on a Unified Patent Court [2013] OJ C 175/1, is the second piece of the EU patent 
package, signed on 19 February 2013 and will enter into force as soon as 13 states, including France, 
Germany and the United Kingdom, have ratified it. Once in operation this framework is predicted to 
‗slowly start generating ―unified‖ patent case law‘, (England P. and Parker S ‗Obviousness in the new 
European order‘ (2012) Journal of Intellectual Property Law and Practice, p.805-815), while others 
have predicted lack of uniformity in case law development because of the considerable discretion in 
practice and procedures in the local or regional divisions of the Unified Patent Court which may impact 
on substantive patent law of validity or infringement (Vary R. ‗The Unified Patent Court puts European 
businesses at a competitive disadvantage‘ (2013) The CIPA Journal, p.249-252, p.249). There was 
concern from some judges and practitioners on whether or not the unitary framework should allow 
elements of substantive patent law to fall under EU law, by virtue of inclusion in a EU legal instrument 
and consequently interpreted by the Court of Justice of the European Union (Callens P. and Granata S. 
Introduction to the unitary patent and the Unified Patent Court: the (draft) rules of procedure of the 
Unified Patent Court (2013) AH Alphen aan den Rijn: Kluwer Law International, p.10 and p.27). 
84 The extent of the rejection of western archetypical patent system varies, with some calling for the 
total overhaul: Adusei, fn.56, p.31.  
85 For example, each of the three most active patent offices has a patent activity greater than that of the 
UK and South Africa combined: WIPO WIPO Patent Report: Statitics on worldwide patent activities, 
2007 edition (2007) Geneva: WIPO. 
86 Due to globalisation and harmonisation of patenting systems for example through the TRIPS 
Agreement, EPC or the draft SPLT. 
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of the respective legal systems. Owing to its colonial past, the South African legal 
system is a mixed or hybrid legal system and one is able to extract suitable authority 
from both systems of law without straining the patentability principle out of context. 
 
An important issue to consider in the comparative methodology is also the procedural 
differences that exist between these two jurisdictions‘ patenting routes. This thesis 
mainly focuses on the resultant post-grant patent and patentability assessment 
methods. These ought to be comparable for the two countries as they are based on 
fairly similar laws. The examination granting procedures are however different 
because in the UK there is actual examination of the applications against a set of rules 
and guidelines, which is not present in South Africa. Although it is not entirely under 
focus in this thesis there is likely to be some correlation between post-grant 
patentability standards with the pre-grant models.
87
 The other difference is in the 
alternatives that a patentee may utilize to obtain a patent. In the UK there are the 
national, regional and international routes, while in South Africa there are the national 
and international routes, with the regional route only just still being contemplated.
88
 
These differences should be of minor consequence, if at all, because it is the resulting 
quality of the patents and the patentability assessment methods that are relevant and 
not the purely procedural elements. 
 
 
1.3.2 Research Sources 
 
As far as specific sources are concerned, the study relies mainly on the domestic 
statutes that have been amended inter alia to meet international obligations while at 
the same time remaining true to internal mandates.
89
 The United Kingdom‘s Patents 
Acts of 1977 (Patents Act 1977) and South Africa‘s Patents Act no. 57 of 1978 
(Patents Act 1978), and their subsidiary rules and regulations are central to this study. 
Since the majority of patents granted or litigated in the UK are under the EPC, and 
                                                             
87 Allison J.R., Lemley A.M., Kimberly and Trunkey R.D. ‗Valuable patents‘ (2004) Georgetown Law 
Journal, p.435-479. There is the basic assumption, or more from an inventor‘s point of view an 
expectation, that granted patents should reasonably stand against validity challenges.  
88 Membership to ARIPO still being contemplated but no official decision has made yet. 
89 Some sections of Patents Act 1977 were promulgated to meet EPC requirements. The Constitution of 
the Republic of South Africa, 1996, (South African Constitution) section 231, requires international 
instruments to conform to the constitution before it can take effect. 
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there is a persuasive influence by European decisions on the local judiciary,
90
 the 
impact of the EPC will be assessed.
91
 The impact of internationally negotiated 
instruments, for instance the Agreement on Trade-Related Aspects of International 
Property Rights
92
 (TRIPS Agreement) will be assessed and so will the potential 
impact of the interminably negotiated SPLT or an alternative substantive patent law 
treaty and the appropriate pre-emptive input that each jurisdiction could make to its 
formulation to prevent what has been called ‗negotiating fatigue‘.93 There is now 
extensive literature on the ills of the TRIPS Agreement which, more usefully, could 
have been raised before the instrument was concluded. 
 
 
1.3.3 Research Approach 
 
As this is a comparative study, parallels are drawn between the two jurisdictions as 
well contrasting their approaches to testing patentability. In view of this, common 
international instruments, in the form of treaties, protocols and agreements are 
studied, as relating to the basis of establishing similar patentability standards. 
Relevant regional or Community legislation and practice are also studied for influence 
exerted on the respective domestic laws, which are central to this research. Case law, 
policy documents, practice manuals, reports as well as journals are examined before 
conclusions are made on whether the patentability standards are adequate for their 
continued relevance in pharmaceutical patent protection.  
 
An auxiliary and triangulation component of the research method in this thesis was 
the carrying out of data-gathering fieldwork in the form of participant observations of 
                                                             
90 House of Lords in Conor MedSystems v Angiotech [2008] UKHL 49 (Conor), was mindful of the 
decisions on the same patent made in the Netherlands. Also the Court of Appeal and the Patent Court 
looked at how a patent for an identical invention was decided in other EPC Contracting States in 
Occlutech GmbH v AGA Medical Corporation [2010] EWCA Civ 702. 
91 The Unitary Patent is set to become relevant for patent law in the UK (see http://www.epo.org/law-
practice/unitary.html) although some tactical forum manoeuvring by patentees and jurisdictional 
tensions between the local and regional courts are predicted to occur: Johnson A. ‗Unitary Patents and 
the Patent Court- Forum Shopping and jurisdictional battles‘ (2013) The CIPA Journal, p.114-116. 
92 Agreement on Trade-Related Aspects of International Property Rights, Apr. 15, 1994, Marrakesh 
Agreement Establishing the World Trade Organization, Annex 1C, 1869 U.N.T.S. 
93 Matthews D. ‗Lessons from negotiating an amendment to the TRIPS Agreement: Compulsory 
licensing and access to medicines‘, in Westkamp, fn.30, p.248, in reference to lack of prerequisite skill 
and competence on the subject matter to maintain emerging-country advantageous mandates in 
negotiations. 
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patent stakeholders in their dealing with the patentability doctrine in patent tribunals 
and other public forums. This entailed observational attendance at conferences and 
informal interaction with delegates. Observations also include conversations with 
subjects and impressions the researcher forms when studying the subjects.
94
 The 
questioning carried out under the observations method is different from interviews 
commonly used in survey research where there is emphasis on a systematic and 
structural approach, although sometimes this rigidity can lead to responses reflective 
of the researcher‘s concerns than that of the subject.95 The underlying premise for a 
flexible observation approach adopted in this thesis is that if something can be 
observed once, it occurrence is indeterminate
96
 and thus this confirmatory method is 
not overtly concerned about standardisation and repeatability of result observed by or 
on a particular subject.
97
 Overall, that is to say the observation method of choice in 
this thesis has a dual purpose; which is to establish the perceptions and interpretation 
of the law by the stakeholder subjects in instantaneous, unedited settings and also 
confirm the validity and practical applicability of conclusions made throughout this 
research. This exercise is especially directed at the invaluable body of tacit knowledge 
or opinion that is not or cannot be articulated, transcribed or conveyed through the 
standard documentary records that are of primary analysis in this thesis.
98
 
 
Research data-gathering is susceptible to subjectivity, which may render it of limited 
use in an objective study. Therefore, data obtained from observing subjects was 
treated with caution; as such the researcher maintained an outsider position with 
                                                             
94 Flood J. ‗Participant observation‘, in Clark D. (ed) Encyclopaedia of law and society: America and 
global perspectives (2007) Los Angeles: SAGE Publications, p.1081. 
95 Bryman A. Social research methods, 2nd ed (2004) Oxford: Oxford University Press, p.318-319. 
96
 ‗…if one quite clearly seen something happen once, it is almost certain to have happened again and 
again. The burden of proof is on those who claim a thing once seen is an exception; if they look hard 
they may find it everywhere, although with some interesting differences in each case‘, Hughes quoted 
in Banakar R. and Travers M. (eds) Theory and method in socio-legal research (2005) Oxford: Hart 
Publishing, p.48. 
97 Bryman, fn.95, p.319-320. Also, ethnography, a long-term form of observation, is not overly 
concerned with validity and reliability in the conventional sense, Flood J. ‗Socio-legal ethnography‘ in 
Banakar R. and Travers M. (eds) Theory and method in socio-legal research (2005) Oxford: Hart 
Publishing, p.34. 
98 Commentators have even said that the inadequacies of reported decisions may lie in them being the 
judges‘ snapshot of the case at a particular time and ‗…extremely important matters may be totally 
omitted from reported decisions‘: Schlanger M. and Lieberman D. ‗Using court records for research, 
teaching and policy-making: The civil rights litigation clearinghouse‘ (2006) UMKC Law Review, 
p.153-167, p.161. Also, Blanck P.D., Rosenthal R., Hart A.J. and Bernieri F. ‗The measure of the 
judge: An empirically-based framework for studying a judges‘ behavior (1990) Iowa Law Review, 
p.653-723, p.654, suggest that verbal and nonverbal behaviour and variables may have significant 
effects on trial processes and outcomes. 
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minimal interaction with subjects. Of related susceptibility to subjectivity are in-depth 
interviews because of the difficulty of mitigating subjectivity as a result of the 
proximity of the researcher to the subject. A common drawback to these research 
endeavours that include interaction with subjects is that the subjects tend to act or 
express opinion differently under study conditions than in normal circumstances.
99
 
Other practical inherent limitations can also stem from tendencies of institutions 
instilling a restrictive official code or even opinion, for employees to abide by in 
relation to communications with external entities.
100
 Even under guarantees of 
confidentiality there could be reluctance by subjects to be interviewed. This was 
therefore decisive for not carrying out in-depth interviews in this thesis because 
unadulterated access to institutional personnel or records could not be guaranteed for 
both jurisdictions to make meaningful comparisons and conclusions. 
 
If the researcher forms conclusions with objectivity as the guiding principle,
101
 
publicly available observation data is helpful. The researcher has discretion to select 
information that they deem relevant. The value of such activity, for example, is that it 
extracts or interprets the data which may have been influential to the judge‘s decision 
but not contained in the case report.
102
 For instance, in Teva UK Limited v Merck & 
                                                             
99 Glod F., Duprel C. and Keenan M. ‗Foresight for science and technology priority setting in a small 
country: the case of Luxembourg‘ (2009) Technology Analysis and Strategic Management, p. 933-951, 
p.939. 
100 The views of interest groups are susceptible to advancing the mandates of that group without regard 
to balanced views. There is growing concern that even academic bodies now tend to follow an 
approach which can compromise the integrity of opinion or research output in terms of its objectivity. 
Pharmaceutical firms‘ sponsorship of medical journals has tainted reliability of research. Authors assert 
that in increasing the public understanding of science and research, the presentation of scientific facts 
must be done in a dispassionate and objective way even if one holds a different view morally or 
otherwise: Bodmer C. The public understanding of science (1986) London: J.R. Ruddock and Sons 
Ltd, p.4. 
101 Attainment of the ideals of objectivity has been doubted but on a flawed assumption equating 
objectivity with neutrality, the former requiring detachment, which is ‗an undeniably ascetic capacity to 
achieve some distance from one‘s own spontaneous perceptions and convictions‘ and interrogation of 
competing and alternative perspectives whilst the latter is usually unnecessarily assigned an inflated 
value requiring scholars to ‗purge themselves of external loyalties‘ and wrongly assumed to be a 
prerequisite for good scholarship and is premised on ‗disengagement from life‘: Haskell T.L. 
‗Objectivity is not neutrality: Rhetoric vs. practice in Peter Novick‘s That Noble Dream‘ (1990) 
History and Theory, p.129-157, p.132, 139-140. 
102 For example it has been said that a formalistic law interpretation approach is problematic to the 
extent that it ‗is a false pretense to objectivity… tended to ‗disguise‘ and ‗minimize‘ the role actually 
played by policy beliefs and personal preferences‘, King, fn.4, p.414. Scholars assert that ‗while it 
provides appropriate answers to guide courtroom or classroom inquiries and is useful for generating 
theories, case analysis is too superficial to allow scholars to prove claims about what the law is in a 
broader context‘ and research scholars are urged to additionally employ social science research 
techniques for making claims on what the law is beyond case outcomes which may not explain the 
complexities of the court processes and therefore not totally satisfying in making future predictions of 
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Co., Inc,
103
 unlike Rennie, an expert witness for Teva and a natural orator held more 
reliable by the court,
104
 a transcript of evidence by Sugrue, an expert witness for 
Merck, would not reveal the many instances of his answering questions with head 
nodding or shaking and occasional confused frowning, to which only towards the end 
of his testimony were there frantic reminders by the defendant‘s legal team that the 
court recording system only captures audio. In the end the judge finding the patent 
obvious, interpreted his evidence as lacking in balance and to be viewed with 
suspicion,
105
 a reason which would not be evident to one reading the court transcript, 
and more so in the case report. However, to a participant observer for instance, this 
scenario could be suggestive inter alia of the fact that patentability assessment 
methods may in practice have subjective elements intolerant of a timid but punctilious 
scientist, not in agreement with ambiguously-framed technical questions posed by 
opposing counsel, to influence or even be decisive of patentability, as opposed to the 
validity of the science under investigation. Using the same observation principles, 
public lectures by legislators, patent administrators as well as academics and judges 
speaking or writing extra-judicially were used in this thesis to gather stakeholder 
views on patentability assessment methods or factors that have a bearing on 
patentability.
106
 The qualitative research method, supplemented and triangulated with 
observations in this way helps elicit patentability factors that could be otherwise 
difficult to discover.
107
 
 
The study sought to interpret patenting policy beyond the stated policy in official 
documents and examine what may be understood as policy-in-action, which is the 
actual implementation of policy frameworks, rather than the merely stated ones.
108
 
                                                                                                                                                                              
similar events: Levine K.L. ‗The law is not the case: Incorporating empirical methods into the culture 
of case analysis‘ (2006) University of Florida Journal of Law and Public Policy, p.283-301, p.300. 
103 [2009] EWHC 2952 (Pat). 
104 Ibid, para.124, 125 and 134. 
105 Ibid, para.28. 
106 Some observers have said ‗this is the mostly oral tradition that constituted the professional 
consensus of judges and lawyers, transmitted through their learning exercises, their legal practice, their 
social activities, and their writings. This …body of law cannot be known in full, of course, and goes 
beyond what judges and lawyers wrote about law, beyond even what they said to each other, to include 
what unspoken assumptions they must have shared‘: Seipp D.J. ‗The law's many bodies, and the 
manuscript tradition in English legal history‘ (2004) The Journal of Legal History, p.74-83, p.75. 
107 The triangulating of different methods in social sciences assists in assessing whether different 
approaches offer similar conclusion, with each method rigorous in its own right although illuminating 
different dimensions of the same subject matter under analysis: Levine fn.102, p.286. 
108 To coin Roscoe Pound‘s celebrated phrase ‗law in the books and law in action‘, Pound R. ‗Law in 
the books and law in action‘ (1910) American Law Review, p.12-36. 
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These two, the stated goals and the implemented, are not necessarily concomitant. 
Patent administrator‘s policy-in-action can, for instance, become evident when there 
has to be a practice change as a result of a court decision by the ease with which that 
change is effected
109
 or the reasoning advanced in multilateral forums negotiations for 
preference of particular features in the patent system.
110
 Such holistic policy analysis 
is of importance because the patent administrators are the usual first point of contact 
for inventors and innovators desiring protection and also have more influence in 
patent law reforms.
111
  
   
 
1.4 Research Questions 
 
The research questions can be summed up thus: 
 
What are the fundamental criteria of patentability standards that are the appropriate 
measure of patents deserving of protection? That is to enquire as to what are qualities 
or components of an optimal patent standard that the assessment methods seek to 
establish. 
 
Do patentability standards in the UK and South Africa significantly differ? This 
enquiry also generally seeks to uncover whether patentability standards in advanced 
and developing nations, fundamentally differ. The significant difference refers to the 
likely difference in result in the prosecution and litigation of an equivalent patent in 
the two jurisdictions, and not a statistical significant difference; that is no statistical 
assumptions are made. 
 
What do those differences, if any, tell us about the compatibility of patentability 
standards with the operation of the pharmaceutical industry in a globalised society? 
 
                                                             
109 Instructive of the real policy would for instance be the UKIPO ease of practice change in the case of 
computer-implemented inventions following EPO approach of excluded subject matter in CFPH LLC‟s 
Patent Application [2005] EWHC 1589. 
110 For instance, contributions to Strasbourg Convention or statements made at SPLT forum by the 
representatives of the respective jurisdictions policymakers could be suggestive of their policy. 
111 Patent Bills are brought to Parliaments usually by promotion of the patent office, and as such reflect 
their standing policy. 
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What reform is needed to attain an ideal patentability standard compatible with the 
needs of inventors and innovators from both jurisdictions in a globalised society? 
 
1.5 Structure of the thesis 
 
The thesis initially focuses on the English origins of patentability standards. The 1624 
Statute of Monopolies was a parliamentary intervention to curb the royal prerogative 
of partially granting monopolies. On the other hand, with Britain‘s drive to catch-up 
with trade and technical competitors, an unintended consequence of the patentability 
definition included newness as inventions ‗first to be imported‘ into Britain. The 
thesis examines the evolution of UK‘s patentability requirements from these unclear 
beginnings into a leading system of encouraging genuine invention and innovation. 
With the advent of knowledge economies, South Africa is contrary faced with 
preventing expropriation of its resources, and at the same time using the system to 
encourage invention and innovation. The thesis explores lessons for South Africa to 
fine-turning the patentability standards and policy to harness these resources in the 
same drive of catching up in world trade and innovation, without compromising the 
patentability standards. Therefore the thesis explores the historical justifications that 
sustain the patentability concept and suggests a patentability model based on these. 
 
Having analyzed the historical origins of the patentability doctrine in chapter two, the 
international obligations that now govern much of how the patentability doctrine is 
applied locally will be studied in chapter three. This is because countries are now 
bound by regional and international obligations for the existence of acceptable 
minimum standards
112
 or pre-grant examination
113
 for effective patent protection. 
There will be a study of the international instruments that have some influence or 
exert control on the patentability requirements. In this chapter a universal patentability 
standard that is simultaneously realistic to the needs of both developing and 
developed nations is proposed. 
 
                                                             
112 Regional obligations arise from ARIPO Agreement for which South Africa is an observer member 
or EPC in which the UK has membership; TRIPS sets minimum standards to be attained for patent and 
other IPR protection as a prerequisite for WTO membership. 
113 The Paris Convention and the Patent Co-operation Treaty objectives. 
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Discoveries, computer programs and business methods are some of the areas that are 
often difficult to demarcate as patentable and are encountered within the 
pharmaceutical industry. In chapter four, an analysis will be made of the approach 
taken by the legislature, patent offices and courts for assessing patentability in cases 
where patentable subject matter demarcation is blurred. In this study, focus will be on 
cases where inventions have embodiments that have both patentable and unpatentable 
subject matter as such cases have aspects which are dispiriting to a potential 
pharmaceutical patentee whose typical activities integrate a range of unpatentable 
subject matter. 
 
The cornerstone of any patent system is that it should grant monopolies in reciprocate 
for inventions that are new. South Africa and UK are jurisdictions of absolute novelty, 
located at the strict end of the patentability scale. Novelty is however threatened 
when, for example, inherent anticipation, a doctrine stating that everything explicitly 
or implicitly resulting from practising prior art is anticipated, is extended as a 
consequence of Synthon BV v Smithkline Beecham plc
114
 or by the South African 
Patents Amendment Act of 2005 requiring origin disclosure as a pseudo novelty 
requirement. This continuous novelty reformulation has major consequences for the 
way the prior art is to be viewed, the role of the skilled worker, experimentation and 
disclosure requirements. A comparative analysis of the newness tests will be made in 
chapter five. 
 
A review by the United Kingdom Intellectual Property Office (UKIPO) of whether 
the inventive step is applied uniformly and objectively was carried out.
115
 The 
consultation process sought to assess and make reform proposals on whether the 
approach toward non-obviousness is set at the right level to fulfil the purposes of the 
patenting policy and system. In these contexts, chapter six will assess legislation, case 
law, and especially the Windsurfing International Inc v Tabur Marine (Great 
Britain)
116
 approach that has come to be applied, sometimes blindly, over the years in 
the Commonwealth, often coupled with heavy criticism. Attention in chapter six will 
be on whether the current methods of assessment non-obviousness tackle the problem 
                                                             
114 [2005] UKHL 59 (Hereafter, Synthon). 
115 http://www.ipo.gov.uk/press-release-20060203.htm. 
116 [1985] RPC 59. 
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of hindsight whereby views of the prior art or the inventive concept or the skilled 
worker‘s qualities distort the inventive quality of an invention when assessment is 
carried out. 
 
At one end, there is great interest in the patenting of biotechnological, 
nanotechnological and genomic inventions given the very promising potential such 
inventions offer for the development of new pharmaceutical products. On the other 
hand, there is considerable legal uncertainty with respect to the statutory requirements 
for the patenting of such inventions, uses and applications of which may not yet be 
entirely clear when making the application. It seems timely to analyse the application 
of the criteria of industrial applicability to these inventions, and to make a comparison 
between South Africa and the UK in chapter seven. 
 
A summary of the reforms as proposed throughout this study will be made in the 
concluding chapter. Considered reform, a little more than cosmetic if necessary,
117
 is 
recommended if a legal system is not optimally functioning or does not fulfil the 
industry purposes for which it was designed. Substantive patent law has various 
influential stakeholders whose points of view are critical to acceptance and 
implementation of reform, unsurprisingly the statutory reforms may be long drawn 
out legislative processes,
118
 extending beyond the timeframe and scope of this thesis. 
This chapter unifies the patentability conclusions made in this thesis. 
                                                             
117 Vaver is of the view that ‗the system is out of touch with both business and ordinary public 
sentiment, and that major rethinking and overhaul are necessary if it is to come in line‘, p.1 
http://papers.ssrn.com/abstract=902793. Some state that ‗a legal order that has become obsolete and 
antiquated is a constant source of legal difficulties, for meaningful interpretation requires adaptation to 
the actual situations.‘: Sherman B. ‗Patent law in a time of change: Non-obviousness and 
biotechnology‘ (1990) Oxford Journal of Legal Studies, p.278 -287, p.278. 
118 Rooklidge W.C. ‗Reform of the patent laws: the US experience in forging legislation from disparate 
interests‘ (2006) Intellectual Property Quarterly, p.1-15, p.3.   
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CHAPTER TWO 
 
PATENTABILITY HISTORY 
 
2.1 Introduction 
 
The carrying out of a legal historical study that unearths historical lessons that could 
be learnt and advance legal principles is not a straightforward venture. This is because 
of some fundamental differences between history and law. According to Maitland, 
‗the process by which old principles and old phrases are charged with a new content is 
from a lawyer‘s point of view an evolution of the true intent and meaning of the old 
law; from the historian‘s point of view it is almost of necessary a process of 
perversion and misunderstanding.‘119 In writing legal history it has been suggested 
that we have ‗to realise that concepts familiar to us may have a profoundly different 
colouration in that other time… It requires that we be willing to subject our own 
presuppositions to testing and revision. Not incidentally, that willingness is also 
essential to good comparative work.‘120 As such, a careful historical inquest in a 
comparative context can provide valuable insight for the legal scholar. Authors have 
said that ‗to think fruitfully about the future of the global governance of IPRs we must 
examine the past.‘121  
 
There are many and varied reasons for tracing and reviewing patentability history. 
One of the reasons for analysing the history of the patenting system is that there are 
lessons to be learnt from the development of the patent system in the UK by South 
Africa as a developing country.
122
 The conclusions from such a study can also be 
carefully inferred to and adapted to other developing countries on how to adjust their 
                                                             
119 Maitland F.W. ‗Why the history of English law is not written‘ in Fisher H.A.L. (ed) The collected 
paper of FW Maitland (1911) Cambridge University Press, Cambridge, at p. 490. Cf. Some argue that 
there is a commonality of interest on the past between the historian and the legal historian or scholar: 
Rose J. ‗Studying the past: Nature and development of legal history as an academic discipline‘ (2010) 
Journal of Legal history, p.101-128. 
120 Webber J. ‗The past and foreign countries‘ (2006) Legal History, p.1-11. 
121 May C. and Sell S.K. Intellectual property rights: A critical history (2006) London: Lynne Rienner 
Publishers Inc., p.5. 
122 There are objections to this view; from unsuitability and incompatibility of the patent system to the 
economic and developmental needs of developing countries to views that this is the ‗downward 
inheritance.‘ For example see Benoliel D. and Salama B. ‗Towards an intellectual property bargaining 
theory: The post-WTO era‘ (2010) University of Pennsylvania Journal of International Law, p.265-
368. 
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patent systems to meet contemporary needs and achieve what developed countries 
have achieved in the patenting arena.
123
 
 
On the other hand, through an understanding of the typical evolution of the 
patentability requirements, developed countries would be in a position to have 
objective and realistic expectations of developmental stages that emerging economies 
may have to go through, before expecting workable patentability standards.
124
 In fact, 
an appreciation of the history of the South African patent system and that of other 
developing countries could result in the UK and the developed world, adjusting their 
local patentability standards if the ‗global patent‘ is to be a reality.125 A re-assessment 
of the patentability history could thus be seen as an enquiry that could reveal new 
patterns and improved interpretations from the foreign law and demonstrate vital 
linkages in trans-boundary concepts that were in existence in the two jurisdictions 
being compared. Indeed, the Law Commissions Act
126
 allows Commissioners in law 
modernisation and reform ventures to ‗obtain such information as to the legal systems 
of other countries as appears to the Commissioners likely to facilitate the performance 
of any of their functions.‘ One such tool could be the historical analysis of the laws in 
South Africa.  
 
It is indeed prudent for IP policy-makers, and practitioners alike, to reflect on the 
history of the patentability requirements and extract the principles and justifications 
that made the patent system subsist, so as to continually improve the system. They 
should also analyse the weaknesses of the patent system, exposed in its the re-
assessment of history, in order to avoid making the same mistakes, or persist in 
following less beneficial patent customs, in principles deducible from the historical 
study. A practice grounded on incorrect or imprecise historical principles could have 
                                                             
123 Van Caenegem W. ‗Intellectual property and the idea of progress‘ (2003) Intellectual Property 
Quarterly, p. 237-256, p.238-239. 
124 May/Sell, fn.121, p.97 argue that patent legislative development followed specific paths and was 
dependent on particular national socio-legal cultures and economic development. Also, Niosi J. 
‗Complexity and path dependence in biotechnology innovation systems‘ (2011) Industrial and 
Corporate Change, p.1795-1826. 
125 The global patent here refers to the continuous harmonisation of substantive and procedural patent 
rules that seek to standardise IP concepts worldwide. The ultimate goal seems to be supranational 
patentability standards. Whatever the policy reasons are for sustaining differing domestic regimes, 
from the perspective of the inventor or innovator there is the yearning and need to protect inventions or 
innovations in a global context or have the option of obtaining simple cover across borders. 
126 Law Commissions Act of 1965, s3(1)(f). 
 41 
dire consequences for the pharmaceutical industry where unsuitable regulation has 
far-reaching adverse effects into the public sphere. These are some of the reasons that 
warrant a study of the history of the patentability requirements. 
 
A cautionary note to this comparative historical analysis is that the current 
patentability principles may have been influenced by unknown or less understood 
underlying factors, which may have been wrongly attributed to a certain element of 
the patenting system.
127
 Therefore a clear understanding of the foundational principles 
and underlying policies that were at play when the patent system was in its 
developmental stage is important. This is especially true as the retrospective viewing 
of the material facts of a historical legislative concept, sometimes called a revisionist 
approach, can blur objectivity from the overanalysis, if not exaggeration, of historical 
principles to the simple subjective interpretation of historical facts or legislative 
provisions in both jurisdictions.
128
 The South African judiciary, cautioning on 
haphazard historical citations has put it thus: ‗it may be useful… to trace the history 
and wording of the corresponding and related sections of previous legislative 
measures passed in this country as well as in England, and to consider judicial 
interpretation (if such exists) thereof in both countries.‘129 
 
In this chapter, there is an exploration of how the historical methodology can be used 
and reflected upon to bring about an interface in the needs and aspirations of the UK 
and South Africa patenting regimes in encouraging and protecting inventions by the 
appropriate patentability standards. This is achieved by examining the historical 
justifications of the patenting systems; a pivot of this chapter. From the onset, it is 
recognised and acknowledged that the patent system does not necessarily fit into any 
of the historical justification models perfectly, but that does not mean there should not 
be a quest for a unifying thread amongst these. This approach assumes that the 
                                                             
127 There are disagreements on what exactly made the patenting system successful. There are the 
classical examples of countries that were successful in industry and development without patents or 
only introduced patents later on in their development cycle. Switzerland refused to introduce patents 
and Netherlands withdrew their patenting systems yet they are considered relatively developed 
countries. 
128 It has been argued that ‗historical facts are seen as prior to and independent of interpretation: the 
value of an interpretation is judged by how well it accounts for the facts; if contradicted by the facts, it 
must be abandoned. Truth is one, not perspectival‘, Novick P. ‗That noble dream: The ―Objectivity 
Question‖ and the American historical profession (1988) Cambridge: Cambridge University Press, p.6 
129 Villoen J, in The Advance Transformet Co v The Registrar of Patents and Basic Products 
Corporation 11/1/1967 SAPJ 40, p.41. 
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justifications commonly employed for the subsistence of the patent system are not 
mutually exclusive especially under the widely accepted view that patents have a 
utilitarian foundation or function.
130
 This chapter argues that the various classical 
justifications for the patenting system are all valuable in the attainment of a system 
that will result in balanced contemporary patentability standards. That leads to the 
notion that the philosophical and legal theories adopted and embraced in this thesis 
are mixed and non-exclusive. A synergistic approach towards patentability standards 
between the so-called North-South is the ideal way a functional global patent system 
would continue to exist and be refined.
131
  
 
The approach that is taken in studying the patentability history is hinged on extracting 
principles underpinning or influential in patentability development or its philosophical 
justifications in order to develop a model based on an integrated view of the different 
justifications. This part of the thesis, therefore, will not be an exhaustive historical 
analysis of every period in the evolution of British and South African patent laws, but 
will be devoted only to the significant milestones in the historical development of the 
English patent law that was inherited into South Africa and continues to have 
authority, persuasive or otherwise.
132
 It is noted though that sometimes the selection 
of periods may lead to skewed assessments, therefore vigilance will be exercised 
when making extractions. Some patenting aspects unique to South Africa and 
developed in South African law will also be considered. 
 
 
2.2 The need for the historical analysis 
 
Intuitively, history could be viewed as the study of the past. The historical standpoints 
that could be taken are varied. One approach is to seek to extract objective historical 
meaning from the past as opposed to the intentions of the authors of the historical 
                                                             
130 The leading justification is the utilitarian: Hettinger E.C. ‗Justifying intellectual property‘ (1989) 
Philosophy and Public Affairs, p.31-52, p.47-51. 
131 Phillips, fn.98, p.227. 
132 The influence of English law in South Africa is encapsulated in Estate Wege v Strauss 1932 AD 76, 
p.80, where Wessels AJ stated that ‗The draftsman of a Union statute may find it convenient to use the 
same words as a similar section in an English statute, but it does not follow that our legislature must be 
considered to have thereby not only the words of the section but the meaning which English courts 
have given that section as interpreted in the light of English common or statute law.‘ 
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records.
133
 The reporting of Sir Cooke, who reported mainly on cases at the Chancery 
division, has been doubted by some although he is considered one of the greatest 
practitioners in English legal history.
134
 The criticism lies in his conflation of personal 
observation and professional opinion in the cases he reported. Some authors have 
doubted the existence of objective historical recording, stating that ‗[w]ether a 
detached and unbiased history can ever exist is another question.‘135 History 
methodology can therefore be seen as the delicate art of selecting and describing 
moments from the entirety of the past to set them, not necessarily in a sequential 
order,
136
 as significant principles in order to make deductions and inferences.
137
 The 
analysis then attaches importance to the selected information or evidence, by the 
creation of informational models so as to explicate other current or future points in 
issue.
138
 Even micro-histories, the study of relatively smaller epochs can be 
instructive in this regard.
139
 For instance one could benefit from the study of the 
negotiation history in the making of a treaty that drastically changes long-established 
concepts even though that history may relatively span a short period compared to the 
longer time period of unchanged custom followed before. The models deduced from 
such a study may be attributed with meaning and consequences to the advancement of 
the patentability concept. 
 
                                                             
133 Brown V. ‗On some problems with weak intentionalism for intellectual history‘ (2002) History and 
Theory, p.198-208.  
134 Powell D. ‗Coke in context: Early modern legal observation and Sir Edward Coke‘s Reports‘ (2007) 
Legal History, p.33–53. 
135 Melton B.F. ‗Clio at the Bar: a guide to historical method for legists and jurists‘ (1998) Minnesota 
Law Review, p.377-472, p.382. Walsh W.H. ‗Truth and fact in history reconsidered‘ (1977) History and 
Theory, p.53-71, analyses the difficulties encountered in historical narratives of events. 
136
 Posner R.A. ‗Past dependency, pragmatism and critique of history in adjudication and legal 
scholarship‘ (2000) University of Chicago Law Review, p.573-606. 
137 Spinello R.A and Bottis M. A defence of intellectual property rights (2009) Cheltenham: Edward 
Elgar Publishing Limited, at p. 37. Also Phillips J. and Simon I. ‗Going down in history: Does history 
have anything to offer today‘s intellectual property lawyer‘ (2005) Intellectual Property Quarterly, 
p.225-235, p.227. 
138 Kang Y. H. ‗An exploration into law and narratives: The case of intellectual property law of 
biotechnology‘ (2006) Law Critique, p. 239-265, p.257. The use of historical evidence in making 
persuasive arguments at adversarial settings or trials at the expense of historical scholarly standards and 
methodologies is identified as one source of the controversy and difficulty in the use of history in the 
interpretation of law which can lead the courts to ‗erroneous but authoritative interpretation of 
historical fact‘:  Festa M. ‗Applying a usable past: The use of history in law‘ (2008) Seton Law Hall 
Review, p.479-553,  p.538. 
139 Phillips J. ‗Why legal history matters‘ (2010) Victoria University Wellington Law Review, p.293-
316, p.313-314. Levi G. ‗On microhistory‘, in Burke P.(ed.) New Perspectives on Historical Writing 
(1991) Cambridge: Polity Press, p.96, regards micro-history as ‗the starting-point for a broader move 
towards generalization.‘ 
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The historical model-building exercise when unchecked has the tendency to be 
subjective.
140
 In such a situation, it could be suspected that historical accounts from 
the viewpoints of historians in advanced nations would, needlessly, tend to be 
contextually-deficient on undesirable past moments in colonial patent development; a 
patriotic inclination of sorts.
141
 As a counter-measure, the legal historical narratives of 
European scholars have been challenged through the broadening of ‗the history of 
global order to encompass inter-imperial politics, including legal relations of imperial 
power and indigenous subjects.‘142 For a more balanced and objective historical 
perspective, there is the need to engage the views of legal historians acquainted with 
the patent systems that were on the receiving end of a non-ideal colonial legal order. 
 
The objective and the subjective elements of the legal historical methodology are 
susceptible of being superimposed upon one another. This would largely emanate 
from the purpose and the subsequent fashion in which the research is carried out. The 
outcomes of historical research and legal research are different as legal ‗practitioners 
are not usually trained to conduct historical research. The skills that are developed at 
law school and in practice focus upon the success for the client and not methods or 
techniques of historical research‘,143 such that objective and balanced policy 
formulation from such historical research when used in non-versarial circumstances 
would likely to be of limited value. This can result in the accumulation of unhelpful 
historical data of a subjective nature.
144
 These superfluous tendencies are further 
compounded by the fact that there is a propensity for legal researchers to cite large 
amounts of historical data without distilling deductions or inferences relevant to 
                                                             
140 Melton, fn.125, p.424. Also, http://www.open2.net/historyandthearts/history/disagree.html.  
141 For instance, European lawyers‘ accounts described legal order in colonies as settled, for example, 
that the British reserved the right to dictate and intervene in legal affairs, when in fact, there were still 
sources of conflict for imperial legislative administration or the viability of imposing imperial 
constitutions, inter alia in southern Africa. See generally, Benton L. ‗From international law to 
imperial constitutions: The problem of quasi-sovereignty, 1870-1900‘ (2008) Law and History Review, 
p.595-619. Also see, generally, Rahmatian A. ‗Neo-colonial aspects of global intellectual property‘ 
(2009) Journal of World Intellectual Property, p.40-74. 
142 Benton, fn.141, p.595. 
143 Bourgeois D. ‗Role of the historian in the litigation process‘ (1986) Canadian Historical Review, p. 
195-205, p.197. 
144 Scholars state that ‗the court must exercise caution in its reliance on scholarship cited by appellant 
and appellee. While that could be said about almost anything the parties submit to the court, there can 
be a certain disarming veneer of objectivity-or credibility-accompanying pragmatic scholarship‘: Nard 
C.A. ‗Toward a cautious approach to obeisance: The role of scholarship in Federal Circuit patent law 
jurisprudence‘ (2002) Houston Law Review, p.667-692, p.686. 
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contemporary issues.
145
 The pharmaceutical patent is sometimes cited in unfavourable 
light within a large body of historical patent custom without the necessary 
connections to an objective benchmark. 
 
When the history of patentability standards is not properly applied, it can lead to the 
mere academic accumulation of unchecked and unrefined information that is not 
helpful to current and future patentability issues.
146
 For instance, justifications that 
were in existence in one jurisdiction thorough statutory grounding may not 
necessarily be applicable in another. More precariously, as it has been observed that 
‗legal educators did not train students in critical skills of historical analysis‘,147 it can 
stifle the development of IP law wherein patentability stakeholders try to fit patenting 
development into a rigid historical model. For example, if an obscure classical 
justification comes to the fore in patent debates, it may be rejected offhand whilst it 
may unlock some solutions in the contemporary patentability landscape. Therefore, 
while such historical data has a possibility of being useful, its use is optimal when its 
consequence or impact is clarified,
148
 especially in such a comparative study of 
jurisdictions in different developmental stages, both in law and in economics. 
 
The pharmaceutical industry in one perspective has seen gradual change over the 
decades, even though there have been periods of exponential growth and radical 
inventions.
149
 Observers have noted how even the radical changes in technology in 
this sector has been comfortably absorbed by the successful firms.
150
 As such, the 
                                                             
145 Macleod C., Tann J., Andrew J. and Stein J. ‗Evaluating inventive activity: the cost of nineteenth-
century UK patents and the fallibility of renewal data‘ (2003) Economic History Review, p.537-562. 
Sometimes legal scholarship may be of limited value to the bar or the bench, and if relevance to 
practice is not clarified ‗academic criticism of the courts is likely to be ineffectual‘: Nard C.A. 
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Wake Forest Law Review, p.348-368, p.348. 
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147 Kirkby D. ‗Law[yer]‘s history, conversationally speaking‘ (2003) Australian Journal of Legal 
History, p.47-52, p.48. 
148 Phillips/Simon, fn.137, p.234. 
149 Lee J. ‗Innovation and strategic divergence: An Empirical study of the U.S. pharmaceutical industry 
from 1920 to 1960‘ (2003) Management Science, p.143-159. The industry products have evolved 
slowly even though the operations strategies have significantly changed, especially into R&D for the 
successful firms. Some commentators assert that the exponential growth in technological development 
may be approaching either its economic limit or physical limit after which the rate of invention and 
innovation on technology development will diminish: Huebner J. ‗A possible declining trend for 
worldwide innovation‘ (2005) Technological Forecasting and Social Change p.980–986. 
150 McKelvey M.D. ‗Discontinues in genetic engineering for pharmaceuticals? Firms jumps and lock-in 
in system innovation (1996) Technology Analysis and Strategic Management, p.107-116. 
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propositions made throughout this thesis are founded on the dynamic and 
evolutionary nature of the patentability standards corresponding to this type of 
change. For this type of research, the function of historical analysis is manifest.
151
 On 
the other hand, some politically or economically charged historical debates may be 
masquerading as legal roots of patentability requirements,
152
 whilst in fact, may not 
have that much relevance in this study. Thus, there is a need to be careful when 
deducting the relevance of the statutory milestones in the development of patentability 
standards. 
 
In the exploration of history, the presumption that contemporary IP law and 
patentability assessment methods have been influenced by historical development is 
made.
153
 However, scholars have stated that ‗[n]o two instances are exactly alike; they 
are never sufficiently identical for us to say that what was best on one occasion will 
also be best on another.‘154 Therefore as a limitation, the history of patentability 
requirements and the lessons it offers are not assumed to be automatically transferable 
without qualification to a different time period or different jurisdiction. As such, 
caution is exercised when making English inferences to South Africa. This is more 
pronounced in pharmaceutical industries where there were different competition rules, 
price controls, and different investor environments at play in the different localities.
155
 
 
Furthermore, although history is by and large descriptive, it is contended that despite 
its limitations when properly utilised it can also be prescriptive.
156
 It is in this context 
then, that reference and reliance on other jurisdictions not in focus in this thesis can be 
introduced to develop the ideal patentability model sought, if they underwent similar 
circumstances or applied similar patentability standards. The courts in different 
                                                             
151 Phillips/Simon, fn.137, p.229. 
152 See generally Aldashev G. ‗Legal institutions, political economy, and development‘ (2009) Oxford 
Review of Economic Policy, p.257-270, arguing that the proper understanding of the legal determinants 
of a legal system must be accompanied by the integration of the historical, political and other factors as 
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153 Kang Y. H. ‗An exploration into law and narratives: The case of intellectual property law of 
biotechnology‘ (2006) Law Critique, p.239-265, p.258. Also, Phillips/Simon, fn.137, p.228. 
154 Hegel G.W.F (translated by H B Nisbet B.H.) Lectures on the Philosophy of World History: 
Introduction: Reason in history (1975) Cambridge: Cambridge University Press, p.21. 
155 Ginburg, fn.46. Djolov G.G. ‗Patents, price controls and pharmaceuticals: Considerations from 
political economy (2005) The Journal of World Intellectual Property, p.611-63. 
156 Phillips/Simon, fn.137, p.229. 
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jurisdictions are accustomed to considering each other‘s previous decisions, even 
though they may not necessarily follow them.
157
  
 
The postulation that history is authoritarian to future ideal patent law developments is 
not absolute.
158
 Indeed, commentators have observed that empirical analysis of 
originally efficient laws that are then prescribed for emerging jurisdictions suggests 
that sometimes there is subsequently no significant correlation between the legal 
protection afforded by prescribed statutes and the effectiveness of enforcement of 
those statutes.
159
 This is due to the ‗transplant effect‘ whereby countries inherit model 
laws developed in another jurisdiction, which are unsuited to their environment.
160
 It 
is for this reason that observers
161
 are supported in their assertion that the developing 
countries should carefully choose only the elements that are helpful to them when 
they study the development of advanced nations‘ patent systems. 
 
In using the historical method, the question that then arises is to what degree the 
application of historical methodology has influence over patentability standards in an 
era subject to regional and international obligations. That is to highlight that 
individual countries can no longer exist in isolation and are not immune to external 
influence, particularly because the pharmaceutical enterprise is largely global. To 
avoid being overambitious, this thesis does not assume that all elements of 
patentability standards are susceptible to the application of historical methodology. 
Statute-making has other considerations that may override the historical lessons from 
                                                             
157 Mak E. ‗Why do Dutch and UK judges cite foreign law?‘ (2011) Cambridge Law Journal, p.420-
450. 
158 Liu D. ‗Reflections on the lack of a patent system throughout China‘s long history ‗ (2009) The 
Journal of World Intellectual Property, p.122-136, p.123. It has been noted that in the early stages in 
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160 Ibid, p.164-165. 
161 Maskus K.E. and Reichman J.H. ‗The globalization of private knowledge goods and the 
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Secretary of State for International Development has urged developing countries to carefully consider 
the impact of internationalization on patentability issues on their localities: Hansard  written answers 
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the international arena or foreign jurisdictions.
162
 Moreover, the political process of 
promulgating laws can result in unexpected outcomes. However, the historical method 
is not to be abandoned just because there are now international obligations and 
compromises in international patent law-making or the local hurdles.
163
 
 
A delicate issue that arises in the historical analysis inference reasoning used for 
patentability standards of different jurisdictions in different eras is the impact of the 
differing socioeconomic settings.
164
 The reality is that contemporary South Africa has 
different obligations and practices to that which the UK had during its development 
stages. The dictates of today‘s patent laws are centred much on international 
consensus and trade-offs in exchange for participation in international trade. The 
conception of the British patent system was in the era of colonialism when activities 
were mainly for the benefit of the Crown. The British and the industrialised 
economies were free to develop their laws as they saw fit and for the development of 
their economies.
165
 The colonies were seen as extensions of the empire and the laws 
not particularly designed for their benefit. It has been noted that even though some 
colonies resisted the patent laws that they perceived as only of benefit to the UK 
businesses, the resultant laws they made themselves in turn resembled the UK laws.
166
 
The issue that cannot be addressed with absolute certainty therefore is the extent to 
which the different contemporary obligations that South Africa has a distortion of our 
historical analysis and conclusions.
167
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 Drewry G. ‗Law-making systems– how to compare‘ (2008) Statute Law Review, p. 100-110, p.105-
107. 
163 De Vos P. ‗A bridge too far? History as context in the interpretation of the South African 
constitution‘ (2001) South African Journal on Human Rights, p.1-31: asserts that although the use of 
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There is the view that developing countries could be allowed greater freedom in 
developing their patent laws.
168
 This compensation mechanism would be for the fact 
that Britain, together with the other advanced nations, historically had no external 
rules to contend with compared to what is are now expected of developing nations. 
The difficulties in such compromises would lie in the way this could be achieved or 
implemented practically. To achieve the lessening of international patent obligations, 
an ingenious strategy by the developing countries has been to shift the patent 
governance regimes to forums and platforms where they have dominant power to 
advance the liberalisation of external encumbrances in patentability.
169
 In any case, 
insofar as to the comparison of the past experiences of free developed countries with 
the present needs of bound developing countries, there is some degree of contrasting 
two different situations which the thesis is mindful of.
170
 While using the historical 
method and historical concepts, there has to be vigilance in making inferences to 
differing jurisdictions. Thus it can be concluded that researchers and scholars should 
take care before applying history and the methodology of history to present and future 
patentability issues. 
 
 
2.3 Historical development of the patent 
 
Commentators have said that ‗[p]erhaps the most obvious issue that has promoted 
historical comparisons is the link between the protection of IP and development.‘171 
The UK is in many respects well developed and it has a longer patent history than 
South Africa. In addition it was a colonial ruler of South Africa, which has 
connotations of power and prosperity. This may be indicative of legislative 
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differences that would be expected in a comparative study between the two 
jurisdictions in such a position. However, this difference does not detract from the 
historical comparison of the two jurisdictions.
172
 
 
The end goal is not to force similarities whilst overlooking the difference in the two 
systems. Attention now turns to historical elements that influenced the development 
of patentability limbs, within the context of progress and development, in each of 
these two countries‘ own rights.  
 
 
2.3.1 The historical development of the British patent  
 
‗The law of patents…has a surprisingly long history.‘173  Although, patents are one of 
the old creations of law, their considered economic analysis is a relatively modern 
phenomenon that has considerably progressed and transposed into policies and 
backbones affecting every facet of the patent framework.
174
 It is largely agreed that 
the patent system is a contributory catalyst for invention and technological 
development.
175
 However, much of the historical justification of the system is based 
on a retrospective perspective through re-assessment of the historical record and 
economic rationale that may have been absent at the conception of the system. The 
thesis now traces the British evolution of the requirements of patentability from its 
embryonic stages to the powerful legal and largely economic tool that it is today. 
 
The exact establishment of patenting laws almost eludes written record.
176
 Prior to the 
establishment of IP laws in Europe, rulers usually used grants for the exclusive 
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Örücü E. and Nelken D. Comparative law: A handbook (2007) Worcester Place: Hart Publishing, 
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importation and exploitation of previously unknown arts in their domain.
177
 The first 
recorded use of such monopoly was in the granting letters patent
178
 in 1311 to John 
Kempe, a Flemish weaver who wanted to pursue his trade in England.
179
 By 1326 the 
British monarch had been encouraging the importation of ‗new arts‘ into the kingdom. 
It is claimed, this is the earliest period that royal protection was given to individuals, 
especially foreigners, for the exploitation of foreign arts.
180
 The practice continued 
with for example ‗letters patent granted in 1440 to John Shiedame to introduce into 
England a newly-invented process of manufacturing salt.‘181 
 
The consideration for such protection, given the social and industrial settings then, 
was that the importers would instruct and teach natives in the trade or guilds such that 
at the expiration of the protection they would freely practice and expand the trade.
182
 
This is why the early protection, the so-called quasi patents, was attributed with the 
migration of foreign skilled labour into Britain.
183
 It is observed that this form of 
protection was used by the Crown more as political control of trade rather than the 
utilitarian justifications that exist today for the maintenance of the patenting 
system.
184
 The grant of protection was based on the relationship between the 
petitioner and the authorities rather than the invention fulfilling an objective 
predetermined criteria.
185
 Some authors view this as the state‘s way of promoting the 
public interest,
186
 although it clearly infringes the private interest of the creator of the 
art. 
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The practice was first given statutory force outside of Britain on 19 March 1474, by 
the Venetian Patent Act of 1474.
187
 Previously, the grants were awarded for new arts 
introduced into Britain but there was no absolute requirement for invention,
188
 or that 
the petitioner should be the originator of the practice.
189
 Some scholars suggest that 
this Venetian Act was to later influence statutory patentability requirement in Britain 
as it introduced the concept of novelty and non-obviousness in Britain.
190
 Other 
commentators do not accept such views arguing that ‗[t]here is scarcely any evidence 
that the Venetians knew about their patent legislation and little to suggest that it 
influenced any legislative or commercial developments elsewhere.‘191  
 
In 1559, the Italian Jacobus (Giacopo) Acontius was the first inventor to receive a 
patent from Elizabeth I exclusively for invention,
192
 although this practice was the 
exception rather than the norm. What is interesting is that in his petition for protection 
he evoked the private argument for protection against copying of his invention as 
promoting the public interest.
193
 This is a standpoint that is adopted in this thesis. The 
optimal balance in setting patentability standards has to be based on the individual 
being granted sufficient protection balanced against undue encroachment on the 
public sphere. 
 
Elizabeth I used her political power to grant patriots privileges in industry that were 
considered unfair to the other industry players of the time.
194
 Although she 
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commanded respect that made parliament disregard these privileges and abuse of the 
royal prerogative, she was eventually pressured to issuing the Proclamation 
concerning Monopolies of 1601.
195
 This instrument mainly sought to reform these 
grants which were causing public misgivings as by then some were to practices that 
were already practiced in the kingdom.
196
 She retained powers to issue grants but they 
were subjected to judicial review when there were disputes. For example, in Darcy v 
Allin
197
 it was decided that the monopolies granted by the Crown for inventions that 
were already known in the kingdom were illegal and contrary to the common law. 
 
James I was not so discreet in granting his political creditors letters of patent for 
monopolies in trade.
198
 Parliament sought to restrain this royal prerogative as invalid 
by promulgating the 1624 Statute of Monopolies.
199
 It declared inter alia that grants 
of privileges and favours were void and of no effect with the exception of those for 
the working or making of new manufactures in the United Kingdom.
200
 In other words 
the Statute of Monopolies ‗had declared that legitimate patents of invention were not 
to be condemned as abuses of Crown prerogative.‘201  
 
The Statute of Monopolies particularly declared that inventions shall be granted to the 
first and true inventor.
202
 However, Hulme
203
 concludes that this statutory 
promulgation was nothing more than the declaration of common law on patentability 
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that was existing this far. He does this by considering that, then, the phraseology to 
invent also meant to be the first to bring into use, so the statute‘s first to invent 
included importers of the arts. ‗The invention, i.e. the exercise of the inventive 
faculty; was not an essential qualification - institution of the manufacture, from 
whatever source derived, was a valid consideration of the patent grant under the 
statute.‘204 Therefore the first and true inventor here is not referring exclusively to 
inventive activities. 
 
Section 6 of the Statute of Monopolies defined the patentable invention as: 
 
‗the sole working or making of any manner of manufactures within this 
Realm……which others at the time of the making of the such Letters Patents 
and Grants shall not use, so as also they be not contrary to the Law, nor 
mischievous to the State, by raising prices of commodities at home, or hurt of 
trade, or generally inconvenient.‘ 
 
An element of this definition is that the working or use of the invention which 
qualified for protection must be within the United Kingdom. In other words that 
definition prescribed local use of the invention as a major patentability standard.
205
 
The theme of local use survived up to the 1949 Patents Act where inventions would 
be protected as long as the patentee intended to ‗make, use, exercise and vent the said 
invention….and to the end that the patentee may have and enjoy the sole use and 
exercises and full benefit of the said invention.‘206 This statute was not concerned 
with protecting foreign inventors or their creations if they were not to be directly used 
in Britain. 
 
Simultaneously in this definition, novelty as a patentability requirement was only 
limited and tied to the existence of the said invention in the United Kingdom.
207
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Therefore foreign prior art had no bearing on UK patentability. Technologies that 
existed and were largely known abroad were patentable when imported to the United 
Kingdom.
208
 Commentators observe that ‗rather, there was an obligation on the 
patentee, expressed as a condition of the patent grant, to introduce and to work the 
invention in England.‘209 Some even observe that in common law decisions before 
this statute, the applicant must have taken steps to introduce the art into British 
industry.
210
 This custom then, not only seems like an economic model that promotes 
local industry empowerment, importation and assimilation of technology,
211
 but 
would now be viewed also as a kind of legalised piracy promoted by patent grants. 
The exploitation of foreign inventions, probably owned by someone else, shows how 
lax a standard the UK had in its formative years in order to attain patentability. For 
example, in 1667 Howard and Watson Patent, No. 154,
212
 an amendment extending 
the patent scope was allowed even though there was evidence that the invention 
existed abroad. It was declared that the invention was ‗a new manufacture, and the 
patentee the true and first inventors thereof, and that it was profitable to the Kingdom, 
and the privilege granted was a just and legal privilege fit to be cherished and 
preserved.‘  
 
This is in stark contrast with the principle of absolute novelty that now exist in the UK 
and also in South Africa where the monopoly is granted dependent on the newness of 
the invention regardless of place of its creation.
213
 The advantage of this custom to 
Britain then, was that the local industry flourished as it absorbed foreign technology. 
It is upon this ground that it could be argued that developing countries should not be 
rushing to develop higher patentability standards if the plan is to advance local 
industries with having low patentability standards in place, as was demonstrated by 
Britain.
214
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The patent gradually developed from being mere privileges, although the grants 
remained discretionary.
215
  It is not clear as to when the lodging of the patent had to 
include a specification.
216
 By 1663 patents were still being filed without a description; 
in 1663-4 Garill‟s Applications,217 the petitioner refused to reveal his secret to the 
King and Council unless his patent was first sealed. In 1670 a Private Act was enacted 
that required the patentee to enter a description of their invention at the Court of 
Exchequer, although this was for the amendment of the patent a Private Act of which 
was previously rejected by the Commons in 1660.
218
  
 
Kingston states that ‗beginning in 1712-1713 in England, patent applications have 
included a written description of an invention which should enable someone who is 
―skilled in the relevant art‖ to replicate it.‘219 One of the earlier cases where the 
specification was in issue was in R v Arkwright,
220
 and is indicative of a long 
existence of the specification custom, where Buller J. stated that: 
 
‗It is clearly settled at law that a man, to entitle himself to the benefit of a 
patent for a monopoly, must disclose his secret, and specify his invention in 
such a way that others may be taught by it to do the thing for which the patent 
is granted; for the end and meaning of the specification is, to teach the public, 
after the term for which the patent is granted, what the art is, and it must put 
the public in possession of the secret, in as simple and beneficial a way as the 
patentee himself uses it. This I take to be clear law, as far as it respects the 
specification.‘ 
 
The specification is the basis of the justification of patentability standards as a public 
education tool, even though such specifications intended to disseminate technology to 
the public were very brief historically. A noteworthy boundary was that it should not 
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mislead. In R v Arkwright, a patent at issue containing extra integers and claims, the 
court said ‗if those are of no use but are to be thrown merely to puzzle, I have no 
difficulty to say, upon that ground alone the patent is void…. If four only were 
necessary instead of ten, the specification does not contain a good account of the 
invention.‘221 The common practice then was that the patentee after grant would teach 
apprentices what is taught by the patent throughout its term. As such there was no 
particular emphasis on the specification as the master would generally impart the art 
and skill on his students practically.  
 
A major patent statutory development after the Statues of Monopolies was in the form 
of the immensely debated Patent Law Amendment Act 1852.
222
 From case law of this 
period, one could glean that the trend that was to follow is more or less similar in 
nature to the requirements of genuinely new inventions that have some usefulness. 
This was seen for instance in Holmes v London & NW Rly Co,
223
 where Jervis, C.J. 
said ‗the object of the condition in the patent requiring a specification is twofold; first 
that useful novelties should be given to the public…‘. Novelty and usefulness were 
already being envisaged by the courts. The need for useful inventions in the patent 
system was expressed but not immediately thereafter realized by the enquiry into the 
operation of the patent system which observed that some patents are ‗practically 
useless, and are employed by patentees only to embarrass rival manufacturers.‘224 
 
The concern for examination of patent application as expressed in the reform 
commission was not addressed.
225
 As there continued to be no examination of patent 
applications, so did disputable patents continue to be registered
226
 especially if they 
existed abroad. In the same era in 1883 the Paris Union
227
 was being formed for the 
reciprocation of protection amongst member states. The patentability standards were 
largely raised through this Union as in theory it prevented the grant of parallel patents 
in member countries through the securing and recognition of foreign priority in local 
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patent applications. In other words this curtailed the ‗workings definition‘ of the 
patentability standard that was generally accepted from the Statutes of Monopolies. 
 
From 1864 to 1872, there was another thorough inquiry into the patent system.
228
 
Afterwards, broad legislation was enacted in the Patents, Designs and Trademarks Act 
1883 (1883 Act) which required for the first time that the patent specification should 
contain claims defining the scope of the monopoly sought by the individual.
229
 It has 
been observed that this requirement was accepted gradually by the judiciary.
230
 
 
The 1883 Act also provided for applications to be deposited to the examiners in the 
Patent Office.
231
 The examiners‘ obligation was to report on whether the 
accompanying specifications contained fair description of the invention.
232
 This was 
not substantive novelty examination. The 1883 statutory tool was, to a certain extent, 
used for judging whether the monopoly granted was appropriate for the invention 
made and did not prevent other local merchants from practising the trade they were 
already involved in.
233
 This evolution in patentability standards shows that economic 
necessities, as opposed to the initial crown control, were now the driving force for 
sustaining the patent system after these much debated legislative reforms.
234
  
 
This 1883 Act purported to protect genuine inventions: ‗An application must contain a 
declaration to the effect that the applicant is in possession of an invention, whereof 
he…claims or claim to be the true and first inventor…‘.235 The reasoning now was 
that ‗he is not called the inventor he who has in his closet invented it, but does not 
communicate it; the first person who discloses that invention to the public is 
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considered as the inventor.‘236 This therefore prevented what Lawson237 asserted then, 
which is that the phrase ‗true and first inventor‘ as including the first importer besides 
the actual inventor is by what has been described as ‗a sort of anomalous decision 
which has acquired by time and recognition the force of law.‘ 
 
An Act to consolidate the enactments relating to Patents for Inventions and the 
Registration of Designs and certain enactments relating to Trade Marks (so far as it 
relates to patents) was promulgated on 28 August 1907. Section 7(1) required novelty 
examination against descriptions in the UK patent records in the previous fifty years. 
That is to say that the novelty patentability standard was of limited term and was 
directed to internal prior art. 
 
Legislative developments culminated in the Patents Act 1949 under which limited 
anticipation in a patent application was still only examined up to the previous fifty 
years.
238
 The 1949 Act provided for the revocation of patents that were considered 
obvious and not useful.
239
 The 1949 Act has been replaced by the current Patents Act 
1977, which was designed to take into consideration the EPC and will be the primary 
statute under study in this thesis.  
 
 
Summary 
 
‗Clearly, when English Kings….granted patents to those who imported innovations 
that had been developed abroad they were not much concerned about the ―natural 
rights‖ of the foreign inventor.‘240 The historical examination shows a metamorphosis 
of the patent system from mere privileges and internal control of subjects and 
activities to being a tool accentuating inventions. Kingston states it this way: 
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‗The modern patent system with its quite different emphasis, is a creation of 
the nineteenth century. Because of its intellectual origins in the natural rights 
thinking ….it protects inventors—―those who find new things‖-in contrast to 
the earlier system, which protected innovators- ―those who get new things 
done‖.‘241 
That is to say the earlier system was more concerned with practical application of the 
inventions or refusing grants for abstract ideas that have not been applied practically 
rather than seeking to identify the deserving inventor. 
 
2.3.2 The historical development of the South African patent 
 
The formation of the Republic of South Africa has a long, somewhat convoluted 
history.
242
 This thesis does not attempt to concern itself with much of this history.
243
 
However, the historical excursion begins from where patent laws first appeared. It 
suffices to state there were four provinces, that were self-governing and also colonies 
of one imperial ruler or another at different times in their history. Hence, there are 
four legislative regions that however, have become of lesser significance than 
formerly with the advent of the new Constitution.
244
 Moreover, the current Patents 
Act 1978 transcends the divisions in provincial jurisdiction that still exist in some 
areas of law, and takes on a national jurisdiction.
245
 
 
The colonies that formed South Africa are the Cape and Natal colonies, considered 
purely British colonies, and the former Boer Republics Transvaal and Orange Free 
State (OFS).  The Cape was a British colony from 1806 and Natal formally annexed 
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in 1843 and became a separate colony in 1847. The OFS was declared by the Cape 
Governor and High Commissioner to be under British rule in 1848, later to be 
withdrawn in 1854. After the war in 1902, it became a British colony. The Transvaal, 
a South African Republic then, was annexed by the British in 1877 and liberated only 
to become a British colony again in 1902, after the war generally known as the Boer 
war and to the Afrikaner more as the Second War of Independence. The South Africa 
Act, 1909, created the Union of South Africa by uniting the four colonies to be 
headed by a British Governor-General and later granted independence in 1931 by the 
Statute of Westminster. 
 
The seemingly somewhat arbitrary historical presentation is not at odds, or to deny the 
premise in this thesis that legal development should and/or does reflect the socio-
economic environment. The repeated annexing and wars, brought about by inter alia 
political and social factors, occurred when this region was largely uninformed on the 
patent system or its utility. Patents were relatively merely imported into statutory 
books by imperial agents, with no significant application in local industry. The 
technical impetus to use the system then was also lacking. On another level, the long 
history of Roman-Dutch law, which was introduced before the English settlers and 
makes the South African system pluralist, offers only little insight into the operation 
of patents and is of limited use when applied to patents than in other areas of law.
246
 
Customary law, which runs parallel with the hybrid system, is also of no relevance to 
the study of patents.
247
 Therefore the history of patent law as informed by 
socioeconomic activities can begin around or after this era when the British 
introduced patent law.
248
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Early patent laws in South Africa were framed upon those of the United Kingdom.
249
 
For example, the Cape Parliament promulgated Act 17 of 1860, which was strongly 
fashioned after the UK‘s Patent Law Amendment Act 1852. The other British 
colonies that would later make up the Republic of South Africa would later adopt 
their own laws that closely followed the Cape Act,
250
 invariably all following UK 
statutory trend. Law 4 of 1870 was the first statute in Natal to deal with patents. In the 
Transvaal Province, Law 10 of 1887 was the first law to be promulgated that dealt 
with patents. 
 
Importantly, the Cape 1860 Act was directed at giving patent protection to encourage 
useful invention. To emphasise this, the preamble of the 1860 Act stated that ‗it is 
expedient that the making new and useful inventions should be encouraged by 
securing to their inventors for a limited time the exclusive enjoyment thereof.‘ South 
Africa emphasised rewarding inventors for inventive activities that resulted in new 
and useful inventions released to the public. This is opposite to the British statute 
which was not specifically clear on the underlying philosophy and purpose for 
securing patents. Only in case law are there pronunciations to this purpose. Notably 
therefore, the South Africa invoked the progress of the arts in its statutes as an 
inspiration for the patent system much earlier on in its development than the UK. 
 
Furthermore, what is omitted from this UK derivative statute is the ‗workings‘ clause 
that was key to the operation of the Statute of Monopolies. The UK statute covered 
situations both for the working and making of inventions while the South African 
view was directed only at the making of inventions. The workings clause covered 
situations where the ‗communicator‘ of foreign inventions imported and worked them 
in the UK without some inventing, whereas in South Africa ‗the object of the patent 
laws (was) to benefit the first inventor and only the first inventor‘251 in its literal sense 
as understood today. 
 
                                                             
249 Burrell T.D. South African patent law (1982) University of Witwatersrand: Unpublished thesis, p. 5. 
[hereafter, Burrell Thesis]. 
250 Slabbert C. Non-obviousness as a requirement for patentability South Africa and in the United 
States of America- A comparative study (1979) University of the Witwatersrand: Unpublished PhD 
thesis, p.45. Also, Burrell Thesis, p.6. 
251 Veasey v Denver Rockdrill and Machinery Co. Ltd. 1930 AD 243, p.270. 
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There was also a clause similar in the initial patent laws of the South African colonies 
to the effect that an invention is not a new invention if there is public use and exercise 
thereof. For example, Section 29(c) of Law No. 6, 1887 of Transvaal prevented a 
patent being granted or if granted be revoked if ‗the invention was not new, i.e. it was 
already published or applied in the State before the insurance of the letters patents.‘252 
It is suggested in this thesis that the newness requirement applying only against prior 
art patents in the local state was influenced by the colonial British administrators‘ 
desire for less burdensome novelty assessment rather than the intention to exploit 
foreign inventions as was the case within initial UK settings. A writer
253
 illustrates an 
instance where in 1862, the British Governor in Ghana, requiring assistance in the 
promulgation of patent legislation in the colony from the Secretary of State for 
Colonies in London, in consultation with the Controller-General of Patents, was given 
a copy of legislation of another colony modelled on existing British patent legislation 
to implement. The only change was that it no longer had the requirement that a person 
shall not receive a patent for an invention which had previously been patented ‗in 
Britain or any other country‘ as, according to the Controller-General the cost of 
official novelty searches and administrative problems prevented any similar 
legislation in the colonies from being approved in Britain. 
 
There was then a shift from local novelty into global novelty. Transvaal Law No. 12, 
1897
254
 defined novelty without reference to where the invention was made or locality 
of the prior art. This trend was further developed by Proclamation No. 22 of 1902 
which stated that an:  
 
„invention means any new and useful art, process, machine manufacture or 
composition of matter or any new and useful improvement thereof capable of 
being used or applied in trade or industry and not known or used by others in 
this Colony and not patented or described in any printed publication in this 
Colony or any foreign country for more than two years prior to such 
application...‘255  
                                                             
252 Similar to Orange Free State Patent Act of 1891, Section 29 (c). 
253 Sipa-Adjah Yankey G. International patents and technology transfer to less developed countries: 
The case Ghana and Nigeria (1987) Hants: Gower Publishing Company Limited, p.99-102. 
254 Transvaal Law that superseded Law No. 6, 1887. 
255 Proclamation No. 22 of 1902, section 5. 
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The concept of statutory ‗local novelty‘ was thus abandoned earlier on in South 
Africa (Law No. 12, 1897) than in the UK where it was only abolished in 1977.
256
 
 
The purpose South Africa was issuing patents was more apparent in the earlier 
statutes and was linked to the prerequisite patentability standards being imposed. The 
1902 OFS Patent Law stated that: 
 
„Any person who makes a new invention, capable of being exploited in 
industry, shall have the exclusive right to exploit such invention to his own 
advantage for such a term and under such conditions as shall hereafter be 
determined.‟257 
That is, the patent was issued for new inventions that are capable of industrial 
application and this was balanced against the monopoly for the inventor. The 
approach to novelty therefore seems to have been a combination of administrative 
convenience of the system and the need to use the system to encourage novel 
industrial activity. 
 
A further condition for patentability that was emphasised within the colonies at the 
outset of the system was that the inventor had to be ‗the first and true inventor‘258 
indeed. This is a major difference between the UK and South African early 
patentability requirements. The UK would grant patents to importers of inventions 
and mainly concerned itself about use within their territories while South Africa 
offered protection to inventors in the true sense of the word.
259
 In this phrase the 
inventor was an individual entitled to the invention.  
 
After the 1910 Union of the colonies, the patent laws were consolidated into the 
Patents, Designs, Trademarks and Copyright Act 9 of 1916. This law was also based 
                                                             
256 Grubb P.W. Patents for chemicals, pharmaceuticals and biotechnology: Fundamentals of global law, 
practice and strategy (2004) Oxford: Oxford University Press, at p. 58. According to Patents Act 1949, 
s32(e) an invention was revoked for lack of novelty if it was ‗not new having regard to what was 
known or used, before the priority date of the claim, in the United Kingdom.‘ 
257 1902 OFS Patent Law in Law Book, CXXII, section 1. 
258 For example the Fifth Schedules of the Cape Act 17 of 1860 and Natal Law no. 4 of 1870. 
259 Steyn J.R. The significance in South African patent law of the claims in a patent specification 
(1974) Unisa: Unpublished LLD Thesis, p.14. 
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on the UK‘s patent law, Patents Act of 1907.260 Act 9 of 1916 was repealed by the 
Patent Act 37 of 1952 (it too was based on the British Act of 1949), which was in turn 
was repealed by the current Patent Act 57 of 1978.  
 
The 1916 Act continued to emphasise novelty as a pre-requisite for grant of the 
patent. Section 6 expressly excluded communicators of the invention from grant of 
the patent. It states that the ‗―inventor‖ shall not include a person importing an 
invention from abroad.‘ Carnes v Maeder261 reiterated that a mere importer cannot be 
the first and true inventor in South African law. The major laws that subsequently 
developed in South Africa are the Patents Act of 1952 and the current Patents Act of 
1978 which form the bedrock of this research. 
 
Summary 
 
Under colonial rule South Africa inherited UK laws, a majority of which may not 
necessarily have, or intended to progress the local industry, more than protect imperial 
interests or convenience. However, an interesting result has been that since Britain 
was ‗foreign‘ it created laws that will protect the interests of other foreigners. Britain 
inevitably created and imposed a ‗national treatment‘ principle, which recognises 
foreigners equally for patenting purposes. As South Africa weaned from British 
administration it continued to create laws to benefit invention, without discrimination 
as to place of invention. These are some of the principles underpinning the system 
that may not have necessarily revealed faults under the day-to-day British 
administration of the system, but are issues that become significant and have impact 
when there are reforms to be made as the local conditions keep on changing.
262
 South 
Africa, after British rule, continued developing a system that incorporated the pillars 
of what constitutes a functional patent system that encouraged and protected 
inventions. This is not to detract advances made by the British in their own right 
within their local jurisdiction. 
 
 
                                                             
260 Burrell Thesis, p.8. 
261 1939 WLD 207, p.214. 
262 Generally Dent C. ‗An exploration of the principles, precepts and purposes that provide structure to 
the patent system‘ (2008) Intellectual Property Quarterly, p.456-477. 
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2.4 The emerging historical justifications of the patenting standards 
  
There are at least four models for justifying the patent system that could be extracted 
from this discussion of the historical development of patents in the two 
jurisdictions.
263
 They exerted different influences in the conception and evolution of 
the patent system into what is now regarded as the modern patent system. 
Commentators point out that any serious scholar of IP can no longer avoid in-depth 
analysis of the economics underlying the patent system,
264
 a focus into their economic 
dimension which was largely absent at their origins. That is to say the legal 
justifications of patents now integrate economic principles in the justification of the 
patent system.
265
 These justifications now underlie global trade
266
 where South Africa 
and the UK are generally on opposite ends in terms of the objectives and 
implementation of the patent system. 
 
Besides the economic considerations, these justifications also mainly revolve around 
the tension between private and public rights arguments.
267
 In pharmaceutical 
industries such tension is more pronounced. The inventors assert that the private right 
results in benefits accruing to the public. The public increasingly does not accept that 
individuals should have rights over inventions that are of benefit to public health.
268
 
The human rights perspective is increasingly being integrated into these 
                                                             
263 More justifications exist, for example patents as commercialization prospecting device or as 
different categorization than the one adopted here. For example, see Duffy J.F ‗Rethinkg the prospect 
theory of patents‘ (2004) University of Chicago Law Review, p.439 and also chapter 2 Spence M. 
Intellectual property (2007) London: Oxford University Press or Spence M. ‗Policy‘ in Roughton A, 
Cook T. and Spence M. (eds) Modern Law of Patents (2005) London: LexisNexis Butterworths, p.8-
13, categorising them into economic and ethical justifications, respectively directed to encouraging 
invention and efficient exploitation of technology and to the treatment of the inventor equitably in view 
of their creative works. 
264 Straus J. ‗Impact of the new world order on economic development: The role of the intellectual 
property rights system‘ (2007) European Review, p.47-63. 
265 May/Sell, fn.121, p.17. Lemley (Lemley M. ‗Ex ante versus ex post justifications for intellectual 
property‘ (2004) University of Chicago Law Review, p.129-149) warns of the conflation of ex ante and 
post ante justifications of IP, with the former fitting the operation of patent frameworks whilst the 
latter, are not suited with the patent regime, such as those explained by Bently and Sharman (Bently L. 
And Sharman B. Intellectual Property Law, 3rd edn (2008) Oxford: Oxford University Press, chapter 
14) concerned with the transformation of potentially valuable intangible artifacts into property rights to 
optimize use. 
266 May/Sell, fn.121, p.20. 
267 Spence, fn.263, p.63. 
268 Adusei, fn.56, p.46. 
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discussions.
269
 As such, the classical justifications have to be modelled on modern 
realities if they can be sustained. 
 
The thesis now turns to the examination of the individual justifications that develop 
from this historical analysis. They each received varying support and objection as a 
basis for the patent system. Despite the distinctions between the justifications, they 
may overlap in some contexts.
270
 The thesis argues that the individual justifications 
have vital roles to play in the attainment of optimal patentability standards. 
 
 
2.4.1 Patents as natural rights to property 
 
From the above historical account it is plausible to suggest that inspired by the need to 
move away from subjective grants, it was accepted that the patent grant determinant 
factor had to reside in an objective quality in the inventor or invention. This innate 
quality is one that could be applied consistently in all patent grants rather than the 
partiality that was occurring. It would be expected that there would have been the 
legislature‘s intervention in prescribing rules applicable equally to all knowledge 
producers ‗…a natural law, a non-arbitrary law grounded (if not ultimately grounded) 
in human nature‘ and ‗not a law based on ―utility‖, but it nonetheless serves the 
interests of all individuals.‘271 That is to advance the premise that positive patent 
statute-making must embrace the principles of natural law. 
   
According to George
272
 natural law or legal positivism are concepts that:  
 
                                                             
269 For instance commentators have noted that ‗what had been essentially policy-based objections 
against minimum standards for pharmaceuticals during the negotiations started to be coined in human 
rights terminology after the TRIPS Agreement came into force‘ based on its adverse impact on some 
human rights guaranteeing accessibility of medicines, but as a counter argument ‗more recently, other  
scholars have added that IP, too, is protected as a human right. Some have even ventured so far as to 
imply that the TRIPS Agreement itself is a human rights agreement.‘ Hestermeyer H. Human Rights 
and the WTO: The case of patents and access to medicines (2007) Oxford: Oxford University Press, 
p.76-78. 
270 Ogoamanam C. ‗Beyond theories: Intellectual property dynamics in the global knowledge economy‘ 
(2008) Wake Forest Intellectual Property Law Journal, p.104-154. 
271 Buckle S. Natural law and the theory of property: Grotius to Hume (1991) Oxford: Oxford 
University Press, p.146. 
272 George R.P. ‗Natural law, the constitution, and the theory and practice of judicial review‘, in 
George R.P. (ed) Natural law (2003) Hants: Dartmouth Publishing Company, p.309.  
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„have no stable meaning in contemporary legal, political and philosophical 
discourse. It is therefore incumbent upon scholars who participate in 
discussions in which these terms are employed to attend carefully to the 
different meanings assigned to them by different writers or by a given writer in 
different contexts. The price of carelessness in this regard is error and 
confusion.‟ 
 
For the purposes of this section it suffices to state that the interface between natural 
law and positivism is the view that the enactment and interpretation of positive law 
ideally ought to conform to natural law principles of human goods and moral 
requirements.
273
 The natural rights justification for the patenting system is viewed as 
introduced largely as a moral justification based upon the thesis that individuals have 
a natural property right in their original or inventive ideas.
274
 Therefore individuals 
have a right in the exclusive exploitation of these creations of their minds. It was 
contended that inventors or originators of scientific arts should have a natural right to 
their inventions in light of the labour to bring forth their inventions, the so-called 
Lockean Labour theory,
275
 under which we ‗prioritise creative labour.‘276 Their 
creations, therefore, gave rise to rights in property, albeit intangible, which non-
originators should respect.
277
  
 
The granted patents represented a natural private right conferred by the state to the 
patentee.
278
 As such the state was responsible for protecting those individual rights in 
common law. The creation of a patentable invention entails the granting of Crown 
privilege; privilege of use to the exclusion of others and privilege to exclude others 
from using it.
279
 Therefore the unauthorised or uncompensated exploitation of the 
                                                             
273 Ibid, p.62 states that ‗commentators assumed that all good positive law ‗grew out of‘ or were 
‗emanations‘ of the law of nature.‘ 
274 Van Caenegem, fn.123.  
275 Bainbridge, fn.179, p.270. 
276 Merges R.P. Justifying Intellectual Property (2011) Massachusetts: Harvard University Press, p.289. 
277 Generally, Moore A.D. ‗Intellectual property: Theory, privilege and pragmatism‘ (2003) Canadian 
Journal of Law and Jurisprudence, p.191-209. Cf. Sherman B. and Bently L. The making of modern 
intellectual property law: The British experience, 1760-1911 (1999) Cambridge: Oxford University 
Press, p.95-100, dispute this position suggesting instead that the recognition of mental labour is a more 
modern concept. 
278 Brennan D.J. ‗The evolution of the English patent claims as property definers‘ (2005) Intellectual 
Property Quarterly, p.361-399. 
279 MacCormick N. ‗On the very idea of intellectual property: an essay according to the institutionalist 
theory of law‘ (2002) Intellectual Property Quarterly, p.227-239, p.233-234. For example, UK Patent 
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ideas in the patents is a wrong to the individual. This justification however did not 
grow in popularity but it forms the basis of IP protection historically.
280
  
 
It is unsurprising that this justification did not readily garner support in Britain, as 
some inventions were imported from abroad.
281
 For instance, about half of witnesses 
before 1851 Select Committee thought it were expedient that patents should be 
granted to mere importers of foreign inventions.
282
 Cornish more pointedly calls this 
practice theft of ideas.
283
 As such, in the UK, it can be argued that it was not 
necessarily the inventive ingenuity of the individual that was recognised in granting 
some patents, as it was perhaps someone else‘s property that was patented or more 
appropriately, misappropriated. 
 
In European systems, especially in civilian systems, the natural rights justification 
was more readily accepted than in the UK. This may have had some influence on the 
UK though, as during statutory reform processes, the commissioners would enquire 
from witnesses what the practice was in other European counterparts, especially in 
France.
284
 The Venetian patent custom at around 1443 was said to be ‗recognising the 
right of  inventors‘ as ‗in European practice this term had connotations of ―basic 
right,‖ especially in times and places where ―basic rights,‖ are given serious 
consideration‘.285 The Venetian Act of 1474 desiring that ‗men of great genius, apt to 
                                                                                                                                                                              
Act 37 of 1952, s.32 conferred the right to use the invention, whilst the South African Patent Act 1978 
s45(1) confers the right to exclude other from using. Tracing the evolution of the patent custom, 
commentators have stated that ‗the patentee had complete control of the disposition of his invention. 
The basis(sic) of the patent system had altered completely, and the obligation to work the invention had 
been commuted into a duty to disclose its limits‘,  a shift from the right to use to the right to exclude: 
Getz L. ‗History of the patentee‘s obligations in Britain (1964) Journal of the Patent Office Society, 
p.62-81,  p.80. 
280 This justification is usually used in civilian systems and emphasizes the morality rights of the 
individual subsisting in the creation of new knowledge. Torremans, fn.189, p.23, calls it unfashionable 
justification. Milgate argues that although natural rights law was not the preoccupation of the English 
lawyer ‗[O]n the contrary, they seem to have accepted it as a component part of the laws of England. 
They did not regard it as an exotic import but rather as a legitimate source of English law‘, Milgate M. 
‗Human rights and natural law: From Bracton to Blackstone‘ (2006) Legal History, p.53-69, p.61. 
281 Cornish W. ‗Secrecy and the evolution of the early patent system‘, in Pyrmont W.P.W., Adelman 
M.J., Brauneis R., Drexl J. and Nack R. (eds) Patents and technological progress in a globalized 
world: Liber Amcorum Joseph Straus (2008) Berlin: Springer. 
282 In response to question nine of the Report of the 1851 Select Committee, ‗Do you think it is 
expedient that patent should be granted to importers of foreign inventions?‘, forty percent of witnesses 
were in agreement with patents for communicators of foreign art: 1851 Select Committee, p.178. 
283 Cornish, fn.281. 
284 This outlook was adopted in both the 1829 and 1851 patent law reforms consultations. 
285 Mandich G. ‗Venetian patents (1450-1550)‘ (1948) Journal of the Patent Office Society, p.166-224, 
p.169, original emphasis. 
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invent and discover ingenious devices…. so that others who may see them could not 
build them and take the inventor‘s honour away‘ provided that: 
 
„every men who shall build any new and ingenious device…shall give notice of 
it …[i]t being forbidden to every other person in any of our terrorise and 
towns to make any further device conforming with or similar.‟ 
 
It has also been used in the French patent law of 1791, the preamble to which 
encapsulates the justification thus: 
 
„That every novel idea whose realization or development can become useful to 
society belongs primarily to him who conceived it, and that it would be a 
violation of the rights of man in their very essence if an industrial invention 
were not regarded as the property of its creator.‟    
 
This establishes that historically there was some justification of the system on the 
basis that it was the application of the natural law principle of patents as property for 
the reward for creative labour,
286
 with some arguing that ‗Locke‘s theory applies 
equally well, if not better to IP‘ than to real property.287 However, this standpoint 
attracted contemporary criticism and continues to do so in both jurisdictions. The 
epitome of the rejection of patents as natural rights to property in the UK historically 
was when it was stated that ‗[n]atural rights is simple nonsense: natural and 
imprescriptible rights, rhetorical nonsense- nonsense upon stilts.‘288 Steyn, prior to the 
commencement of the current South Africa Patents Act, concluded that ‗a patent right 
does not exist because of natural and basic ―rights of man‖ as the inventor‘s natural 
right of property in the product of his creative mind, i.e. his invention.‘289 Instead it 
was argued that the law in South Africa establishes there is no property right of the 
                                                             
286 Notably, the John Locke‘s labour theory of property. See Ostergard R. L. The development 
dilemma- The political economy of intellectual property rights in the international system (2003) New 
York: LFB Scholarly Publishing, p.11-13. Also see Machlup F. and Penrose E. ‗The patent controversy 
in the nineteenth century‘ (1950) Journal of Economic History, p.1-29. 
287 Merges, fn.276, p.32. 
288 Davies claims that Bentham criticised this justification because he believed only the government 
had power to confer rights and there existed no absolute rights so it would be illogical to establish 
rights that could be upheld against the government: Davies A. ‗Jeremy Bentham (1748-1832): The 
utilitarian foundations of collectivism‘ (1995) Libertarian Heritage: Libertarian Alliance. 
http://www.utilitarianism.com/jeremy-bentham/bentham.html. 
289 Steyn fn.259, p.102.  
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inventor, as ‗a patent right is not a property right of the inventor‘ but a mere 
privilege
.290
 As a consequence, depending on circumstances, it may require emphasis 
to be placed on one of the other functions of the patent system, with a result that 
sometimes the natural right of the inventor is disregarded. As a result, a radical call 
was made by Steyn of the appropriateness of granting patents sometimes even in the 
absence of a natural person as an inventor.
291
 That means patents would have been 
granted without regard to the originator of the invention for administrative 
convenience or practical purposes.  
 
This view, it is respectfully submitted, can no longer be good law in the modern 
patenting system, where there is recognition of patents as rights of the creator.
292
 The 
UK Patents Act 1977 recognises that ‗any patent or application for a patent is personal 
property, and any patent or any such application and rights in or under it may be 
transferred, created or granted…‘293 and ‗shall vest by the operation of law in the 
same way as any other personal property…‘294 There is however no express provision 
in the current South African Patent Act 1978 that recognises the patent as personal 
property of the inventor. The South African Constitution though guarantees that ‗no 
one may be deprived of property,‘295 which includes intangible property. The 
Constitutional Court has said that even though previously there may have been 
‗judicial reluctance‘, the constitutionally guaranteed right to property applies to IP 
albeit it being incorporeal and IP laws must be interpreted in a constitutionally tenable 
fashion including weighing up IP rights against other constitutionally guaranteed 
fundamental rights.
296
  
 
Moreover, international instruments now recognise or create such natural rights in that 
‗everyone has the right to the protection of the moral and material resulting from any 
                                                             
290 Ibid. 
291 Ibid, p.103. 
292 Patents Act 1977, s.7 and Patents Act 1978, s.27 address the identity of the person who has the right 
to apply for a patent. Patents Act 1977, s.39 deals with employer-employee situations, which are 
prevalent in inventive activities: Giuri P., Mariani M. And Brusoni ‗Inventors and invention processes 
in Europe‘ (2007) Research Policy, p.1107-1127. Patents Act 1978, s.59(2) bars contractual assignment 
of inventions made outside the course and scope of employment in order to protect employee interests. 
293 Patents Act 1977, s.30(1). 
294 Patents Act 1977, s.30(3). 
295 South African Constitution Chapter 25(1). 
296 Laugh It Off Promotions CC v South African Breweries International (Finance) BV t/a Sabmark 
International and Freedom of Expression Institute 2006 (1) SA 144(CC), para.17 and 18. 
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scientific, literary or artistic production of which he is the author.‘297 Furthermore, 
The United Nations Declaration on the Rights of Indigenous People has accentuated 
this right by declaring that indigenous peoples have rights over their knowledge or 
resources.
298
 
 
Therefore, it could be said that an inventor or a group of inventors have a natural right 
in their creations which should be protected including through patents. Patents 
captured as a natural right does indeed reshape our approach to patentability from a 
purely utilitarian and economic balance between private and societal rights to a far 
more exacting approach of the indispensable right of the owners or originators of 
knowledge.
299
 This view can indeed reinforce the range of patentees that are admitted 
to protect their inventions through patents. Knowledge producers, including those 
who typically do not have large economic capabilities, for example one-time 
inventors and even traditional communities, would be guaranteed patent protection of 
their property through this right captured this way. 
 
The main criticisms of natural rights as a justification for the patent system stems 
from the property‘s non-exhaustive character throughout the protection period.300 
Thus, if property right in knowledge is a natural right, it seems illogical that it is 
limited as opposed to being perpetual.
301
 That is to say that once an invention 
achieves the required patentability standard, it must remain valid for the rest of the 
life of the patentee,
302
 as opposed to the reverting of the ownership to the public after 
a limited time.
303
  
 
                                                             
297 The Universal Declaration of Human Rights, Article 27(2); the same language was subsequently 
used in the International Covenant on Economic, Social and Cultural Rights Article 15(1)(c). The 
Constitution of South Africa, s.233 provides that the courts must interpret legislation with preference 
for reasonable interpretation that is consistent with international law over any alternative interpretation 
that is inconsistent with international law. 
298 Art 31 (1) United Nations Declaration on the Rights of Indigenous People accepted by the General 
Assembly on 13 September 2007. 
299 Chapman A.R. ‗The Human Rights implications of intellectual property protection‘ (2002) Journal 
of International Economic Law, p.861-882, p.867.  The goal of human rights subsisting in the IP 
regime is to improve human welfare in the social context rather than strict emphasis of the 
maximization of profits. 
300 Spence, fn.263, p.46. 
301 Colston C. and Galloway J. Modern Intellectual Property Law, 3rd ed (2010) Oxon: Routledge, p.47. 
302 May/Sell, fn.121, p.18. 
303 Steyn, fn.259, p.31. 
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Furthermore, it was suggested that the scope of the right awarded should be associated 
with actual effort, or degree of labour, exercised in creating the invention, with more 
time or effort deserving greater protection.
304
 This however, would unnecessarily 
concern itself with case-by-case-determination of the proportionality of the labour 
which brought about the invention, with the result that heavily invested inventions 
would get more protection than simple solutions to technical problems. Some have 
proposed conceptual proportionality models to account for this by interposing what is 
called ‗midlevel principles‘ that prescribe that an inventor‘s reward ought not to be 
out of proportion to the effort that went into the invention.
305
 
 
It is unsurprising that this theory viewed this way would find little support in modern 
patenting industries. The thesis suggests that the patentability standard should be set 
at a constant threshold whereby the rights to the invention are enjoyed irrespective of 
the actual effort of the inventor but be based on the quality of the resultant invention, 
as determined by meeting the pre-determined patentability standards by the originator. 
It is irrelevant that this standard is arbitrary or artificial, as it is an agreed standard and 
objective benchmark that once patentees‘ inventions attain, they are free to do with 
the protection as they deem fit within that time. Whether or not market forces accept 
the invention becomes irrelevant in determining the grant of this right. This eliminates 
subjectivity in patentability assessment that is introduced by focusing on events after 
grant. 
  
Other pragmatic mechanisms of the patent system seeking to identify the inventor are 
compatible with the natural rights theory captured this way, particularly in an era 
where there are more patent stakeholders beyond borders. The first-to-file mechanism 
where the system rewards the one who reaches the patent office first is not contrary to 
natural rights principles because the one who reaches the patent office first still has to 
show entitlement to the invention. It is also for that reason that the grace period 
features are in place as they allow the one entitled to the invention to approach the 
patent offices even after the public disclosure or unauthorised disclosure of the 
invention. 
 
                                                             
304 Fisher, fn.201, p.8. 
305 Merges, fn.276, p.160-162. 
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Anti-patent lobbyists formed commendable alliances to influence what is identified by 
commentators as the crucial legislative intervention to cast patents as a political and 
civic issue beyond the traditional legal and administrative stakeholders.
306
 However it 
remained public opinion that although the system was not totally efficient it was not 
to be abolished, but reformed.
307
 In the end there was divided opinion on how it was 
to be reformed and therefore there were modest reform proposals made.
308
 Tension 
between the Crown and Parliament had begun with the Statute of Monopolies where 
many compromises were made. It seems a likely explanation for the reticence to 
debate on the natural right justification lay in the close association that the patent 
granting procedures maintained with the monarch at that time. In South Africa, the 
influence of British royal authority was extended by the granting of these privileges 
through the Crown-appointment of British Governor-General. 
 
An aspect that was not settled historically and continues to be widely debated is how 
strict the standard should be. In the past, inventions were clearly distinct, such that 
new knowledge and ideas were easily distinguishable from the works of others.
309
 
This is contrasted to present circumstances, where there is integration and multi-
disciplinary of industries and knowledge-generation activities. The consequences is 
that the natural rights justification has limitations by virtue of the fact that although 
the individual may come up with the patentable idea, that knowledge is always based 
on existing knowledge or the work of others which may themselves be just be a little 
short of the patentability standard. The standard set by patent law should encourage 
creators of knowledge to improve on the knowledge they have for the betterment of 
society. That is to say then society places an obligation on the person soliciting a 
patent to make full disclosure of his invention and usable idea to the public which 
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meets the set patentability standard to be granted protection.
310
 This demonstrates the 
importance of the system setting the appropriate patentability standards, which as was 
said in Veasey v Denver Rockdrill and Machinery Company Ltd, ‗will reward those 
who make substantial discovery or invention which adds to our knowledge and makes 
a step in advance in the useful arts.‘311 People who derive and possess such level of 
knowledge are therefore entitled to patents if they use their right to that knowledge 
and forgo their secret to the public. 
 
Patents seen as rights have consequences that are absent when it is seen as privilege. 
A privilege conveys the impression that it is more of a favour that can be withdrawn 
at any time or for any reason. What is often overlooked, especially in the context of 
policy flexibilities within the system, is that although rights may be curtailed, there 
has to be specific pre-conditions for such curtailment. In such a rights model, a 
patentee would be certain that his rights within the protection term can only be 
disturbed if it surfaces that it suffers an objective and reasonable pre-stated defect or 
only in the case of recognized extraordinary circumstances.  
 
The viewing of patents as more than mere privileges also finds support in a 
commentary that asserts that patents suffer incorrect categorization as special legal 
privileges rather than natural rights because they are only largely viewed through a 
historical error perpetuated by misreading of history by legal historians and then 
compounded by legal scholars reciting that information without question as to the 
entirety or holistic accuracy of historical record relied on.
312
 Contending that the 
labour theory of property and social contract doctrine of natural rights was established 
and functional at the conception of patents, the commentator disputes the accepted 
line of thought that patents were merely viewed as special privileges then. He asserts 
that the interpretation of history ‗from today‘s positivist, utilitarian world to the 
natural rights world of the eighteenth and early nineteenth century‘ is negatively 
affected by the different cultural and social concepts and connotations of the legal 
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term of art ‗privilege‘ such that there is no appreciation of the fact that privilege 
consisted of natural rights and even fundamental rights.
313
 
 
A suggestion that an error could occur through the narrow reading of history is 
demonstrable in the fact that the underpinnings of the concept of novelty cannot be 
identical if the patent was both for importation and for true invention. Patents 
resulting from mere importation are likely to be based on different grounds from those 
of genuine invention. The justification for mere importation patents bears more roots 
in utilitarian foundations, whilst true inventor patents have, in addition, to do with 
rights conferred on inventor. And this plurality of foundation, it is suggested here, 
could be one overlooked or at least one alternative basis of patents as natural rights. 
Indeed some medieval scholars dispute the accounts conveying the impression that 
historically, society ‗did not think of individuals as possessing inalienable rights to 
anything.‘314 It is on this ambivalent historical basis of the operation of the newness 
criteria in the patent system, or at least plurality of history, that the pejorative view of 
patents as natural rights by scholars, using a narrow interpretation of history to 
criticize what is perceived as expansion of patents in contemporary discussion, is 
discouraged.
315
 
 
 
2.4.2 Patents as reward by monopoly 
 
Lord Blackburn in Bailey v Roberton
316
 stated that ‗patent law, dating from the time 
of James, gave a monopoly to the invention of the first inventor‘, highlighting that 
patents have for a long time been viewed as monopolies. ‗Just like the natural-law 
theory, the reward theory is premised on the idea that the individual should be 
rewarded for his labour and effort, but the reward theory specifically takes into 
account the benefit to society in general which flows from the individual‘s effort.‘317   
As opposed to the natural right theory, the reward by monopoly thesis advocates for 
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protection on the demands of justice or fairness grounds as opposed to moral 
obligations. It was thought that it was ‗just and right that some reward should attach to 
inventors‘318 for the usefulness of the invention to society. That means that the patent 
system is established on a quid pro quo between the inventor and the public 
represented by the state. The consideration in this exchange was the temporal 
monopoly that the patentee enjoyed for making the invention.
319
 This reasoning as 
such relates the patentability standard which inventions have to attain in order to be 
patentable to the value of the monopoly for the invention made. 
 
It was believed that the provision of a temporary monopoly was a suitable mechanism 
the state could use to remunerate the patentee as ‗commercial ventures were attended 
with great risk, both to life and capital, due to the unsettled conditions of the times.‘320 
State intervention through the provision of temporary monopoly was warranted as the 
reward could not be guaranteed by ordinary market forces. Other rewards, for 
example monetary ones,
321
 would be difficult to make proportional to the merit of the 
invention. The grant of such a monopoly was harmless to society as the consideration 
for the monopoly granted was considered adequate as the invention would benefit the 
public interest.  
 
The reward by monopoly theory was not without difficulties. The basis of rewarding 
the inventors with monopolies for making an invention were not entirely clear, as 
initially, many patents were granted as special patriotic distinction, for example to 
those who made the voyage beyond the sea where they imported technologies from 
abroad.
322
 As such, there was a long-standing association of patents with Crown 
privilege engraved in society‘s psyche as writers have observed that the patent was 
the Crown‘s central tool in furtherance of royal policies.323 There was no clear 
corresponding basis for awarding those who made inventions locally. A reasoning 
advanced to justify granting monopolies for inventions that meet the patentability 
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standard is that there is some labour involved in working the invention to perfect it for 
introduction to the general public.
324
 Therefore the ultimate reasoning was that the 
provision of a temporal monopoly was so that others but the patentee should be 
excluded from practising the invention for a while. 
    
However, this accepted view, that the inventor deserved reward through a monopoly 
did not seem satisfactory in view of the value of the inventor‘s contribution to the 
progression of human knowledge. The criticism of patents as reward is based on the 
notion that the contribution of any one individual is infinitesimal to deserve a 
monopoly reward.
325
 Commentators believed that virtually all useful inventions could 
not be attributed to individual contribution but rather on society as a whole.
326
 As 
such, there is no compelling reason to reward the one who made a technological 
breakthrough before everyone else.
327
 This criticism, it is observed, suggests that 
inventions are an inevitable result of industrial activities or dynamism of knowledge; 
therefore any person, without effort could just stumble upon them.  
 
At the same time this criticism further manifests the need for exacting patentability 
standards that can accurately measure this supposedly infinitesimal addition which 
has no guarantee to be made. It could be said such view fails to acknowledge that in 
the knowledge economy where there is abundance of information, it may take a lot of 
labour and time to reach a known or desired goal, which in hindsight looks very 
simple. In fact, sometimes in pharmaceutical discovery, the ultimate result that is 
desired can be known but impossible to practically reach even over decades, which 
after the fact does not look like a medical breakthrough.
328
 In such fields therefore, 
there needs to be a mechanism that would reward those who engage in such activities 
that do not always have an achievable or predictable outcome. 
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Other opponents of the rewards theory accepted that inventors had the right to be 
rewarded for their effort.
329
 However, they thought this reward would derive naturally 
in the market forces without the need for legal intervention. They reasoned that the 
head-start the first user of an invention gained within the market would, as a general 
rule, provide sufficient reward for the inventor.
330
 In today‘s market economies in the 
fields of pharmaceuticals, biotechnology, genetic engineering and others, the lead 
time would be insignificant without such protection,
331
 because of the channels of 
rapid dissemination of knowledge, ease of copying and bureaucracy before practice of 
the said inventions. Therefore, as some industrialists believed historically, the patent 
monopoly is essential security for maintaining the first-mover advantage in fields 
where none is ordinarily possible.
332
 
 
Regulators, persuaded by activists for cheaper new medicines access in South Africa, 
have persisted in viewing the pharmaceutical industry as one that exercises significant 
monopoly at unwarranted social cost.
333
 Such monopoly costs have been doubted by 
analysts and empirical evidence advanced that does not support such view.
334
 Djolov 
argues that ‗[t]he reward for being first to market with new products is the so-called 
―monopoly‖ price, which is temporary precisely because its very existence attracts 
new entry, and which must both cover the current R&D costs and generate profits that 
pay for the profits of tomorrow.‘ 335 He concludes that ‗the cost of the patent system 
to the South African public is… a minuscule price to pay for access to the advances in 
medicinal treatment, innovation and the concomitant assurance of choice when it 
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comes to product variety.‘336 It is therefore doubtful that the social costs are 
disproportionately high when viewed in light of the input costs that have to be paid by 
the inventor. 
 
Undeniable is the opinion that the open market could not always be useful to the 
inventor ‗to receive an adequate recompense for his labour, expense and time.‘337 To 
illustrate this reality is the practice that was developed both in the UK and South 
Africa where patent terms were extendable based on whether there had been profits 
made from the invention at the expiry of the initial term.
338
 This, at least to some 
extent, confirms that standardised patents monopoly terms are hardly in proportion to 
their contribution to the state of the art.
339
 It is observed here that the monopoly 
rewards argument is a useful mechanism to assist inventors to reap their just rewards 
by preventing adverse competition which would occur in open markets. 
    
At a glance, this justification thus has little bearing on the imposition of patentability 
requirements for inventions. Patentability is independent of the market response to the 
invention, even though sometimes market success could be an indicator of the 
usefulness of the invention.  It would not be practical to examine and determine how 
much time-limited monopoly reward should be granted for patents that are just a little 
above the patentability standard as opposed to those that are far above. Breakthrough 
inventions would probably deserve more time rewards. The proportionality of the 
monopoly reward seems undeterminable, except on a case-by-case basis which would 
be cumbersome and undesirable for administrators of the system.
340
 Hence, the 
rewards justification, although arbitrary, serves the purpose of rewarding inventors 
with the monopoly which can only exists with the time-limited exclusion of others. In 
an industry where rivalry is driven by competition, in order to be fair and meet the 
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demands of justice, the law can only set an artificial standard, after which it is 
incumbent upon the patentee to utilise the monopoly granted. 
 
 
2.4.3 Patents as incentive to invent and innovate 
 
The incentive justification for patents principally has utilitarian roots. It is not 
concerned with moral arguments or whether justice for individuals calls for inventors 
to be rewarded. It was thought that under the patent system, ‗gratitude toward the 
inventor is only of secondary importance‘341 to the need to incentivise innovation and 
inventive development. In Liardet v Johnson,
342
 the specification was framed in the 
words ‗His said Majesty, being willing to give encouragement to all arts and 
inventions which might be for the public good…‘ highlighting the fact that invention 
and innovation inducement by the patent was assumed.  
  
The incentive theory although sometimes criticized is offered as a mainstream 
justification underpinning the system in market economies whereby the firm sees the 
patent as an incentive that safeguards returns on investment of resources in its 
inventive activities.
343
 Despite having been criticised as an overly simplistic analysis 
as far as the modern economics of the patent system is concerned,
344
 it is an argument 
that is still routinely utilised to justify the system today even though the incentive is 
one amongst many that have to be considered by the inventor. 
 
The historical study of patents is usually associated with the industrial progression of 
Britain. The industrial policy of generating and assimilating technology is usually 
attributed to the existence of the patent system. Thus writers alluded that the 
protection policy had, despite its problems, produced a ‗system of patents for the 
effective encouragement of invention‘.345 Countries that were ambitious to prosper 
modelled their policies in line with what they perceived as the key to the successes of 
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Britain. For example the Japanese proclaimed that ‗we looked about us to see what 
nations are the greatest, so that we can be like them ... we investigated and found that 
it was patents, and we shall have patents.‘ 346 
 
What this justification raises is that developing countries, which have been typically 
identified as offering no or little patent protection historically, could use the patenting 
system to foster development and industrialisation. This is in spite of the lack of solid 
and conclusive evidence that indeed the historical development of the UK was 
integral with patents. At least there is some correlation, although the extent of the 
incentives‘ effect is not entirely known.347 South Africa‘s first patents were in the 
mining industry.
348
 It is likely that that its prominence in the mining trade, over its 
neighbours who also had significant resources but introduced the patent much later 
on, could be a result of the patent, but this cannot be conclusive. 
  
Historically, observers could not easily accept that there was any intervention 
necessary to induce invention and innovation. It was assumed that the inventive 
activities were natural processes that were embedded in industrial culture.
349
 As such, 
the patent was not necessary; self-promotion in the trades and guilds would be 
adequate for optimal invention and innovation.
350
 This was a view shared by 
industrialists who thought the patent was not integral to the functioning of industry, 
stating ‗people will always invent anything that is useful and good, if it will answer 
their purpose to do so, even without reference to a patent.‘351  
  
Views against the incentive theory seemed inadequate. The main thrust of opposition 
is the argument that scientists do not need patent incentives to carry out their 
activities. This argument seems resonant with our modern realities, where for 
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example, university research output is a result of the primary quest to improve 
knowledge, rather than inventing or innovation. Nonetheless, individuals involved in 
inventing could hardly be said to be doing this only out of pleasure. It is not 
satisfactory that basic research be merely carried out with no particular purpose as, 
although valuable, is of little use to the public. The ‗law looks to the inventor or 
discoverer who finds out and introduces a manufacture‘ that could be a ‗little more 
than the ornament of a museum.‘352 There has to be application of that research in 
practice, hence one plausible reason patents are not granted for mere scientific 
principles and theories as will be seen in chapter four. The sprouting of commercial 
R&D divisions is a testament to the need for inventing more useful inventions that can 
be pursued to commercialisation,
353
 as opposed to basic or primary knowledge that 
remains stagnant in scientific journals and libraries. 
 
It may perhaps be strained logic to make a correlation between patents and the 
incentive to innovate and invent in all industries. That, however, does not preclude the 
conclusion that it may be possible for patents to induce inventive activity in some 
fields of technology. It is sensible to assert that although patents have their 
shortcomings in some fields, the benefit that they provide generally outweighs any 
such considerations; the so-called patent cost-benefit analysis of the system.
354
 One 
witness before the 1851 Select Committee conveyed the impression that workers were 
restricted only to routine work if they were to avoid infringement of patents.
355
  
Indeed, one industrialist gave examples of how his own patents could prevent him 
from making improvements.
356
 More concerning is the opinion that in the 
contemplation of the patent, the application and grant process stopped scientists from 
practice, destroy models or any vestige of them remaining or even send workmen on 
distant missions, to prevent leaking of technical details of the invention to 
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competitors.
357
 The patent system, the abolitionists opined, served to rob inventors of 
the opportunity to evolve and improve upon inventions. This concern thus requires the 
setting of the system such that continuous improvements are not blocked by the 
system. As is common in the sciences that more than one inventor may have been 
working towards the same or similar goal, the system also has to guard against the 
dispiriting influence of the first-to-file system that does not acknowledge the other 
active inventors who came close to the patented invention. Therefore the system must 
guard against the discouraging of ‗near-patentees.‘  
 
 
2.4.4 Patents as an information system 
 
Patents represent a quid pro quo between the state and the inventor.
358
 The quid is the 
monopoly conferred on the patentee and the quo is the new knowledge entering the 
public domain through the invention. In other words, the consideration in this contract 
is the disclosure of previously unknown knowledge into the public domain by the 
patentee in light of the state‘s protection.359 In Miller v Boxes & Shooks (Pty) Ltd,360 it 
was established that it is in the public interest that persons with inventive minds 
should be encouraged to disclose the results of their efforts to the public.  
 
The concept of such a bargain gathered eminence from the emergence of the patent 
specification.
361
 The public might temporarily have been limited in utilising 
information contained in the specification, but this was in return for the disclosure 
made by the patentee. In Walton v Potter
362
 the court held that the ‗specification is the 
price paid by the inventor for the patent he obtains.‘ Consent for this exchange was 
deemed to exist because of the benefits accruing to society from the publication of the 
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invention where it might have remained secret.
363
 This has origins in the case of 
Cartwright v Eamer
364
 in which Lord Eldon C.J. opined that the patent grant should 
not be considered ‗in the light of a monopoly, as it had before been put by the judges, 
but as a bargain with the public.‘ A qualification to the identity of the public was 
clarified in Bichfird v Skewew
365
 where it was held that the ‗specification is addressed, 
not to persons entirely ignorant of the subject-matter, but to artists of competent skill 
in the branch of manufactures to which it relates.‘ It is deducible that the patentability 
standard that is set should be one that guarantees that a granted patent gives detailed 
information and knowledge to the public that is valuable and can be put into use by 
appropriate scientists. 
 
For a long time after the enactment of the Statute of Monopolies, there existed no 
general, formalised requirement to furnish a detailed specification that set out 
precisely what the invention was. This would cast some doubt on the justification of 
the patent on the public education premise. It is asserted that this justification may be 
viewed more as an adaptation of the patent system to changing times and evolving 
demands of industry practices.
366
 Hulme suggested that with the introduction of the 
specification ‗the doctrine of the instruction of the public by means of the personal 
efforts and supervision of the grantee was definitely and finally laid aside in favour of 
the novel theory that this function belongs to the patent specification.‘367 That is not to 
say the other justifications were to be obsolete, but the public education premise was 
becoming more relevant with the times and in practice. 
  
The specification had other functions that it came to fulfil besides the public 
disclosure function. In Holmes v London & NW Rly Co,
368
 the court said ‗the object of 
the condition in the patent requiring the specification is twofold; first, that useful  
novelties should be given to the public,… and, secondly, that no person should 
inadvertently infringe the rights of the patentee.‘ Contemporary, in Kirin-Amgen v 
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Hoechst Marion Roussel,
369
 Lord Hoffmann acknowledged that ‗during the course of 
the 18th and 19th centuries, practice and common law had come to distinguish 
between the part of the specification in which the patentee discharged his duty to 
disclose… and the section which delimited the scope of the monopoly which he 
claimed.‘ This supports the view that patents were granted partly for imparting 
knowledge to the public on how to perform the invention, in addition to their 
monopoly-claiming function. In other words, this justification has fundamentals in the 
exchange of secrets with the public through the specification. In South Africa, it was 
acknowledged by the Appellate Division in Anglo American Corp. v Osterreichische 
Eisen und Stahlwerke A.G.,
370
 that ‗amongst the benefits conferred by the patentee on 
the public must be counted the benefit which he conferred by the disclosure of a 
valuable invention.‘ Moreover, the patentee was under the duty to disclose the best 
method of carrying out the invention,
371
 with this confirming useful knowledge given 
to the public as a standard for patentability. 
 
The principle that was brought by the patent specification is that it accentuates the 
need to make a public disclosure, as the patentee may only claim protection for what 
he has actually created and fully disclosed to the public. As an ideology, the 
justification therefore fits with the model that promotes dissemination of technology 
more than only giving an incentive to create pioneer inventions. When setting the 
patentability standards it should be borne in mind that the exchange price should not 
be too high to an extent that they discourage disclosure as an option to all kinds of 
knowledge producers, holders and improvers.
372
 
 
The information disclosure argument did not proceed unchallenged over the years. 
Observers doubted that the technological progress of the state would be at all harmed 
if inventors were not encouraged to disclose their inventions as ‗nearly all useful 
inventions depend less on any individual than on the progress of society.‘373 It is 
                                                             
369 [2005] 1 All E.R. 667, p.677 citing Fletcher-Moulton L.J. in British United Shoe Machinery v A. 
Fussell & Sons (1908) 25 RPC 631, p.650. 
370 1967(4) SA 332(AD), p.331D and 333D. 
371 In South Africa, the repealed 1952 Patents Act, s.10(3)(a) and 23(1)(f). 
372 It has been suggested that even in developing countries the patent plays a role as a source of 
information of diverse research and inventive activities: Pretnar P. ‗Patent applications as an 
information source for managing exports in less-developed countries‘ (1990) World Patent 
Information, p.216-221. 
373 Machlup/Penrose, fn.286, p.27. 
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inevitable that when keeping inventions secret someone else will make the discovery 
with the willingness to bring it to the general public.
374
 Such an argument is less 
convincing when viewed under this justification of the patent. It assumes that an 
alternative scientist in the invention chain will have the same patentable idea and will 
choose to disclose or inadvertently have the invention leaked to the public. To prove a 
point, trade secrets are still a major practice in industry and some have successfully 
been long standing.
375
 Phillips riposting a contention that trade secrets may be 
exaggerated pointed out that the fact that they are intrinsically secret makes 
quantification of their use or value challenging.
376
 
 
There were also views that questioned the granting of a patent to an inventor because 
knowledge is cumulative and why one should be granted protection for this relatively 
minute knowledge he adds to the large store of human knowledge under the guise of 
incentive to disclose.
377
 This view seems to fail to acknowledge incremental 
inventions, which if disclosed, can have enormous effects in putting some idle 
historical information or knowledge into a useful practical application. There are 
situations where there may have existed technical problems before which could not be 
solved but by the seemingly minor inventive idea of latter disclosures. The case in 
point is cases where there is a lot of work done on a disease, the target solution of 
which is known or a mechanism of the disease is known, but no solution found for a 
long time. It may turn out to be a simple disclosure that triggers a solution to the 
stagnancy. The non-obviousness of that disclosure has to be accounted for within the 
patentability system. Therefore current patentability standards should recognise the 
importance of disclosures by incremental innovators, who are the cornerstone of 
today‘s industrial creativity. 
    
                                                             
374 Schachman H.K. ‗From ―publish or perish‖ to ―patent and prosper‖‘ (2006) Journal of Biological 
Chemistry, p.6889-6903. 
375 Phillips insightfully proposed that the reason such pronunciations cannot be substantiated or 
quantified is because of the very reason of secrecy: Phillips J. ‗Protection of trade secrets: a property 
right, equitable right or contractual obligation? Does it matter?‘ Lovell Seminar, 14 December 2009. 
Studies have analysed how firms leverage non-patented inventions without the risk of imitation: Coff, 
R.W., Coff, D.C. and Eastvold R. ‗The knowledge-leveraging paradox: how to achieve scale without 
making knowledge imitable‘ (2006) Academy of Management Review, p.452–465. 
376 Phillips J. ‗Protection of trade secrets: a property right, equitable right or contractual obligation? 
Does it matter?‘ Lovell Seminar, 14 December 2009. 
377 Spence, fn.263, p.46. 
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As consequence of the need to keep an invention secret before a patent application 
was granted,
378
 there were arguments that the system was actually encouraging 
secrecy. Commentators stated that, in the absence of a patent system, ‗secret and 
isolated work would cease and its place would be taken by a cooperation of all 
qualified talent.‘379 Interestingly, the model of scientific research advocated closely 
resembles the corporate-led research efforts of the present day.
380
 Even where there is 
industrial cooperation and partnerships, parties still keep some information secret, 
hence this argument does not hold.
381
 Moreover, the keeping of inventions secret is 
only temporary until the patent has been applied for, whereby all the information is 
disclosed to the public systematically. Systematic disclosure of knowledge is 
therefore a justification of the patent system. 
 
 
2.5 The historical justification model advancing adequate patentability standards 
 
Various models have been proposed that justify IP. One such model useful in concrete 
IP policy formulation, is centred on ‗midlevel principles‘ of proportionality, non-
removal from the public domain, efficiency and dignity, which are generalised and 
informed by specific doctrine, practice and operational detail on the lower level and, 
at the high-level, are an embodiment of broader normative principles corresponding to 
deep ethical or foundational values and, more significantly, such model enables 
debates on IP regardless of one‘s normative commitment.382 Cognisant of this model, 
this thesis suggests, for patents specifically, a more balanced model of all the 
justifications without ranking them and retracts the dominant utilitarian view from 
supremacy. An optimal overall justification is achievable this way as it has been noted 
                                                             
378 For instance, Nasmith, an industrialist who refused to disclose his invention until the Office of the 
Attorney General granted him the patent, Davies D.S. ‗The early history of the patent specification‘ 
(1934) Law Quarterly Review, p.86-109, p.87-88. 
379 Machlup/Penrose, fn.286, p.28. 
380 Dutfield G.M. and Suthersanen U. ‗The innovation dilemma: Intellectual property and the historical 
legacy of cumulative creativity‘ (2004) Intellectual Property Quarterly, p.379-421. 
381 See generally Hagedoorn J. ‗Sharing intellectual property rights – an exploratory study of joint 
patenting amongst companies‘ (2003) Industrial and Corporate Change, p.1035-1050.  
382 Merges, fn.276, p.304-305. Also, Paine suggests two levels of justification, with one dealing with 
the objectives, purposes and explanations of practice or an IP institution and the other linking those 
objectives to our most basic legitimising ideas for IP such as common good: Paine L.S. ‗Trade secrets 
and the justification of intellectual property‘ (1991) Philosophy and Public Affairs, p. 247-263, p.249. 
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that ‗as applied to IP law, utilitarian theory could not bear the load that has been 
assigned to it.‘383 
 
Focus now turns to how the modified and balanced classical justification model could 
be viewed from different perspectives, namely from the policy-making perspective, 
from industry perspective and the courts. A limitation to be mindful of in the creation 
of models is that they could be grounded on unique rules and practice in one 
jurisdiction and have an uneasy fit when attempting to apply into a different 
jurisdiction.
384
 
 
2.5.1 At policy level 
 
At the dawn of a new epoch in patentability laws where a lot of effort and consensus 
is sought for the reform of the patent system, it is prudent to consider whether any 
proposed change will improve the purpose and function of the system. It is important 
to understand the strength and weakness of the justifications in order to assess 
whether a particular proposed approach to patentability minimises the weaknesses and 
optimises the strengths of the system.  
 
The justifications that were utilised throughout history may reveal useful 
characteristics of the patent which may be used to model a patenting system that is 
effective in encouraging and protecting inventions.
385
 This is not to say the patent 
justifications are to be utilised in their historical context, but should offer an 
inspiration and a nudge forward to make the system work to higher efficiencies. It 
would be detrimental to inventive activity if they were to be completely ignored by 
contemporary policy and law makers. The policymakers under pressure for good 
public perceptions in handling public health problems have sometimes made adverse 
regulatory changes even if expert findings for instance ‗indicate that the total profits 
                                                             
383 Merges, fn.276, p.305. 
384 Merges, f.276, p.143-144. 
385 This modeling is what writers have called social-scientific prognostication-a history of the future- 
which is methodologically rigorous and informative, allowing one to depict a number of plausible 
alternative and empirically-grounded scenarios that may develop in the future, as differentiated from 
mere predictions which are a ‗little more than extrapolations from present trends or imaginative 
projections of hopes or fears, and in either case are consequently doomed to fail‘: Fay B. 
‗Unconventional History‘ (2002) History and Theory, p.1-6. 
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made on pharmaceuticals are not exorbitant.‘386 As such, a balanced and integrated 
justification model, which is explained below, is proposed. 
    
Although the natural rights justification is rarely relied on, it appears to offer a 
balancing function to the whole patenting regime. It reiterates that patents are rights. 
Individuals come up with the inventions. The inventors overcome the barrier in the 
state of the art and come up with new and non-obvious inventions. This justification 
demands an exacting patentability standard to be set, both to qualify for the right and 
also how far the right should extend and the circumstances in which the right should 
be curtailed or denied. In contentious cases, it seems to be a good candidate in 
justifying the setting of patentability standards that seek to identify the true and 
deserving inventor. Rules of newness and priority crystallize upon the identity of the 
source or origin of the invention. The natural rights justification, for example, appears 
to offer the critical ingredient to transform patentees from previously disadvantaged 
groups mainly located in the developing world into the mainstream patenting field 
through the recognition of these participants as the natural private right holders of 
patentable subject-matter, if patenting is their option chosen. Conversely, it offers the 
rationale for rejecting some technologies or patentees from the patenting arena. 
Animals or plants, for example, are hardly classifiable as falling within the control of 
an individual to be patentable.
387
  
 
There may be some unease on the adequacy of the monopoly reward justification for 
setting optimal patentability standards. It may not be adequate or appropriate across 
all fields of technology, but it is constant amongst competitors within the same fields 
of technology. Some inventions are stumbled upon without much thought or have 
short investment return periods but still get the same terms of protection as laborious 
and complex breakthrough inventions that may have longer return-on-investment 
periods. However, it is agreeable that time-limited monopolies are a form of reward 
                                                             
386 Browne Report: Fifth Interim Report of the Commission of Inquiry into Health Services -Interim 
report on pharmaceutical services, 1985 Pretoria: The Government Printer. 
387 For instance, TRIPS Art 27(3)(b), South African Patent Act 1978 s.25(4). The degree of 
modification in genetically modified animals in order to be patentable has been difficult to resolve and 
continues to be debated, with many models for the demarcation being suggested; for instance Safrin S. 
‗Chain reaction: How property begets property‘ (2007) Notre Dame Law Review, p.1917-1969, 
suggests a chain reaction theory whereby the granting of private property evolves into unanticipated 
second generation rights encroaching on the public domain over time. 
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that is practicable and suitable; it is then the patentee‘s burden to make the most out of 
this monopoly reward for inventions meeting the required patentability standard. 
 
The incentive to invent or innovate encourages the practical exploitation of 
knowledge through activities that prioritises inventing solutions to problems.
388
 The 
reality is that for the inventive process to sustain development and improvement of 
the state of the art beyond mere discovery of fascinating scientific principles and 
knowledge, it has to be applied, often with costly activities carried out. It is 
recognised that there are ‗hobby inventors‘, but most industrially useful inventions 
can only be sustained with considerable economic investment.
389
 Scholars observe 
that the system has to ‗induce risk-takers, whether they are researchers or investors, to 
search for novel ideas that are capable of becoming marketable innovations.‘390 In 
other words this justification acknowledges the practical advantage that the invention 
possesses as evidenced by the willingness to make actual, often strategic, investment 
input into the invention.
391
  
 
In return, society enjoys the inventive and innovative advances that are perfected in 
practice from this inducement. The policy makers should not assume it is an 
automatic process or perceive the return of that investment in bad light, for instance in 
perpetuating historically incorrect opinions about the inventive processes of the 
industry even though, for instance, empirical ‗investigation do not support the view 
that the pharmaceutical industry in South Africa is, as a whole, earning excessive 
profits, particularly if the risks are borne in mind.‘392 Hence, contemporary 
patentability standards must be set at a level where inventors are inspired and 
encouraged to make useful and practical inventions to qualify for a patent. 
 
The information disclosure or public education justification brings the patentability 
standards to levels where protection is offered if and only if the patent will teach the 
                                                             
388 Kitch E. ‗An economic review of the patent system‘ (1977) Journal of Law and Economics, p.265-
302. 
389 von Hippel E. ‗People don‘t need a profit motive to innovate‘ (2011) Harvard Business Review, 
p.36-37. 
390 Cornish, fn.281, p.751. 
391 Van Caenegem, fn.123, p.250. 
392 Steenkamp Report: Report of the Commission of Inquiry into the pharmaceutical industry, 1978 
Pretoria: The Government Printer. 
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public something new and valuable which could otherwise be kept out of the public 
domain. This disclosure element of the patent grant has strengthened significantly 
since the Elizabethan era. As such it should not just be seen as a late-comer in the 
patenting field, but more as a critical element which is undoubtedly a valuable 
consideration for patent protection in contemporary knowledge economies. 
 
Generally, the natural rights and monopolies justifications could be viewed as geared 
up more for the benefit of the knowledge producers in the system. The incentive and 
public disclosure justifications are more of public policy levers to the system. Some 
suggest that although there is close relationship between them, ‗the difference 
between them lies in the relative value placed on the individual or societal interest.‘393 
It is therefore these competing perspectives that have to be balanced if the system is to 
attain an optimal level of encouraging invention and innovation and offering 
reasonable protection for the resulting inventions.  
 
This leads to a caution in the balancing of the justifications in the design of the 
patentability standards. It is easy to assume that the public or policy inspired 
justifications override those of industry or private interest. Mainly, this is because 
policy can be set without consensus with industry players.
394
 In such a situation 
industry would have to go through a metamorphosis to survive and adapt to the 
changes thrust upon it.
395
 However, this does not necessarily mean the resultant 
system would be optimal. A desirable view is one that recognises that creator-centred 
justifications are also essential
396
 for the system to work and so there always has to be 
a balanced view of the justifications which accommodates the private interests. The 
                                                             
393 Mostert F. ‗The development of the natural-law principle as recognition of intellectual property: A 
survey from Roman law to modern-day law‘ (1987), South African Law Journal, p.480-501, p.500. 
394 Approaches to IP policy-making have been expanded from the traditional social or welfare view 
focusing on the balancing of IP benefits and costs to society to include, as equally important, the 
industrial dimension viewing knowledge, information and intellectual creations as assets of strategic 
economic importance, the creation and exploitation of which should be boosted by the formulated IP 
policy and recognising that such industry or business considerations in policy formulations are 
vulnerable to unreasoned political pressures and compromises that may undermine their entire 
rationale: Pugatch M.P. ‗The process of intellectual property policy-making in the 21st century- shifting 
from general welfare model to a multi-dimensional one‘ (2009) European Intellectual Property 
Review, p.307-315. 
395 Wertheimer A. and Santella T. ‗History and economics of the pharmaceutical patents‘, in Farquhar 
I., Summers K.H. and Sorkin A.(eds), Research in Human Capital and Development, Bingley: Emerald 
Group Publishing, p.101-119. 
396 Spence, fn.263, p.45-46. 
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beneficial outcome of fulfilling the creator interests are bestowed onto the public via 
the advance in the state of the art or the exploitation of the inventions. 
 
Complementary to a necessary balanced view of the justifications, one theme 
resonates in all the justifications outlined above: they all have a vital contribution to 
make in setting the appropriate patentability standards. That is to say the system 
properly operates on an integrated view of the justifications. It does not matter 
whether they were deployed later on in the patent debate such as the public education 
justification
397
 or they have dropped off along the way as unfashionable such as the 
natural rights justification. If the patenting system is to be properly understood, 
retained, refined, and harmonised, it would be worthwhile to carefully deploy all of 
these classical justifications. It is proposed that when setting policy or making 
assessment of whether an invention meets the patentability standards, regard should 
be taken of all of them. Even at the international level, there is the recognition of the 
natural rights justification, which was overlooked when the other justifications were 
well-accepted and deployed. This puts this justification at par with the other classical 
justifications
398
 and brings it to the fore of the reform discussions. That is to say they 
each contribute without the exclusion of the others. 
 
The integrated view of the justifications can be attained by way of not ranking or 
prioritising some the justifications when formulating the appropriate patentability 
standard. Ranking is unhelpful and distorts their historical function or uses within the 
system. What would be low-ranked justification is essential to the system as a whole 
in achieving equilibrium. For instance the late-comer public education premise cannot 
be relegated, certainly not eliminated. A societal or public focused policy cannot 
properly function when a pejorative view is held of private rights. The devastating 
effects of such a negative view may not be manifested instantaneously, but could be 
long-term and long-lasting, when the private actors in the systems start to shun the 
system in preference to other modes of invention protection, even if less secure or less 
optimal than the patent system. 
 
                                                             
397 Cornish suggests that the role of advancing public knowledge, although important, was nonetheless 
secondary: Cornish, fn.281, p.751. 
398 Mossoff, fn.323. 
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Such a non-ranking approach keeps in check a populist or even sensationalist or 
alarmist public policy in the patent administrative and legislative forums.
399
 A 
position of this kind is susceptible to manipulation by media and politicking rather 
than well-reasoned long-term principles to optimise the system.
400
 For example, the 
monopolistic justification is easily cast in unfavourable light. The danger of an 
emotive approach, both in setting the patentability standards and assessing whether 
the standards have been met, rather than one that uses pre-ordained triggers for 
disturbing patentability standards is evident.  
 
2.5.2 In industry 
 
The justifications as a whole also have to be appreciative of the reality of the 
pharmaceutical industry, from conception of the idea to engage in these activities to 
the daily operations and decisions that confront practitioners and also of the need for 
constant re-evaluation of remaining in the pharmaceutical industry. This need is 
critical in Africa which is historically a neglected market compared to other markets 
perceived to have significant buying power or at least being larger non-segmented 
jurisdictions.
401
 Therefore a patent system must exist that comports with the practical 
realities of a pharmaceutical industry. 
 
There are some indications that the industry could be consolidated in emerging 
markets. Some observers even suggest that with the rapid industrialisation and 
improvement of the standard of living in India and the Far East, there may be the 
diminishing advantages of cheaper labour that, inter alia, initially attracted 
pharmaceutical companies to these regions, and they may in turn consider more 
investment in Africa that was historically neglected.
402
 This trend of setting up more 
                                                             
399 For instance, some organisations and advocacy groups can generally be anti-patent and alarmist in 
IP issues: Ghafele R. ‗Of war and peace: analyzing the international discourse on intellectual property 
law‘ (2010) Intellectual Property Quarterly, p.237-255, particularly at p.249-250.  
400 It has been cautioned that ‗the public is the whole community- which at times may not be 
represented by the majority or the media‘, Justice Susan Kenny ‗Maintaining public confidence in the 
judiciary: A precarious equilibrium‘ (1999) Monash University Law Review, p.209-224. 
401 Market reforms to address healthcare institutions and infrastructure more than just healthcare 
products such as pharmaceuticals have been identified as crucial in addressing disease eradication in 
developing countries: Callahan D. and Wasunna A.A. Medicine and the market: Equity v choice (2006) 
Baltimore: The John Hopkins University, p.116-117. 
402 Aldridge S. ‗Is Pharma moving to Africa‘ Pharmaceutical Technology Europe, December 2007, 
Advanstar Communications Inc, p.15. 
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pharmaceutical plants locally is of benefit in fighting diseases within Africa. For 
instance, commentators have noted that the pharmaceutical industry in South Africa in 
one particular area of treatment or disease, for instance Galderma Pharmaceuticals 
focuses on African dermatology because ‗there is little research on African skins 
worldwide.‘403 Regulation must be with the intent of encouraging localised 
pharmaceutical research. Therefore setting a policy underlined by patentability laws 
that recognise this industry reality is imperative.  
 
Considering the justifications, it can be said that the natural rights doctrine could 
confer confidence in firms that they will be entitled to the rights arising from their 
invention in the previously ignored medical fields. Most of the inventive stages in the 
pharmaceutical process are indeed laborious and require a considered choice to be 
made to follow that line of research. This will often take years and a lot of investment. 
Therefore the monopoly reward will act as security for making the decision that has 
no guarantees of success.
404
 The incentive justification is especially important for 
inducing firms into research areas that are neglected. It would be unwise to assume 
that an inventor would pursue research in an area without any incentive to do so.
405
 
The disclosure justification is perhaps less attractive to industry because secret 
information the firms hold usually represents competitive advantage. The disclosure 
requirement must be such that it is nevertheless viewed as a worthwhile business 
exchange of secrets.  
 
2.5.3 In court 
 
It is submitted that the classical justifications are essential in explaining the stipulated 
patentability standards or why particular tests are applied or particular questions are 
asked as part of patentability assessment. The patentability assessment questions or 
tests customarily used in court are a summary of the applicable law. Arguably, the 
tests or questions could work even if the one making the patentability decision has no 
                                                             
403 (Unkown) ‗Carving out a space- niche players in South Africa‘ Pharmaceutical Technology Europe, 
May 2009, Advanstar Communications Inc, p.44. 
404 Grabowski, H.G.,et al ‗Returns on Research and Development for 1990s new drug introductions‘ 
(2007) Pharmacoeconomics, p.11-29. 
405 Sonderholm J. ‗A reform proposal in need of reform: A critique of Thomas  Pogge‘s proposal for 
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thorough knowledge of the underlying justifications, but follows them carefully. 
However in some borderline cases, following these without understanding their origin 
could lead to incorrect decisions.
406
 It is in these circumstances that the use of the 
classical justifications becomes particularly valuable. 
 
As a result of asking the patentability questions against the background of the 
justifications, it is suggested that this would prevent the questions or assessment 
becoming merely mechanistic, especially if the tests seem to work in the majority of 
cases in practice without the need of reverting to exhaustive examination of why a 
particular patentability criterion exists. This is to say that although the final 
assessment tool may be a practical shortcut to answering why a particular invention is 
deemed patentable, this practice has to correspond with the underlying reason for 
making that choice,
407
 even though one does not necessarily have to investigate this in 
all cases when judging patentability. Moreover, the justifications could explain why 
even a particular patentability assessment approach is preferable over another. 
 
Formulating the justifications as an aid to interpretation of the patentability questions 
or approach has its advantages. This is significant when the justifications are 
considered by academics and legal history scholars as contrasted with practitioners 
mainly due to their different approaches to the analysis and use of the law.
408
 Due to 
the tensions between the classical justifications and the need to choose the best one to 
                                                             
406 To improve on fact-specific patentability judgments, policy-based decision-making has been 
identified as a viable approach: Rai A.K ‗Engaging facts and policy: A multi-institutional approach to 
patent system reform‘ (2003) Columbia Law Review, p.1035-1135, generally and particularly, p.1101-
1103. 
407
 One view is that legal argument and judicial decision-making must be grounded in philosophy and 
reasoning and be structured and unified, even though there may be practical limitations on judges, but 
‗any practical difficulties would not exclude such a philosophical goal from at least informing legal 
argument and it could be argued that those who supported principled reasoning certainly seems to have 
such a goal and to seek to see law displaying a character which is logical and rational. This would 
suggest judges and philosophers have similar roles and goals‘: Malloch, V.A. Persuasion : a historical-
comparative study of the role of persuasion within the judicial decision-making process.(2002) 
University of Glasgow: Unpublished PhD thesis, p.239-240. 
408 Some analysts have criticised the overall disjunction between the academia and practitioners as a 
result of the growing divergence amongst academics, with one group being seen as ‗impractical‘ 
scholars who produce abstract scholarship that has no regard for legal doctrine that may constrain or 
guide the practitioner and has little relevance to concrete issues to the practitioner and the ‗practical‘ 
scholar who ‗gives due weight to cases, statutes and other authoritative texts, but also employs theory 
to criticize doctrine, to resolve problems that doctrine leaves open, and to propose changes in the law or 
in systems of justice. Ideally, the ―practical‖ scholar always integrates theory with doctrine.‘ Edwards 
H.T. ‗The growing disjunction between legal education and the legal profession‘ (1992) Michigan Law 
Review, p.34-78, p.35. 
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explain their position in court, legal practitioners have usually sought to present their 
preferred justification as the best view supporting or sustaining the patent system. A 
shortfall of this analysis is that this can be done at the expense of the other 
justifications whereas, on the other hand, the academics or scholars present the 
justifications as a balance of possibilities in explaining the patent system. This may 
lead to different conclusions. 
 
To elucidate this point of how interpretation could be different between these groups,   
Webber states that the interpretation of law from the academic or legal historical 
perspective adopts what has been called an external approach which focuses on the 
historical and sociological account of the law and addresses the same phenomenon, 
but for different reasons as the internal approach which focuses on how arguments are 
fashioned and deployed within legal practice to make decisions, although it is 
common to rely on both kinds of explanations to understand legal development.
409
  He 
argues that the law therefore exists in two distinct modes, on the one hand being the 
descriptive mode which encompasses good legal history and seeks to describe the 
legal order in effect in a particular society and particular time and examines a range of 
possible arguments and as a result is inevitably plural as its conclusions are 
imperfectly rationalised as there remains as yet unresolved controversies.
410
 On the 
other hand, operating in the exhortative mode, legal practitioners seek to eliminate the 
normative range of possibilities and establish a common and best procedural 
mechanism that is peremptory and ‗assist in the process of winnowing normative 
controversy and determining a single, authoritative interpretation‘ although the 
underlying controversies remain and may appear in future appear.
411
 In the 
exhortative mode the practitioners are supporting one specific outcome, the best 
interpretation and not necessarily dictated by the raw or historical material to form 
that particular best outcome.
412
  
                                                             
409 Webber, fn.120, p.2. 
410 Webber, fn.120, p.6. There is opinion that the development of the law is enhanced if there is 
plurality of opinion in judgement rather than reaching a final conclusion prematurely, even though this 
may lead to some uncertainty: Lord Reid, The Judge as Lawmaker (1972) Journal of the Society of 
Public Teachers of Law, p.28–39, p.28. 
411 Webber, fn.120, p.6-7. Lord Hope is of the view that a judgment style could be a declaratory type, 
bringing finality to a matter or an exploratory type, where the judge sets out to persuade the reader by 
debate: Lord Hope Writing judgments: Annual Lecture 2005 (2005) Judicial Studies Board, London, 
p.7. 
412 Webber, fn.120, p.7. 
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Such an approach to patentability interpretation illustrates the plurality of the law that 
can result as the descriptive and exhortative modes are not independent.
413
 The 
justifications represent the descriptive mode where the source, origin and rationale for 
the patentability decision is based and on the other hand the patentability assessment 
questions represent the exhortative mode where the arguments in practice are 
presented by the respective parties in dispute only to achieve their preferred outcome. 
The implication for viewing the law of patentability standards in both modes is that it 
can be used to resolve dissonance in cases where there is difference of opinion in the 
development of case law. For instance, Burrell argues that the latest South African 
Court of Appeals authority on the assessment of non-obviousness is incorrect and is 
not the law operative in South Africa, preferring instead the approach that was 
previously formulated by the Court of Appeals under the first patent statute after 
British rule.
414
 One notices that the Court of Appeals is operating in the exhortative 
mode, simply stating the questions that have to be answered pragmatically to get to 
the answer whilst Burrell seem to be relying on the descriptive mode relying on the 
history and incorporating the classical justifications in his analysis. As these 
approaches can lead to different outcomes, it is preferable therefore that the 
exhortative mode incorporates elements from the descriptive mode and hence the 
suggestion that patentability assessment tests or questions be informed and aligned 
with the classical justifications. Noting the difference between the two modes of 
looking at the law has the implication that ‗it can prevent us from writing history that 
is entirely divorced from the law as it was lived and experienced.‘415 
 
Formulating the model in this way not only exposes the disjoint that could occur in 
the historical study of patentability in practice, but could also highlight the limitations 
of comparative law. The comparative element imports into this discussion concepts 
that may seem identical in different jurisdictions but are not, more especially in a 
globalised world. Arguments may be perpetuated that are founded on assumed facts 
which have a different meaning in another jurisdiction or society as seen with regards 
to the history of the patent custom in the two jurisdictions compared in this thesis. To 
                                                             
413 Webber, fn.120, p.4. 
414 Ensign-Bickford (South Africa) (Pty) Ltd and Other v AECI Explosives and Chemicals 1998 BIP 
271 (SCA); Burrell, p.158. 
415 Webber, fn.120, p.9. 
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remedy this, we have to constantly re-define what the basic meaning of these concepts 
as applying to current conditions is. That is not to eliminate the individual history of 
the converging societies or the case law thereof, but it is to develop a tool that could 
resolve some of the borderline issues that confront a patent practitioner in a world of 
diminishing borders in which the pharmaceutical activities are typically carried out. 
Retaining previous local customs may not be helpful when other jurisdictions align 
themselves with an emerging internationalised justification for the patent system.  
 
In this comparative context South Africa is at the risk of appearing as a jurisdiction 
which easily curtails pharmaceutical patent rights, mostly because of the challenges it 
faces not only in trying to develop an internal pharmaceutical industry, but at the 
same time appease advocates against the patent regime in the arena of pharmaceutical 
patenting. The UK challenges lies in its position as a long time dispenser of the law 
and originator of the Commonwealth case law. With increasing growth of the 
pharmaceutical industry activity occurring outside of the UK and the mobility of the 
pharmaceutical firm, the emerging influence of the patent justifications from other 
jurisdictions may take pre-eminence. The relevance of the historical context of the 
English judgements may become doubted over time.
416
 As authors note, ‗the key issue 
we take from this pluralized historical context, however, is that any particular 
settlement can never be the final political economic settlement for IP, its protection, 
and enforcement.‘417 The preferable position is one where a converging view of the 
justifications is achieved relative to other jurisdictions. It is easier to set and make 
patentability decisions when there are closely approximated justifications for the 
patent between different jurisdictions. This is manifest in borderline cases where 
reliance on a particular justification could prove decisive in one jurisdiction where it 
would be opposite in another when the justifications are viewed differently.  
 
2.6 Conclusion 
 
From this exploration, the thesis forms the central argument that the historical 
justifications are all important in shaping a system that meets today‘s challenges in 
                                                             
416 Mustill LJ in Genentech Inc's Patent (Human Growth Hormone) [1989] RPC 147 stated that the UK 
has a rich history of case law and patentability principles, but warned that it should not be applied 
without regard to new and contemporary law. 
417 May/Sell, fn.121, p.27. 
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the pharmaceutical industry and serves to direct the making of enhanced patentability 
decisions. In pursuance of this argument, it has been suggested a conceptual 
framework under which to formulate an optimal contemporary patentability standard 
importing rationales from the history of the system. 
 
One of the fundamental qualities of the desirable patentability standard under the 
suggested conceptual framework is that anyone who has created an idea has a right to 
apply for, and be granted, protection for their creations, local or foreign, as long as it 
meets certain objective and universal criteria. Whilst Britain was free to formulate its 
own practices and implement an invention and innovation policy that exclusively 
benefited its population, this may not be feasible today. Then, there was no external 
agenda to contend with, no pressure on the local system for conformity to an 
international level.
418
 Thus, one way to promote and protect inventions now is by 
establishing a local patentability model that resonates with all types of patentees at a 
cross-jurisdictional level. South Africa is in a delicate position, as there are 
international treaties to take into consideration when tweaking the local patent system. 
International trade would be hurt by patent regimes not complying with international 
treaties
419
 that restrict national favourism policies that existed historically. 
  
The examination of the patentability history through the lens of what can be viewed a 
prosecutorial spirit for the ills and compensations for the past runs the risk of reducing 
patentability discussions and philosophy into mere politics of the direction the law is 
to develop. In such an environment, the merits of the historical justifications of the 
patent system may be lost. To prevent retrogression of the system, it is therefore 
concluded that the present patentability standards need to be developed in ways that 
recognise the interconnectivity, cumulative and global nature of most inventions and 
innovations. This has to be done while ensuring that patent holders, irrespective of 
origin, size or type, have, in the patent system, access and the opportunity to secure a 
reasonable return on their investment in producing inventions and are incentivised in 
bringing them to the public. 
 
                                                             
418 Fisher, fn.346, p.92. 
419 TRIPS Art 3 in particular requiring treatment of all patentees as equal. 
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CHAPTER 3 
 
THE INTERNATIONAL PATENTABILITY DIMENSION  
 
3.1 Introduction 
 
Integration and harmonisation of patentability laws is a continual process in the 
international arena. The cumulative convergence of international legal obligations 
restricts the domestic law-making process to narrower confines than what legislators 
are accustomed to.
420
 In the previous chapter it was established that historically, the 
UK and South Africa, were at liberty to develop their laws and patentability was 
decided domestically. There is now progressively less freedom for internal patent law-
making and the international and regional dimension of patentability takes more 
prominence in both the UK and South Africa. 
 
Numerous models are proposed that seek to attain the goal of a ‗global‘ patent. A 
growing consensus on appropriate international and regional instruments emerges, 
albeit slowly. Informal forums are increasingly used as stepping-stones to fully-
fledged binding legal instruments that both directly and indirectly determine the 
patentability standard.
421
 Nonetheless, shortfalls are apparent in most of the reforms 
suggested in the negotiations that have virtually divided developed and developing 
nations, North-South divide where the UK and South Africa usually find themselves 
on opposite ends. If a lasting or satisfactory solution of the appropriate legal standard 
is to be attained, the international instruments being formulated could seek to 
understand and incorporate the viewpoints, perspective and priorities of stakeholders 
in local jurisdictions where it is to be ultimately implemented. At the same time, the 
resultant harmonisation of laws should allow for the patentability standards to be 
compatible with industry practices and technological development and exploitation, 
                                                             
420  Bilateralism in Intellectual Property (2001) A Paper Prepared for Oxfam by Peter Drahos, Herchel 
Smith Senior Fellow in Intellectual Property, Queen Mary College, University of London, p.14. 
421 Informal discussion on patentability requirements are for example the WIPO SPLT informal 
Casablanca talks convened by WIPO director-General to ‗recommend future course of action for WIPO 
work program‘ http://www.wipo.int/edocs/prdocs/en/2005/wipo_upd_2005_241.html or USPTO 
informal talks with partner offices on driving substantive patentability harmonization initiative: 
USPTO David Kappos transcript of speech at an event entitled ‗A Dialogue with David Kappos, 
Director of the US Patent & Trademark Office‘, 
http://www.directorsroundtable.com/pdf/London%20Patent%20Program%204-4-11.pdf. 
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otherwise the laws would be ineffective in encouraging and protecting inventive 
activities. 
 
In recent times, there increasingly have been arguments that South Africa and 
developing countries generally have not benefited from high patentability standards or 
the patent system generally, especially in the area of public health and technology 
transfer.
422
 Despite the different underpinnings of the North-South patenting systems, 
it is suggested in this thesis that patentability should be universal for identical 
inventions, mainly due to globalized nature of the scientific world and uniformity in 
knowledge generation and utilization and trade practices.
423
 Despite the historically 
different patentability law development of the South African and UK jurisdictions, it 
is desirable that the protection of an identical invention should yield the same result, 
irrespective of the type, size or domicile of the patentee. That is to say any aspect of 
knowledge or invention, regardless of the beholder, should be protected similarly if it 
possesses similar predetermined characteristics. Indeed, it has been said that ‗[a]ny 
science, theoretical or applied, that would limit itself to one nation would be 
                                                             
422 Tensions include the realization that the benefits from TRIPS may have been over-estimated and 
from generally viewing IP as unsuitable to developing country‘s technological realities to arguments 
that higher patent requirements cannot suit developing countries‘ access to medicine needs.  For 
instance some have stated that ‗developing countries that used to have low patent protection 
standards…enjoyed a strong flow of information and technological development‘ and developed strong 
generic-based pharmaceutical industries and competitive markets. Pharmaceutical patenting both in 
developing countries and least-developing countries will negatively affect access to treatment: Wanis 
H. ‗Agreement on Trade-Related Aspects of Intellectual Property Rights and access to medication: 
Does Egypt have sufficient safeguards against potential public health implications of the agreement‘ 
(2010) The Journal of World Intellectual Property, p.24-46.  Some assert that developing countries 
sign TRIPS-plus deals as a way of competing for foreign direct investment (FDI) when they were 
united in resisting TRIPS which only has minimum standards: Bernieri R.C. ‗Intellectual property 
rights in bilateral investment treaties and access to medicine: The case of Latin America‘ (2006) 
Journal of World Intellectual Property, p.548-572, p.560. Some have asserted that high IP standards 
from TRIPS-Plus agreements have negative impact on developing countries, especially access to 
medicine whereby the ‗companies are pursuing the higher level of protection, not to increase R&D, but 
to limit generic competition‘, Kuanpoth J. ‗TRIPS-Plus intellectual property rules: Impact on 
Thailand‘s public health‘ (2006) The Journal of World Intellectual Property, p.573-591, p.589. There 
has been concern that the balance between IPR holders interests and technological achievement has not 
been achieved, para.3(ii) WT/WGTTT/W/6, p.7.  
423 Merton R.K. Social theory and social structure (1957) New York: Freepress, provides a doctrinal 
perspective positing that the behaviour and action of scientists is controlled by adherence to a set of 
universal norm of universalism, communism, disinterestedness, organised scepticism originality and 
autonomy and good science is argued to transcend cultural or geographical boundaries: Corbern W.W. 
and Loving C.C. ‗Defining science in a multicultural world‘ in Murphy P (ed) Reconsidering science 
learning (2004) London: Routledge.  Rimmer D ‗Learning about economic development from Africa‘ 
(2003) African Affairs, p.469-491 examines the causes of the differences in realities for the science 
human capital in national development and technology settings for developing countries. 
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laughable.‘424 This section of the thesis therefore argues for a universal but realistic 
patentability standard from this continuous international harmonization of 
patentability laws. This proposition is dual in nature. Firstly, it addresses the 
desirability of universal patentability standards, at least within the same fields of 
technologies.
425
 At the same time it is equally mindful and appreciative of the 
industrial realities and the possible effects of the history and technological 
developmental stages of different nations and trading regions seeking to attain a 
harmonized patent standard.
426
 
 
Such a standpoint seems appropriate for pharmaceutical activities. On one level, the 
universality of patentability standards at the global level puts an emphasis on the 
harmonisation and coordination of patentability laws. This is a complex task 
involving stakeholder consensus and agreement on the appropriate framework and 
often persuaded by an array of interests beyond the patentability standard, although 
the patentee and invention commercialisation maximization are the major 
beneficiaries. On another level, the realities of the implementation of those 
internationally negotiated instruments is an endeavour that requires careful thought 
and manoeuvring if it is to be successful practically and at industry level. 
Misunderstandings in the harmonisation process causes misapplication of the 
instruments and actions that undermine patentability standards and indeed abandoning 
of the regime by industrial players.
427
 To avoid not achieving the desired standard, it 
                                                             
424 Kozyris P.J. ‗Comparative law for the twenty-first century: New horizons and new technologies‘ 
(1994) Tulane Law Review, p.165-179. Cf Marković S.M. ‗The patent system- Not more than an 
instrument of public policy‘ in Pyrmont et al, fn.281, p.829, although acknowledging the desirability of 
uniformity, comments about the suboptimal value of patents in some geographical and social 
environments, which in order to be optimal would have to be directed at the use of the knowledge 
rather than its intrinsic qualities. 
425 There are views that patentability requirements in practice shift toward being technology-specific. 
See Burk D.L and Lemley M.A. ‗Is patent law technology-specific‘, University of California School of 
Law Public law and Legal Theory Research Paper Series, 2002, Research Paper No. 106, p.1-65 
available at http://papers.ssrn.com/sol3/papers.cfm?abstract_id=349761. 
426 A spectrum of views are expressed in this regard; some insist that developing countries should 
strictly comply with international patent instruments as they already serve their benefit (Straus, fn.264, 
p.47-63), some suggest that it is plausible that developing countries could use patents to their advantage 
as a transition tool in industrial development (Matthews D. Patents in the global economy: A Report to 
the Strategic Advisory Board for Intellectual Property Policy (SABIP), 2010, UKIPO, p.11-14, p.26 
and also, Maskus K.E. ‗Intellectual property challenges for developing countries‘ (2001) University of 
Illinois Law Review, p.457-473) whilst others are of the view that  patents are irreconcilable with 
developing nations‘ economies (Adusei, fn.56). 
427 Commentators assert that for inventive pharmaceutical processes, inventors are often faced with the 
dilemma of whether to patent them or keep them as trade secrets, a choice swayed by their perception 
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therefore requires a study of how the harmonisation process occurred and continues to 
occur in order to attain a realistic optimal patentability standard. 
 
The task of attaining a universal but realistic patentability standard is accomplished in 
the following manner. The chapter begins with an assessment of the universality and 
cross-jurisdictional characteristics of pharmaceutical knowledge and operation of the 
pharmaceutical industry. This sheds light on the qualities of pharmaceutical 
knowledge and forms the foundation for suggestions of optimal patentability 
standards for this sector at the international level. The chapter then moves onto an 
overview examination of the rationale for the patentability harmonisation efforts. This 
forms the basis for the subsequent individual examination of some of the international 
regimes that were instrumental in setting patentability standards that are consequently 
applied in the two countries compared in this study. Some of these instruments have a 
direct bearing on patentability standards, for instance the TRIPS Agreement. Others 
only brought to the fore particular aspects that are operative in the limbs to 
patentability standards and play a supplementary, yet significant role in establishing 
an optimal international standard, for instance the Paris Convention. That is to say the 
chapter not only looks at instruments that had the express intention of controlling 
patentability, but also the instruments that have a consequential effect even if it was 
unintended. An assessment is made of how these instruments can and are being used 
and also optimised for setting patentability standards that are suitable to the 
stakeholders in the two countries being studied. This assessment also briefly extends 
to patentability instruments that are designed for the regions of the two jurisdictions 
under study. This is because it is at this level that knowledge localization and 
clustering is observed and therefore studying harmonisation of patent law at regional 
level would be useful in revealing patentability issues peculiar to the countries under 
study.  
 
3.2 The international environment of pharmaceuticals activities 
 
Since the basic law of science applicable to pharmaceutical and related technologies is 
the same and applies everywhere, there is an underlying unified technology which in 
                                                                                                                                                                              
of the two regimes: Milgrim R.M. ‗Trade secret protection and licensing- a true alternative‘, in Costner 
T.E. (ed) Patent law review- 1972 (1972) New York: Clark Boardman Co, p.376. 
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principle can be applied everywhere.
428
 In knowledge economies therefore, 
knowledge resulting from innovation and inventive activities is not confined to 
national boundaries. The globalization of knowledge has been defined as the 
intensified interaction and interlinking of knowledge systems located in distant 
places.
429
 As such, there is potentially a random dispersion of knowledge or research 
output worldwide. 
 
However, the globalization of knowledge has limitations. Knowledge intensive 
industries tend to be geographically clustered to particular regions as opposed to being 
uniformly or randomly distributed across the world.
430
 This spatially selective 
expansion of knowledge is more pronounced in pharmaceutical industries.
431
 This is 
not incidental but fundamental in high-technology industries. As a result, over time 
there emerges centres of knowledge in particular regions of the world.
432
 
 
This regional knowledge clustering could be within particular countries and also 
between closely interrelated regions.
433
 The local political boundary can play a role in 
determining the extent of those knowledge clusters and sometimes the regional 
centres develop out of close-knit collaborations and alliances amongst industry actors 
across borders.
434
 That is to say political intervention of national states does not 
exclusively play a role in fostering the technological growth of those centres. National 
innovations systems play a role whereby the national government intervene in the 
markets in attempt to boost the competitiveness of national firms. For instance 
governments could seek to support local high-technology and inventive firms with 
                                                             
428 Freeman C. ‗The ―national system of innovation‖ in historical perspective‘ (1995) Cambridge 
Journal of Economics, p.5-24, p.15. 
429 Giddens A. Consequences of Modernity (1990) Cambridge, Polity Press, p.64. 
430 Storper M. ‗The limits to globalization: Technology districts and international trade‘ (1992) 
Economic Geography, p.60-93. 
431 Zeller C. ‗North Atlantic Innovative Relations of Swiss Pharmaceuticals and the Proximities with 
Regional Biotech Arenas‘ (2004) Economic Geography, p.83-111. Some assert that the growth and 
diffusion of intellectual human capital was the main determinant of where and when the American 
biotechnology industry developed: Zucker L.G., Darby M.R. and Brewer M.B. ‗Intellectual human 
capital and the birth of the U.S. biotechnology enterprises‘ (1998) The American Economic Review, 
p.290-306. 
432 Maskell P. Towards a Knowledge-based Theory of the Geographical Cluster (2001) Industrial and 
Corporate Change, p.921-943. 
433 Cooke P. ‗Regional innovation systems, Clusters, and the knowledge economy‘ (2001) Industrial 
and Corporate Change, p.945-974, p.952. 
434 McKelvey M., Alm H. and Riccaboni M. ‗Does co-location matter for formal knowledge 
collaboration in the Swedish biotechnology–pharmaceutical sector?‘ (2003) Research Policy, p.483-
501. 
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incentives or other frameworks intended to make firms more competitive.
435
 As a 
result, the pharmaceutical knowledge although freely available globally tends to 
remain embedded in particular regions where there is government support or a 
conducive environment for research work. 
 
The regional affinity of high-technology fields has a profound consequence for 
understanding pharmaceutical R&D activities at the global stage. Basic research 
knowledge, although valuable,
436
 becomes inadequate to remain competitive over 
rivals and applied knowledge takes more prominence.
437
 The applied knowledge is 
enhanced by proximity of the knowledge-generation stakeholders within a region and 
the constant interaction between the producers and users of the knowledge. As 
knowledge generation and utilisation becomes increasingly organised and structured, 
firms rely on tacit knowledge and know-how for achieving competitive advantage.
438
 
This results from the practice and application of that knowledge within those 
regions.
439
 Tacit knowledge is exchanged easier over short distances where there is 
more interaction between those stakeholders.
440
 Because there is the constant loop 
feeding into the life cycle of knowledge generation, there is more improved 
knowledge resulting from those interactions. The location or geography of the activity 
therefore in reality becomes a significant factor for the success of research intensive 
activities in the pharmaceutical industries. 
 
                                                             
435 For instance the South African Department of Science and Technology has shifted to a strategy to 
support biotechnology innovation hubs in selected provinces under the ‗Farmer to Pharma Innovation 
Plan‘; a concept that has been used in the UK for some time. Also, empirical research has shown that 
for investments made between 2002 and 2009 in 27 European countries, investors in 
biopharmaceuticals were less likely to choose countries with stringent price controls, preferring instead 
to move investments to countries perceived less stringent: Koenig P. and MacGarvie M. ‗Regulatory 
policy and the location of bio-pharmaceutical foreign direct investment in Europe‘ (2011) Journal of 
Health Economics, p.950-965; Also Kyle M.K. ‗Pharmaceutical price controls and entry strategies‘ 
(2007) Review of Economics and Statistics, p.88-99. 
436 Bush V. ‗Science-the endless frontier (1945) Washington DC: National Science Foundation, p.18-
19, views ‗basic research as the pacemaker of technological progress.‘ 
437 Basic and applied research co-evolve and interacting in a complex and iterative manner. David P., 
Mowery D. and Steinmueller E. ‗Analysing the economic pay-offs from basic research‘ (1992) 
Economics of Innovation and New Technology, p.79–90. Applied research enhances competitiveness: 
Stoke D.E. Pasteur‟s Quadrant-Basic science and technological innovation (1997) Washington: 
Brookings Institution Press, p.73. 
438 Johnson B., Lorenz E. and Lundvall B. ‗Why all this fuss about codified and tacit knowledge?‘ 
(2002) Industrial and Corporate Change, p.245–262, p.249. 
439 Malerba F. and Orsenigo L. ‗Knowledge, Innovative activities and industrial evolution‘ (2000) 
Industrial and Corporate Change, p.281-314. 
440Cornish S.L. ‗Product Innovation and the spatial dynamics of market intelligence: Does proximity to 
markets matter?‘ (1997) Economic Geography, p.143-165.  
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As a result of this particular characteristic of geographic affinity of knowledge 
generation and output, unlike the UK which is considered to be one of the global 
centres of pharmaceutical research, South Africa and developing countries are 
observed to lack significant pharmaceutical centres or complementary industries.
441
 
The region will in turn have less developed research capacities to address their health 
related and pharmaceutical needs and only resort to external providers for fulfilling 
those needs. To move to a stage where they can produce their own, they need 
coordinated strategies to forge alliances and develop regional research capabilities.
442
 
 
There have been suggestions that national technology policies, designed to give 
national firms competitive advantage based on superior technology have some 
limitations in a globalized world but there is evidence that if national governments 
internationalize its national cooperative R&D programmes while retaining their 
national objectives there is potential for national industries to thrive.
443
 It is important 
that South African develops its own R&D infrastructure.
444
 The market size may not 
be attractive to entry of new innovative drugs by foreign firms.
445
 The trend by home 
firms in developed countries toward shifting R&D for new pharmaceuticals abroad 
slowed down in the early 1980s.
446
 Therefore, there must be an impetus on South 
                                                             
441 There is acknowledgement by the South African government that pharmaceutical and biotechnology 
R&D lags behind comparable developing countries and hence the development of the ‗Farmer to 
Pharma‘ Innovation Plan by the Department of Science and Technology: 
www.engineeringnews.co.za/article/dst-to-build-south-africas-bioeconomy-2008-07-04. 
442 Tijssen R.J.W. ‗Internationalisation of pharmaceutical R&D: how globalised are Europe‘s largest 
multinational companies?‘ (2009) Technology Analysis & Strategic Management, p.859-879, p.875. 
Publicly funded health related research is considered to be helpful in this regard: Henderson R, 
Orsenigo L. and Pisano G. ‗The pharmaceutical industry and the revolution in molecular biology: 
Interactions among scientific, institutional and organizational change‘ in Mowery D.C. and Nelson 
R.R. (eds) Sources of industrial leadership: Studies of seven industries (1999) Cambridge: Cambridge 
University Press, p.276. An endogenous process of coalitional change has been observed with the 
parties that have attained a considerable R&D capacity: Shadlen K.C. ‗The political contradictions of 
incremental innovation: Lessons from pharmaceutical examination in Brazil‘ (2011) Politics and 
Society, p.143-174 
443 Fransman M. ‗Is national technology policy obsolete in a globalised world? The Japanese response‘ 
(1995) Cambridge Journal of Economics, p.95-119, p.118. 
444 Pharmaceutical and biotechnology researchers have suggested that the R&D infrastructure presents 
an opportunity to address many national health problems, 
http://www.pub.ac.za/docs/bio2biz2009_pharm.pdf. 
445 Authors argue that innovation leading to new pharmaceuticals specific for that market is dependent 
on the size and predicted profitability of that market: Linn J. and Acemoglu D. ‗The market size in 
innovation: Theory and evidence from the pharmaceutical industry‘ (2004) The Quarterly Journal of 
Economics, p.1049-1089, p.1084. 
446 Schnee J.E. ‗International shifts in innovative activity: The case of pharmaceuticals‘ (2001) 
Columbia Journal of World Business, p.122-132. Recently though there have been indications that 
some alliances are emerging whereby R&D is carried out in South Africa, but it is mostly with not-for-
profit organizations and academic institutes in the US. 
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Africa and developing countries to establish and sustain centres of pharmaceutical 
research directed to their local and regional needs. This is possible given that today‘s 
pharmaceutical R&D is no longer exclusively a stand-alone activity by single large 
companies, but can rather be defined by a complex web of inter-firm agreements and 
alliances that link the complementary assets of one firm to another.
447
 Pharmaceutical 
companies form the nodes in large-scale scientific networks that include 
biotechnology firms as well as universities.
448
 
 
It is suggested in this thesis that the strategies adopted for engagement in international 
debates on the appropriate patentability standard should reflect a forward-looking 
position of harnessing inventive and innovation potential and moving away from a 
laissez-faire attitude to pharmaceutical R&D by South Africa.
449
 ‗Moving from 
technology user to knowledge producer and innovator, however, cannot be effected 
without significant changes in the traditional institutions and the habits and practices 
of economic agents in developing countries, notably those related to learning, 
linkages, long-term investment and innovation.‘450 There has to be active organization 
of frameworks to meet those targets. Indeed it has been observed that the 
globalization of markets and harmonization of laws has meant an increased 
significance of the R&D of the pharmaceutical industry of South Africa and other 
developing countries at the world stage.
451
 
 
                                                             
447 It has been found that broad-based company capabilities, complementarities and similarities are 
factors that directly influence alliance formation between pharmaceutical and biotechnology 
companies, particularly when the biotechnology companies are newer and this influence is even more 
significant than other factors like patent common citations and patent cross-citations which are 
indicators of the research, science and technology relatedness between the pairs predicted to forge 
alliances: Rothaermel F.T. and Boeker W. ‗Old technology meets new technology: Complementarities, 
similarities and alliance formation‘ (2008) Strategic Management Journal, p.47-77. Some have 
suggested that intra-company, the large pharmaceutical organisational pyramid is an obsolete model, 
preferring instead the dividing of big firms ‗into a constellation of highly focused centers of excellence 
designed to improve transparency, increase the speed of decision making, and restore freedom of action 
to the scientists actually conducting the research‘, Garnier J. ‗Rebuilding the R&D engine in Big 
Pharma‘ (2008) Harvard Business Review, p.68-76, p.72. 
448Gassmann O. and Reepmeyer G. ‗Organizing pharmaceutical innovation: From science-based 
knowledge creators to drug-oriented knowledge brokers‘ (2005) Creativity and Innovation 
Management, p.233-245, p.235.  
449 Kruss G. ‗Balancing old and new organisational forms: changing dynamics of government, industry 
and university interaction in South Africa‘ (2008) Technology Analysis & Strategic Management, 
p.667-682, p.675. 
450 Mytelka L. ‗Pathways and Policies to (bio) pharmaceutical innovation systems in developing 
countries‘ (2006) Industry and Innovation, p.415-435, p.418. 
451  Fabio P. and Massimo R. Innovation and industry leadership (2007) Washington: John Hopkins 
University, p.134-135. 
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It can be concluded that pharmaceutical knowledge has a significant dual character at 
global level. The knowledge has a seemingly conflicting quality. It is universal and 
global but has tendency for regional clustering. Therefore legal engagement on 
patentability at global level must be appreciative of these realities if the UK and South 
Africa have the desire to develop and sustain technological capacities appropriate for 
their states and regions through the patentability standards they prescribe or 
support.
452
 The patentability suggestions they make at international platforms should 
acknowledge that innovation and invention activities is drawn to areas that are 
conducive for such activities. 
 
 
3.3 The international harmonizing legal frameworks 
 
Protecting one‘s invention is important not only in one country, but often around the 
world.
453
 As established in the preceding chapter, South Africa and the UK have their 
own laws and trading customs that developed in their particular histories. Most other 
countries also have their local patent laws.
454
 That means protecting an invention 
worldwide is an involved task that requires the adjustment of patent specifications and 
other formal and substantive obligations to specific requirements of the individual 
countries where protection is sought. To overcome this daunting task, for more than a 
century, some effort was spent in trying to harmonize patentability standards among 
different countries. South Africa and the UK have both been part of this process. The 
shift from the industrial era to the era of the knowledge-economies necessitated and 
expedited the blending of national and international law-making processes in order to 
standardise how patents are granted in different jurisdictions. The optimization and 
reform of local patentability requirements therefore takes some influence from 
international instruments that were initiated historically to attain standardised patent 
protection amongst trading partners. These international instruments range from 
                                                             
452 Commentators argue that obstruction of work on the harmonisation of technical patent law is 
counterproductive and misguided in view of industrial realities: Straus, fn.264, p.57. 
453 It is acknowledged that market segmentation by geographical regions still continues as a result of 
company patenting strategies and, to a lesser extent, as a result of patent fees. For example, the GSK 
patent pool shows patents for neglected tropical disease are obtained, counterintuitive, mainly in the 
developed countries, revealing that there must be a strategic element to such a decision. 
454 For a survey of historical patent laws of the world see Chartered Institute of Patent Agents, Patent 
laws of the world (1899) London: CIPA. 
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procedural and formal rules and customs for obtaining a patent to substantive rules 
governing patentability. They also range from regional institutions to international 
treaties that seek to prescribe the requirements of the appropriate patentability levels 
for protecting inventions by patents. 
 
In the midst of the resistance, or at least unease about convergence or harmonization 
of patenting requirements,
455
 there are legitimate grounds for the continual 
harmonization of the substantive patenting criteria. However, in order for different 
states to embrace a harmonized patent system, there are several pre-conditions to be 
met by the participating states. Ideally, the countries must have evaluated the classical 
justifications that sustain the patent system existence, including a cost-benefit 
analysis, and found it to be suitable for their locality.
456
 In the previous chapter it was 
established that the patent system is a system that promotes and protects inventing 
activity by conferring rights on individuals as rewards so that they are encouraged and 
incentivized to disclose their inventions to the public domain. The politicians or 
government policy makers engaged at international level patentability negotiations 
have to be convinced to effectively participate in a harmonized international system 
plan, which in their local constituencies may be perceived to mean loss of national 
identity or would face resistance from local lawmakers for the adopted instrument to 
be implemented.
457
 An important factor to the success of any international proposal is 
that the political stakeholders should accept a model that emphasizes invention and 
innovation, R&D and technology policies based on cross-jurisdictional economic 
interrelations rather than any isolationist stance that assumes domestic self-
sufficiency, which was feasible in less-intense knowledge economies. 
 
                                                             
455 Commentators criticise the standards as ‗international norms that do not fit African realities, needs 
and priorities‘: Ringo F.S. ‗The Trade-Related Aspects of Intellectual Property Rights Agreement in 
the GATT and legal implications for Sub-Saharan Africa‘ (1994) Journal of World Trade, p.122-123.  
456 Colonies generally did not have this freedom of choice and there are now very few countries that 
have no patent system. There are compromises to be made in any system; in the classical justification 
of the patent system, benefits accruing have to be more than costs. 
457 Both the UK and South Africa have parliamentary mechanisms for scrutiny of treaties before 
approval; notably there were constitutional debates on the role of the legislature and executive which 
arose from the signing and coming into force of the Agreement establishing the WTO in South Africa: 
Harrington J. ‗Scrutiny and approval: the role of Westminster-style Parliaments in treaty-making‘ 
(2006) International and Comparative Law Quarterly, p. 121-160, p. 144-146. Cf. Alabi M.O. ‗The 
legislatures in Africa: A trajectory of weakness‘ (2009) African Journal of Political Science and 
International Relations, p.233-241, asserting that unlike their developed counterparts, African 
legislatures are seen as constrained in the capacity to effectively influence and scrutinize public policy 
and law making processes. 
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As a consequence therefore any proposed statutory changes must be mutually and 
directly or indirectly beneficial to the country‘s domestic invention and development 
mandate and international trading mandate in order to motivate the legislatures‘ 
resolve that is needed to implement them.
458
 The resultant patent benefits are assumed 
to filter to society or the public of the country. The necessary statutory changes must 
also be perceived to benefit industry in the countries concerned in order to encourage 
the lobbying of statutory changes that political actors might tend to ignore.
459
 The 
industry benefits are essential because on the one hand there would be no point in 
having a patent system in place that is not in use
460
 and on the other, industry has 
proven the ability to lobby an unconvinced legislature for monumental statutory 
changes. That is to say therefore, there exists a symbiotic relationship between the 
law-makers, both internationally and locally-mandated, and the industry stakeholders 
to be controlled by those rules. Without attaining this delicate harmonization 
equilibrium, the system would fail to address the concerns of industry. As Coleman 
reminds us ‗patenting is not obligatory‘,461 an off-balance system would consequently 
be of limited relevance in practice. 
 
There has been a significant similarity of statutes in countries over the years 
concerning patentability.
462
 Given the convergence of technology-creation and 
innovation activities, it is logical that the patentability laws be refined towards true 
similarity beyond the pseudo-similarity in the statute books. Hence, substantive patent 
law harmonisation fulfils the needs of technology-generation and knowledge-
intensive industries beyond their localities or jurisdictions. It does this by lowering the 
need to carefully study multiple patentability requirements in multi-country patent 
application, litigation or enforcement efforts for the same invention or technology. 
                                                             
458 There are assertions that pharmaceutical companies canvassed legislative players to bring about 
TRIPS, Drahos P. and Braithwaite J. Information feudalism: Who owns the knowledge economy (2002) 
London: Earthscan, p.14. Others assert that the TRIPS Agreement was established on a quad pro quo 
basis, with states advancing parochial issues on the agenda: Lehman B.A. ‗Intellectual property as a 
trade, health and economic issue‘ (2003) St John‟s Journal of Legal Commentary, p.417-427. 
459 Economic nationalism by politicians mitigates against regional political and economic integration 
initiatives, which are beneficial to businesses involved in cross-border businesses and ‗this explains 
why in Southern Africa there is so much inertia but little progress‘ in harmonisation initiatives: 
Chingono M. and Nakana S. ‗The challenges of regional integration in Southern Africa‘ (2009) African 
Journal of Political Science and International Relations, p.396-408. 
460 Grubb, fn.256, p.45. 
461 Coleman A. Intellectual Property Law (1994) London: Longman Group Ltd, p.40. 
462 As shown in chapter two and as will be shown later in the chapter, for example that South Africa 
law is based on the EPC. 
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This in turn means harmonization creates certainty of patent rights and patentability 
standards across the jurisdictions participating in the harmonisation. Industry thrives 
on certainty of protection afforded by the granted patent in different jurisdictions. The 
more certainty is brought to the patent worldwide, the more relevance and 
significance of the international patent system is created for the users. 
 
It is submitted that harmonization should be more than the simplification of the 
administration of the system or imparting certainty and clarity for the user. It should 
be in tandem with the philosophy and justification of the optimal patent system. That 
means the desirability of the similarity of laws is premised on attaining and 
perpetuating the ideals of the elements to be protected in an invention. This is directed 
to the intrinsic qualities that the patentability standard should always seek out of a 
patentable invention. The tension in this process is that the local innovation and 
inventing policies usually seek to protect their own knowledge and inventions yet 
these are universal. The standpoint adopted in this thesis is that an identical invention 
must be given identical protection at the international level. Other promotion 
strategies and supplementary mechanisms for supporting the inventing activity may 
differ between countries according to their needs but not the patent protection for the 
ensuing invention.
463
 That is to say the patentability standard between South Africa 
and UK must be similar even though the respective domestic policy makers may 
employ different mechanisms of promoting internal innovation. 
 
The thesis now turns to examine some of the international instruments that have a 
bearing on the patentability standards in South Africa and the UK. It highlights and 
examines the features that were introduced by the instruments as they relate to the 
limbs to patentability in the two countries under study. Some of these instruments 
introduced aspects that were only incidental to patentability but form the basis of 
setting an optimal patentability standard for international pharmaceutical inventions. 
Observations are made of how the patentability elements from the international 
instruments were integrated into both South Africa and the UK laws. 
 
 
                                                             
463 Rzakhanov Z. ‗Regulatory policy, value of knowledge assets and innovation strategy: The case of 
the Orphan Drug Act‘ (2008) Research Policy, p.673–689. 
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3.3.1   The Paris Convention 
 
Over a century ago, some form of harmonisation of patent laws started with the Paris 
Industrial Property Convention of 1883.
464
 The desire for harmonised patent laws was 
influential and laid the foundation for establishing the Paris Convention.
465
 The 
Convention was founded on the principle of reciprocity such that inventors from 
member states could enjoy foreign protection for their inventions. This instrument 
reduced the practical hardship faced by inventors desiring to have protection in other 
countries by securing them the same filling date and priority in other countries.
466
  
 
This Convention guaranteed the nationals of all member states the same treatment that 
was received by a member‘s own nationals, at least notionally.467 This is the concept 
of national treatment that is prevalent in contemporary international agreements to 
which South Africa and the UK are party to. Countries joined the Convention with the 
expectation of patent protection for their citizens abroad.  
 
The principle to be extracted from this instrument is that it presents a foundation upon 
which to base patentability standards for inventions to be patentable in multiple 
jurisdictions. Under this harmonising framework is established the concept that 
applicants are, irrespective of origin, not prejudiced of rights subsisting in their 
inventions.
468
 The merit of the invention rests upon the qualities of the invention, and 
not the background of its originator. This Convention is thus a platform upon which 
appropriate harmonised standards could be set. The patentability standards should not 
                                                             
464
 Paris Convention for the Protection of Industrial Property, 20 March 1883,828 U.N.T.S. 107, as 
revised at Brussels on December 14, 1900, at Washington on June 2, 1911, at the Hague on November 
6, 1925, at London on June 2, 1934, at Lisbon on October 31, 1958, and at Stockholm on June 14, 1967 
and as amended on September 28, 1979. The UK acceded in 1884 while South Africa only acceded in 
1947. There have been constant revisions of the Convention since its inception: Paterson G. The 
European patent system: The law and practice of the European Patent Convention, 2nd ed (2001) 
London: Sweet and Maxwell, p.13. The UK ratified the latest version in 1969, which took place in 
1967 in a Revision Conference in Stockholm: Notification date 10 March 1969. 
http://www.wipo.int/edocs/notdocs/en/paris/treaty_paris_7.html. South Africa also acceded to the 1967 
(Stockholm) text, in 1974: Notification date 24 December 1974 
http://www.wipo.int/edocs/notdocs/en/paris/treaty_paris_60.html 
465 Neumeyer F. ‗Unification of European Patent legislation on the Common Market‘ (1967) Modern 
Law Review, p. 725-737, p. 726. 
466 Vojacek J. ‗A survey of the principal national patent systems‘ (1936) New York: Prentice-Hall, Inc, 
p.21. 
467 Art 2(1) of the Paris Convention. 
468 Paris Convention, Art.2(2). 
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deprive the inventors the rights in their inventions as a result of originating or being 
based in a foreign territory yet the invention benefits society at large, even beyond 
borders. 
 
Practically, this Convention allows inventors in a signatory country to file an 
application in their home country first and then file corresponding applications within 
one year in any other signatory country.
469
 The filing date for the second applications 
is recognised to be the date the patent was first filed in the original country. This 
means this legal instrument is directed mainly at establishing priority.
470
 This is an 
important advantage for prior art purposes, on which novelty and non-obviousness 
assessments and other patentability requirements are based.  
 
The Paris Convention is not accurately a harmonising instrument.
471
 It is unsurprising 
that its features contributing to patentability standards could be seen as of limited 
value.  This is because it only provided for easier access to foreign patent systems 
through the priority system and national treatment principle. The Convention was 
directed at allowing applicants from another signatory country to be treated just like 
resident citizens of the foreign country with respect to the patent application and 
prosecution process only. There were no express arrangements for standardising 
patentability requirements in the national treatment received and priority that was 
claimed. Therefore for the instrument to be more useful, countries would additionally 
have to have similar substantive patentability standards. The current similarity of the 
UK and South African patentability standards will be examined in more detail in 
subsequent chapters. 
 
The establishment of priority for foreigners helps in the creation of a system that is 
appreciative of foreign prior art. It counteracts the effect of an invention 
communicator being treated as the true-and-first inventor. This sets the theme for 
establishing strict novelty, which is now in existence both in South Africa and the 
UK. As seen in the historical analysis in the previous chapter, the Paris Convention 
establishment occurred when there was a still a remnant of worldwide legalised 
                                                             
469 Paris Convention, Art.4C(1). 
470 Paris Convention Art.4A(1). 
471 Torremans, fn.189, p.29. 
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misappropriation practices and so nations were becoming interested in protecting their 
nationals over larger geographical areas. However, they did not necessarily have an 
interest in providing reciprocal protection to foreigners per se themselves. 
Recognition of foreign applicants was more of a trade-off or a by-product. Therefore, 
the full potential integral to the Convention‘s foundational principles were not 
attained because of this stance.
472
 It is also likely that due to the developmental stages 
some of the advanced economies were in at that time as net consumers of technology, 
there was no motivation to fully embrace and enforce this standard. A paradigm shift 
gradually occurred out of the realisation that a jurisdiction that is becoming net-
exporter of technology needs global patent protection to maintain its competitive 
advantage globally. 
 
The Convention‘s limited harmonising effect and substantive patentability utility does 
not detract from its significant contribution to patentability requirements setting. It has 
been said by the WTO Appellate Body that the national treatment principle has been 
‗the cornerstone of the Paris Convention and subsequent IPR international 
conventions‘.473 The impact of the Paris Convention has further been magnified by 
the TRIPS Agreement. TRIPS Agreement, Art.2 requires WTO members to comply 
with the minimum requirement of the Paris Convention even if they are not members 
of the Convention.  
 
The Convention also established a mechanism whereby inventions are patentable if 
there is acknowledgement of the true inventor.
474
 This principle took a while to be 
accepted especially with the existence of the convenient and pragmatic first-to file 
system which emphasises the first to reach the patent office rather than the one to 
invent. Building on this foundation is the idea that the purpose of patent protection 
should be directed to the originator or inventor with the exclusion of undeserving 
individuals. Both South Africa and the UK observe this principle. This right is 
incorporated into UK law as a result of EPC Art.62. The Patent Act 1977, s.7 requires 
an inventor (or joint inventor) or deviser to make a patent application in the same way 
as Patents Act 1978, s.27. Consequently, the Convention is a foundation of a system 
                                                             
472 Paterson, fn.464, p.13. 
473 United States – Section 211 Omnibus Appropriations Act of 1998, Appellate Body Report, 
WT/DS176/AB/R, 2 January 2002, para.241. 
474 Paris Convention, Article 4ter. 
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that imposes a moral obligation for the granting of patents to the originators of the 
invention. Thus, the Convention supports the idea that the inventors have to have 
natural rights in the invention that receives protection, a standard suggested in the 
previous chapter. 
 
Furthermore, the recognising of originators of inventions for patent grant prevents a 
convoluted definition of newness. Vaver suggests that even an intelligent IP-lay 
person would not understand the definitional and linguistic meanings of patent 
statutes which may articulate one thing whilst meaning another.
475
 The standard 
should be such that when newness is assessed, it should not be possible for one 
individual to re-invent old knowledge, especially of foreign origin or claim it as their 
own. The starting point for any enquiry into the novelty of an invention is enhanced 
when there is a clear identity of the originator of the patentable knowledge, because it 
is from this standpoint that prior art can be properly demarcated. A practical 
illustration of this is when small inventors approach big companies whereby they are 
given an option to either to disclose their inventions, with no guarantees that the firms 
will not usurp their ideas, or simply lose audience and the opportunity to 
commercialise the invention.
476
 This is significant as it has been suggested above that 
the smaller biotechnology inventor, characteristic in both the UK and South Africa 
pharmaceutical industries, plays an important role in pharmaceutical research output. 
 
The Paris Convention was intended for purposes other than establishing a harmonised 
patentability standard. It however introduced and established the fundamental 
principles and components that have a remnant effect that are usefully incorporated 
into a global system that seeks to optimise patentability standards. It has been shown 
that South Africa and the UK both embrace these principles. 
 
  
                                                             
475 Vaver, fn.11, p.147. 
476 Wilkof N. ‗Protection of trade and other secrets: A property right, equitable right or contractual 
obligation? Does it matter?‘ 14 December 2009, Lovells LLP Lecture Series, London. 
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3.3.2   Patent Cooperation Treaty  
 
The chapter now turns to the Patent Cooperation Treaty (PCT)
477
 which is a 
procedural instrument that has some aspects that impact on substantive patentability at 
the global dimension for both the UK and South Africa. The PCT generally provides a 
mechanism for patent applications across different jurisdictions. It allows for a single 
international application to be made in local patent offices designating member states 
in which protection is sought.
478
 In other words, the PCT‘s focus is to simplify the 
procedural aspects of making applications in different countries.
479
 Alluding to the 
fact that the instrument may play multiple roles, the view of some delegations to this 
treaty negotiations was that ‗one of the aims of the…PCT, which should be the 
principal aim above all other aims, is to save effort, time, work and money – both for 
the applicant and for the national offices where patents are sought for the same 
invention in a number of other countries.
480
 By implication therefore the treaty could 
be viewed as one that functions more than just as a procedural convenience 
mechanism. A wide array of secondary functions has been attributed to the PCT. For 
instance, commentators state that the ‗instrument aims to contribute to the progress of 
science and technology, to perfect the legal protection of inventions, …to foster and 
accelerate the economic development of developing countries through the adoption of 
measures designed to increase efficiency of their legal systems instituted for the 
protection of inventions.‘481 
 
The instrument has the effect of standardising and harmonising the process of filling 
patent applications simultaneously in many countries because of the uniform 
requirements for applications. After the application is made, a search and examination 
is conducted by one of the search authorities.
482
 A report is issued on the state of 
patentability requirements. This implies assessment is made of novelty, non-
                                                             
477 The PCT was signed on 19 June 1970, came into force on 1 June 1978 and was amended in 1979, 
1984, and 2001. 
478 In South Africa, Chapter VA (section 43A-43F) of Patent Act 1978 is inserted by s.38 of Act no. 38 
of 1997, date of entry into force 16 March 1999.  Date of entry into force in the UK was 24 January 
1978 by Patents Act 1977, s.89. 
479 PCT Art 1(2) provides that one of its objects ‗is to simplify and render economic the obtaining of 
protection for inventions…‘. 
480 Document PCT/DC/7, Observations of the delegation from Austria. 
481 Baxter J.W. World patent law and practice, 2nd ed (1973) Sweet and Maxwell: London, p.209. 
482 The International Bureau of WIPO in Geneva receives the application from the receiving office and 
sends it to a patent office designated as an International Search Authority. 
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obviousness, industrial applicability and patentable subject matter in accordance with 
the Treaty provisions.
483
  However, these are non-binding in the member states and 
are only indicative of validity as ‗the objective of the international preliminary 
examination is to formulate a preliminary and non-binding opinion‘ of validity.484 If a 
member state has patentability standards that are significantly different from those of 
the treaty, the search report will be of less use, especially in many borderline cases of 
patent validity. 
 
Unexamined patents can end up being administrative inconveniences.
485
 A patent 
system of unexamined or inadequately examined patents falls short of the public 
information justification that is attributed to the existence and perpetuation of an 
optimal patent standard as suggested in the previous chapter. Advocates for 
establishment of the PCT system in fact ‗thought that the interest of the public would, 
to a great extent, be served if the application were made public within a relatively 
short period of time after filing.‘486 Therefore, this treaty is of importance when 
examination of the patent disclosure made to the public is emphasised. The UK, 
unlike South Africa, examines patent applications. South Africa, on the other hand, 
theoretically benefits from this instrument as there is an absence of substantive pre-
grant examination when a patent is applied for through the national route. The Patents 
Act 1978, section 34 and Patent Regulations 1978 Rule 41 only prescribes formal 
examination.  
 
South Africa can complement the quality of granted patents by introducing a search 
and examination for the national route or making PCT search reports compulsory for 
the international application route, which is currently barred for international 
applications.
487
 This is important in light of the statistics that reveal that almost half of 
court disputed patents were found to be invalid.
488
 In industrial inventive activities 
                                                             
483 PCT Art.33, PCT Rule 64. 
484 PCT Art.33(1). 
485 Seville C. EU intellectual property law and policy (2009) Cheltenham: Edward Elgar, p.73. 
486 WIPO, The first twenty-five years of the Patent Cooperation Treaty (PCT) 1970-1995 (1995) WIPO 
Publication, Geneva, p.10. 
487 South African Patent Act s43F(3)(j), substituted by s6 of Act no. 58 of 2002, barring the public the 
right to require the patentee to provide anyone with search reports of the patented subject matter issued 
in any country after the expiry of five years after grant. 
488 There are estimates that almost half of granted South African patents are invalid based on the 
number of success in infringement defenses or failed prosecutions. Generally, Harms L.T.C. ‗The role 
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reliant on patents for extensive prior art searches,
489
 a situation where a high number 
of patents that fall below the required patentability levels are allowed to be in 
existence, even for a short time before disputes could be lodged, are unhelpful. It can 
even prevent others from entering the market. A redeeming assumption for allowing 
some potentially invalid patents would be that the patentee would be prevented by 
patent maintenance costs from maintaining a patent which in all likelihood would be 
held invalid in litigation. However this only applies to smaller-sized inventors; larger 
firms can afford to maintain doubtable patents. 
 
The PCT is not an instrument for the actual grant; that is left to the national patent 
offices. The main advantage of the PCT in this respect is that it delays the entering 
into national phase of the application. This means that the patentee has time to 
experiment and validate the invention before proceeding with cross-jurisdictional 
protection. It also gives them time to reflect on whether their application actually 
meets the patentability standards in light of the search report.
490
 This can in effect 
increase the quality of patents granted under this route. The public education 
justification of the system in the two jurisdictions is therefore potentially enhanced as 
a result of the delay mechanism for applications made under the PCT. 
 
The PCT is also helpful with regard to the quality of the patented inventions at the 
international level. Some patent applications would not be pursued in other 
jurisdictions if it is determined that they would not survive validity assessments. That 
is because when the application is made the applicant ‗receives information on prior 
art and patentability early enough to decide whether or not to file in other 
countries.‘491 In addition, in some peculiar way, the public store of knowledge is 
enriched with new but obvious knowledge, whereby the applicant discloses the new 
information in an application but then considers this to be below the obviousness 
                                                                                                                                                                              
of the judiciary in the enforcement of intellectual property rights: intellectual property litigation under 
the common law system with special emphasis on the experience in South Africa‘ (2004) European 
International Property Review, p.483-492. 
489 More efficient patent search and ranking tools have been designed to facilitate high-technology 
R&D because patent literature is seen as an invaluable source of knowledge progression: Li Z., Tate D, 
Lane C. and Adams C. ‗A framework for automatic TRIZ level of invention estimation of patents using 
natural language processing, knowledge-transfer and patent citation metrics‘ (2012) Computer-Aided 
Design, p.987-1010. 
490 Tritton G. (et al) Intellectual property in Europe (2008) London: Sweet and Maxwell, p.70. 
491 Document PCT/DC/7. 
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bar.
492
 As a result, even competitors and third parties can be nudged in the direction of 
the applicant‘s research interest and acquire some insight into the new but non-
inventive knowledge. 
 
The concept of priority developed under the Paris Convention is further modified 
under the PCT. PCT Art.11(3) states that the filing date of an international patent 
application ‗shall be considered to be the actual filing date in each designated State.‘ 
This means that, whilst the Paris Convention provides for an automatic right in 
international priority whenever a national application is made, the PTC provides for 
an automatic right to convert an international application into a national application 
within 20 months from the priority date of the international application.
493
 This is 
beneficial for applicants to the extent that at this stage after the priority date, they 
would be in position to establish which jurisdictions their patents would be valid in. 
At this point, making the decision to protect an invention in the two countries for 
instance is then dependent on the domestic patentability standards as perceived by the 
applicant. 
 
The PCT is a procedural and formalities instruments. However, it is concluded that it 
plays a crucial role in patentability determination because it standardises the 
definition of prior art and priority amongst the member states. These are important 
elements in the definition and determination of patentability as will be seen in more 
detail in subsequent chapters dealing with the novelty and non-obviousness 
requirements. The instrument also provides the option of examination of applications, 
thus fulfilling the public disclosure justification for the patent. As a result the 
instrument plays a significant role in the assessment of South African and UK 
patentability standards for inventions that emanate from foreign jurisdictions. 
 
 
  
                                                             
492 After the expiration of 18 months WIPO publishes applications, unless were withdrawn earlier, 
together with the international search report, which is contained in the copies sent to PCT Contracting 
States. 
493 Paterson, fn.464, p.19. 
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3.3.3  The Agreement on Trade Related Aspects of International Property Rights 
 
The General Agreement on Tariffs and Trade (GATT) negotiations commenced when 
the nations of the world recognized the desirability of international trade agreements 
that prevented national protectionism that existed.
494
 The GATT is a multilateral 
instrument governing international trade aimed at reducing trade barriers. The 
Uruguay Round created the TRIPS Agreement. The Uruguay Round also established 
the WTO to oversee GATT and TRIPS. The TRIPS Agreement is primarily the result 
of concern among developed countries that lobbied for protection against international 
piracy of IPRs.
495
 
 
The TRIPS Agreement formally recognizes the need to promote ‗effective and 
appropriate means for the enforcement‘
496
 of IPRs and provides for procedures for the 
multilateral prevention and settlement of disputes relating to private IPRs. One of the 
practical effects on patents has been the harmonization of the world‘s patent laws on 
minimum protection requirements. To this end, the TRIPS Agreement requires that all 
signatories enact domestic legislation, or any appropriate measure, to implement the 
minimum levels of patent protection provided by the Agreement.
497
 Thus, developed 
and non-developed signatories alike must adhere to an international baseline for 
patent protection and ensure effective, expeditious, and impartial application of patent 
rights. This means the patent granted in the UK and South Africa should theoretically 
be similar, in terms of minimum standards in novelty, non-obviousness, industrial 
application and excluded subject matter.
498
 However variations of patentability 
between the two jurisdictions could occur as a result of the adoption of standards 
higher than the minimum or different domestic interpretations of what those minimum 
standards are. 
                                                             
494 Byrne J.G. ‗Changes on the frontier of intellectual property law: An overview of the changes 
required by GATT (1995) Duquesne Law Review, p.121-137, p.125. Although ‗the South African 
government...purposely adopted a policy of secrecy regarding its position in the GATT‘, it was 
understood it participated on the basis of tariff reductions, implementation of a more liberalised trading 
system than formerly and an endeavor to enter world markets competitively: Eisenberg G.S. ‗South 
Africa, countertrade and the General Agreement on Tariffs and Trade‘ (1993) Stellenbosch Law 
Review, p.143-175, p.143-145. 
495 Correa C.M. and Yusuf A.A. (ed) Intellectual property and international trade: The TRIPS 
Agreement, 2nd  ed (2008) AH Alphen aan den Rijn: Kluwer Law International, p.30. 
496 TRIPS Preamble. 
497 TRIPS Art.1(1). 
498 TRIPS Art.27(1). 
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As shown in the previous chapter, it is generally accepted that patents existence are 
justified as they encourage innovation and dissemination of practical technical 
knowledge. The TRIPS Agreement Art 7 affirms that patents ‗should contribute to the 
promotion of technological innovation and to the transfer and dissemination of 
technology‘ in the global trading regimes. The TRIPS Agreement therefore has 
intrinsically the justifications as suggested in the previous chapter that patentability 
standards should encourage and incentivise invention and innovation and the transfer 
of knowledge to the public domain. Therefore both South Africa and the UK as 
signatories have the mandate to design patent laws that achieve this standard. 
 
The TRIPS Agreement Art.7 affirm the notion that patents involve a balance of rights 
between patent holders and the public that can be extracted from the classical 
justifications of the patent system. Continuing the theme of rewarding inventors with 
monopolies, while preserving an informed public domain for society seems to be the 
centre of the protection regime presented by this instrument as it provides that the 
whole purpose of the protection should be ‗to the mutual advantage of producers and 
users of technological knowledge and in a manner conducive to social and economic 
welfare, and to a balance of rights and obligations.‘499 This is a critical point that any 
domestic patentability standard must seek to attain. The definition of what is 
patentable must not be detrimental to the interests of either party to this delicate 
balance. Therefore, in as much as innovation advancing society is important, so are 
the interests of knowledge producers in that process. 
 
The TRIPS Agreement is viewed as undoubtedly the most important international 
instrument on patents.
500
 It has the most impact on patent issues in local patenting 
regimes. It accomplishes partial harmonisation of patentability by prescribing the 
minimum patentability standards. However, the TRIPS Agreement does not explicitly 
define what the minimum standards really are. This in one way can be viewed as its 
main flaw for clarity and certainty for the international inventor. It only prescribes 
what may be called de facto patentability standards: the minimum standards are 
stipulated but open to wide interpretation by domestic courts that could be 
                                                             
499 TRIPS Art.7. 
500 Guist J.E. ‗Noncompliance with TRIPS by Developed and Developing Countries: Is TRIPs 
Working?‘ (1997) Indiana International & Comparative Law Review, p.69-85, p.70. 
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substantially different so as to refer to standards at the opposite end of the 
patentability scale. Chisum observes that ‗as long as inconsistencies persist between 
courts….it is difficult to claim that any sort of ―minimum standard‖ can be said to 
exist on a global scale.‘501 This makes TRIPS patentability standards more of a 
theoretical stipulation that can be undermined by the interpretation domestic policy-
makers adopt or the assessment methods adopted by courts in developing case law. 
The existence of different patentability standards across world jurisdictions can be 
attributed to this aspect. For example, ‗local‘ novelty and ‗strict‘ novelty requirements 
can and do meet the TRIPS Agreement obligations of a patentable invention being 
new. Local and strict novelty respectively refers to recognition of only local prior art 
and all prior art including foreign prior art for newness assessment. This wide 
asymmetry in interpretation distorts the handling of other patentability issues that are 
being discussed, for example the international definition of prior art or the appropriate 
judicial tools or integers in the enquiry of patentability benchmark attainment by 
inventions. It will be seen in more detail in chapter five how the newness patentability 
standard is currently judged in the UK and South Africa. 
 
Given the historical patentability requirements of the UK one had to fulfil based on 
the nationality or domicile in order to gain protection, TRIPS is an improvement for 
patentees.
502
 At the start of the internationalisation of IP laws, countries sought to 
prevent discrimination against their nationals. As it was seen above, this objective was 
pursued in the Paris Convention by recognising the principle of national treatment. 
The national treatment principle, continuing under the TRIPS Agreement, protects 
against discrimination of foreigners vis-a-vis nationals. It means that ‗each Member 
shall accord to the Members treatment no less favourable than it accords to its own 
nationals.‘503 The Paris Convention only sought to enforce this principle of national 
treatment and no other sets of standards to be complied with in this respect. The 
TRIPS Agreement on the other hand, although restricting the members in providing 
no more favourable treatment to its nationals than foreigners, positively prescribes the 
designing of IP laws that have inherent minimum standards for all IPR holders. This 
                                                             
501 Chisum D.S. ‗Patentability under TRIPS: The need for uniformity‘ (2006) The Indian Journal of 
Law and Technology, p.1-7. 
502 As seen in chapter two, unlike South Africa, the UK historically discriminated against foreigners 
although in the intervening period this practice was removed. 
503 TRIPS Art 3.1. 
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prevents discriminatory treatment of foreign inventors. For pharmaceutical inventions, 
the discrimination of foreigners has become a contentious issue in South Africa and 
policy makers have at times expressed the desire to treat locals differently.
504
 
 
There tends to be some observable differences in the way the TRIPS Agreement 
standards are viewed in the two jurisdictions under comparison in this thesis. The law 
makers in the UK and other developed Members States have largely agreed with the 
private rights arguments, particularly highlighted by pharmaceutical companies, that 
patents are necessary to encourage the research into and production of better 
medicines.
505
 The patent must give their proprietor control over the R&D, production 
and marketing of their new medicines nationally and internationally. There is also a 
perception that developed signatories support the TRIPS Agreement because it 
promotes enhanced enforcement of rights in both developed and developing countries 
by undertaking a proactive marketing and trade surveillance role.
506
 The essence of 
the argument is that more innovative and better medicines will thus be produced 
under this model. 
 
This demonstrates that the UK deploys the argument that public interest will be 
served through allowing the individual or private right to subsist through provision of 
adequate legal protection to the individual if their pharmaceutical invention meets the 
patentability standard. Only effective and harmonised legal protection of individual 
rights can sustain the high-risk investment that results in innovation benefits to 
                                                             
504 A shift in South African patent policy has been the desire to offer more protection to domestic 
inventors or domestic knowledge, a policy which Harms, who is the chair of the Department of Trade 
and Industry ministerial advisory council and deputy president of the Supreme Court of Appeals, 
considers ‗ill-conceived‘, Harms L.T.C. ‗A few negative trends in the field of intellectual property 
rights‘ (2009) European Intellectual Property Review, p.540-548, p.545-547. 
505 An empirical study found that over sixty percent of pharmaceutical inventions would not have been 
introduced had it not been for patents; See Mansfield E. ‗Patents and innovation: An empirical study‘ 
(1986) Management Science, p.173-181. Also, Drahos P. ‗Global Property Rights in Information: The 
Story of TRIPS at the GATT (1995)‘ Prometheus, p.6-19. 
506 Callahan/Wasunna, fn.401, p.190-192. Other commentators take the view that the linkage or 
convergence of trade with IP in not a novel feature with TRIPS but dates back to the first half of the 
twentieth century and neither was the erosion of public interest introduced by TRIPS but rather is a 
result of the international patent system securing the private rights of patentees: Menescal A.K. ‗Those 
behind the TRIPS Agreement: The influence of the ICC and the AIPPI on intellectual property 
decisions‘ (2005) Intellectual Property Quarterly, p.155-182. 
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society.
507
 The patentability standards and accompanying policy could be said to 
reflect this standpoint. 
 
The development of new pharmaceutical, biotechnology and others technologies is 
important to South Africa and developing countries too, in the field of health and 
combating major epidemic and endemic diseases.
508
 The TRIPS Agreement has been 
receiving criticism from developing countries for raising patentability standards that 
impede such ambitions.
509
 Sometimes mistakenly so. Although the end goal is similar, 
the approach taken by South Africa, and developing countries generally, emphasises 
that the public interest comes before private interest in patents.
510
 Questions however, 
arise as to the sustainability of this approach wherein there is no feeder mechanism for 
creation of those inventions that the public asserts control over.
511
 That is to say a 
precursor condition is that the patentability standard must allow or encourage 
inventors to engage in research that will result in future solutions that benefit the 
public before public interest assertions could be made over that resulting knowledge 
or technology. Indeed commentators have stated that ‗there is a need for a 
fundamental change in development strategy and a transformation of SADC 
economies from being mere producers of raw materials and passive consumers of 
manufactured goods into dynamic and industrially diversified economies. Central to 
this project of industrial development and diversification, is more investment in, and 
                                                             
507 Smith K.G.D. ‗Profitability, risk and investment in research and development–the UK 
pharmaceutical industry‘, in Teeling-Smith G.(ed) The pharmaceutical industry and society: A study of 
the changing environment and economics of the international industry (1972) London: Office of Health 
Economics. 
508
 Gastrow M. ‗Great expectations: The state of biotechnology research and development in South 
Africa‘ (2008) African Journal of Biotechnology, p.342-348. 
509 Kongolo T. and Mori M. ‗Is the dilemma of developing countries real under TRIPS?‘ (1998) The 
Management Review, p.73-91. Also, Attaran A. and Gillespie-White L. Do patents for antiretroviral 
drugs constrain access to AIDS treatment in Africa? (2001) Journal of American Medical Association, 
p.1886-1892. 
510 Lanoszka A. ‗The global politics of intellectual property rights and pharmaceutical drug policies in 
developing countries‘ (2003) International Political Science Review, p.181-197, p.190-191. 
511 Authors assert that the setting of national patent policy is a policy lever that directly contributes to 
the incentivising and funding for private enterprise to create new pharmaceutical products within a 
jurisdiction as part of an innovative global collective: Pazderka B. and Stegeman K. Pharmaceutical 
innovation as a collective action problem: An application of the economic theory of alliances (2002) 
Journal of World Intellectual Property, p.158-191. Nwabueze R.N. ‗What can genomics and health 
biotechnology do for developing countries‘ (2005) Albany Law Journal of Science and Technology, 
p.369-432, analyses genomics and health biotechnology that is of actual and potential benefit to 
developing countries and the strategies that could transform them from mere consumers into producers 
of IP. 
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mainstreaming of, R&D.‘512 The success of such ambitions to be producers of IP 
goods rather than merely consumers, seem to be dependent on engaging private 
players in patent frameworks that are certain to bring some reward to them. 
Guaranteeing protection if resulting inventions attain the patentability benchmarks is 
one such way. 
 
Indeed the patent system should be used to encourage research in these fields, as 
provided for by TRIPS Art.7. International procedures for the dissemination of such 
technology in the developing countries and to the benefit of the population could 
primarily be promoted by the patenting standards that are put in place. To nurture the 
growth of local industries, the patent system could be modelled and perceived by 
those willing to make research investments to be sustainable in the long-term,
513
 
without undue space that allows unfavourable arbitrary policy decisions against that 
venture. That is to say, it would be counterproductive to the public health cause to 
have a system that would make scientists, and their venture capitalists, consider 
investing or engaging in other technology sectors where their patent rights would not 
be abridged on vague policy grounds.
514
 
 
It can be concluded that the TRIPS Agreement encompasses the classical 
justifications for the patent system to operate effectively in a global society. The 
prescribed minimum standards seek to make patentable an invention only if it meets 
the predetermined patentability conditions. This however could be complicated by the 
fact that there is no agreement generally between South Africa and the UK or 
developing and developed countries as to the right balance between the interests of 
the individual against the public in the set patentability standards. As such, the TRIPS 
Agreement highlights the need for balanced policy setting as this can impact on 
patentability rules by shifting the balance to either party. 
 
 
                                                             
512 Chingono/Nakana, fn.459, p.406. 
513 Dimasi J.A., Hansen R.W., Grabowski H.G, Lasagna L. ‗Cost of innovation in the pharmaceutical 
industry‘ (1991) Journal of Health Economics, p.107-142. 
514 Lal D. Appraising foreign investments in developing countries (1975) London: Heinemann 
Educational Books Ltd, p.89-91 and 266. 
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3.3.4   Substantive Patent Law Treaty (SPLT) 
 
As it has been seen in previous sections of the chapter, there have been numerous 
attempts to harmonise the procedural aspects of patentability.
515
 Substantive 
patentability harmonization and standardisation has been lagging behind and is to a 
limited extent. There have been arguments against such moves.
516
 Nevertheless, it has 
been attempted so as to complement the strides made in procedural aspects. This 
section of the chapter seeks to highlight some of the key milestones in the attempts at 
multilateral level to harmonize substantive patentability standards. It is suggested here 
that although the instrument may not have been successful, it presented a platform and 
opportunity for the examination of substantive patentability elements which are 
pertinent to pharmaceutical industry activities at the global level.  
 
In the WIPO‘s Standing Committee on the law of Patents (SCP), substantive patent 
law harmonisation through the draft SPLT was perhaps the most ambitious and yet 
the most unsuccessful patentability instrument proposed at the international stage. It is 
notable that the UK and South Africa were largely on opposing sides on the 
negotiation debates on this instrument. Its ambitious aims were met with considerable 
resistance and magnifying of North-South divisions, resulting in intermittent 
negotiations and numerous deadlocks. Consequently, patentability harmonisation in 
this forum could technically either still proceed, albeit with modified goals, or finally 
declaring that the causes of the negotiations stalling are irresolvable and therefore 
dropping the whole idea.
517
 Whatever the status of the negotiations, it can be pointed 
out that the needs the instrument sought to address are not automatically eradicated 
because there was disagreement in the negotiations at this forum. A danger with non-
progress is that this instrument may be overtaken by other events which could be 
adverse to South Africa and developing countries as they may not be party to those 
                                                             
515 For instance the Paris Convention and PCT. 
516 Reichman J.H.R. and Dreyfuss R.C. ‗Harmonization without consensus: Critical reflections on 
drafting a Substantive Patent Law Treaty‘ (2007) Duke Law Journal, p.85-129. 
517 The former comptroller of the UKIPO has stated that in the harmonisation initiatives under the 
SPLT, ‗if we are not prepared to change, due to misapprehension of our national interests or any other 
reason, we should indeed also have the courage to say so and refuse another round that would be 
doomed to fail‘: Brimelow A. ‗―Not seeing the woods for trees‖: Is the patent system still fit for 
purpose?‘ (2011) The Journal of World Intellectual Property, p.230-237, p.236. 
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break-away negotiations but could be compelled by the need to enter into those 
resultant regimes by market necessities.
518
 
 
Discussions on the draft SPLT started at the fifth session of the SCP.
519
 The 
discussions focused on issues of direct relevance to the standard of grant and validity 
of patents, in particular, the definition of prior art, novelty, inventive step or non-
obviousness, industrial applicability or utility, the drafting and interpretation of claims 
and the requirement of sufficient disclosure of the invention. At the tenth session of 
the SCP,
520
 the EPO submitted a proposal designed to focus on what was referred to 
as an initial package of priority items including the definition of prior art, grace 
period, novelty and inventive step.
 
This could be viewed as a reasonable segmented 
tackling of substantive patentability issues in this committee. According to the 
proposal, once international agreement was reached on those prior art related issues, 
discussions in the SCP could then focus on the other broader issues that may be 
affected by patentability.
521
 While this proposal obtained the support of a number of 
delegations,
522
 a number of other delegations opposed it including South Africa, and 
emphasized the need to examine all the provisions of the draft as a whole.
523
 This was 
an occasion where South Africa and the UK seemed to have opposing approaches to 
the setting of substantive requirements. 
 
A contentious issue within the discussions for the SPLT was prior art.
524
 This is 
important in the sense that many issues of patentability crystallises upon this concept, 
                                                             
518 According to Kappos, the USPTO is on mission to engage significant patenting players in a regime 
to harmonise patentability whatever the form of that regime could be: 
http://www.directorsroundtable.com/pdf/London%20Patent%20Program%204-4-11.pdf. Also, the 
executive director of the American Intellectual Property Law Association asserts that the continued 
frustration of the goal of a harmonized system by Friends of Development within WIPO could be 
overcome by like-minded countries agreeing on a harmonized system outside of WIPO if necessary. He 
stated that ‗just as European nations took advantage of Article 19 of the Paris Convention to conclude 
the EPC in 1973, so too should like-minded countries not fear… to adopt the limited package outside 
WIPO if necessary‘: Remarks of Kirk (1991) American Intellectual Property Law Bulletin, p.442-43. 
Also, some American policy-makers promised unilateral action at international forum because of 
constant resistance by developing countries at WTO: Zoellick R.B. ‗America will not wait for the 
won't-do countries‘ Financial Times, September 23, 2003. 
519 ‗Draft Report, prepared by Secretariat‘ WIPO, Geneva: WIPO/SCP/9/8. 
520 The EPO together with the United States and Japan submitted a proposal harmonising patent law: 
Document SCP10/9. 
521 Document SCP10/9, p.2-3. 
522 ‗Statement received from Brazil‘ WIPO, Geneva: WIPO/SCP/11/4, p.2. 
523 ‗Statement received from Brazil‘ WIPO, Geneva: WIPO/SCP/11/4, p.2, para.5. 
524 ‗Draft Substantive Patent Law Treaty‘ WIPO, Geneva: WIPO/SCP/10/4, p.15. 
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procedural or substantive. If there is no agreement on the definition and handling of 
prior art there is likely to be no agreement on many other issues on substantive patent 
law, and indeed procedural law. If the definition of prior art is settled then the 
substantive or procedural determination of novelty and non-obviousness for instance, 
becomes less complex. 
 
An example of a mechanism that is intrinsically built into the substantive patentability 
system and tackled in the SPLT negotiations, is a well-defined and exacting newness 
requirement. This is not adverse to developing countries. Such requirement promotes 
the protection of only novel or non-trivial knowledge. Setting a standard that requires 
patent quality to be of levels where the public is taught something new or previously 
not known would not have been achievable only when the SPLT was turned into a 
kind of developmental treaty emphasising broad development objectives. IP 
academics, IP policy-makers and legislators versed in IP are capable of evaluating 
this. Developmental and other non-IP officers on the contrary, would have an 
inclination toward broader developmental goals that are of interest to their wider-
composed constituencies.
525
 Negotiations for a developmental treaty would 
necessarily have to include a wider stakeholder range. 
 
Besides defining each limb to patentability, the draft treaty also had allowable tests 
for patentability evaluation.
526
 Various alternative proposals were negotiated for use 
in ascertaining whether each limb to patentability was satisfied. These would be 
helpful to the scientists working in the pharmaceutical field in establishing whether an 
invention would be judged patentable or not under the new harmonised framework. 
There would not be the need to know the case law of numerous jurisdictions in order 
to form an opinion on whether the invention would meet the patentability standards. 
This aspect of the treaty would have narrowed down tests that could be used in 
                                                             
525 With developing countries it is notable that the negotiations are attended by individuals who have no 
direct or significant influence in local patent policy and practice, even though there is a fund for 
attendance at these negotiations. Some commentators state that ‗the truth remains that most delegations 
from developing countries attending the SCP meeting are members of the diplomatic corps and are not 
versed in IP‘: Visser C. ‗The policy-making dynamics in intergovernmental organisations: a 
Commentary on the remarks of Geoffrey Yu‘ (2007) Chicago-Kent Law Review, p.1457-1466, p.1459. 
Statement of the Group of the Friends of Development, Document SCP/11/4, included a wide array of 
development goals in the negotiations. 
526 These are contained in the ‗Draft Regulation under the Substantive Patent Law Treaty‘, Document 
SCP/10/3 and ‗Practice Guidelines Under the Draft Substantive Patent Law Treaty‘, Document 
SCP/10/6. 
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assessing patentability. A positive effect of this feature therefore would have been 
fore knowledge of the test to use in each patentability circumstance. At the same time 
this would compromise the ability to apply a more situation-specific test to particular 
circumstances, particularly in addressing new or immature technologies. The tests as 
applied in both the UK and South Africa would have been narrowed down as a result 
of this substantive harmonisation instrument. 
 
 
3.3.5 Summary of the international patentability instruments 
 
The international instruments examined above seek to standardize and harmonize the 
various essential elements of patentability standards in cross-border patenting. They 
also seek to prescribe the rules of making the determination as to whether an 
invention does indeed have those patentability qualities in practice. They contribute 
components that assist in the formulation of a harmonised patentability standard. 
 
The Paris Convention brought recognition to the international arena that inventors 
must not be discriminated against by their origin; rather it is the quality of the 
invention that is to be judged for whether it meets the requisite patentability standards. 
In global economies this principle has gained more significance than at the time when 
it was originally proposed. The patentability laws in both South Africa and the UK are 
grounded on this principle. 
 
 The PCT is an improvement to the global patent system as it acts as the interface 
between the procedural and substantive requirements of the system and complements 
the practical attainment of the classical justifications of the patent system. It does this 
by standardising the identification of prior art between independent states, which is a 
central concept in setting patentability standards or assessment methods. Global 
agreement on the assessment of novelty or non-obviousness is thus brought closer to 
conclusion.  
 
The TRIPS Agreement harmonises international patent law by prescribing the 
minimum patentability standards for inventions to be considered patentable. These 
have been shown to have been in existence in both the UK and South Africa 
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legislations prior to the conclusion of the instrument. The standards are however open 
to different interpretation in the respective national courts.  
 
The SPLT represented a typical instrument that could be used in the interpretation of 
patentability standards agreed on at an international level. However, differences 
existed, mainly between the developing and developed nations, particularly on 
whether the instrument is at present appropriate for setting patentability requirements 
across the globe. The SPLT also went further and sought to prescribe allowable tests 
that could be used in interpreting those standards in practice. Both the UK and South 
Africa would have had to reform their domestic rules of assessing the patentability of 
inventions. The intended effect of these harmonising instruments is that an identical 
invention would receive more or less identical practical patent protection worldwide. 
 
 
3.4  The influence of regional patentability instruments 
 
The chapter now turns to examine instruments that govern patentability at the regional 
level. The section compares the influence of regional patentability law as exerted on 
both the UK and South Africa. 
 
Historically there has been a gradual erosion of patent law differences between 
countries by the harmonization of regional patenting instruments. This trend has been 
running in parallel with those instruments that can be seen as truly international 
harmonization in nature. In Europe, the patentability in previously contrasted systems 
of law is consistently being approximated to a single European patent system, which 
some membership of the judiciary view as the de facto standard inherited into the 
South African jurisprudence.
527
  
 
The current European regional patent system, which the UK is party to, is not strictly 
a regional patent, but it is a bundle of national patents effective in designated 
nations.
528
 Commentators assert that reform is needed for ‗a single unified European 
                                                             
527 Harms, fn.488, p.483. 
528 Di Cataldo V. ‗From the European patent to a Community patent‘ (2002) Columbia Journal of 
European Law, p.19-32, p.20. 
 132 
patent system, rather the madness of needing to litigate validity and infringement of 
equivalent patents in every European jurisdiction.‘529 This reveals that there is a long-
standing desire to have a truly European patent more than the one that is currently 
available. It can therefore be said that European regional influences are already 
shaping the scope of patent law in the UK.
530
 Indeed, an EU unitary patent framework 
has been agreed on that creates a unitary patent and unified patent court.
531
 
 
South Africa on the other hand is not yet bound by any regional instrument of IP law. 
There is the debate on whether she should indeed be part of the English-speaking 
African patent regime,
532
 more than merely as an observer member in this system. As 
there is still no firm commitment taken to join the regional patent system, the laws in 
South Africa do not have any formal or binding influence to or from this regional 
regime.
533
 
 
 
3.4.2 The Strasbourg Convention 
 
This section aims to show how the Strasbourg Convention
534
 established the norm for 
generally accepted patentability standards, which are incorporated into both UK and 
South African law. The Convention is regarded as having laid the ground for 
internationalization of patent law.
535
 As regard was paid to the Paris Convention,
536
 it 
                                                             
529 Taylor R. ‗Against an integrated intellectual property code: a response to ―Reforming intellectual 
property law: an obvious and not-so-obvious agenda‖‘ (2009) Intellectual Property Quarterly, p.281-
287, p.286. 
530 Huniar K. ‗The enforcement Directive– Its effects on UK law‘ (2006) European Intellectual 
Property Review, p.92-99, p.92. 
531 See http://www.epo.org/law-practice/unitary.html. Debates remain on the ultimate effectiveness, 
extent of use and costs of the system: Pagenberg J ‗Unitary patent protection in the EU‘ (2012) The 
CIPA Journal, p.687-693. 
532 Some practitioners are opposed to joining of ARIPO, mainly on the basis that it would serve no 
useful practical purpose and it would degrade the South African patent system practice: Burrell, p.24-
25. 
533 There are no regulatory or statutory instrument that proves South Africa is willing to commit to 
ARIPO, beyond the public utterances that South Africa intends to join by ARIPO Secretariat, 
Department of Trade and Industry officials and Ministerial Advisory Committee members. 
534 Convention on the Unification of Certain Points of Substantive Law on Patents for Inventions, 
opened for signature 27 November 1963, ETS 47, entered into force 1 August 1980 (Strasbourg 
Convention). 
535 For instance, Terrell on Patents, p.7; CIPA Guide to Patents Act, p.40. Pila states that the purpose of 
the Strasbourg Convention ‗is to establish certain foundational principles of European patentability‘: 
Pila J. ‗Article 53(b) EPC: A Challenge to the Novartis Theory of European Patent History(2009) 
Modern Law Review, p.436-462, p.437. 
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incorporated principles from earlier established instruments. Importantly, as it turned 
out, the provisions of the Convention were incorporated into the EPC as will be seen 
later in the next subsection.
537
  
 
The Strasbourg Convention was initiated within the framework of the Council of 
Europe in 1949 with the aim to create a European Patent Office, a proposal which was 
initially rejected by the Council‘s committee of experts.538 However, work continued 
but there was broad division of the harmonization of patent law negotiations into 
procedural and substantive reforms, which took different paths. 
  
Negotiations on the procedural and administrative aspects of patent law resulted in the 
Formalities Convention.
539
 The Formalities Convention provided for establishing 
maximum requirements for a filing date and other requirements during the application 
stages of a patent. South Africa and Israel were the only Non-member States of the 
Council of Europe to join the Formalities Convention.
540
 The UK ratified this 
Convention in 1955 and later denounced it in 1976. 
  
Work on harmonizing substantive patent law continued and resulted in the Strasbourg 
Convention in 1963, which the UK signed in the same year. The Convention was 
ratified in 1977 and entered into force in 1980.
541
 
 
The Strasbourg Convention preamble points out that the unification of substantive 
patent law assists innovation in the European context, more than just within the 
national boundaries.
542
 The preamble also recognizes that successful unification 
                                                                                                                                                                              
536 Preamble states that having regard to Art.15 of Paris Convention. 
537 For instance in Netherlands (supported by Italy and another) v European Parliament and another 
(supported by the European Commission) (Case C-377/98) [2002] FSR 574, para.22, the court noted 
that in defining an invention the EPC reproduced verbatim the first sentence of the Strasbourg 
Convention Art.1. 
538 The so-called ‗Longchambon Proposal‘ which was rejected by the Consultative Assembly but 
formed further work for European patent harmonisation: Pila J. ‗Article 52(2) of the Convention on the 
Grant of European Patents: What did the framers intend? A study of the travaux preparatoires‘ (2005) 
International Review of Intellectual Property and Competition Law, p.755-787, p.756 and Wadlow C. 
‗Strasbourg, the Forgotten Patent Convention, and the Origins of the European Patents Jurisdiction‘ 
(2010) International Review of Intellectual Property and Competition Law, p.123-149. 
539 European Convention relating to the Formalities required for Patent Applications, signed in Paris 
1953. 
540 South Africa accessed 28 November 1957 and it entered into force 1st January 1957. 
541 Ratification was on 16 November 1977 and entered into force on 1st August 1980. 
542 Strasbourg Convention Preamble. 
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significantly contributes to the realization of the global patent. This convention may 
have been drafted for European states, but membership was later opened to members 
of the Paris Convention.
543
 South Africa however did not join the final substantive 
instrument. 
 
For South Africa, even though it was not party to these negotiations as the UK, the 
final instrument has had internal influence on the direction of patent law development 
in its jurisdiction. The current South African Act is based on precedents of the 
Strasbourg Convention. This soft law influence derives from the association of the 
country to the earlier negotiations of the final regime. That is, although the 
participation of South Africa ended with its joining only of the intermediate 
instrument, it is unsurprising that the subsequent and final substantive convention 
would be influential in the domestic patentability requirements. As such, South 
African commentators are of the view that a major milestone on the path to the 
signing of substantive and procedural patent conventions was the signing of the 
Strasbourg Convention.
544
 
 
The substantive patentability criteria provisions of the Strasbourg Convention are 
almost identical to those of the EPC.
545
 Article 1 provides that patent shall be granted 
for inventions that are susceptible of industrial application, which are new and which 
involve an inventive step. Article 3 to 5 respectively qualifies what industrial 
application, newness and non-obviousness are. 
 
Prior to conclusion of the convention, European nations had varied patentability 
requirements, and the negotiation helped narrow down these divergent views. As a 
transition condition, Article 12(1)(a), a reservation clause, provided for countries the 
right to refuse grant of pharmaceutical and food product patents.
546
 This instrument 
therefore smoothed the transition of the patenting of pharmaceuticals within this 
regional group, such that it became acceptable for these to be patentable within the 
various domestic regimes some of which heretofore barred their patenting. 
                                                             
543 Article 10, Strasbourg Convention. 
544 Domanski A. ‗Multinational patent conventions and their role in South African law‘ (1998) South 
African Law Journal, p.310-321, p.315. 
545 Wadlow, fn.538, even though the original EPC had 180, while the Strasbourg Convention had 12 
articles. 
546 The UK is part of the majority that did not use this clause, but Italy and Switzerland opted to use it. 
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3.4.3 European Patent Convention (EPC) 
 
The individual patent systems of Europe have their long histories which, as was 
shown in the previous chapter, provided the origin of most of the modern patent laws 
of the world. This section is now concerned with the patentability requirements 
established under the EPC and with its relationship to the coexisting domestic system 
in the UK. The statutory drafting of the current South African patent law was copied 
from this regional instrument.
547
 The aim therefore is to show how the EPC 
contributed to unifying not only diversified patent laws within the European region, 
but also had influence in bringing South African laws into more or less similar 
patentability standards with the UK. This convergence brings closer the attainment of 
a universal patentability as suggested in this thesis. 
 
By 1949 there were voices that advocated for the setting up of a European Patent 
Office.
548
 At the time patent customs in Europe were extremely varied ranging from 
registration systems to systems with some form of search and examination before 
grant such as that in the UK.
 549
 This diversity of laws posed a challenge to the 
creation of a single European market and for this reason the possibility of a unified 
patent system of some sort, coexisting with the economic system, was proposed. By 
1959 the possibility of a separate patent system alongside national systems emerged 
and the move towards an EC patent system began. This however was thwarted by the 
failure of the UK to join the EC and when negotiations on UK membership of the EC 
finally broke down in 1963 the debate as to whether a European or EC system should 
be adopted intensified. At the same time a basis for the harmonization of European 
patent law was established through the Strasbourg Convention. By this stage though, 
the project had already split into two moves, on the one hand a system for members 
                                                             
547 Burrell, p.34. Berman C. ‗Patents and trade marks- moves toward internationalism‘ (1973) De 
Rebus, p.181-183. 
548 Bossung, O. ‗The Return of the European Patent Law to the European Union‘(1996) International 
Review of Intellectual Property Law Review, p.287-315. 
549 Mahne K.P. ‗A Unitary Patent and Unified Patent Court of the European Union: An analysis of 
Europe‘s long standing attempt to create a supranational patent system‘ (2012) Journal of the Patent 
and Trademark Office Society, p.162-191. 
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and non-members of the EC and on the other hand a unitary system primarily aimed 
at EC membership. 
 
These two diverging paths led to the EPC and the Community Patent Convention 
(CPC)
550
 and by 1975 both conventions had been signed. However, whilst the EPC 
eventually came into force in 1977, the CPC never came into force, at least in its 
original form. 
 
The purpose and object of the EPC is to establish a mechanism within the European 
states whereby ‗protection may be obtained in those States by a single procedure for 
the grant of patents, and the establishment of certain standards governing patents so 
granted.‘551 This is to say the EPC intends to harmonize European patent law both in 
grant procedure and to a certain extent the patentability standards granted patents.
552
 
Therefore the EPC has to be implemented and interpreted with harmonization of 
patent laws between the states in mind. However this desired situation has not been 
possible to fully attain in practice. There have been divergent reasoning and decisions 
between national courts and the Enlarged Board of Appeal for instance.
553
  
 
EPC Art.2(1) states that patents granted by virtue of this Convention shall be called 
European patents. Such patents in the UK shall ‗have the effect of and be subject to 
the same conditions as a national patent.‘554 To give effect to this provision the EPC 
was statutory transposed into UK national law by Patents Act 1977 section 77(1). 
That is a European patent designating the UK is to be treated as a patent under the 
Patents Act 1977. The only difference is that the European patent as a whole is open 
for limited period to opposition proceedings before the EPO.
555
 In the end, the granted 
patents through either route are considered to be equivalent. 
 
Domestic law provided for a mechanism for eliminating inconsistencies between 
domestic and regional patents though Patent Act 1977, section 130(7). The courts 
                                                             
550 Convention for the European Patent for the Common Market as revised, Luxembourg, 15 December 
1989. 
551 EPC Preamble. 
552 Paterson, fn.464, p.24. 
553 Paterson, fn.464, p.24-28. 
554 EPC Art.2(2). 
555 Third parties can launch opposition in the EPO within nine months after grant: EPC Art.99.  
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have explained, in Merrell Dow Pharmaceutical Inc v HN Norton & Co. Limited,
556
 
that UK tribunals must construe patentability such that so far as possible it has the 
same effect as the EPC, being cognisant of the decisions of the EPO. 
 
It has been said that when interpreting, inter alia, patentability, regard should be had, 
not only to the equivalent provisions of the EPC, but also their travaux preparatories, 
for instance, the official minutes which led to the adoption of the final text of the 
Convention.
557
This, in effect, has meant tribunals and courts must treat the 
preparatory text and foreign decisions interpreting the EPC as persuasive authority.  
 
The UK is bound to follow the patentability requirements in the EPC and is 
influenced by the EPO or EPC Contracting States interpretation. The difference with 
South Africa lies in the fact that although the patentability requirements are copied 
from the same instrument, there is no obligation to observe interpretation by the EPO 
or the member state. South Africa has to interpret the laws, although derived from the 
EPC, according to its local policy prescription. This potentially leads to an identical 
invention assessed for patentability differently in South Africa and the UK even 
though an identical original statutory source is used. This shows how harmonisation is 
a complex undertaking that goes beyond mere similarity of laws in statute books. 
 
The UK is bound to interpret patentability in line with EPC. Although South African 
courts are not bound to follow European law, they have however gleaned assistance 
from the interpretation of EPC patentability law. In McCauley Corporation Ltd v 
Brickor Precast (Pty) Ltd,
558
 MacArthur J. resorted to EPO policy guidelines for 
elucidation of terms that have a bearing on patentability limbs, where he said ‗a 
similar view is expressed in the European Patents Handbook‘ and ‗I proposed to 
follow that approach in considering whether the present invention is new.‘ 
 
Although such similar patentability interpretations may be achieved in some cases, as 
more official policy is formulated that may be dissimilar in the two jurisdictions, the 
interpretation of the statutes may progressively differ. As such, disparities in national 
                                                             
556 [1996] RPC 76, para.12. 
557 CIPA Guide to the Patents Act, p.1240. 
558 1989 BP 314 (CP), p.334. 
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law continue to grow between the two regions and nations under comparison in this 
study. That is, in using a very similar law derived from an identical source, there is 
still the possibility of disparities in patentability interpretation in the protection of 
identical inventions in South Africa and UK. The need for similar obligations in 
patentability interpretation is manifest if identical inventions are to be protected to the 
same extent in what are becoming progressively transnational innovative 
pharmaceutical activities. 
 
It is important that harmonizing instruments highlight the basic tenets upon which 
ideal patentability standards should be built. A robust patentability mechanism devoid 
of subjective influences is needed to deal with the technical realities of the 
pharmaceutical industries which spans beyond the confines of any particular country. 
Any international instrument, proposed or reconsidered, must embrace the 
justifications for an optimal standard in order to be acceptable and implemented by 
the respective stakeholders. Instruments that seek to deviate from this would have to 
be carefully considered to establish how it would enhance the established patentability 
rules.  
 
 
3.5 Conclusion 
 
The harmonization of patentability standards follows an intricate network of paths. 
Continual optimization of the system means gains through one forum can be 
relinquished in another forum if the potential consequences of international 
agreements are not carefully studied as to how they would impact on patentability of 
inventions. Thus, coordinated and integrated reforms are crucial to attain a clear, 
consistent and robust patentability standard especially within a system that is forward 
looking and far-sighted. Not only should attention be paid to the harmonization of 
patentability standards and methods of patentability assessment but also to the 
formalities rules that can influence the substantive patentability standard. 
 
Patents granted in the UK and South Africa do not exclusively originate in these 
countries. This is an indication of the cross-jurisdictional and globalized nature of the 
inventive and industrial processes and the necessity of foreign protection for 
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inventions. There can no longer be a view of indifference as to whether inventions by 
foreigners are protected or not as was in the UK historically. On the other hand there 
has to be a paradigm shift to move South Africa from being a simple deposit system 
of patents by foreigners and international actors into a regime where these patents 
represent technology generation and exploitation within the domestic environment. It 
is suggested that countries focus on making international patentability standards work 
within a framework that is also appropriate for their needs.
559
 
 
Harmonization of patentability can start or consolidate a culture of invention and 
innovation across borders. In order for the patent system to optimally promote and 
protect inventions, the basic tenet is that there must be a worldwide agreement on how 
an identical invention receives identical protection. Although different assessment 
methods of an identical invention do lead to the same result, there are situations where 
this is not so and it is unhelpful to have to predict the likely result of validity for a 
single invention using varied assessment methods of different parts of the world. In 
the next chapters, there will be examination of whether the respective patentability 
assessment methods in the UK and South Africa for the patentability limbs achieve 
this benchmark. 
                                                             
559 For instance commentators, pointing out that the current pharmaceutical R&D pipeline for most 
neglected and tropical diseases remains weak, suggest strategies that would allow international 
collaborative drug discovery relying on clear IP systems: Nwaka S, Ramirez B, Brun R, Maes L, 
Douglas F, et al. ‗Advancing Drug Innovation for Neglected Diseases-Criteria for Lead Progression.‘ 
(2009) PLoS Neglected Tropical Diseases 3(8): e440. doi:10.1371/journal.pntd.0000440. 
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CHAPTER FOUR 
 
UNPATENTABLE AND EXCLUDED SUBJECT MATTER 
 
 
4.1 Introduction 
 
The thesis so far has mainly focused on the philosophical and theoretical aspects of 
the general patentability requirements as applied in the two jurisdictions. Attention 
now turns to the detailed examination of the specific individual limbs to patentability. 
The first limb to be explored is the requirement that to be patentable an invention is 
not to be constituted of excluded subject matter and the complementary question of 
how subject matter is considered a patentable invention in law. 
 
The continual release of new pharmaceuticals into the market is usually attributed to 
innovation and invention. In industry, innovation is generally considered as the 
generation and turning of new ideas into marketable products and services.
560
 Others 
have conceptualised innovation as ‗a process that begins with an invention, proceeds 
with the development of that invention, and results in the introduction of a new 
product, process or service to the market place.‘561 It is noted that there tends to be an 
interchange in the use of the invention and innovation terms which may be acceptable 
within business circles but could be misleading in the context of patent law.
562
 There 
are caveats to be attached to such definitions if innovation and invention is to be 
clearly understood and distinguished in the context of unpatentable and excluded 
subject matter in patent law.
563
 Innovation is broader in the sense that ‗it has a 
                                                             
560 Kirchhoff B.A. Entrepreneurship and dynamic capitalism: the economics of business firm formation 
and growth (1994) Westport: Praeger Publishers Inc. 
561 Edwards K.L. and Gordon T.J. Characterization of innovations introduced on the US market in 
1982: Final Report (1984) Small Business Administration: The Futures Group, USA., p.1. 
562 Piatier A. ‗Innovation patent, invention patent, or both‘ in Kingston W. (ed) Direct protection of 
innovation (1987) Lancaster: Kluwer Academic Publishers, p.125, stating that ‗invention and 
innovation are often confused...Facts fight a losing battle against the tyranny of categories generated by 
human mental activity‘, and asserts, generally, that it is necessary to separate the two meanings of the 
word innovation, referring to the new product on the one hand and the progression from invention to 
marketing of the product on the other . 
563 Dutfield, for instance, warns that the use of scientific metaphors and analogies, although useful in 
explaining the key science to a wider audience, may lead to misleading conception of the real science 
and inappropriate expansion of patentable subject matter: Dutfield G. ‗Patent law, the emerging 
biotechnologies and the role of language in subject matter expansionism‘ in Rimmer M. and McLennan 
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definition that turns on the interpretation of the key phrase ―new or significantly 
improved‖ whilst invention is directed to new and non-obvious ideas.‘564 That is to 
say what qualifies for an invention in law covers more restricted and narrow subject 
matter than what could be generally regarded as innovation in business circles, 
making the conceptual translation from the business context into law of potentially 
protectable subject matter intricate. 
 
A further restriction on what could be patented in the context of patent law is that 
even subject matter alleged to be inventions in law can also be excluded from 
patentability. In both the UK and South Africa, legislation narrows down what could 
be patentable by explicitly excluding some categories of subject matter from 
patentability.
565
 This is to say that the pre-determined standard of what is patentable is 
set by the explicit exclusion of some alleged inventions from patenting. This provides 
the policy-makers with the lever to adjust the patentability standard by excluding 
categories deemed not to be fulfilling the purpose of the patent system, for instance 
scientific theories which if were patentable would block the downstream advance of 
subsequent technologies.
566
 Excluded subject matter is therefore important for its role 
in determining the extent ‗public goods‘ fall outside the realm of individual control.567 
This comports with the justification for patents that optimal patentability must balance 
private and public the interests, as established in chapter two. 
 
                                                                                                                                                                              
A. Intellectual property and emerging technologies (2012) Cheltenham: Edward Elgar Publishing 
Limited.  
564 Kahn M. ‗Measuring innovation and development: A case for treatment‘ Conference proceedings of 
the innovation for development: Frontiers of research, policy and practice symposium, 24-26 February 
2010, University of Witwatersrand. Also, Ruttan asserts that if a practically significant and precise 
Schumpeter distinction between innovation and invention is needed, the term innovation would simply 
be preceded by an appropriate adjective such as ‗technical innovation‘ and ‗[i]nvention then becomes a 
special subset of technical innovation on which patents can be obtained‘: Ruttan V.W. ‗Usher and 
Schumpeter on invention, innovation, and technological change‘ (1959) Quarterly Journal of 
Economics, p.596-606, p.603. Also, Kingston, fn.2, p.354. 
565 Most of these exclusions in some jurisdictions, Canada and the United States for example, are 
judicially created, see Crowne-Mohammed E.A. ‗A review of the as ―such‖ exclusions to patentable 
subject matter in the United Kingdom: Lesson for Canadian and American courts‘(2010) Albany Law 
Journal of Science and Technology, p.457-486, p.459. 
566 Ohlmeyer/Zhou, fn.33.  
567 Shaffer G. ‗Recognising public goods in WTO dispute settlement: Who participates? Who decides? 
The case of TRIPS and pharmaceutical patent protection‘ (2004) Journal of International Economic 
Law, p.459-482, p.461: in the context of new pharmaceutical knowledge-generation where the 
knowledge may have private and public attributes, public goods are those considered non-excludable in 
their benefit. 
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On another dimension, the categorising of excluded matter makes the assessment of 
what qualifies for patenting easier. Thus, the explicit statutory listing of unpatentable 
subject matter helps with identifying if a particular scientific activity or output thereof 
is indeed an invention or considered patentable under the law. Debates remain on how 
excluded subject matter should most appropriately be assessed as there are overlaps 
between some of the excluded categories and also as to the appropriate stage when the 
assessment of whether subject matter is indeed a patentable invention should be 
carried out in patentability evaluation.
568
 The thesis concentrates on the 
methodologies and tests for making this judgement. 
 
The thesis focuses on pharmaceutical inventions. However as alluded to in the first 
chapter, this sector is multidisciplinary. As such, it is appropriate to examine excluded 
subject matter in the sectors integral to the operation of the industry and life cycle of 
the pharmaceutical invention. This is important given that some of the categories of 
excluded subject matter contribute to the conception, actualisation or improvement of 
the final pharmaceutical product and that the pharmaceutical processes and methods 
are intractably linked with various excluded subject matter.
569
 
 
The section will begin with an exploration of the pharmaceutical industry innovations 
and inventions with reference to the issues that arise in the context of assessment of 
excluded subject matter. The section will then turn to an examination of what an 
invention is, with the objective of identifying subject matter that is excluded from 
patentability by virtue of not being defined as patentable inventions in the laws of 
both jurisdictions. There will then be a discussion of what is explicitly excluded from 
patentability and the approach that is taken in accessing the exclusions. Not all 
exclusions categories will be under scrutiny.
570
 Moreover, detailed focus will be on 
fields that enhance the generation, processing and analysis of vast amounts of 
                                                             
568 Pila J. The requirement for an invention in patent law (2010) Oxford University Press: Oxford, 
p.58-59. 
569 For instance, in Fujitsu Ltd's Pat. App (1997) RPC 608, the Court of Appeal examined the 
patentability of software that allowed chemists to design new chemical compounds and was found to be 
excluded subject matter as such. 
570 Under examination in this study are the ‗as such‘ exclusions and what is typically referred to as 
exceptions will not be covered. Focus will be on the ‗as such‘ exclusions which are mainly directed to 
the exclusion of abstract subject matter or subject matter covered by other IP law especially copyright 
law insofar as the invention in the patent or patent application relates to that those items per se or as 
such. 
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pharmaceutical research information, for instance software and business methods as 
these have been controversial and have a significant bearing on the success of the 
pharmaceutical venture.
571
 
 
 
4.2 The innovation cycle in pharmaceutical industries 
 
The patent system grants protection for inventions. A robust and meaningful 
definition of what constitutes an invention and how subject matter could properly be 
conceived as invention is important as it helps in the determination of appropriate 
thresholds of categories of subject matter for which a patent may be granted.
572
 As it 
has been noted that ‗whoever controls the meaning of ―invention‖ controls what could 
be patented,‘573 it is important for industrialists to know which of their research 
activity or output will be captured by the definition of an invention and thus 
protectable. This section introduces how patentable inventions are defined in law and 
how industry tends to conceive it. Understanding patentable subject matter helps in 
the assessment of whether innovations and inventions encountered in pharmaceutical 
activities fall within those boundaries and hence are patentable. 
 
Scholars assert that early patent grants were directed to innovation and only indirectly 
to invention and contemporary this has been reversed to offer protection to invention 
directly and only innovation indirectly.
574
 This evolution in the nature of legal 
protection offered by the patent was seen in chapter two, whereby historically the 
patent system also protected those who merely practically introduced new arts into 
local economies rather than create them. Innovation is more concerned with 
                                                             
571 For instance, Debnath demonstrated predictive computer modelling that eliminates the need to 
carryout expensive experiments on a large chemical series and also resulted in promising candidates 
molecules for HIV treatment and showed the predicted activity in reality and were patented by 
pharmaceutical firms. Debnath A.K. ‗Generation of predictive pharmacophore models for CCR5 
antagonists: Study with piperidine- and piperazine-based compounds as a new class of HIV-1entry 
inhibitors (2003) Journal of Medicinal Chemistry, p.4501-4515. 
572 Pila J. ‗The future of the requirement for an invention: inherent patentability as pre- and post-patent 
determinant‘ in Arezzo E. and Ghidini G. Biotechnology and software patent law (2011) Cheltenham: 
Edward Elgar, p.55. Schmookler J. Invention and economic growth (1966) Massachusetts: Harvard 
University Press, p.12-17. 
573 CFPH Application [2005] EWHC 1589, para.10. 
574 Kingston, fn.638, p.2-3. 
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commercial ends than invention which focuses more on technical result.
575
 Since 
pharmaceutical activity occurs mainly in commercial settings, it can be argued that to 
industrialists there could be the expectation that to be useful for protecting what they 
may indiscriminately perceive and define as inventions or innovations, the protection 
offered by the patent must not then effectively be undermined by how the subject 
matter is ultimately defined as unprotectable in patent law.
576
 Nonetheless, in law, the 
definition of invention and innovation remains different. Therefore, when seeking 
patent protection, the legal rules as they protect the invention must be clearly 
understood and then appropriately fitted into the commercial context. 
 
Others are of the view that the differentiation between invention and innovation is not 
of practical value.
577
 Some analysts state that for pharmaceuticals ‗because of the 
near-perfect identity between what is invented and what is innovated...it would make 
little difference to the chemical and pharmaceutical firms from the strict point of view 
of protecting any discovery, whether the patent system protected innovation indirectly 
or directly.‘578 Indeed, that may be the case but the thesis asserts that it is helpful to 
separate these especially because the inventive process which results in the final 
invention occurs in intertwining and overlapping R&D stages and in diverse fields of 
technology that may involve some excluded subject matter.
579
 For example, in what 
has become a routine and significant contributor to new medicines pipeline, 
innovative or inventive pharmaceutical compounds are created in silico long before it 
is known whether they could exist in reality.
580
 In addition, the overlapping stages in 
                                                             
575 ‗In scientific and industrial environments, there is a major difference between innovation and 
invention‘ with the innovation status ‗acquired when society adopts this, apparently new, artifact within 
a community of consumers that boasts certain legitimacy‘ and invention characterised by ‗a special 
capacity to solve certain specific problems‘: Cavallucci D. ‗A research agenda for computing 
developments associated with innovation pipelines‘ (2011) Computers in Industry, p.377–383, p. 378. 
576 The perception of how the courts would ultimately adjudicate matters has been seen as influential in 
the delineation of rights: Barzel Y. Economic analysis of property rights, 2nd ed (1997) Cambridge: 
Cambridge University Press, p.98. 
577 Cullis R. Patents, inventions and the dynamics of innovation: A multidisciplinary study (2007) 
Cheltenham: Edward Elgar, p.6. 
578 Kingston W. (ed) Direct protection of innovation (1987) Lancaster: Kluwer Academic Publishers, 
p.13. 
579 Caraça J., Lundvall B. and Mendonça S. ‗The changing role of science in the innovation process: 
From Queen to Cinderella?‘ (2008) Technological Forecasting & Social Change, p.861–867. 
580 The term in silico is coined from the reference to Silicon Valley‘s fame to computers and has gained 
popularity within pharmaceutical discovery practitioners, with more pharmaceutical companies 
developing in silico tools in the past two decades: Shekhar C. ‗In Silico pharmacology: Computer-aided 
methods could transform drug development (2008) Chemistry and  Biology, p.413-414. Computer 
programs per se are not patentable but such created compounds may be. 
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R&D make it difficult to identify which aspects of the process could be classified as 
technical and thus contribute to the invention aspect and which ones are commercially 
inclined and thus more likely to be classified as innovation.
581
 
 
Besides the ramifications of the inaccurate conceptualisation of innovation and 
invention, the category of subject matter that qualifies for protection can be of 
concern. Before the advent of the TRIPS Agreement, which has mandated the 
protection of both product and process type of inventions, there were debates and 
division as to whether the pharmaceutical product should be excluded from 
patentability at all, but now the debate has shifted such that the patent system is 
usually cited as critical for the protection of pharmaceutical products.
582
 The view 
commonly held is that in patents for pharmaceutical products ‗the disclosure is a 
chemical formula, which is identical for both the laboratory sample embodying the 
invention and for tonnage production.‘583 The relative ease with which the final 
pharmaceutical product can be identified and copied makes the patent system the best 
choice for protecting these inventions. Advances in analytical technologies and 
chemical retro-synthesis make it easier to figure out the theoretical starting materials 
of the final product.
584
 Nevertheless, on its own, such a view that emphasises 
supremacy of product protection would seem narrow and would not reflect 
appreciation of the entire pharmaceutical undertaking. 
 
The controversy and emphasis on product protection has tended to overshadow the 
equally important role of patents in protecting the pharmaceutical processes by which 
those products are produced.
585
 Inventive and innovative processes are important and 
                                                             
581 Caraça et al, fn.579, p.866, a multi-channel interactive innovation model has been proposed, 
wherein there is a multiplicity of intertwining innovative processes and feedback channels compared to 
earlier linear innovation models or the slightly improved chain-linked model of innovation which, 
respectively, assumed that the R&D stages occurred in a linear fashion or one-directional sequential 
cycle. 
582 For instance, Yu P.K. ‗A tale of two Development Agendas‘ (2009) Ohio Northern University Law 
Review, p.465-573, especially, p.506-507; Dutfield G. and Suthersanen U. Global intellectual property 
law (2008) Cheltenham: Edward Elgar, p.115. 
583 Kingston W. Innovation, creativity and the law, (1990) Kluwer Academic Publishers, p.121. 
584 Even low cost analytical methods can have high analytical capabilities: Kaale E, Risha P. and 
Layloff T. ‗TLC for pharmaceutical analysis in resource limited countries‘ (2011) Journal of 
Chromatography A, p.2732–2736. 
585 Though important, process claims are considered to be of less economic value and difficult to 
monitor than product claims and hence the practice that is considered more useful is product-by-
process claiming which gives a monopoly on the product by whatever means it is produced: Kartal 
M. ‗Intellectual property protection in the natural product drug discovery, traditional medicine and 
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play a significant role in the sustainability of a pharmaceutical firm.
586
 Masking the 
importance and contribution of inventive or innovative processes, for instance, is the 
fact that ‗the Trade journals report relatively few processes, service and management 
innovations and tend to capture product innovations.‘587 Therefore indicators and 
indices of pharmaceutical innovation and invention levels have arguably understated 
the role of inventive processes and the continuing need to protect them. 
 
There is little benefit in reverse engineering and retrosynthesis of products alone.
588
 
The innovative and inventive industrial-scale processes give a competitive advantage 
to industrial firms.
589
 The processes, which may be based on excluded subject matter, 
are important to the practical implementation of inventions and innovation into 
industry reality. These inventive and innovative processes are helpful to the 
realisation of more efficient scale-up projects and the resulting pharmaceutical 
product.
590
 Some commentators have even observed that ‗in all sectors ... a large 
proportion of innovative activity takes place outside research laboratories, e.g. in 
design and planning, or in the production plants themselves.‘591 The competitive 
advantage of the firm, therefore, does not reside only in the final product produced but 
also in the efficiency of the processes of producing it, aspects of which may be 
deemed excluded from protection.
592
 
 
                                                                                                                                                                              
herbal medicinal products‘ (2007) Phytotherapy Research, p.113-119. Kirin-Amgen Inc v Hoechst 
Marion Roussel Ltd [2004] UKHL 46, para.88-91, decided that UK should not accept product-by-
process claims as a matter of practice. 
586 ‗[T]he design and optimization of synthetic routes for active molecules is at the very core of the 
business‘: Federsel H.J. ‗Process R&D under the magnifying glass: Organization, business model, 
challenges and scientific context‘ (2010) Medicinal and Bioinorganic Chemistry, p.5775–5794, p.5793. 
587
 Acs Z.J. and Audretsch D.B. ‗Innovation in large and small firms: An empirical analysis‘ (1998) 
American Economic Review, p.679-690, p.680. 
588 ‗Of processes, pills and profits‟, The Economist, 11/09/96, Vol. 341, Issue 7991. 
589 Scale-up processes continue to present problems as there is a multiplicity of variables to be 
addressed even for simple processes: Portillo P.M., et al ‗Quality by design methodology for 
development and scale-up of batch mixing processes‘(2008) Journal of Pharmaceutical Innovation, 
p.258–270. 
590 Guidance for Industry: PAT - A Framework for Innovative Pharmaceutical Development, 
Manufacturing, and Quality Assurance: Pharmaceutical CGMPs (September 2004) US. Department of 
Health and Human Services: Food and Drug Administration. 
591 Williams D. and Kang S., ‗Manufacturing and production‘, in Jacobsen T.M. and Wertheimer A.I. 
Modern pharmaceutical industry (2010) Sudbury: Jones and Bartlett Publishers LLC. 
592 Emphasising the need for process innovation, it has been observed that ‗pharmaceutical 
manufacturing operations are inefficient and costly... Low efficiency is predominantly due to ‗self-
imposed‘ constraints in the system (e.g., static manufacturing processes, focus on testing as opposed to 
quality by design‘: Hussain A.S. ‗An innovative, consensus building tool for the 21st century‘ (2006) 
Journal of Pharmaceutical Innovation, p.9-10. 
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A typical pharmaceutical process or the ensuing product is brought into the market by 
a series of multidisciplinary and integrated stages and activities,
593
 some of which do 
not fall under the patentable categories or the definition of patentable inventions. As 
such, whilst working on what will be a patentable output, it would be difficult for the 
scientist or industrialist to discern a clear division in what would be excluded in patent 
law in the enabling or platform technologies relied upon. Hence, the statutory 
construct of what is within the legal definition of a patentable invention is important. 
At the same time, the legal definition must be concomitant with the operational 
principles and realities of those industries where innovation and invention is 
emphasised for survival. Indeed, some innovations that have considerable technical 
contributions could be outside of the system by virtue of being in the non-patentable 
category. The conceptualisation of what is patentable is therefore not as clear cut as it 
would initially be thought especially if it is taken from the position of the person in 
industry. The thesis now turns to the definition of patentable invention and excluded 
subject matter in law, examining the two jurisdictions in turn. 
 
 
The United Kingdom 
 
4.3 Definition of patentable inventions and excluded subject matter 
 
The legal definition of an invention is a complex concept that impacts on the 
exclusion of some subject matter from patentability. To further complicate matters, 
the definition sometimes has to encompass and define a technology that has not come 
about.
594
 Even more difficulty is encountered when it is acknowledged that the rate of 
technology evolution is very high.
595
 Even current technology is susceptible of 
refinements as there are always advances in previously unpredictable directions, 
                                                             
593 Bennani Y.L. ‗Drug discovery in the next decade: innovation needed ASAP‘ (2011) Drug Discovery 
Today, p.779-792, p.782-784, quoting Janssen stating that ‗a good scientist in someone who succeeds 
in getting the different scientific disciplines to work in harmony with one another‘ in recognition of the 
multidisciplinary nature of the pharmaceutical R&D.  
594 During Parliamentary debate, there was consensus that the definition must be flexible to keep up 
with technology changes: Hansard, HL Deb 15 February 1977 vol 379 cc1409-12. The Strasbourg 
Convention, forming the basis of much harmonised patent law, did not expressly define the term 
invention. 
595 Tessensohn J.A. and Yamamoto S. ‗Japan: utility models- improvement to the system‘ (2005) 
European Intellectual Property Review, n.119-121. 
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rendering inadequate a definition which may have previously sufficed. It is likely that 
a rigid statutory definition of an invention would prevent judges in developing the law 
to keep up with advances in industry.
596
 
 
The question of what inventions are has been posed and debated in court.
597
 
Establishing this would assist in assessing whether an innovative or inventive output 
by scientists is patentable. It has been acknowledged that it is difficult to have a 
certain definition of what characterises an invention.
598
 The term has not been 
satisfactorily defined in any patent act, and it is questionable as to whether a precise 
definition can ever be given.
599
 Lord Hoffmann, prescribing the sidestepping of 
establishing whether or not subject matter is an invention in a patentability enquiry, 
stated in Biogen Inc v Medeva
600
 that ‗judges would therefore be well advised to put 
on one side their intuitive sense of what constitutes an invention until they have 
considered the questions of novelty, inventiveness and so forth.‘  
 
Another issue for consideration is also ascertaining whether or not what is alleged to 
be an invention is patentable under law. As seen in the previous chapter, patentability 
in the UK is to some extent influenced by external instruments to which it subscribes 
to at the international and regional levels. A definition of patentable inventions has 
been canvassed at the international arena and an all-encompassing definition is 
indicated under the TRIPS Agreement. TRIPS Art.27(1) requires Member States to 
grant patents for all fields of technology. This obligation has been used by those 
countries, notably the US, for allowing the patenting of pure software and life-
forms.
601
 However, the broad language in TRIPS is narrowed by the fact that the 
TRIPS Agreement itself, also allows some exclusions to what is included within the 
                                                             
596 Lord Irvine, fn.27, p.336. 
597 For instance, in Generics v Lundbeck [2009] UKHL 12, para.12, refers to the statute as one ‗which 
notoriously does not define ―invention.‖‘ Also, Prescott sitting as a Deputy Judge in CFPH LLC‟s 
Patent Application [2005] EWHC 1589, remarked ‗what is an ‗invention‘...is a topic bedeviled by 
verbal formulae - and by the sweeping of problems under the carpet.‘ 
 
598 CFPH LLC‟s Patent Application [2005] EWHC 1589, para.15. 
599 Loc cit. Patents Act 1949, s.101 positively defined an invention, and also South Africa Patents Act 
1952, s(1)(v) but were seen as inadequate. 
600 [1996] UKHL 18. 
601 ‗US govt promoting patent extremism in the European Parliament‘, available at 
www.swpat.ffii.org/papers/index. Also, in the US, Diamond v. Chakrabarty, 447 U.S. 303 (1980) 
established that Congress had intended patentable subject matter to ‗include anything under the sun that 
is made by man.‘ 
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concept of patentable inventions. These, generally, are public policy and morality 
exceptions to the definition of patentable inventions.
602
 Thus it could be said that the 
definition of patentable invention is constrained between these parameters. 
 
At regional level, the excluded subject matter from patentability is found in EPC 
Art.52 and Art.53. The thesis in this chapter focuses on Art.52 and not Art 53 which 
generally deals with exceptions to patentability. The international influence for wider 
patentability of subject matter in the European definition of patentable inventions was 
observed in Aerotel Ltd. v Telco Holdings Ltd & Ors Rev 1,
603
  where the court stated 
that: 
‗First there has been some political pressure on Europe to remove or reduce 
the categories of non-inventions. Part of that has come, from the fact that 
TRIPS does not have the same explicit categories of non-invention as the 
EPC... 
Some of the Art.52(2) excluded categories are not fairly within the description 
―field of technology‖ and so not within TRIPS (e.g. aesthetic creations) but 
others seem to be within it – the paradigm example being computer programs. 
Hence the pressure. Whether ―methods for doing business‖ are a ―field of 
technology‖ within the meaning of TRIPS is perhaps debatable.‘ 
 
On the domestic level, the 1977 Patents Act, s.1(1) prescribes that ‗a patent may be 
granted only for an invention in respect of which the following conditions are 
satisfied… and references in this Act to a patentable invention shall be construed 
accordingly.‘ This according to some commentators604 either means any innovative or 
inventive research output that complies with the conditions set out in the subsections 
of the Act is deemed a patentable invention or the subject matter must both be an 
‗invention‘ and satisfy the conditions. The former approach, as opposed to the latter, 
seems to be the preferable definition of an invention in UK law because it allows the 
definition to remain current and applicable to emerging fields of technologies and an 
                                                             
602 TRIPS Art.27(2) and (3). 
603 [2006] EWCA Civ 1371, para.16. 
604 Colston C. ‗Genetic engineering – Failure to invent? The House of Lords‘ decision in Biogen Inc v 
Medeva plc‘ (1997) Intellectual Property Quarterly, p.521-529, p.522. 
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effective definition would almost be impossible to achieve as demonstrated during the 
EPC negotiations.
605
  
 
In Genentech Inc's Patent,
606
 it was considered essential to identify the invention 
accurately when making assessment of whether subject matter is not excluded from 
patentability. This case was concerned with a new synthesis method of a compound 
identical to one that occurs in nature and thus alleged to be consisted of excluded 
subject matter according 1977 Patents Act, s.1(2). Lord Mustill considering whether 
the statute additionally requires the applicant to have made an invention as opposed to 
the alternate interpretation of whether it merely possesses the patentability 
requirements of section 1(1) stated that ‗compliance with these four conditions turns 
the invention into a ―patentable invention‖ and then section 1(2) goes on to exclude 
certain matters from the scope of ―invention‖ – not ―patentable invention‖‘.607  The 
Court of Appeal in Biogen Inc v Medeva
608
 essentially followed this approach of 
establishing whether an invention has been made and separately whether the invention 
was new, involves an inventive step and capable of industrial application. 
 
Lord Hoffmann, giving a majority opinion in the House of Lords rejected this 
evaluation approach in Biogen Inc v Medeva
609
 stating that initially seeking whether 
there is an invention will lead to unnecessary complexity and will ‗almost invariably 
be academic‘ and the important requirement is to simply evaluate whether subject 
matter in new, inventive and industrially applicable. He was of the view that the four 
patentability conditions in section 1(1) reduce the class of inventions that could be 
patented and probably covers every aspect of the meaning of the term invention.
610
 
Lord Mustill, sitting in the same House, did not accept this approach saying 
sometimes ‗close conceptual analysis of the nature of patentability will not be a waste 
                                                             
605 Ibid, p.522-523. For changes in the definition of inventions see generally Comments on the first 
Preliminary Draft Convention relating to a European patent law of 14 March 1961 (Articles 11 to 29), 
Council of Europe Doc IV/2071/61 – E (1961) 4 and Proceedings of the 1st meeting of the Patent 
Working Party held at Brussels from 17 to 28 April 1961, Council of Europe Doc IV/2767/61-E (1961) 
Section 5, 4. Swift Application [1962] RPC 37, para.44, per Lord Parker CJ. 
606 [1989] RPC 147, per Mustill, p.262. 
607 Ibid, and a definition in compliance with the TRIPS Agreement. 
608 [1995] RPC 25. 
609 [1996] UKHL 18, para.44. 
610 Ibid, para.42-43. 
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of time.‘611 Some commentators have rejected the UK conceptualization of what an 
invention is, in preference to the EPO approach which considers the definition of an 
invention on the basis of whether the subject matter has technical character as 
separate from the secondary criteria of patentability.
612
 
 
The pharmaceutical field is inundated with inventions derived from seemingly 
excluded categories, for instance products of nature.
613
 Agreement on what constitute 
a patentable invention or an excluded category paves the way for clarity in the 
patenting of some pharmaceutical inventions embodying products of nature which, as 
shown in chapter one, are a source of new pharmaceuticals or motivation for their 
derivation. 
 
The 1977 Patents Act defines what an invention is by expressly listing what is 
excluded from the definition of an invention.
614
 Prescott notes that ‗in telling us about 
patentable inventions, the Patents Act 1977 does not try to define what an invention 
is. Instead it contains a list of things that are not inventions.‘615 A potential limitation 
to the usefulness of this exclusion listing tool is that technological development is 
now of an intertwining and converging nature. The pharmaceutical inventions are 
integrated with elements from the different fields of technology, as it has been shown 
in the previous subsection. As a result, it will be difficult to simply look at the list and 
apply it to judging whether the invention is excluded. 
 
Another difficulty is that the listed items have no common thread linking them.
616
 It 
has been said that it is policy exclusion that make up this list. For example, in Fijitsu 
Limited‟s Application,617 Laddie LJ said the items in Art.52 were excluded for reasons 
of public policy. As such, it cannot be predicted that a similar article to that in the list 
                                                             
611 Ibid, para.5, and was of the view that it was not matter that the court should address in that instance. 
612 Pila J. ‗On the European requirement for an invention‘ (2010) International Review of Intellectual 
Property and Competition Law, p.906-926, p.908-909. 
613 Du Pont‘s strategy of entering human pharmaceuticals research was launched through the synthesis 
of the analogues of the natural compound chloramphenicol in order to improve it, Hounshell D.A. and 
Smith J.K. Science and corporate strategy: Du Pont R&D, 1902-1980 (1988) Cambridge: Press 
Syndicate of the University of Cambridge, p.465. Also, Bull A.T. and Stach J.E.M. ‗Marine 
actinobacteria: New opportunities for natural product search and discovery‘ (2004) Trends in 
Microbiology, p.491-509. 
614 Patents Act 1977, s.1(2). 
615 CFPH, para.18. 
616 Aerotel Ltd v Telco Holdings Ltd [2006] EWCA Civ 1371, para.9. 
617 [1996] RPC 507, p.530. 
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will be handled in a similar way.
618
 This makes it complicated advancing arguments 
for or against inclusion of related fields into the exclusion listing. 
 
The listing, although useful, cannot in practice always resolve cases where an 
invention consists partly of items in the list and some that are not. Nowadays, for 
example, routine R&D of traditional pharmaceutical inventions is highly integrated of 
many excluded and non-excluded components and therefore has a higher probability 
of ending in disputes resulting in court action.
619
 For optimisation of the system, the 
patent system needs to provide a means and guidance of evaluating the contribution or 
degree of integration of excluded and patentable matter that is necessary for the 
invention to be deemed not excluded from patentability as a whole. The next 
subsection will examine how the courts have sought to resolve this. 
 
The excluded subject matter list as found in Patents Act 1977, s.1 implements EPC 
Art.52. Sub-sections (2) lists the various categories of excluded subject and is among 
the statutory provisions that are specifically mentioned in s.130(7) of the 1977 Act as 
having been ‗so framed as to have, as nearly as practicable, the same effects in the 
United Kingdom as the corresponding provisions of the EPC.‘ Hence, the 
interpretation of these sections must converge with that of the EPC. Reference to EPC 
cases has therefore occasionally been used by the UK courts in the evaluation of 
appropriate the degree of integration of excluded and patentable subject matter in an 
invention.  
 
In Aerotel, Lord Justice Jacob went further and advanced an exclusion interpretation 
that relies more on the Convention than the domestic statute. That is to say that for 
interpretation of excluded subject matter in the UK, reliance could be placed on the 
original document than on the implementation domestic instrument. He stated that: 
 
                                                             
618 CFPH, para.31. 
619 Examination Guidelines for patent applications relating to biotechnological inventions in the UK 
Intellectual Property Office (2013) UKIPO, Newport, UK, para.6-7. 
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„Although s.1(2) pointlessly uses somewhat different wording from that of the 
EPC no-one suggests that it has any different meaning. So we, like the parties 
before us, work directly from the source.‟620  
 
The thesis will now examine the groups of excluded items in the UK in turn. 
 
 
4.4  The Excluded Items 
 
It has been acknowledged that the excluded categories from patentability have no 
common theme or purpose amongst them.
621
 In Aerotel the court cautioned against 
arbitrary preference of some excluded category over others in case law, once the 
policy considerations have been promulgated into law. The court said ‗in our opinion, 
therefore, the court must approach the categories without bias in favour of or against 
exclusion. All that is clear is that there was a positive intention and policy to exclude 
the categories concerned from being regarded as patentable inventions.‘622  
 
In this subsection of the thesis the categories of excluded subject matter will not be 
examined according to the precise format in the statutory groupings. This serves two 
purposes. The first is that the express statutory groupings do not identically match 
between the two jurisdictions under study. The second is that not all the categories 
will be examined and only those that are pertinent to activities in the modern 
pharmaceutical industry are considered relevant here.
623
 The exclusions of prime 
examination are found in s.1(2) which ‗essentially covers abstract subject matter that 
is either ephemeral in nature (like discoveries, scientific theories and mathematical 
methods), or subject matter that is generally covered by the law of copyright insofar 
                                                             
620 Aerotel, para.6. Cf. EPO 1990: T0022/85 Document Abstracting and Retrieving. 
621 Symbian Ltd v Comptroller General of Patents [2008] EWHC 518 (Pat), para.23. 
622 Aerotel, para.21. Also, during the Parliamentary debate on the current Patent Act there was the view 
that grouping together some of the ‗as such‘ exclusions with computer programmes was intended ‗to 
ensure that computer programmes are construed together with other schemes and methods so that...the 
exclusion will bite only on so-called computer softwear (sic) and not on programmes which may be 
embodied in the hardwear (sic)‘, Hansard, HL Deb 15 February 1977 vol 379 cc1409. 
623 In Aerotel, para.21 and 45, the court stated that courts must approach the categories without bias in 
favour of or against and accepted that ‗although the policy behind different exclusions is not uniform, 
the structure of the legislation requires that they ought to work the same way.‘ 
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as the patent application relates to those items in-and-of themselves‘624 such as 
computer programs. 
 
 
4.4.1 Discoveries and scientific theories 
 
There are various ways in which inventions are brought about. One way of inventing 
involves thought and logic where theory is developed and applied to solve problems 
in most cases basing this on old principles and possibly also new ones.
625
 Nowadays 
in industry, hardly any new discovery is made without a preceding theory. At the 
same time, some surprising results from application of the theory occur and may not 
only lead to new products but also feed back into fine-tuning and modifying earlier 
theories. As such, at the earlier point in the R&D chain, where securing priority is 
important, it is plausible that there is a close association between a discovery, a theory 
or what may subsequently held to be an invention. 
 
The UK Patents Act s.1(2)(a) is expressly prescriptive of the non-patentability of a 
discovery and scientific theory. One of the challenges that confront research scientists 
is how an invention that could be patented is differentiated from a discovery or 
theory. Picciotto
626
 observes that TRIPS does not ‗make any attempt to clarify the all-
important distinction between a discovery and an invention.‘ UK case law provides 
guidance in this regard. 
 
A discovery is the making available of something that is already available in nature. 
The mere discovery of a substance does not amount to repeatable method of 
producing that substance, but only to a one-time process of obtaining that substance.  
It has been said that ‗while both discoveries and inventions contribute new knowledge 
to the sum total of human understanding, an invention does so through the application 
of human endeavour to produce a technical solution to an unresolved technical 
                                                             
624 Crowne-Mohammed, fn.565, p.462. Lord Hoffmann referred to this general group as ‗inherently 
abstract subject matter‘: Pila, J. ‗On the European requirement for an invention‘ (2010) International 
Review of Intellectual Property and Competition Law, p.906-926, p.907. 
625 Cullis, fn.577, p.2. 
626 At p.13, Picciotto.S, ‗Defending the public interest in TRIPS and the WTO‘, available at 
www.lancs.ac.uk/staff/lwasp/sp-trips.pdf . 
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problem.‘627 In Reynolds v Hebert Smith,628 it was established that a discovery merely 
disclosed what was not seen whereas an invention involved suggestion of an act that 
resulted in something new. The principle established therefore is that ‗an invention is 
a practical product or process, not information about the natural world.‘629 
 
An artefact or process that is devised from the making of the discovery is patentable. 
This principle was extended in Genentech‟s Patent630 where it was established that an 
invention is patentable even when it was a result obvious from the making of the 
discovery.
631
 The same approach was applied in CFPH LLC‟s Application632 in which 
the court said ‗an instance of a ―soft exclusion‖ is a discovery. It is well-settled law 
that, although you cannot patent a discovery, you can patent a useful artefact or 
process that you were able to devise once you had made your discovery. This is so 
even where it was perfectly obvious how to devise the artefact or process, once you 
had made the discovery.‘ 
 
 In the EPO Guidelines
633
 it is stated that: 
 
„To find a substance freely occurring in nature is also mere discovery and 
therefore unpatentable. However, if a substance found in nature has first to be 
isolated from its surroundings and a process for obtaining it is developed, that 
process is patentable. Moreover, if the substance can be properly characterised 
either by its structure, by the process by which it is obtained or by other 
parameters and is „new‟ in the absolute sense of having no previously recognised 
existence, then that substance per se may be patentable.‘ 
 
Reasoning to the same end is found in Directive 98/44/EC, which is concerned more 
specifically with biotechnological inventions, which have been held to be a subset of 
chemicals compounds, albeit more complicated ones.
634
 The Directive states that 
                                                             
627 Laurie G. ‗Intellectual property protection of biotechnological inventions and related material‘: 
www.law.ed.ac.uk/ahib/publications/online/INNOGENscopingpaperpatents.doc, p.4.  
628 (1903)20 RPC 123, p.126. 
629 Kirin-Amgen Inc. v. Hoechst Marion Roussel, [2005] RPC 9, (H.L.), p196. 
630 [1987] RPC 553, p.556. 
631 Also in Genentech Inc's Patent (Human Growth Hormone) [1989] RPC 147, p.202 (C.A.). 
632 [2006] RPC 5, para.34. 
633 EPO Examination Guidelines 2.3.1. 
634 Amgen Inc v Chugai Company Ltd, 927 F,2d 1200, 1206 (Fed. Cir 1991). 
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‗material which is isolated from its natural environment or produced by means of a 
technical process may be the subject of an invention even if it previously occurred in 
nature.‘635 This view seems to embrace the natural right justification of patents which 
recognises the labour input in coming up with inventions. 
 
The Court of Appeal, in Fujitsu Limited‟s Application,636 prescribed the criteria that 
differentiate whether discoveries are patentable or not and this lies in the technical 
contribution that it makes to the state of the art. In his judgment Aldous LJ stated:
637
 
 
„However, it is and always has been a principle of patent law that mere 
discoveries or ideas are not patentable, but those discoveries and ideas which 
have a technical aspect or technical contribution are. Thus the concept that 
what is needed to make an excluded thing patentable is a technical 
contribution is not surprising. This was the basis for the decision of the Board 
in Vicom. It has been accepted by this court and by the EPO and has been 
applied since 1987. It is a concept at the heart of patent law.‟ 
 
The principle of technical contribution in Aldous LJ‘s judgment in Fujitsu was 
referred to and followed by Neuberger J in Kirin-Amgen Inc v Roche Diagnostics 
GmbH,
638
 stating that ‗[i]t is ... a principle of patent law that mere discoveries or ideas 
are not patentable, but those discoveries and ideas which have technical aspect or 
make a technical contribution are. Thus the concept that what is needed to make an 
excluded thing patentable is a technical contribution is not surprising.‘ Technical 
contribution is viewed therefore as the criterion that is decisive for finding for 
patentability for what is potentially an excluded discovery. 
 
 
  
                                                             
635 Directive 98/44/EC, Art 3(2). 
636 [1997] RPC 608. 
637 [1997] RPC 608, p.614. 
638 [2002] RPC 1, especially para.535. 
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4.4.2 Computer and computer-related inventions 
 
The thesis now turns to examine the exclusion of computer and computer-related 
inventions from patentability. This is a group of exclusions that are interrelated and 
interconnected, central of which is the computer program.
639
 
 
It is now accepted that in pharmaceutical research activity, it is no longer the lone 
scientist working alone on a lab bench that finds the pharmaceutically useful 
compounds but a team or collaboration of scientists relying on computers and 
automation for worthwhile output.
640
 The courts have observed that ‗[a]ll modern 
industry depends upon programmed computers…‘.641 Jacob LJ observed that there is 
an exponential increase in the number of business methods and computer program 
patents.
642
 Patent administrators also make the same observation.
643
 This has given 
rise to the need for the courts to properly demarcate appropriate boundaries of how 
this exclusion is to be objectively and consistently made. In Symbian Ltd v 
Comptroller General of Patents,
644
 the court observed that ‗the issue raised on this 
appeal requires us to consider the reach of the exclusion of ―programs for computers‖ 
from patentable inventions, a topic which is inherently difficult and on which there is 
apparently inconsistent authority domestically and in the EPO.‘ 
 
Exclusions in the computer-related category are found in the Patents Act, s.1(2)(c) 
and (d). An illustration of connectivity of these fields as experienced in industry 
would include the so-called chemical informatics field which uses computer 
programmes and interface displays in simulating chemical compounds or chemical 
processes.
645
 The typical exclusions of an invention in this field could therefore be on 
                                                             
639 Shemtov N. ‗The characteristics of technical character and the ongoing saga in the EPO and the 
English courts‘ (2009) Journal of Intellectual Property Law and Practice, p.506-514, p.507, defining 
computer-implemented as inventions ‗implementation of which involves the use of a computer, 
computer network, or other programmable apparatus, with features realized wholly or partially by 
means of a computer program.‘ 
640 Frearson J.A. and  Collie I.T. ‗HTS and hit finding in academia – from chemical genomics to drug 
discovery (2009) Drug Discovery Today, p.1150–1158. 
641 Research in Motion v Inpro [2006] EWHC 70 (Pat), Pumfrey J., p.187. 
642 Aerotel Ltd v Telco Holdings Ltd [2006] EWCA Civ 1371, para.17. 
643 See generally Examination Guidelines for patent applications relating to biotechnological 
inventions in the UK Intellectual Property Office, September 2007, UKIPO, Newport, UK. 
644 [2008] EWCA Civ 1066, para.1. 
645 Gardner S.P. ‗Ontologies in drug discovery‘ (2005) Drug Discovery Today, p.236, DOI: 
10.1016/j.ddtec.2005.08.004. 
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the ground of consisting of computer programs, display of information or even 
mathematical methods which are excluded according to s.1(2)(a). Examples of 
problems solved by using chemical informatics are in the managing of the 
complicated data in pharmaceutical discovery and screening and the molecular 
modelling processes.
646
 Related to this is an algorithm which is a method for solving 
technical problems and ‗may be suitable for implementation in a computer program 
but is not itself a computer program.‘ 647 Thus, it has been asserted that ‗the purposive 
use of mathematical algorithms in providing solutions to technical problems in the 
field of drug discovery or related technical fields can provide opportunities for 
securing valid patents.‘648 Computer programs, business methods and display of 
information dissect every aspect of pharmaceutical discovery activity.
649
  
 
The 1949 Act had no expressis verbis rules for computer programs. There were 
applications for software patents filed even though they did not succeed. Although 
previously ‗the trend of the UK cases has been to deny the patentability of software-
related invention‘,650 the UKIPO observed that in practice some computer-dependent 
invention are patentable while others were not.
651
 Though the EPC and the Patents 
Act excludes the patenting of computer software, business methods or algorithms as 
such, it is possible to patent such inventions if they involve technical consideration or 
technical effect. It has been said for example that ‗in deciding if a method is a 
business method, consideration is given to whether the overall contribution is in a 
technological area.‘652 Hence this category is generally excluded from patentability if 
there is no substantial technical contribution made other than by the thing as such, 
although the difficulty lies in resolving the extent of the contribution. 
 
The thesis will now turn to examine the approach to exclusions for computer 
programs as a particular illustration of this group with the objective of establishing the 
                                                             
646 Available at http://grids.usc.indiana.edu.  
647 Christie A. and Syme S. (1998) ‗Patents for algorithms in Australia‘, Sydney Law Review, available 
online at http://www.austlii.edu.au//cgi-bin/disp.pl/au/journals/SydLRev/1998/23.html  
648 Cookson B.E. ‗Protecting mathematical innovation in the life sciences‘ (2005) IP and IT law. 
649 Guidance for Industry: PAT - A Framework for Innovative Pharmaceutical Development, 
Manufacturing, and Quality Assurance: Pharmaceutical CGMPs (September 2004) US. Department of 
Health and Human Services: Food and Drug Administration. 
650 Christie/Syme, fn.647.  Slee & Harris' Application [1966] RPC 194. 
651 At http://www.patent.gov.uk/press/press-release/press-release-2006/press-release-20061027.htm. 
652‗Can I patent business methods‘ (2006) Available at http://www.intellectual-
property.gov.uk/faq/patents/business_methods.htm. 
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features of the exclusion approach in the UK jurisdiction without reciting the law that 
specifically applies to the other subject matter within this group. 
 
 
4.5   Exclusions approaches in particular to computer programs 
 
Pharmaceutical activities significantly rely on computers, from the research tools used 
in the R&D stages to the production plants.
653
 New research tools and fields are 
continually developing, such as bioinformatics, which has a role to play in data 
storage, management and analysis in the quest to develop pharmaceuticals for unmet 
medical needs or more effective and safer ones using computational programs for in 
silico modelling and simulation of disease targets and biological systems.
654
 
Execution of inventive pharmaceutical processes is reliant on computer or computer-
implemented inventions.
655
 
 
There is general agreement that an invention is excluded from patentability if it has no 
technical contribution. However, inventions are becoming increasingly highly 
integrated with the excluded matter such that the excluded subject matter may form 
complex matrix with aspects embodying the essential technical character of the 
invention. To add to the complexity of making the distinction, there is general 
confusion on what should be characterised as technical in patentability assessment.
656
 
                                                             
653 Computational technologies have been used by pharmaceutical firms, for example Wyeth, to shorten 
the R&D process and the scale-up and synthesis of new compounds: Potoski J. ‗Timely synthetic 
support for medicinal chemists‘ (2005) Drug Discovery Today, p.1115-120, or Abbott, to generate, 
merge and coordinate molecular data from different pharmaceutical discovery sources early in the 
R&D process: Holzman T. And Hebert E. ‗Transforming the work of early-stage drug discovery 
through bioprocess informatics‘ (2005) Drug Discovery Today, p.61-67. 
654 Whittaker P.A. ‗What is the relevance of bioinformatics to pharmacology?‘ (2003) Trends in 
Pharmacological Sciences, p.434-439. 
655 Computational analysis for virtual molecules and use of information technology is considered an 
integral step in an affordable pharmaceutical discovery model: Scott W.L. and O‘Donnell M.J. 
‗Distributed drug discovery: Linking academia and combinatorial chemistry to finding drug leads for 
the developing world diseases‘ (2009) Journal of Combinatorial Chemistry, p.3-13. Medicinal and 
computational chemists have been shown to use novel computer-aided design programs in their routine 
pharmaceutical discovery efforts: Ritchie T and McLay I ‗Should medicinal chemists do molecular 
modelling?‘ (2012) Drug Discovery Today, doi:10.1016/j.drudis.2012.01.005.For example, computer-
automated design of pharmaceutically-active compounds has been shown to yield innovative and 
patentable molecules although the software does not always produce exploitable results: Hartenfeller 
M, Zettl H, Walter M, Rupp M, Reisen F, et al. ‗DOGS: Reaction-Driven de novo Design of Bioactive 
Compounds‘ (2012) PLoS Computational Biology, doi:10.1371/journal.pcbi.1002380. 
656 Esteve A. ‗Patent protection of computer-implemented inventions vis-à-vis open source 
software‘(2006) The Journal of World Intellectual Property, p.276-300, p.279. 
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In addition, in the UK there is preference for the convergence of the assessment of 
excluded subject matter with that of the EPO but this has not been fully achieved.
657
 
As such, in patentability assessment it has not always been clear as to how and when 
the evaluation of the excluded subject matter is to be made. 
 
In the past the practice in the UK for making patentability decisions was to look first 
for ‗technical contribution‘ by the alleged invention into the known art.658 If there was 
none the subject matter would be deemed not to be an invention. If it had some 
technical contribution, it was then assessed for obviousness.
659
 The ‗technical 
contribution‘ test was the assessment of whether an invention adds something new to 
the stock of public knowledge.
660
 The technical contribution test emanates from 
Vicom/Computer-related invention.
661
  
 
In Genentech Inc‟s Patent,662 the Court of Appeal approved the reasoning of the 
Board of Appeal in Vicom. The Court of Appeal in Merrill Lynch,
663
 which also 
adopted the Vicom approach, making the ‗technical contribution‘ approach part of UK 
precedent, had Fox LJ saying: 
‗The position seems to me to be this. Genentech decides that the reasoning of 
Falconer J. is wrong. On the other hand, it seems to me to be clear, for the 
reasons indicated by Dillon L.J., that it cannot be permissible to patent an item 
excluded by section 1(2) under the guise of an item which contains that item – 
that is to say, in the case of a computer program, the patenting of a 
conventional computer containing that program. Something further is 
necessary. The nature of that addition is, I think, to be found in the Vicom case 
where it is stated: ‗Decisive is what technical contribution the invention makes 
                                                             
657 In Symbian, Court of Appeal, observed that the chequered history of the UK and EPO approaches to 
exclusions generally  has not been fully resolved and showed willingness to depart from its previous 
line of authorities, but not in this case: generally Lundie-Smith R. ‗How much longer can 
Aerotel/Macrossan test survive? (2011) Journal of Intellectual Property and Practice, p.6-7 and 
Wilson D. and Sharp C. ‗Patents: patentability of computer programs‘ (2009) European Intellectual 
Property Review, n.17-19. 
658 Fujitsu Ltd's Application [1997] RPC 608. The test used in the EPO at that time, developed in 
Hitachi T258/03, was only used as a cross-check to confirm that the UKIPO ‗technical contribution test 
was the right one: Patent Office—Practice Note [2006] RPC 6, para.3. 
659 CFPH, para.44. 
660 CFPH, para.70. 
661 (T208/84) [1987] E.P.O.R 74, para.16. 
662 [1989] RPC 147. 
663 [1989] RPC 561, per Fox LJ, p.569. 
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to the known art‘. There must, I think, be some technical advance on the prior 
art in the form of a new result (e.g., a substantial increase in processing speed 
as in Vicom).‘ 
 
Since the UK decision in Futjitsu, the EPO shifted from its technical contribution 
approach to adopt the ‗any hardware‘ approach.664 This approach departing from the 
technical contribution approach, developed from the EPO‘s jurisprudence so-called 
trio of cases.
665
 Assessment is made by asking whether the claim involves the use of 
physical hardware, however mundane, and if it does, Art.52(2) does not apply.
666
 One 
would first look for ‗technical features‘ in the invention or the alleged invention.667 If 
it has none, it was rejected as not being an invention. The technical feature definition 
is said to be broader or more literal than the UKIPO practice in the sense of holding 
more subject matter as being technical.
668
 The assessment would then consider if it 
was old or obvious, ignoring everything that is not a technical feature. This in effect 
meant the UKIPO under its test considered excluded subject-matter initially while the 
EPO did so at the end of patentability analysis. According to Prescott,
669
 the UKIPO 
considered excluded matter under the novelty description, while the EPO did so under 
the inventive description.
670
 Nonetheless, since these approaches are based on the 
same legislation, they were expected to produce the same results when properly 
applied and the UK courts have sought to achieve this.    
 
Prescott in CFPH LLC‟s Patent Application held that the EPO was correct in no 
longer using the ‗technical contribution‘ test671 with the suggestion that the UKIPO 
                                                             
664 Aerotel, para.26. Marsnik S. and Thomas R.E ‗Drawing a line in the patent subject-matter sands: 
does Europe provide a solution to the software and business method patent problem‘ (2011) Boston 
College International and Comparative Law Review, p. 227-327, p.310. 
665 Pension Benefit Systems (T931/95), Hitachi (2004) T258/03 and Microsoft/Data Transfer (2006) 
T424/03. Shemtov N. ‗The characteristics of technical character and the ongoing saga in the EPO and 
the English courts‘ (2009) Journal of Intellectual Property Law and Practice, p.506-514, provides a 
detail review of the EPO case law relating to exclusion unpatentable subject matter. 
666 Aerotel, para.26. 
667 CFPH, para.45. 
668 CFPH, para.45 and 87. 
669 CFPH, para.46. 
670 Pension Benefit Systems Partnership established that the technical contribution approach is to be 
used for assessing the inventive step. 
671 CFPH, para.94. 
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should follow such departure.
672
 The first step of the formulated test under CFPH was 
to identify ‗what is the advance in the art that is said to be new and non-obvious (and 
susceptible of industrial application).‘673 The second step is to consider whether the 
alleged invention is indeed an invention. In other words, the second step tests whether 
the invention is not of excluded subject matter under the description of an invention 
under EPC Art.52. According to the Examination Guidelines of the EPO, it is clear 
that the test of whether there is an invention within the meaning Art.52 (1) is separate 
and distinct from the question of whether it is new, inventive and susceptible of 
industrial application.
674
 Thus, Park
675
 asserted that the invention must satisfy the 
patentability requirements of newness, non-obviousness and industrial applicability 
after which it is established if it is a non-excluded invention under Art.52(2). 
 
In Research in Motion (UK) Ltd v Inpro Licensing SARL,
676
 Pumfrey J approved this 
approach that in essence extracts the technical contribution of the invention to 
evaluate the degree of excluded subject-matter. He stated that ‗it is now settled…that 
the right approach to the exclusions can be stated as follows. Taking the claims 
correctly construed, what does the claimed invention contribute to the art outside of 
the excluded subject-matter.‘677  In other words, as the Court of Appeal later observed 
in Aerotel, Pumfrey was ‗warning against saying ―well the claim involves the use of a 
computer program so it must be excluded.‖‘ 
 
The Court of Appeal gave a more structured prescription on how to evaluate whether 
inventions are of patentable subject-matter in Aerotel Ltd v Telco Holdings Ltd (and 
others) and Macrossan‟s Application678 (Aerotel/Macrossan). It is considered the 
‗technical effect‘ approach with a rider.679 Under the test, one asks whether the 
invention defined in the claim made a technical contribution to the known art, and if it 
                                                             
672 There were suggestions that CFPH approach will have the effect of changing the practice in the 
UKPO and UK courts. http://ipgeek.blogspot.com/2006/10/british-court-of-appeal-reviews.html, but 
Kitchin J was not so convinced in Crawford‟s Application [2005] EWHC 2417 (Pat), para.11. 
673 CFPH, para.95. 
674 Guidelines for Examination in the EPO, Part C, Chapter IV, patentability, EPO. 
675 Generally, in Park J. ‗Has patentable subject matter been expanded? A comparative study on 
software patent practices in the European Patent Office, the Unites States Patent and Trademarks 
Office and the Japanese Patent Office‘(2005) International Journal of Law and Information 
Technology, p.336-358. 
676 [2006] EWHC 70 (Pat). 
677 [2006] EWHC 70 (Pat), para.186. 
678 [2006] EWCA Civ 1371. 
679 Aerotel, para.26(2) and 38. 
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did Art.52(2) applied, with the rider that novel or inventive purely excluded subject 
matter did not count as technical contribution. 
 
The Court laid out a structured way of patentable subject-matter evaluation, which the 
UKIPO was to immediately follow.
680
 It is considered a re-formulation of the order of 
the Merrill Lynch steps.
681
 The test is made up of common four-steps to be followed 
for the different listed exclusions to patentability:
682
  
1 Properly construe the claim. 
2 Identify the actual contribution 
3 Ask whether is falls solely within the excluded subject-matter 
4 Check whether the actual or alleged contribution is actually technical in 
nature. 
 
Of the first step, the court said ‗you first have to decide what the monopoly is before 
going onto the question of whether it is excluded.‘683 Lord Mustill, in Genentech Inc.‟ 
Patent
684
 emphasised the importance of making a patentability evaluation that is in 
line with the monopoly conferred on the patentee. Lord Hoffmann has emphasised 
that claims are the benchmarks for assessing whether the patentee deserves the 
monopoly.
685
 
 
The assessment then moves onto making valuations of the contribution made by the 
invention: ‗The second step – identify the contribution - is said to be more 
problematical. How do you assess the contribution?...In the end the test must be what 
contribution has actually been made, not what the inventor says he has made.‘686 
 
                                                             
680 http://www.patent.gov.uk/press/press-release/press-release-2006/press-release-20061103.htm. 
681 Aerotel, para.41; Symbian, para.30. 
682 Aerotel, para.40. In HTC Europe Co Ltd v Apple Inc [2013] EWCA Civ 451, para.44, the Court of 
Appeal said ‗it remains appropriate(though not strictly necessary) to follow this approach. 
683 Aerotel, para.42. 
684 [2003] RPC 203. 
685 Conor, para.19, stating the patentee deserves that the patentability of their invention be judged 
according to their claim and not according ‗to some vague paraphrase based upon the extent of his 
disclosure in the description.‘ Also, in Kirin-Amgen, Inc. v Hoechst Marion Roussel Ltd. [2004] UKHL 
46, para.18-21. 
686 Aerotel, para.43. 
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The courts have emphasised the ultimate objective of the whole analysis: ‗what has 
the applicant really added to human knowledge?‘687 Confirming that the disclosure of 
a racemate does not amount to the disclosure of its enantiomers, the court in Generics 
(UK) Limited and others v H Lundbeck A/S,
688
 said that in conceptualizing subject 
matter as an invention, it is not enough to determine that it contributes to the art, but 
must do so sufficiently to justify a patent. Part of the justification of the patentability 
standard lies in encouraging inventors disclosing to the public new knowledge that 
advances the state of the art. This, as asserted in chapter two, must feature in 
patentability assessment to ensure a method that achieves the purposes of the patent 
system. 
 
Thirdly, the analysis then seeks to discern whether the essence of added knowledge is 
in excluded subject matter. ‗The third step– is the contribution solely of excluded 
matter? – is merely an expression of the ―as such‖ qualification of Art.52(3).‘689 Fox 
LJ said in Oneida Indian Nation's Application,
690
 ‗even if there was a technical 
contribution, if the result was still within an exclusion then that is the end of it.‘ Jacob 
LJ put it this way in Aerotel ‗the ―technical contribution‖ theory was adopted by this 
court but with the important rider that inventive excluded matter could not count as a 
technical contribution.‘691 
 
The fourth step seeks to confirm that the contribution is indeed technical. It was 
thought that the fourth step of checking whether the contribution is ‗technical‘ may 
not be necessary because the third step should have covered this.
692
 The High Court, 
for instance, said in IGT / Acres Gaming Inc, Re,
693
 ‗the fourth or last step is just a 
cross-check, because ―technical‖ is too vague a test to be used on its own.‘ 
Nonetheless, it is a necessary check under the proper test. The court, in Symbian, 
                                                             
687 IGT Application [2007] EWHC 1341 (Ch), para.22. Kitchen J. ‗How much for how little‘ (2009) 
Chartered Institute of Patent Agents Journal, p.522-527 asserting that for pharmaceutical patents the 
claims must reflect the actual advances made by the inventors and Pila, fn.612, claiming that the 
contribution to the art is the invention and therefore the need to define an invention in a way that 
recognizes the invention as the manifestation of different human inventive activities and seeking to 
reward contributions to the industrial arts. 
688 [2009] RPC 13. 
689 Aerotel, para.45. 
690 [2007] EWHC 0954 (Pat) para.10. 
691 Aerotel, 85. 
692 Astron Clinica Ltd v Comptroller-General [2008] RPC. 14, para.49, Kitchin J. was of this view. 
693 [2008] EWHC 568 (Pat), para.20. 
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emphasised that this step is not optional as the UKIPO had tended to do with 
applications for patents.
694
 
 
Although the test in Aerotel/Macrossan clarified the appropriate practical exclusion 
approach, there are still some issues that have been hard to settle. Overall, the 
approach by the UK domestic courts is said to be consistent.
695
 There are others who 
are not convinced.
696
 Some have gone further and suggested that the UK courts have 
failed to apply Art.52 in good faith.
697
 The TBA in Duns Licensing 
Associates/Estimating sales activity
698
 was of the view that the approach in the UK is 
different from the EPO approach because there was confusion between the legal 
concept of invention as used by the EPO and the ordinary meaning of invention which 
is used in Aerotel/Macrossan. 
 
Furthermore, there is still some divide perceived between the domestic and EPO 
approach to exclusions, suggesting that optimal patentability standards may not yet 
have been attained.
699
 The EPO exclusions approach has been considered by the 
courts to be the inappropriate one.
700
 The Patents Court in Halliburton‟s Applications 
did not accept the argument that it should abandon the Aerotel/Macrossan approach as 
it differed from the EPO approach and follow the EPO.
701
 Birss J, detecting ‗a 
familiar and illegitimate submission which has been made before by those who argue 
that the EPO‘s approach should be followed...‘ said the ‗EPO‘s approach when 
applied as a whole and correctly‘ should be similar to the UK and ‗difficulties 
perceived in the UK with the way the EPO approaches computer implemented 
inventions are genuine jurisdictional concerns of a respectful nature.‘702 The decisions 
                                                             
694 Symbian, para.8. 
695 Feros A. ‗A comprehensive analysis of the approach to patentable subject matter in the UK and 
EPO‘ (2010) Journal of Intellectual Property and Practice, p.577-594. 
696 Pila J. The requirement for an invention in patent law (2010) Oxford: Oxford University Press, 
p.334. Ballardini R.M. ‗Software patents in Europe: The technical requirement dilemma‘ (2008) 
Journal of Intellectual Property and Practice, p.563-575. 
697 Decision T0154/04, Duns Licensing Associates, 15 November 2006, Board of Appeal, EPO, 
para.12. 
698 (T154/04) (Unreported, October 1, 2007) (EPO (Technical Bd App). 
699 For instance, Patentability of computer software case G3/08. 
700 Cappellini's Applicaton/Bloomberg LLP's Application [2007] EWHC 476 (Pat), para.9, Pumfrey J 
applying Aerotel, said whilst he was in agreement with the result, he was of the view that the EPO 
reasoning was incorrect. 
701 [2011] EWHC 2508(Pat), para.4. 
702 Halliburton Energy Services Inc's Patent Applications [2011] EWHC 2508 (Pat), para.4 and 79. 
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of the EPO are persuasive but not binding authority,
703
 although the Court of Appeals 
could depart from its previous decision if it is of the opinion that the EPO has formed 
as settled view that differs from one arrived at in a previous UK decision, but is not 
obliged to do so if it is of the view that the jurisprudence was plainly unsatisfactory.
704
 
In Halliburton‟s Applications,705 the court observed without deciding, whether the 
question of the EPO approach is a consistent and settled one, saying the precedent in 
Aerotel/Macrossan was binding on UK courts and that the apparent difference with 
the EPO approach was that the EPO approach goes together with a special approach 
to inventive step. It is therefore likely that the UK courts would continue following 
the Aerotel/Macrossan approach as the EPO approach is not considered settled so as 
to be followed.
706
 
It is submitted that the adoption by the UKIPO of the exclusion approach identical to 
that which will be used by the courts imparts certainty in high technology fields 
engaged in inventive activities. It is helpful that the tests applied by the patent office 
and courts consistently result to the same outcome. In addition, this brings closer the 
idea of uniform standards and practice throughout the region such that research output 
could be subjected to the same practical exclusion rules. It is logical to have an 
identical law interpreted in an identical way, especially starting at the examinations 
stages in the patent offices. 
 
 
South Africa 
 
4.6 Definition of patentable inventions and excluded subject matter 
 
It has already been shown that patent law in South Africa was historically developed 
from British influences. With the advent of partially harmonised European patent law, 
the practice continued, with South Africa receiving influence from the European laws. 
This was through the adaptation and use of the EPC in promulgating the current 1978 
                                                             
703 Genentech‘s Patent [1989] R.P.C. 147. 
704 Actavis UK Ltd v Merck & Co Inc [2008] EWCA Civ 444. Also, Human Genome Sciences Inc v Eli 
Lilly and Company [2011] UKSC 5, para.87 decided, inter alia, that ‗while national courts should 
normally follow established jurisprudence of the EPO, that does not mean we should regard each 
reasoning of the Board as effectively binging on us.‘. 
705 [2011] EWHC 2508 (Pat), para.79. 
706 Ibid, para.79(iii) and (v). Also, HGS, para.87. 
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Patents Act as seen in chapter two and three. Despite similarities that would be 
expected, there are differences in the domestic statutes of the two jurisdictions under 
study.  
 
Patents Act 1978, s.25(1) begins with positively defining a patentable invention as 
one that is new, and involving an inventive step and capable of being used or applied 
in trade or industry or agriculture. This means that to be patentable an invention has to 
meet these three conditions of patentability as is the case in the UK.  
 
The statutory definition of a patentable invention, like the UK statute, is neutral on 
whether subject matter should first be judged as an invention before satisfying the 
prescribed patentability conditions or it simply has to meet the prescribed conditions. 
There has been no case to provide guidance as to which approach should be taken in 
South Africa. In the UK this was partially resolved in case law and also by reference 
to the EPC as the founding instrument as was seen in the previous section. 
 
Under the South African 1978 Patents Act s.25(2), as in the UK statute, the definition 
of an invention makes reference to subject matter that is expressly excluded from 
what is considered a patentable invention. This exclusion is directed to subject matter 
‗as such‘ according to s.25(3). That is to say that the exclusion is made on a similar 
ground as in the UK where the invention is excluded only to the extent that it relates 
to the subject matter as such. 
 
The definition of a patentable invention makes reference to what is excluded from the 
definition of an invention for the purposes of the Act by listing the subject matter in 
section 25(2). What is noteworthy is that the list has no indication of whether it is 
exhaustive or not as the UK counterpart which is non-exhaustive. This section will 
now discuss the listed exclusions in the groupings that were used for discussing the 
UK exclusions. 
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4.7 Excluded Items  
 
The Patents Act 1978 makes a list of excluded items from patentability. There is a 
qualification for these exclusions, which is similar to the one in the UK statute. 
Section 25(3) provides that the exclusion is made ‗only to the extent to which a patent 
or an application relates to that thing ‗as such‘‘. Inventions possessing these items in 
and of themselves are unpatentable, but could be patentable to the extent of 
embodying other allowed subject matter.  
 
The most common criterion amongst these exclusions is their abstract or mental 
nature, which is the position in the UK. Taking this reasoning further, commentators 
have stated that the exclusions are based on the doctrine of ‗mental steps‘ which states 
that res communes mental processes will not exclude from patentability an apparatus 
whose subject matter results to an identical method or process as one that can be 
carried out by the human brain.
707
 Therefore, even if the subject matter of some 
inventions may seem to be in the excluded categories, the inventions may not merely 
be considered unpatentable on the basis of physically carrying out an identical 
abstract or mental function. 
 
4.7.1 Discoveries and scientific theories 
 
The Patents Act s.25(2) provides that discoveries and scientific theories are not 
patentable. It is often difficult to differentiate between the discovery or theory and the 
method of applying it, but the South African courts have addressed this. For example, 
in Hay v African Gold Recovery Co
708
 it was established that:  
‗chemical affinity is, however, a law of nature, which… can no more be 
patented than the law of gravity. If the matter rested there, there would be 
nothing more to say about it. But when a natural principle or chemical law is 
applied in a novel way to some practical and useful purpose, the process by 
which it is done may well be patented. That is beyond all question.‘ 
 
                                                             
707 Burrell, p.38. 
708 (1896) 3 OR 244, p.260. 
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That would be to say that to receive a patent, one has to generally physically change 
something in a new and unobvious manner.
709
 In other words, there has to be some 
transformation of the physical world through the discovery or theory. This is a similar 
principle to the UK exclusion of discoveries and theories from patentability in which 
the application of the discovery or theory is patentable. 
 
What is perhaps debatable is how a substance occurring naturally in the body or in 
nature and subsequently characterised would be treated in South Africa. In the UK, 
since the coming into effect of the current patent statute there has been some impact 
on the principle of excluding discoveries through the influence of the Biotechnology 
Directive and domestic case law development that takes into consideration external 
judgments of the EPO. In the EPO Manual
710
 for instance, it is stated that: 
 
‗To find a previously unrecognised substance occurring in nature is also mere 
discovery and therefore unpatentable. However, if a substance found in nature 
can be shown to produce a technical effect, it may be patentable. An example 
of such a case is that of a substance occurring in nature which is found to have 
an antibiotic effect.‘ 
 
Authors express some unease with the patenting of naturally occurring biological 
compounds regardless of the novelty of the process that isolates the naturally 
occurring material in view of the fact that the material has always existed.
711
 It is 
unclear as to what extent this principle would be embraced in South Africa. South 
Africa has no external obligations on how it should interpret exclusions as the UK has 
had to do through the subsequent coming into effect of the Biotechnology Directive. 
Persuasive influence could be gained from a recent US Supreme Court, holding that 
merely isolating genes that are found in nature does not make them patentable.
712
  
However, a broad impact of the decision is uncertain as the court was specific and 
                                                             
709 Kuhn J.M. ‗Patentable subject matter matters: New uses for an old doctrine‘ (2007) Berkeley 
Technology Law Journal, p.89-114, p.89. 
710 Examination Guidelines, Section 3.2.1. 
711 Crowne-Mohammed, fn.565, p.469. 
712 Association for Molecular Pathology v Myiad Genetics, 569 U.S. 12-398 (2013). 
 170 
clear in narrowing down its opinion and setting out what is not implicated by the 
decision.
713
  
 
South Africa seems to have a domestic policy that shows less recognition of the 
technical contribution of inventions that relate to isolation and characterisation of 
natural products.
714
 This, it seems, is intended to ensure that natural products found in 
this region are not easily patented by virtue of being scientifically replicated or 
isolated.
715
 Such a view is reinforced by the fact that South Africa promulgated the 
Patents Amendment Acts of 2005 requiring a declaration for all domestic patent 
applications that the inventions are not derived from naturally occurring resources in 
South Africa. A view that has been expressed has been that the South African 
government does not seem to be focusing on exploitation, but rather on preservation 
of South African resources.
716
 The effect of this position is yet to be seen as there are 
concerns that this prevents the patenting of pharmaceutically active compounds 
resembling or derived from those that are natural in South Africa. This is to say that 
pharmaceutical companies may have less interest in engaging in research that may fall 
within the scope of natural products found in South Africa if the perception is that the 
technical input in isolation or characterisation pharmaceutical compounds will not be 
recognised under patent protection. Indeed, Dutfield warning on the need to strike a 
balance amongst the stakeholders in pharmaceutical discovery, states that natural 
products research is relevant to pharmaceutical discovery, although it only forms a 
part in a wide array of available options for discovery.
717
 
 
                                                             
713 Ibid, part III, specifying that the decision was not about method claims, or new applications of 
known knowledge and was not an enquiry about naturally occurring compounds that have been 
scientifically altered. 
714 Authors point out that although there is promise in nature-derived pharmaceutical products, there is 
limited support from the South African government for R&D: Rybicki, fn.36. 
715 Harms viewed the intentions of the Draft Intellectual Property Bill of 2009 as laudable in protecting 
South African natural resources and traditional knowledge, but lamented this protection being 
superimposed onto IP regimes as it would it would prevent South Africa‘s increase in technological 
capacity through innovation. Harms, fn.504, p.544; Previously, there was the view that South African 
resources are inappropriately manipulated, especially by foreigners: Visser C. ‗Biodiversity, 
bioprospecting, biopiracy: A prior informed consent requirement (2006) South African Mercantile Law, 
p.497-507. 
716 Dean O., ‗Move to reinvigorate IP law‘ (2011) De Rebus, p.10: Also at http://www.commercial-
property.co.za/2706_news_Intellectual-Bill-An-Abomination.html. Straus asserts that such measures 
by government preventing patent protection for such resources, ‗stand in clear contradiction to their 
own argument‘ of harnessing innovation for economic growth: Straus, fn.281. 
717 Dutfield G., ‗A critical analysis of the debate on traditional knowledge, drug discovery and patent-
based biopiracy‘ (2011) European Intellectual Property Review, p.238-244, p.241. 
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4.7.2 Computer and computer-related inventions 
 
The patentability exclusions for computer program and computer-related inventions 
are similar in the South African statute as in the UK. Computer programs are 
excluded from patentable by Patents Act s.25(2)(f). Section 25(2)(g) prescribes the 
exclusion of presentation of information from patentability. Section 25(2)(e) excludes 
from patentability schemes, rules or methods of doing business. South African 
commentators have questioned why this should be so. Burrell for instance, contrasting 
the current position with the position in the former Patents Act, which had no 
provision expressly precluding these categories, opines that ‗there seems to be no 
good theoretical reason why such a scheme, rule or method should not be patentable 
under the current law.‘718  
 
According to commentators, the fundamentals of the UK and South African 
approaches to the exclusion of computer programs are considered similar.
719
 ‗A claim 
to a computer characterised by having a particular program stored in its memory or to 
a process for operating a computer is patentable and would not be regarded as a claim 
to the program per se.‘720 This, according to Burrell, is not defeated by the ‗clever 
claim-drafting‘ that would seek to disguise the invention as composed of non-
excluded subject matter.
721
 This means in exclusions evaluation, substance over form 
is also important in South Africa and the exclusion decision is not merely made on the 
basis that the invention contains a computer program. 
 
In South Africa, it is not clear whether the exclusion of computer-related subject-
matter utilises an approach based on the so-called ‗technical contribution‘ or 
‗technical effect‘ methods as was the question that has been addressed by the UK 
courts. As shown above, the UK approach initially used the technical contribution test 
and there has been a gradual change converging with the EPO approach, albeit a 
                                                             
718 Burrell Thesis, p.36. 
719 Ibid, p.38. 
720 Ibid, p.32. 
721 Ibid, p.32. 
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difficult convergence.
722
 This is particularly evident in the area of computer programs. 
In South Africa, the nature of the decisive requisite contribution has not been analysed 
by the courts. 
 
 
4.8  Exclusions approaches in particular to computer programs 
 
As alluded to above, in South Africa, the courts have not had the opportunity to offer 
detailed guidance on how the approach to the exclusion of computer programs ‗as 
such‘ should be carried out. This may also be one aspect which highlights the lack of 
substantive patent application examination as proving problematic as it leads to less 
guidance on the patentability requirements. Patents for computer programs or 
computer-implemented inventions have been issued in South Africa, but not many 
have been contested. In Murray v Vodacom (pty) Ltd,
723
 the plaintiff sued for 
infringement of a patent for a computer-implemented invention and the defendant 
counterclaimed, inter alia, that the invention of the patent was not patentable on the 
ground of consisting a scheme, rule or method of performing a mental act or business 
according to section 25(2)(e), but this challenge on excluded subject matter was not 
pursued during trial.  
 
The need to clarify the position on how the actual exclusions would be carried out in 
South African courts is perhaps evident. This inadequacy seems to be a contribution 
from multiple sources. Dean argues that IP practitioners are not doing enough to 
improve the law by bringing arguable case before the courts.
724
 Justice Harms states 
that there has been lack of movement in improving the law to keep up with 
technology development on the part of the legislature.
725
 There is generally lack of 
                                                             
722 Shemtov N. ‗The characteristics of technical character and the ongoing saga in the EPO and the 
English courts (2009) Journal of Intellectual Property Law & Practice, p.506-514. De Mauny C. 
‗Court of Appeal clarifies patenting of computer programs‘ (2009) European Intellectual Property 
Review, p.147-151, asserts that the decision in Symbian was a move seeking compromise with the EPO 
position. 
723 [2008] ZACCP 1. 
724 Dean, fn.716. 
725 Ibid. 
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significant discussion on how patents would be assessed in court for patentability, 
although there are indications that this may change.
726
 
 
Such discussions are useful in bringing up the legal issues that are important and 
would have to be addressed for South African industries to be competitive in global 
economies where computers are central to most activities. It seems a more meaningful 
debate would be to clearly formulate the extent South African policy allows the 
patenting of computer related inventions rather than viewing computer-related patents 
as totalling unacceptable without due regard to the fact that all competitive industry 
relies on computers.
727
 Legal scholars attribute the misconception by policy makers 
that computer-related inventions are not patentable, to the overlooking of the fact that 
section 25(3) precludes only what could be called ‗pure‘ software.728 Whatever line of 
research is chosen by pharmaceutical firms or research firms generally, there are vast 
amounts of information that needs to be processed and analysed. The primary 
efficient tools used in R&D have been shown to be computers in various 
embodiments or applications. It seems, therefore, a clear policy decision would be 
helpful as currently there are conflicting assertions by the different agencies of 
government on the extent of the ‗as such‘ exclusion for computer-related inventions. 
 
 
United Kingdom and South Africa 
 
4.9 Discussion of the general principle to patentability exclusion of subject 
matter in the UK and South Africa 
 
The general statutory exclusions of subject matter from patentability in South Africa 
and the UK are comparatively similar. The UK law is based on the EPC, but there 
have been some differences in domestic interpretation of exclusions compared to EPO 
or EPC Contracting States with which the courts have expressed preference for 
                                                             
726 Ibid, South African Intellectual Property Institute president, making a speech that the institute of 
patent attorneys will play a more active role in reforming patent law. 
727 ‗―SA minister slams software patents‖: Public Service and Administration minister quoted as saying 
there‘s no reason to believe that society benefits from [patent] monopolies being granted for computer 
programs‘, http://tectonic.co.za/?p=2304.  
728 de Villiers C. and Tshaya T. ‗Software and business method patents‘ (2008) Journal of Information 
Law and Technology:  http://go.warwick.ac.uk/jilt/2008_2/devilliersandtshaya. 
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convergence. Although, as Nicholls LJ observed, ‗it would be absurd if, on an issue of 
patentability, a patent application should suffer a different fate according to whether it 
was made in the United Kingdom under the Act or was made in Munich for a 
European patent under the Convention‘,729 it is unsurprising that there is less than 
perfect harmony in interpretation of the statute between the UK and its counterparts in 
Europe.  
 
At first glance, the South African law is similar to the UK. It is mainly due to the fact 
that, historically, UK statutes was used in drafting South African law and the current 
law is based on the EPC. It is unsurprising that there would be some difference 
between the UK law and South Africa given that it is not bound by the European laws 
as the UK. South Africa has a domestic statutory patent instrument in which it seeks 
to give its own interpretation, which may not exactly be synchronous with the 
objectives of the founding instrument or travaux preparatoires which has been 
gaining popularity as a tool to interpret UK domestic law.
730
 The South African 
Patents Act remains a South African statute in all other respects.
731
 As such, it has to 
be applied and interpreted in view of the prevailing Constitutional order and 
compatible with other applicable domestic laws. The approach to patentability 
exclusions must reflect the policy considerations unique to South Africa.  
 
The main exclusion examined in this chapter centred on the use of the phrase ‗as 
such‘ and whether the alleged invention embodies the excluded categories ‗as such‘. 
Making excluded subject matter comparisons with other major patenting jurisdictions, 
some authors advocate for an approach to the ‗as such‘ exclusions that is similar to 
the UK, stating that ‗the UK courts appear more willing to construe these exclusions 
strictly and narrowly, in furtherance of the goals of the patent system itself. I suggest 
that this is the approach that all courts should take in assessing the patentability of an 
‗invention‘; since broad categorical exclusions of patentable subject matter by the 
courts defeat the underlying purposes of the patent system by foreclosing entire 
avenues of progress ab initio.‘732 It is unclear whether the South African courts would 
                                                             
729 Gale‟s Application [1991] RPC 305, p.323. 
730 Pila fn.550, p.110. 
731 See Khan‟s Chemical Industry cc v Unilever plc SAPJ June 2004 206 (RTM) 213. 
732 Crowne-Mohammed, fn.565, p.463-464. Also in Astron Clinica Ltd & Ors v The Comptroller 
General of Patents, Designs and Trade Marks [2008] EWHC 85 (Pat), para.24, the court rejected the 
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adopt a similar approach as the UK courts, although it could be expected that, to some 
degree, it would do so in view the commonality of the origins of the statutes. 
 
Despite policy differences that the respective domestic mandates may dictate, the 
statutory exclusions are seemingly directed towards similar ends for both 
jurisdictions. It could be said that for both countries the exclusions are ‗of particular 
interest because it is a statutory codification of certain a priori ‗truths‘ or ‗skill‘ that 
seem inappropriate to protect through a patent monopoly.‘733 However if the right 
balance is not struck in structuring this patentability limb to exclude subject matter 
considered undesirable for protection, there is the risk that the patent may not attain 
its purposes of preventing the monopolisation of public goods. 
 
There are significant differences, however, on how the evaluation is carried out. 
Patents Act 1977, s.1(5) provides some pre-emptive mechanisms of allowing some 
review and appropriate addition to the exclusions to patentability for domestic 
industry to remain competitive in globalised world or at least the recognition that the 
need may arise as technology changes: ‗The Secretary of State may by order vary the 
provisions of subsection (2) above for the purpose of maintaining them in conformity 
with developments in science and technology.‘734 On the other hand, in South Africa 
there seems to be no considered policy mechanism for reviewing and keeping the 
exclusions compatible with technology development and the statute has no such 
mechanism. The lack of preparedness to keep up with technology has been lamented 
by members of the judiciary, stating extra-judiciary, that government has the 
perception that IP was for rich countries and views the patent system with some 
disdain.
735
 
 
A phrase that is present in the UK statute but not in the South African one is the 
‗amongst other things‘ phrase when listing the excluded categories. This turns out to 
                                                                                                                                                                              
suggestion that it takes a wide view to the exclusion of computer programs and in Re Halliburton 
Energy Services Inc [2011] EWHC 2508 (Pat), at para.57 the court was in favour of a narrow view to 
mental exclusion in this case that involved the computer simulation of drill bits. 
733 Crowne-Mohammed, fn.565, p.464. 
734 The provision to advance patentability exclusions with changing technology has never been used in 
the UK and the feasibility of its use is unclear given the obligations to the EPC. The EPC does not have 
such a provision, but it was acknowledged that the extent of the patentability exclusions can change 
with times and technology in Programs for Computers (G3/08) [2010] EPOR 36, para.7.3.3. 
735 http://afro-ip.blogspot.com/2011/09/stellenbosch-ip-conference-part-4.html. 
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be only a difference in the statutes, but practically mean the same. In South Africa 
there could, and indeed there is no suggestion that there are other additional categories 
that exist but are not explicitly expressed in the subject matter excluded from 
patentability. This was a suggestion in the UK, but the courts dismissed it in Chiron 
Corp v Organon Teknika Ltd,
736
 stating: 
‗[W]e do not consider that the words ‗(among other things)‘ open up a new 
range of objections to the conclusion that something new is an invention. 
Rather it is a recognition that that sub-section is not exhaustive and has 
therefore not changed the law any further than the subsection itself expressly 
provides. It seems to us that any other conclusion would be inconsistent with 
the different emphasis apparent in the EPC.‘ 
The non-exhaustive nature of exclusions listing is dependent on the existence of the 
power to introduce further categories by the UK Secretary of State if need be, but has 
never been used therefore the categories are still similar to those statutorily provided 
for in South Africa. 
 
The interpretation of the statutes shows some dissimilarity when viewed in the context 
of the respective patenting policies in the two jurisdictions. The interpretation of some 
of the exclusions in the UK is influenced by subsequent Directives. For example, the 
Biotechnology Directive plays a role in the interpretation of the patentability of 
natural products isolated or used in pharmaceuticals. The draft EU Software Patents 
Directive, which sought to harmonise laws relating to software, but rejected by the 
European Parliament, would have altered the way the statutory interpretation of the 
exclusions relating to software implemented inventions are interpreted. On the other 
hand, in South Africa which has no such dynamic obligations, the judiciary has 
lamented the stagnancy of the patent law in keeping with technology development and 
the issues that may arise therein which the legislature is seemingly resistant to 
modify.
737
 
 
In some respects, the influence of the TRIPS Agreement would be expected to bring a 
convergence into the interpretation of domestic law on unpatentable subject matter. 
                                                             
736 [1996] RPC 535, p.606. 
737 Dean, fn.683, quoting Harms in a lecture entitled ‗The ossification of IP law‘ stating that IP law ‗is 
not adapting at a rate appropriate for economic growth‘ in the era of technology driven economies. 
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However, it tends to be of less effect in the sense that the TRIPS Agreement allows a 
wide discretion for member states on what could be excluded from patentability and 
the interpretation to be attached to this patentability limb.
738
 South Africa seems to 
takes a conservative approach to what can be patented.
739
 Public policy is emphasised 
as the overriding factor to what should be unpatentable, demonstrated for instance in 
the occasions where the state grants more authority to the Registrar of Patents to 
invalidate patents.
740
 This is public policy somewhat different to that where 
‗knowledge and technology development can be viewed as public goods generated 
through the recognition and enforcement of private patent rights, provided that the 
invention is published in a public registry and the rights are limited in scope and 
time.‘741 The UK courts prescribe a balanced approach in making the ‗as such‘ 
exclusions.
742
 
 
The use of the phrase ‗as such‘ seem to be central to the operation of the exclusions in 
both the UK and South African statutes and is used to prevent the patenting of the 
categories scrutinised in this chapter on the ground that they generally lack technical 
contribution, technical result or technical effect. The UK courts have applied 
numerous tests in assessing excluded subject matter for this technical aspect as seen 
above. The case law of excluded subject matter in South Africa is limited compared to 
the other limbs of patentability and also to the UK, with reported cases showing 
absence of guidance on excluded subject matter. Authors have suggested that the 
patentability system of other jurisdictions, imitating the general approach of the UK, 
could concentrate on the other limbs of patentability, making those limbs more robust 
                                                             
738
 Chandiramani N. ‗The legal factors in TRIPS‘ (2002) Economic and Political Weekly, p.200-203, at 
p.202. Compared to the TRIPS Agreement, the Draft SPLT provided only for a few categories to be 
excluded from patentability. 
739 Government disregarded protestations to the Bill to protect traditional knowledge under IP rules 
which has been lamented by practitioners, academics and judges as encroaching on what could be 
patented in South Africa and destined to ‗change IP law as we know it‘, according to Harms: Dean, 
fn.683, ‗The ossification of IP law‘ (2011) De Rebus, p.10. 
740 The Patents Amendment Act of 2005 provided the Registrar with power to invalidate patents where 
patentee ought to have known they were derived from South African resources; Justice Harms‘ view 
being that this is arbitrary and gives the registrar the unfettered power to determine what extent is the 
derivation: Harms, fn.504, p.546. Dutfield has pointed out that typical new pharmaceuticals could be 
said to have a long history of derivation from natural compounds, Dutfield G., ‗A critical analysis of 
the debate on traditional knowledge, drug discovery and patent-based biopiracy‘ (2011) European 
Intellectual Property Review, p.238-244, at p.241. Therefore, effectively the South African government 
foreclosed a class of substances that could be patented. 
741 Shaffer, fn.567, p.461. 
742 Aerotel, para.9, per Jacob LJ. 
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as they could be easily offset by broad exclusion of subject matter.
743
 In South Africa, 
because of the lack of patent application examination and little challenge on granted 
patents, this suggestion would be of limited impact. Nonetheless, for those cases that 
ultimately reach the courts, there is no reason why the suggestion to interpret 
exclusions narrowly or in a more balanced fashion and developing more robust tests 
for novelty and obviousness, would not be beneficial.
744
 
 
The UK seems to be proactive in keeping the law on exclusions up-to-date with 
technology. An example would be the issuance of practice manuals inter alia on the 
excluded subject matter, that seek to adapt to technology development, practice 
notices in reaction to court decisions and also having a law in place with a mechanism 
that allows the expansion of exclusions to be made at the discretion of the Secretary 
of State, although this option has never been exercised. With regard to this, in South 
Africa there has not been a reform of the law to keep up with technology.
745
 Even 
though the South African judges have once observed ‗that it is against public interest 
that persons with inventive minds should be discouraged from giving the result of 
their efforts to the public in exchange for the grant of a patent‘,746 there is an absence 
of a mechanism that monitors whether the balance is attained or a recalibration is 
needed in the balance between the public and private interest in patentability 
exclusions made as technology develops. A practice manual is recommended to 
compensate for these shortfalls. 
 
 
4.10 Conclusion 
 
Defining what an invention is difficult. Its conceptualization takes influence from 
diverse stakeholder, as shown in the chapter, with each imposing its own 
understanding of the meaning of an invention. A recommendation is made that the 
meaning must be reduced to and aligned with its legal attributes. This would reduce 
some of the confusion of how courts would ultimately interpret the invention to be. 
                                                             
743 Crowne-Mohammed, fn.565, p.485. 
744 Some authors emphasize that the patent office is the best place in applying and refining patentable 
subject matter applicable within a jurisdiction: Golden J.M. ‗Patentable subject matter and institutional 
choice‘ (2011) Texas Law Review, p.1041-1111, at p.1075. 
745 Harms, fn.504. 
746 Miller v. Boxes & Shooks (Pty.), Ltd., 1945 A.D 561, p.578. 
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In defining a patentable invention the statutes of both jurisdictions define what is 
excluded from the definition of a patentable invention. The negative defining of an 
invention by exclusion is generally centred and directed to assessment of the subject 
matter that is considered to be the core of the technical contribution, character or 
feature of the invention. The difficulty in evaluating the technical contribution, 
aspects or features of the invention lies in the fact that sometimes the technical aspects 
or features of the invention are not easy to resolve as they are sometimes made up of 
patentable subject matter and excluded subject matter. Recent UK case law has 
provided a structured sequence of steps to follow in identifying if an invention is 
patentable or not under the rule of not consisting of excluded subject matter. Some 
doubt remains on whether consistency has been achieved when compared with EPO 
jurisprudence. South Africa on the other hand has not, for some of the excluded 
categories, addressed the question of the exclusion analysis where patentable 
inventions are integrated with unpatentable subject matter. 
 
The UK and South Africa have similar statutory exclusions from patentability. There 
are debates on the items that constitute the exclusion list, with computer programs as 
such, being the most debated. It is concluded that the critical aspect of the discourse 
on unpatentable subject matter lies in how the exclusions are actually interpreted in 
court and that determines if the policy reasons for making the exclusions in the first 
place are attained. Although the debate on what should be excluded by express 
statutory listing is likely to remain, the UK seems settled on the categories and how to 
approach inventions integrated with patentable and unpatentable subject matter. With 
regards to the South African approach to exclusions, it is noted that there has not been 
significant application of the methodology in practice and as a result there is some 
uncertainty as to the position that the courts would take in practice, even though the 
exclusions are based on the EPC as the UK laws. A recommendation is made of the 
need to have an express statement of the policy for the exclusions. This could be the 
foundation of the development of a guideline informing how the contentious 
exclusions should be approached. 
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CHAPTER 5 
     
NOVELTY 
 
 
5.1 Introduction  
 
The novelty of an invention is the cornerstone of the patent system. In chapter two it 
was established that the patent is premised on advancing the state of the art. This is 
achieved both if the inventor is encouraged to engage in inventive activities and if 
there is encouragement for the divulging of that new knowledge to the public for the 
progression of science. In essence therefore, the patent is pivoted on the resultant 
making available of new knowledge.
747
  
 
International legal instruments prescribe that member states must have legal 
mechanisms that protect new inventions, as seen in chapter three. The domestic 
statutes of the respective jurisdictions prescribe that newness is a quality that must be 
present in that knowledge that is granted protection. However, assessing whether or 
not an invention is sufficiently novel is difficult because newness is a binary decision; 
either something is new or not and yet there is often close resemblance between the 
old and the new. The legislatures in both jurisdictions provided for qualitative 
benchmarks for judging novelty. Nonetheless, besides the qualitative assessment that 
the courts have to carry out as prescribed in the statutes, there is a need to quantify 
that newness to establish if it meets the statutory benchmark.
748
 It then becomes an 
issue of evaluating the extent of the newness of that disclosed knowledge as 
compared to the state of the art in order to make the binary decision. 
 
The long history in the case law of the UK and South Africa has on some occasions 
shown difficulties in achieving the right balance of what constitutes newness or how 
it should be assessed.
749
 Contemporary, the UK case Synthon v SmithKline Beecham 
                                                             
747 Bently/Sherman, fn.265, p.471-472. 
748 Burrell, p.214. 
749 Van Der Merwe A. ‗The significance of ―matter which has been made available to the public‖ in the 
assessment of the novelty and inventiveness of a claimed invention‘ (1995) South African Mercantile 
Law Journal, p.37-45. 
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Plc
750
 epitomises some of the difficulties in the test of what is adequate for novelty in 
the innovation race in the pharmaceutical field. It is of concern that the Court of 
Appeal got novelty assessment wrong such that the Supreme Court had to reaffirm 
the foundation of how newness is to be judged,
751
 yet it is a patentability limb that has 
been part of the system for a long time. It has also been asserted by commentators 
that in South African there could be improvement in the understanding of the 
concept.
752
 The wider and underlying question that then arises is whether it would 
really be expected of inventors, whose viewpoint is adopted in this thesis, to know 
how newness is to be judged from a legal perspective when the senior courts 
themselves sometimes seem be unclear on the concept. In both jurisdictions it is 
critical, therefore, to translate the novelty requirement as legislators intended into a 
feasible mechanism of practical application of that statutory intent on the required 
novelty threshold. 
 
The implication of the outcome of the Synthon case, which will be explored in more 
detail below, is more than that newness as a requirement to patentability is to be 
reassessed and properly understood. The material facts of the case also show how a 
seemingly straightforward legal principle can give odd results.
753
 In South Africa, 
especially, where there is more effort to promote local pharmaceutical ingenuity and 
production
754
 and transition to research based output,
755
 such seemingly illogical 
results raise the question, in industry, of the continued relevance and reliability of the 
novelty criteria as a driver of the development of new pharmaceuticals, especially in 
light of assertions that they ‗have never been indispensable.‘756 At face value, it 
would be difficult to fault industry if there is the perception that the system allows 
earlier patentees to patent what the scientists do not yet fully know or understand. 
Such a state of affairs is contrary to the tenets of patents in encouraging novel 
research output. The policy-makers and the public at large have to remain convinced 
                                                             
750 Synthon BV v SmithKline Beecham Plc (No.2) [2005] UKHL 59. 
751 With regard to the Court of Appeal reasoning, Lord Hoffman, para.54, stated that ‗[t]his passage 
again suggests to me serious confusion‘ in the application of novelty rules.  
752 Burrell, para 4.71.2, suggesting ‗the best workable method to test for novelty.‘ 
753 Sharples A. and Curley D. ‗Experimental novelty: Synthon v Smithkline Beecham‟ (2006) European 
Intellectual Property Review, p.304-311. 
754 Reddy M. ‗The economic and socio-economic benefits of R&D-based multinational 
pharmaceuticals on the South African economy‘, 2007, Deloitte Consulting (Pty) Ltd. 
755 Gastrow, fn.508. 
756 Kingston, fn.2, p.350. 
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that indeed when one undertakes novelty assessment, the system sifts out undeserving 
patents and does not impinge on dynamic public knowledge generation. 
  
This chapter will begin with a background of the industrial invention and innovation 
process as it relates to the main components of the production of novel 
pharmaceuticals from conception to finished products and the concerns that arise in 
the protection of those resulting products.
757
 The legal nature of anticipation and how 
it is to be ultimately assessed in court will be examined. To achieve this, first the 
decisions in Synthon from the High Court, and the Court of Appeal through to the 
Supreme Court, as they streamline and consolidate the various facets of the law of 
anticipation, will be explored in detail as a guide to anticipation standards and how 
inventions attain the novelty limb to patentability in the UK. The practical 
significance of the case is noted to be the consolidation of the different authorities and 
novelty aspects from the series of case law on novelty and thus reducing the need to 
wade through the bulk of decided cases.
758
 There will then be case law examination 
of the novelty test in South Africa, encapsulating the tension as to the applicable 
novelty test between the patenting stakeholders. Consequently, from the analysis of 
these respective pertinent cases, the role of the skilled worker in the understanding 
and perception of novelty, and the R&D activity in influencing an invention passing 
the novelty test will be comparatively examined between the two jurisdictions. The 
significant principle here is a convergent view on novelty between these 
representative developing and developed economies, particularly of the final legal 
novelty assessment outcome of an identical invention. In the end suggestions are 
made on how the industrial and legal spheres would come to have a converging view 
of what is indeed novel when patenting is the objective. 
 
 
  
                                                             
757 Other stages or factors that have no bearing on patentability will not be explored, for instance 
marketing authorisations and other regulatory approvals needed before the novel invention is practiced. 
758 Freeland R. ‗Disclosure and enablement: The House of Lords clarifies the law on novelty‘ (2006) 
Journal of Intellectual Property Law and Practice, p.163-165, p.165. 
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5.2 The Inventing Process 
 
It has been noted that the innovation race amongst pharmaceutical entities is fierce.
759
 
The way by which they bring about new products or processes plays a central role in 
their success. It has been said that ‗the greatest invention of the nineteenth century 
was the method of invention itself.‘760 This was when the pharmaceutical industry 
‗realised that it could be profitable to put the business of research for new products 
and development of new chemical processes on a more regular, systematic and 
professional basis‘761 rather than the sporadic and unpredictable approach adopted 
during its infancy. 
 
The model has remained unchanged in the last 50 years.
762
 Competition within the 
industry places a premium on research, such that the successful firms will have an 
extensive portfolio of new drugs in their research pipeline.
763
 Typically, research-
intensive activities have been the focus of large firms with multiple internalized 
activities from research to distribution. The smaller entities on the other hand could be 
classified as specialized biotechnology firms whose activities are directed at selling 
their discoveries to the larger firms who will commercialize and bear the cost of 
perfecting the invention for the market.
764
 The synergy therefore between the two is 
that although they each can develop new molecular entities (NME) on their own, they 
usually rely on each other for complementary functions for the different stages in the 
inventive process.
765
  
                                                             
759 Generic companies have been noted to play an increasing role in the innovation race, inducing 
additional competition to originator companies by progressively earlier litigation challenges to ‗basic 
compound patents on high-sales drugs-indiscriminately...in the hope of winning a few‘: Hemphill C.S. 
and Sampat B.N. ‗When do generics challenge drug patents? (2011) Journal of Empirical Legal 
Studies, p.613-649, p.614-615. 
760 Freeman C. and Soete L. The economics of industrial innovation,3rd ed (1997) Cambridge, MA: The 
MIT Press, p.299. 
761 Ibid. 
762 Kaitin K. „Deconstructing the drug development process: The new face of innovation‘ (2010) 
Nature, p.356-361. 
763 Balance R., Pogany J. and Forstner H. The world‟s pharmaceutical industries: An international 
perspective on innovation, competition and policy (1992) Harts: Edward Elgar Publishing Limited, 
p85. Aronson J.K. ‗Old drugs- new uses‘ (2007) British Journal of Clinical Pharmacology, p.563-565: 
for pharmaceutical interventions it is also common to use old drugs for new uses even if they are not 
patented. 
764 Gambardella A. Science and innovation: The US pharmaceutical industry during the 1980s (1995) 
Cambridge: Cambridge University Press, p.61. 
765 Zucker L.G and Darby M.R. ‗Present at the biotechnological revolution: transformation of 
technological identity for a large incumbent pharmaceutical firm‘ (1997) Research Policy, p. 429-446. 
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The need to continually bring about new pharmaceuticals for diseases has brought 
eminence to the R&D process. R&D is one of the crucial phases in the production of 
new pharmaceuticals.
766
 R&D involves investigating a wide array of sources of new 
compounds, as seen in chapter one, in a systematic and efficient fashion. It involves 
studying the chemical structures of target molecules, screening and testing of 
candidate molecules and examining the mechanism of action or pathway of the 
disease. The R&D process is a sequential series of stages, but efficiency is attained 
when there is a high level of interaction between all the different stages.
767
  
 
The resulting compounds from the quest to find new pharmaceuticals do not always 
significantly differ from what is already known. This is perhaps where the pejorative 
view of patents for pharmaceuticals emanates.
768
 The general principle for what could 
be claimed as new is that ‗no man can have a patent for merely ascertaining the 
properties of a known substance‘,769 unless some modification is needed to make it 
useful for the new use. The reality in pharmaceutical R&D is that a seemingly small 
difference in chemical structure would for instance result in stereo-selectivity of a 
compound imparting considerable pharmaco-activity.
770
 Such incremental inventions 
                                                             
766 Ballance R., Pogany J. Forstner H. The world‟s pharmaceutical industries: An international 
perspective on innovation, competition and policy (1992) Harts: Edward Elgar Publishing Limited., 
p.85. Paul S. et al ‗How to improve R&D productivity: The pharmaceutical industry‘s grand challenge‘ 
(2010) Nature Reviews Drug Discovery, p.203-214. 
767 Littler D. ‗Marketing and innovation‘ in Dogson M. and Rothwell R.(ed) The Handbook of 
Industrial Innovation (1995) Harts: Edward Elgar, p.297. 
768 Dwivedi G., Hallihosur S. and Rangan L. ‗Evergreening: A deceptive device in patent rights‘ (2010) 
Technology in Society, p.324-330. 
769
 Re I. G. Farbenindustrie A.G.'s Patents (1930) 47 RPC 239, p.322. A UK exception to the rule for 
second medical use is discussed in section 7.6.1 of the thesis. At the EPO, the approach to novelty-of-
purpose for non-medical use of known products is that a claim to a new use of a known product is 
possible if the claim identifies the new use as a previously unknown technical effect, such as in G2/88 
Mobil III/Friction Reducing Additive [1990] O.J.E.P.O. 93, considered in Merrell Dow, where a 
product originally developed as a lubricant to prevent rust was found to reduce friction and was 
patentable as a new functional technical feature that reduces friction. That is a new purpose had been 
discovered: Bently/Sharman, fn.265, p.484. The practice at the UKIPO (Patent Manual, para.2.14, 
October 2013) regarding use claims based on previously unrecognized technical effect is different and 
based on the position in Tate & Lyle Technology Ltd v Roquette Freres [2010] FSR 1, upheld on 
appeal, where in the known process for synthesizing a sugar substitute maltitol by hydrogenation of 
maltose, the by-product maltotriiol was found to affect the crystal formation and therefore the patent 
claim of ‗the use of maltotriitol to modify or control the formation of maltitol crystals‘ was found by 
the court to be anticipated by prior art, as maltitriiol‘s previous unsuspected effect has always been to 
‗modify or control the form‘ of resulting maltitol crystals. 
770 Agranat I. and Wainschtein S.R. ‗The strategy of enantiomer patents of drugs‘ (2010) Drug 
Discovery Today, p.163-170. 
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have been asserted as a significant incentive to the pharmaceutical industry that 
should not be discouraged by policy-makers.
771
 
 
In the R&D process it is also common that a series of chemical compounds that 
closely resemble each other is investigated.
772
 Commonly used are Markush claims in 
respect of a general formula that covers a group of numerous compounds found to be 
sharing common characteristics or activity.
773
 It is possible to select some members 
from the series to claim for protection. Selection inventions are those that select a 
group of individually novel members from a previously known group.
774
 Selection 
patents are therefore said to be useful in making and claiming inventions in fields 
which are generally known.
775
 In litigation however, substantive issues of the 
selection patents would initially be addressed in the evaluation of the novelty criteria 
even though it may still be necessary to determine the validity of the selection under 
the obviousness limb.
776
 In Dr Reddy‟s,777 Floyd J concluded that a prior disclosure 
does not take way the novelty of a specific claim to a compound unless the compound 
was disclosed in an individual form.
778
 Affirming this principle, Court of Appeal
779
 
rejected the argument that the mere disclosure of a generic formula or class of 
compounds discloses every possible compound falling within that class. 
 
There exists a characteristic divide in pharmaceutical development between South 
Africa and the UK. NMEs have originated largely in the developed countries. 
Nevertheless, it is important to note that the nationality of the NME is an ambiguous 
concept.
780
 This is due to the international nature of the pharmaceutical model and the 
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 Cohen F.J. ‗Micro trends in pharmaceutical innovation‘ (2005) Nature Reviews Drug Discovery, 
p.78-84. 
772 Barnard J.M. and Wright P.M. ‗Towards in-house searching of Markush structures from patents‘ 
(2009) World Patent Information, p.79-103. 
773 PCT Applicant‘s Guide – International Phase, 14 January 2010, para.5.119. 
774 Van Overwalle G. ‗Policy levers tailoring patent law to biotechnology: comparing US and European 
approaches‘ (1999) UC Irvine Law Review, p.433-514, p.455-556. 
775 Jeffs J. ‗Selection patents‘ (1988) European Intellectual Property Review, p. 291-301. 
776 Minssen T. ‗Meanwhile on the other side of the Pond: Why biopharmaceutical inventions that were 
‗obvious-to-try‘ might be non-obvious‘ (2010) Chicago-Kent Journal of Intellectual Property, p.60-
131, p.81. 
777 [2008] EWCH 2345 (Pat). 
778 Wyld O. ‗High Court considers Markush claims and doctrine of UK selection patents‘ (2009) 
Journal of Intellectual Property Law & Practice, p147-149, p.148. 
779 Dr Reddy‟s Laboratories (UK) Ltd v Eli Lilly & Co Ltd [2010] RPC 9. 
780 Ballance, et al, fn.766, p.86. Boyd notes that cooperating or collaborating parties of different 
backgrounds have a crucial role to play at various stages and in the eventual success of the discovery 
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fact that new drugs can be seen as incremental improvements on existing products 
which may have been developed in other countries. Moreover, there is a trend 
whereby the research facilities are headquartered in a developed nation even though 
most of the work, usually preparatory work, is based in another nation. In cases where 
the disease is largely prevalent in developing countries, an opportunity for the 
development of solutions to serve the needs of the locality opens up. Thus, an 
important caveat to the prevailing trend of developed nations dictating research 
direction would be ensuring a deliberate line of research according to national needs 
of the country from which the raw data is taken even though the R&D is eventually 
completed in the headquarters. For instance South Africa is developing an AIDS 
vaccine against the HIV strain that is prevalent in sub-Saharan Africa, which has 
entered clinical trial stages even though the final stages are completed elsewhere.
781
 
 
The divide also extends to the typical size of the innovating firm found in the 
different countries. The UK has both the large and small firm sizes, thus 
complementing each other‘s research on new disease that affects its population. South 
Africa has a limited number of large pharmaceutical firms compared to the smaller 
firms, although this is changing.
782
 However, what could be harnessed from its 
relative novice in systematic R&D, is that with dedicated investment the ‗[n]ew 
entrant, or newly established firms, with no sunken costs or organisational biases 
toward the old technology, can be far more effective than incumbents in exploiting 
the new fields.‘783 
 
The issue of size also extends to other aspects of the innovative process. Previously 
when NME discovery resulted mainly from the extensive screening of chemical 
entities, the critical resource for success was sufficiently large laboratories and 
screening became a fairly routine and automated task. Now with the complexity of 
needed NME, which often requires varied investigations, the emerging industrial 
                                                                                                                                                                              
process: Boyd M.R. ‗The position of intellectual property rights in drug discovery and development 
from natural products‘ (1996) Journal of Ethnopharmacology, p.17-27. 
781 http://www.saavi.org.za/1press2009.htm: The collaboration is of South African scientists with US 
partners in the different stages of R&D. 
782 ‗Medicines procurement in the public sector: Challenges and opportunities for improvement of 
medicines procurement in South Africa‘s public sector- March 2010‘ (2010) South African Department 
of Health: Pretoria, p.80-83. 
783 Gambardella, fn.764, p.61. 
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model is ‗relatively small in size… often conducive to the production of ideas of great 
originality.‘784 This has meant that there has to be more focus on studying the disease 
mechanism of action, rather than requiring large scale screenings with low output.
785
 
This has impacted on traditional R&D settings by lessening the need to have large, 
capital-intensive and rigid organisations as almost the only source of new 
pharmaceuticals.
786
 
 
Hence, it can be plausibly suggested that South Africa can increase its inventive 
pharmaceutical output.
787
 For instance, it has been observed that visionary scientists 
made proposals to increase R&D in Britain by order of magnitude seemingly utopian 
at the time.
788
 South Africa needs a strategic long-term plan on how to improve its 
innovative pharmaceutical industry that will focus on the most prevalent diseases 
within its population. One way is to recognise that ‗patents that are wrongly granted 
can be very expensive to challenge, and perhaps beyond the means or inclination of 
small and medium enterprises. An accumulation of patents of that sort… may be a 
serious barrier to entry.‘789 
 
Experimentation is a critical aspect of discovering new pharmaceutical inventions.
790
 
The primary input into pharmaceutical discovery is not only fundamental science or 
science per se, but it is the complex blend of scientific knowledge and experimental 
                                                             
784 Ibid, p.45. For instance, in a study of 16 pharmaceutical firms over a 19 year period, it was observed 
that beyond a particular point, innovative productivity declined with increasing firm size because 
‗despite their use of more resources, large organizations are inherently inefficient so that their very size 
stands as an impediment to innovative results‘: Graves S.B. and Langowitz N.S. ‗Innovative 
productivity and returns to scale in the pharmaceutical industry‘ (1993) Strategic Management Journal, 
p. 593-605, p.604. 
785 Scott W.L. and O‘Donnell M.J. ‗Distributed drug discovery: Linking academia and combinatorial 
chemistry to finding drug leads for the developing world diseases‘ (2009) Journal of Combinatorial 
Chemistry, p.3-13. 
786 For instance, even micropharma -academia originated start-up companies and research units 
characterised by being small, innovative, more efficient and product focused - have been identified as 
capable of fulfilling the R&D shortages in the new pharmaceutical product pipelines: Barden/Weaver, 
fn.24. 
787 For instance, South Africa is seen a candidate country that can increase its biopharmaceutical R&D: 
International Federation of Pharmaceutical Manufacturers Associations, ‗Encouraging pharmaceutical 
R&D in developing countries (2003) Geneva Switzerland, p.51. 
788 Freeman/Soete, fn.725, p.300. 
789 CFPH's Application [2005] EWHC 1589 (Pat). 
790 Thomke S., von Hippel E. and Roland Franke R. ‗Modes of experimentation: an innovation process-
and competitive- variable‘ (1998) Research Policy, p.315-332. 
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research.
791
 Trial-and-error that formerly existed was cost effective, as there was little 
exploration of the drug mechanism of action, but may not be optimally suitable for 
more complex disease problems that now need to be tackled.
792
 Increased efficiency 
in experimental methodologies correlates with the ability and skill to comprehend 
complex problems in a more economically useful way. With more experimentation 
there is the increase in ability to use experimental observation more efficiently.
793
 
This allows firms to use theoretical technologies and principles, for instance 
genomics and bio-informatics, to predict the mechanisms of actions before synthesis 
in the laboratory or even on scaling-up novel processes. 
 
This lends support to the value of the person who carries out the pharmaceutical 
work. The value of the skilled person is manifold. Such a person skilled in the art 
plays a crucial role as the reference point in bringing inventions into the public 
domain. He is proxy for the standard of what is judged as new. It has been said that 
successful pharmaceutical firms typically organise their discovery process around 
skilled scientists.
794
 The companies have to choose the core therapeutic area of focus 
and then give the scientists the autonomy to research according to their skill. The 
scientists have ‗greater technical competence to pinpoint the best opportunities for 
technological and even commercial success.‘795 They are therefore indispensible for 
both the commercial and the legal decision of the novelty of the research activity or 
output thereof. 
 
Also important in the inventing process is conducting novelty searches in order to 
evaluate whether the new compounds will not infringe existing patents or under what 
circumstances they in turn would be infringed.
796
 This is not within the focus of the 
                                                             
791 The ultimate success in new product introduction has been correlated to the technological 
experience of the firm in the given therapeutic area deriving from R&D activities and previous market 
participation: Nerkar A. and Roberts P.W. ‗Technological and product-market experience and the 
success of new product introductions in the pharmaceutical industry‘ (2004) Strategic Management 
Journal, p.779-799. 
792 Gambardella, fn.764, p.42. 
793 Ibid. 
794 Ibid, p.45. 
795 Ibid. 
796 Rockman H.B. Intellectual Property Law for engineers and scientists (2004) Hoboken: John Wiley 
& Sons, p 130-140. Even generic companies are concerned about infringement because the reality is 
that the chemical processes involved in working a known compound can be new: Laird T. ‗Innovation 
in Generic API Synthesis and Manufacture‘ (2012) Organic Process Research & Development, p.365. 
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thesis but will be outlined here for how it illuminates the overlaps between a new 
pharmaceutical‘s patentability and the enforcement of rights arising thereof. The 
infringement of patents for pharmaceutical inventions is governed by the detailed 
statutory rules on infringement,
797
 revocation,
798
 protection from groundless threats
799
 
and the defenses that the alleged infringer may raise.
800
 Infringement is classified 
according to whether it is textual or non-textual depending on whether the infringing 
acts fall squarely within the claims of the patent.
801
 The rules for determining this 
have proven to be complex in application and much has been written about 
infringement in this context.
802
 For instance, Brennan traces the UK evolution of the 
function of patent claims up to the explicit statutory statement as a result of EPC 
Art.69‘s role in determining the scope of protection and suggests a critical view of 
claim construction jurisprudence and methodologies,
803
 Fisher traces the history of the 
EPC Art.69 and the underlying sources of divergence between EPC Contracting 
States in interpreting claims
804
 and Hellfeld traces the divergence in EPC Contracting 
States in how claims are constructed.
805
 South African authors have traced the source 
of the tensions and differences between successive South African Supreme Court of 
                                                                                                                                                                              
Denicolo V. ‗Two-stage patent races and patent policy‘ (2002) RAND Journal of Economics, p.488-
501. 
797 UKPA, s.60 and SAPA, s.65. and acts of non-infringement in UKPA,s.60(5) and SAPA, s.69. 
798 UKPA, s.72 and s.73 and SAPA, s.61. 
799 UKPA, s.70 and SAPA s.70. 
800 UKPA, s.74 and SAPA, s.65(4). 
801 ‗It is seldom that the infringer does the thing, the whole thing, and nothing but the thing claimed by 
the specification‘: Schreiner JA in Frank and Hirsch (Pty) Ltd v Rodi and Weinenberger 
Aktiengesellschaft 1960 BP162(A), p.177, quoting from Birmingham Sound Reproducers v Collaro 
1956 RPC 232, p.242. 
802 Pumfrey N., et al, ‗The doctrine of equivalents in various patent regimes-Does anybody have it 
right?‘ (2009) Yale Journal of Law and Technology, p.261-308: In a review of the doctrine of 
equivalents in leading jurisdictions, even though the UK judges were not in agreement as to the 
practical application of the doctrine, it was shown that the law provides that in order for a variant or 
equivalent to infringe it must fall within the language of the claim, properly interpreted, otherwise it 
does not infringe even if it amounts to nothing more than unfair copying of the essences of the 
inventive concept. 
803 Brennan D.J. ‗The evolution of the English patent claims as property definers‘ (2005) Intellectual 
Property Quarterly, p.361-399. 
804 Fisher M. ‗New protocol, same old story? Patent claim construction in 2007: Looking back with a 
view to the future‘ (2008) Intellectual Property Quarterly, p.133-162, concludes that because of the 
fundamental differences in the philosophy between the EPC members, the matter can only be resolved 
once a new unification framework is in place. 
805 Hellfeld A. ‗Patent infringement in Europe: the British and the German approaches to claim 
construction or purposive construction versus equivalency‘ (2008) European Intellectual Property 
Review, p.364-370, p.368: Critiquing the tools that have been applied by the courts in construing patent 
claims, saying ‗it is simply distracting from the real issues, namely construing the claimed invention 
(which includes understanding the prior art) and comparing it with the accused product or method.‘ 
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Appeal‘s approach to claim construction and also in relation to UK approaches 
persuasive in South Africa.
806
 
 
The overarching rule on anticipation which the R&D scientist needs to be aware of is 
that prior art may disclose the substance of the invention they thought was new. 
Indeed, in a South African case study of research output that is ultimately patented it 
was found that the new knowledge and the state of the art was ‗bi-directional, capable 
of overlap‘,807 such that it is difficult to distinguish between the two. At the same 
time, it is also important to note that patent infringement does not require one to be 
aware that one is infringing. In Merrell Dow, p.90, it was said that ‗whether or not a 
person is working [an]...invention is an objective fact independent of what he knows 
or thinks about what he is doing.‘ Peculiar to the UK is the mechanism introduced by 
Patents Act 1977, s.74A(1) that allows anyone to request a non-binding opinion of 
whether a particular act or contemplated act infringes on existing patents,
808
 although 
this will not absolve the infringement unless a specific declaration as to non-
infringement has been made.
809
 Therefore the creation of new substances involves a 
balance between providing new knowledge and guarding against infringing on 
knowledge that may already be claimed by third parties. 
  
The thesis now turns focus onto the nature of anticipation in the two jurisdictions. 
 
 
                                                             
806
 Burrell, p.256; Visser C. ‗The interpretation of patent claims: A chronology of the vestitudes of the 
pith and marrow doctrine and doctrine of purposive construction in the Appellate Division‘, in Kahn E. 
„In Quest for justice (1995) Durban: Juta Publishers. Nampak Products and another v Man-Dirk (Pty) 
Ltd 1999(3) SA 708, Aktiebolaget Hässle and another v Triomed (Pty) Ltd 
[2002] 4 All SA 138 (SCA), Vari-Deals 101 v Sunsmart Products (Pty) Ltd 2008(3) SA 447 (SCA) are  
the South African Supreme Court authoritative cases, but considered to be unclear on the appropriate 
principles of purposive construction approach to adopt in the move from the ‗pith and marrow‘ doctrine 
to the Catnic test as embraced in South Africa: Zondo R. The replacement of the doctrine of pith and 
marrow by the Catnic test in English patent law: A historical evaluation‘ (2012) UNISA: Unpublished 
thesis.  p.239-246.  
807 Lubango L. And Pouris A. ‗Is patenting of technical inventions in university sectors impeding the 
flow of scientific knowledge to the public? A case study of South Africa‘ (2010) Technology in 
Society, p.241-248, p.242. 
808 The potential application of this framework has been explored: Phillips J. ‗Pouring oil on troubled 
waters or inflaming the passions? Comptrollers‘ opinions and the quest for happiness‘ (2005) European 
Intellectual Property Review, p.226-231. 
809 Patents Act 1977, s.71 and Patents Act 1978, s.69. 
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United Kingdom 
 
5.3 Nature of anticipation 
 
The basis of patent systems is that they should grant monopolies in reciprocate for 
inventions that are new. As the UK‘s criteria for patentability is based on the EPC, 
the Supreme Court said on many occasions the practice of UK courts should closely 
follow those of EPO.
810
 Under UK domestic law, Patents Act 1977, s.1(1)(a) provides 
that a patentable invention should be new. It is elaborated in s.2(1) that the new 
invention should not be anticipated by prior art. This means the invention must not be 
found at the priority date in any ‗matter (whether a product, a process, information 
about either, or anything else) which has at any time been made available to the 
public (whether in the United Kingdom or elsewhere) by written or oral description, 
by use, or in any other way.‘811 Besides the making available of subject matter of the 
invention, another category of anticipation is when information is found in a patent 
application and subsequent publication.
812
 A consequence of the lack of novelty is 
patent revocation or refusal of the application.
813
 
 
 
5.4 The test for novelty 
 
According to some commentators
814
 ‗the essential standard is ‗absolute‘ and ‗global‘ 
novelty‘ against which the invention is measured. This is the one end of the novelty 
spectrum and considered a high patentability standard to set, compared with other 
jurisdictions where inventions can be novel according to a less scrutinising 
criterion.
815
 There is now a worldwide general trend towards elimination of local 
                                                             
810 Tilmann W. ‗Harmonization of invalidity and scope-of-protection practice of national courts of EPC 
member states‘ (2006) European Intellectual Property Review, p.169-173. Also in Merrell Dow, p.82. 
811 Patents Act 1977, s.2(2). One way of classifying novelty is by dividing it into two groups, novelty 
by use and novelty by disclosure: Booton D.L. ‗Novelty of invention under the Patents Act 1977 and 
the European Patent Convention‘ (1996) Web Journal of Current Legal Issues, and was so divided in 
Merrell Dow. 
812 Article 54(3) EPC and Section 2(3) of the 1977 Act. Asahi Kasei Kogyo KK‟s Application [1991] 
RPC 485 held that enabling disclosure applied equally for s.2(2) and s.2(3). 
813 Respectively s.72 and s.14. 
814 Story A. ‗Biopiracy and the dangers of patent over-protection‘(1999) New law journal, p.158. 
815 Von Braun J. and Pagatch M.P. ‗The changing face of the pharmaceutical industry and intellectual 
property rights‘ (2004) The journal of world intellectual property, p.599-623, p.611. 
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novelty and this effectively shows increasing respect for foreign inventions and 
foreign prior art,
816
 a principle in line with the natural rights justification as advanced 
in the second chapter. 
 
Under the novelty limb, the thesis takes the view that certainty and consistency in the 
treatment of subject-matter under scrutiny is a central ingredient to attaining what is 
an optimal and balanced novelty standard. The certainty of meeting the newness test 
is crucial, both for patentee and third party, in the pharmaceutical sectors. It is 
difficult to research and develop new drugs, gain regulatory approval and recoup costs 
from sales, if free-riders and those who ‗invent around‘ patents have a low 
inconsistently judged newness standard to attain before they, in turn, are granted a 
patent
817
 or are held to be non-infringing when performing acts resembling those 
claimed under the new invention.  
 
The balanced standard therefore comes about due to a rigorous disclosure 
requirement
818
 for what the inventor claims to be novel. This builds on the 
justification suggested in chapter two, which is that the patent is consideration in 
exchange for new disclosure. Commentators have observed that the novelty 
requirement is linked to the sufficiency of disclosure requirement although the two 
concepts are not identical.
819
 Allowing a vague disclosure is detrimental to the system. 
Some have observed that ‗low patentability standards resulting from inadequate 
disclosure of new bits of information in patent applications would result in failure by 
those skilled in the art to replicate the inventions.‘820  
 
                                                             
816 Bagley M. ‗Patently Unconstitutional: The geographical limitation on prior art in a small world‘ 
(2003) Minnesota Law Review, 679-726, while others are not so convinced: Crouch D. ‗Is novelty 
obsolete? Chronicling the irrelevance of the invention date in the US patent law‘ (2009) Michigan 
Telecommunications and Technology Law Review, p.53-107. 
817 Grabowski,H. ‗Patents, innovation and access to new pharmaceuticals‘ (2004) Journal of 
International Economic Law, p.849-860. 
818 Branstetter L.G. ‗Do stronger patents induce more local innovation‘ (2004) Journal of International 
Economic Law, p.359-370, p.361. 
819 England P. ‗Novelty and sufficiency in a single, pan-European standard‘ (2010) European 
Intellectual Property Review, p.467-475, p.470. In Asahi p.553, Lord Oliver of Aylmerton observed the 
overlap, saying ‗this need for an enabling disclosure not only applied to documents cited under 
Art.54(2) and (3) but is also in conformity with the principle expressed in Art.83 EPC for patent 
applications must, accordingly, disclose the invention in manner sufficiently clear and complete for it 
to be carried out by the person skilled in the art‘ (original emphasis). 
820 Kanwar S. and Evenson R. ‗Does intellectual property protection spur technological change‘(2003) 
Oxford Economic Papers, p.235-264, p.237. 
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The balanced patentability standard also results from stringent enablement 
requirements. Disclosures or claims demarcating the effective patent ‗should not be 
issued that go beyond what is enabled.‘821 The test should prevent applicants claiming 
what they predict to be enabled using technology models that can simulate or 
approximate real life situations, without having achieved this in reality. On the other 
hand it should prevent third parties using disclosures that are not enabling to 
anticipate inventions. 
 
Premising the novelty test on enabled disclosures therefore, it could be said that 
novelty assessment, in its simplicity, involves a factual comparison between the 
invention and the information disclosed by prior art.
822
 As a starting point, the prior 
art document must sufficiently disclose the later invention although sufficiency will 
not necessarily be in issue in all novelty cases. According to writers
823
 the anticipation 
test for the sufficiency of prior art disclosure by a claimed or later process or method 
invention is generally that it must give ‗clear and unmistakeable directions to do what 
the patentee claims to have invented‘.824 For a new product, the test is that a skilled 
reader must be enabled ‗at once to perceive and understand and be able practically to 
apply the discovery without the necessity of making further experiments.‘825 
 
 
5.4.1 Synthon in the High Court  
 
The case SmithKline Beecham Plc's Patent (No.2)
826
 was a revocation application of a 
SmithKline Beecham Plc (SKB) patent of new crystalline methanesulfonate salt of 
known paroxetine and its general process of manufacture. This is a compound used in 
the treatment of depression and related disorders. At the priority date of the patent in 
suit, Synthon had a prior unpublished concurrent application which related to 
paroxetine methanesulfonate (PMS) and other close chemical equivalents. The 
                                                             
821 Barton J.H. ‗Issues posed by a world patent system‘ (2004) Journal of International Economic Law, 
p.341-357, p.347. 
822 General Tire and Rubber Co v Firestone Tyre and Rubber Co Ltd [1972] RPC 457, p.485. 
823 Cornish W., Llewelyn D. and Aplin T. Intellectual property: Patents, copyrights, trademarks & 
allied rights, 8th edn. (2013) London: Sweet and Maxwell, para.5-18. 
824 Parker J., Flour Oxidising v Carr (1908) 25 RPC 428, p.457. 
825 Lord Westbury, Hill v Evans (1862) 4 De G. F. & J. 288, p.300. 
826 SmithKline Beecham Plc's Patent (No.2) [2003] RPC 33;[2002] EWHC 2573 (Pat). 
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application described specific experiments for the manufacture of PMS oil, which 
turned into a waxy solid, characterised as that of the patent in issue except for an 
infrared (IR) reading.
827
 Notwithstanding the incorrect IR, Synthon argued that the 
prior application was enabled as it enabled a man skilled in the art to make PMS. SKB 
asserted that for an earlier disclosure to be enabling it was a necessary but not 
sufficient condition for anticipation
828
 and their crystalline structure was not similar to 
that of Synthon, having regard to the differing IR spectrums or that their crystalline 
structure was not an ‗inevitable result‘ of practising prior disclosure. 
  
The first instance court‘s novelty fact-finding mission was to evaluate whether SKB‘s 
invention was new having regard to Synthon‘s prior disclosure. Jacob J (as he was 
then) pointed out that Inhale Therapeutic Systems v Quadrant
829
 emphasised that 
anticipation occurred through the ‗inevitable result‘ route and also through enabling 
disclosure.
830
 To show the ‗inevitable result‘ one has to prove that carrying out what 
is described by the prior art falls within the invention‘s claims. If prior art describes 
something failing within the invention‘s scope, the inventions‘ claims are anticipated.  
 
The ‗inevitable result‘ is premised on showing that the inevitable result of carrying 
out what is described in the prior art would be a process or product falling within the 
scope of the invention. In General Tire & Rubber Co. v Firestone Tyre and Rubber 
Co. Ltd,
831
 Sachs LJ said ‗if carrying out the directions contained in the prior 
inventor‘s publication will inevitably result in something being made or done which, 
if the patentee‘s patent were valid, would constitute an infringement of the patentee‘s 
claim, this demonstrate that the patentee‘s claim has in fact been anticipated.‘ The 
‗inevitable result‘ as explained in Merrell Dow centred on a claim to an acid 
metabolite formed in the liver after administration of terfenadine by the subjects, 
where Lord Hoffmann held that if the specification of the earlier terfenadine was 
                                                             
827 IR is a technique that uses light absorption for the characterisation of simple and complex 
molecules. 
828 [2003] RPC 33, para.94. 
829 [2002] RPC 21, para.43-44. 
830 Per Jacob, [2003] RPC 33, para.83, quoting Laddie J, para.43. Inevitable result: the principle that for 
prior art teaching to inherently anticipate the claimed invention, the invention claimed must be the 
inevitable result of following the prior art teaching. Merrell Dow held that a claim to an acid metabolite 
formed in the liver after administration of terfenadine was anticipated as it was an inevitable result of 
carrying out directions in the earlier terfenadine patent. Also, Mobil Oil/Friction Reducing Additive, 
Decision G2/88 OJ EPO 1990, 93. 
831 [1972] RPC 475, p.485. 
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followed, then the production of the acid metabolite was inevitable, and thus the acid 
metabolite was part of the state of the art. 
Jacob J, at first instance, said it was less of a case of the inevitable result as there were 
no repeatable experiments that formed any crystals.
832
 He warned against the ‗mere 
mechanical application of an inevitable result rule‘ and suggested that anticipation be 
carefully handled where the prior art and the disclosure document make disclosures at 
different levels of generalities and descriptions.
833
 This, on one level confirms that 
deciding novelty is an involved task. It also serves as a warning to underscore to some 
observers who believe that this case ‗was certainly not an inevitable result that could 
have been predicted at the outset of this litigation‘834 to tread carefully before 
discarding the inevitable result argument. In addition, the court has said that the 
disclosure by inevitable result is possible even where the prior art teaching can be 
carried out in more than one way.
835
 
 
For anticipation through enabling disclosure the judge said the pivotal question is 
whether the earlier disclosure was enabling. This is a principle established in Asahi, 
holding that any piece of prior art must be enabling to invalidate for lack of novelty, 
although Jacob in Synthon BV v. Smithkline Beecham Plc
836
 was of the view that at 
that stage in the development of patent law the enabling disclosure doctrine was not 
fully established but was rather made clear in Merrell Dow. The prior enabling 
disclosure doctrine was elucidated in Merrell Dow, where Lord Hoffmann held that 
Patents Act 1977, s.2(2) does not confine the state of the art about products to 
knowledge of their chemical composition. It is the invention which must be new and 
which must therefore not be part of the state of the art. It is therefore part of the state 
of the art if the information which has been disclosed enables the public to know the 
product under a description sufficient to work the invention. 
 
                                                             
832 [2003] RPC 33, para.97. 
833 [2003] RPC 33, para.90. 
834 Sharples/Curley, fn.753. 
835 Leo Pharma A/S, Leo Laboratories Limited v Sandoz Limited [2009] EWHC 996 (Pat) para.58, 
although the court has to be satisfied that on the balance of probabilities, each way will produce the 
same result. 
836 [2002] EWHC 1172 (Pat), para.32. 
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Jacob J in the Patents Court had to assess whether the inventors has adequately 
stipulated how to make the invention and had in essence reached the same result
837
 
as the challengers. In this case the court held that there was adequate disclosure of 
the existence of the crystals.
838
 Synthon‘s disclosure was at the same general level as 
latter application by SKB and Jacob J held it to be sufficient for the enabling 
manufacture of PMS, thus the patent was found to be invalid.
839
 
 
 
5.4.2 Synthon in the Court of Appeal 
 
On appeal by SKB, the Court of Appeal held that Synthon application claims did not 
specifically mention PMS although it was within the general formula. Although 
recognizing that disclosure could be extracted from the application, whether it was 
implicit or explicit,
840
 it however viewed that the application did not make any 
explicit claim to the crystalline product.
841
 This would lead one skilled in the art to 
think that the focus of the application lies somewhere else other than in the crystalline 
product. Looking forward from the priority date, it certainly would look like Synthon 
was not interested in the crystalline structure. To substantiate this view is the fact that 
PMS was mentioned only as an example in an experiment. If indeed the skilled reader 
were to conclude that the product is disclosed, he would be inclined to think it was a 
different form of crystalline structure to that of SKB. This was the essence of the 
Court of Appeal‘s enquiry into whether there was prior disclosure. The court 
concentrated on the description of crystalline PMS in the application. This is 
consistent with Doble‘s opinion that ‗it is clear that the invention must first be 
identified and that only then can novelty be determined.‘842 
 
The vague disclosure of PMS in Synthon‘s application, which the trial court held to 
form part of the state of the art, did not invalidate SBK‘s patent for lack of newness, 
                                                             
837 [2003] RPC 33, para.93. 
838 Ibid, para.99. 
839 Ibid, para.96. 
840 Lundbeck A/S v Norpharma SpA [2011] RPC 23, confirmed that prior art disclosures, on one end, 
included implicit disclosures and on the other end subject matter may be embedded in a prior art 
document such that it does not form a disclosure. 
841 SmithKline Beecham Plc's Patent (No.2) [2003] EWCA Civ 861, para.51. 
842 Doble R. ‗Novelty under the EPC and the Patents Act 1977: A unified view of Merrell Dow and 
Mobil‘ (1996) European Intellectual Property Review, p.511-516, p.516. 
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as it did not make PMS available to the public.
843
 In other words, enablement was 
dependent on the information being made available to the public. The Court said for 
information to be made available to the public it had to enable the skilled reader to 
implement the disclosure.
844
 Since the skilled worker should be enabled to perform 
the invention, the Court found that there was no clear and unmistakeable directions to 
make PMS by the Synthon application as required in General Tire and Rubber Co v 
Firestone Tyre and Rubber Co Ltd.
845
 This was because ‗if they sought to carry out 
the specific directions of production, they would fail.‘846 For enablement the Court 
concentrated on whether directions of making PMS contained strictly in the 
application would lead the skilled reader to make or think possible to make the 
crystalline PMS. 
 
 
5.4.3 Synthon in the Supreme Court 
 
The Supreme Court assessing newness, reiterated the basis of the concept of enabling 
disclosure, as a composite tool used by the courts but with statutory basis. Enabling 
disclosure is when the prior art document discloses the invention claimed in a later 
patent and the person skilled in the art is enabled to perform the invention without any 
undue effort using the prior art and common general knowledge.
847
 Lord Walker 
stated that enabling disclosure arises in two distinct statutory contexts; explicitly and 
implicitly.
848
  
 
The effect of the difference between the explicit and implicit contexts for the 
determination of the state of art is that, in low technology inventions simple disclosure 
will normally suffice while in the complex and high technology sectors as in the 
                                                             
843 ‗It is now well established that a novelty destroying disclosure must be ―enabling‖ if what it 
discloses is to be regarded as being ―made available to the public‖‘, para.10, The Patent Office 
‗Examination guidelines for patent applications relating to biotechnological inventions in the UK 
Patent Office‘, May 2005. 
844 SmithKline Beecham Plc's Patent (No.2) [2003] EWCA Civ 861, para.8.  
845 Ibid, para.47 and 50. 
846 Ibid, para.51. 
847 Applied, for instance by Kitchin J, in Ratiopharm (UK) Limited v Alza Corporation, Janssen-Cilag 
Limited Alza Corporation, Janssen-Cilag Limited v Sandoz Limited [2009] EWHC 213 (Pat), para.72. 
848 Synthon, para.63. There exists complementarities and influence between these disclosures: Ancori 
B., Bureth A. and Cohendet P. ‗The economics of knowledge‘ (2000) Industrial and Corporate Change, 
p.255-287. 
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pharmaceutical and by extension biotechnological industries ‗assertation of the 
existence of the invention may have to be accompanied by detailed disclosure 
enabling a skilled person to perform invention.‘849  
 
Lord Hoffmann restated the test for novelty under the enabling disclosure route more 
explicitly. He postulated that anticipation had two distinct requirements, each with its 
own rules and functions,
850
 which the Court of Appeal failed to satisfy. The Court of 
Appeal in trying to find the enabling disclosure mixed these, thus finding the patent 
valid. To succeed Synthon had to prove that their application had disclosed 
something, which had been patented and separately show that an ordinary skilled man 
would be able to perform the disclosed invention if he attempted to do so by using the 
disclosed matter and common general knowledge. He called these requirements 
respectively, disclosure and enablement.
851
 
 
Disclosure is concerned with appropriate description of the invention. In Hills v 
Evans
852
 it was stated that the disclosure ‗must be such that a person of ordinary 
knowledge of the subject must at once perceive and understand‘ the invention. This 
illustrates that the disclosure is addressed to the skilled worker who is required to 
understand it. The skilled person in pharmaceutical innovations therefore plays a 
central role.  
 
In General Tire it was established that approaching the invention from different 
directions or using different methodologies or expressions, can result in anticipation 
even if it is not immediately discernable from the disclosure that it is the same 
invention being described. However, an exception to this is where the route that ends 
up in the invention, compared to other disclosed possible routes is not likely to be 
taken.
853
 
 
                                                             
849 Ibid, para.64. 
850 Ibid, para.28. 
851 Ibid, para.28. 
852 (1862) 31 L.J. (NS) 457. 
853 Synthon, para.22. 
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The prior art, including a patent application as subsequently granted, must therefore 
disclose an invention, which if performed must necessarily infringe.
854
 This is the 
overriding factor as ‗if there is more than one possible consequence one cannot say 
that performing the invention will infringe.‘855 The flag has to be planted, and is 
planted when the disclosure is perceived at once and is capable of being performed 
and is such that if performed it must result in a patent being infringed. In General Tire 
it was put this way: ‗a signpost, however clear, upon the road to the patented 
invention will not suffice. The prior inventor must be clearly shown to have planted 
his flag at the precise destination before the patentee.‘856 As such the disclosure limb 
is seen as a strict one.
857
 It is submitted that the implication of this is that the novelty 
standard maintains an equilibrium between allowing challengers retrospectively 
interpreting disclosures in light of the subsequent technological developments and the 
predictive claiming by applicant. 
 
Enablement on the other end is concerned with performance of the disclosure. It 
describes the requirement that the ordinary skilled person would be able to perform 
the disclosed invention, including the use of appropriate examples.
858
 That is, the 
question of enablement addresses whether the requirement of ‗if performed‘ in the 
disclosure test is satisfied in fact.
859
 The enablement requirement applies both when 
the disclosure is in the matter forming the state of the art by virtue of s.2(2) or s.2(3), 
with the latter settled in Asahi,
860
 where the court was of the view that it would be 
illogical to treat the disclosures differently for purposes of the requirements for 
enablement merely because of the differences in the means of making available to the 
public by virtue of s.2(2) or s.2(3). Asahi, where in issue was a patent for a 
physiologically active polypeptide, human necrosis factor produced by genetic 
engineering and useful in the treatment of human tumours, was decided on the 
assumed facts that there had been a prior disclosure of the same invention but that 
                                                             
854Some call it the ‗reverse-infringement‘ test: Bently/Sharman, fn.265, p.472. 
855 General Tire and Rubber Co v Firestone Tyre and Rubber Co Ltd [1972] RPC 457, p.486. 
856 loc cit. 
857 Ratiopharm (UK) Limited v Alza Corporation, Janssen-Cilag Limited Alza Corporation, Janssen-
Cilag Limited v Sandoz Limited [2009] EWHC 213 (Pat), para.73. 
858 R.27(1)(e) of Examination Guidelines of the EPO. 
859 Freeland, fn.758, p.164. 
860 Asahi, p.547-548, p.552. 
 200 
neither the disclosed information nor common general knowledge would have enabled 
the skilled man to make it. 
 
The Lords also clarified the confusion surrounding the fact that enablement of a prior 
art disclosure for novelty purposes is the same test as patent enablement for the 
purposes of sufficiency.
861
 This is helpful to inventors in the sense that it is desirable 
that there must be a consistency of standard for the enablement limb of novelty and 
enablement for sufficiency.
862
 That is to say novelty assessment is concomitant with 
sufficiency of disclosure. Indeed the reasoning in Hill v Evans supports this view 
wherein Lord Westbury said ‗[u]pon principle therefore, I conclude that the prior 
knowledge of an invention to avoid the patent must be knowledge equal to that 
required to be given by a specification, namely, such knowledge as will enable the 
public to perceive the very discovery, and to carry the invention into practical use.‘ 
 
In practical industrial terms, the enabling disclosure can be seen as a continuous event 
yet in legal terms it is separate concepts describing the instantaneous phenomena. 
That is to say for the scientist to decide whether the invention is new, as viewed 
through the specification, judgment is simultaneously on disclosure and enablement. 
The legal decision-making process resolves the event into separate compartments with 
different rules to be followed. 
 
 
5.5 The role of the skilled worker 
 
It can be said that, at face value, the role of the skilled worker was somehow reduced 
by Synthon. Lord Hoffmann acknowledged that the skilled worker would think that 
the claimed products are different when reading disputed claims,
863
 which would be a 
case of non-infringement. This raises the question of what use the skilled workers‘ 
                                                             
861 Synthon, para28. Batteson. A. ‗Patents: enabling disclosures‘ (2006) European Intellectual Property 
Review, n.28, points out that there may be differences in application of each test to the facts, for 
instance with sufficiency the skilled person may be trying to perform an invention and implicitly has 
that goal in mind while with novelty‘s prior art the disclosure of the invention may not necessarily be 
identified as such. 
862 ‗...a compound defined by its chemical structure can only be regarded as being disclosed in a 
particular document if it has been ―made available to the public‖‘ and this enabling disclosure for 
novelty is in conformity with the principles expressed for enablement for sufficiency: Asahi, p.552. 
863 [2005] UKHL 59, para.9. 
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thoughts are on reading the disclosure documents if what they conclude is irrelevant 
in finding for patent validity under the disclosure limb.  
 
This scenario seems to support the Court of Appeal‘s conclusion of no valid enabling 
disclosure as there was ‗no clear and unmistaken direction‘ to make the claimed 
invention.
864
 If the skilled worker is not able to make the claimed product or thinks 
they are not making an infringing product, it is easy to envision the confusion and 
lack of clarity on the public from the information that was introduced into the public 
domain as new under the enabling disclosure doctrine. The system is founded upon 
the exchange of protection for disclosure of usable information by the public. 
Opponents of the system would dwell on this point as illustrative of the incapacity of 
the system to attain that balance.
865
  
 
It is through deeper insight into the novelty rules that these normative concerns are 
properly addressed. Under the disclosure limb the skilled worker is trying to 
understand the disclosure of the invention.
866
 Common general knowledge only forms 
the background to his enquiry and perception of the invention.
867
 Under enablement 
the skilled worker‘s thoughts have no direct role to play as assessment is of the ability 
to perform the disclosed invention and the question is no longer what he would think 
the disclosure meant.
868
 Once the meaning has been ascertained, the disclosed 
invention performed is either infringing or not, at which point the skill person‘s 
thought is not relevant. 
 
Such apparent reduced role of the person skilled in the art is resolved when one looks 
at the two-step nature of the test the Supreme Court introduced. This approach 
resolves borderline cases where for example the skilled person thinks they are doing 
one thing when in actual fact they are doing another.  
 
                                                             
864 General Tire and Rubber Co v Firestone Tyre and Rubber Co Ltd [1972] RPC 457, p.486. 
865 Olin J.M. ‗The disclosure function of the patent system (or lack thereof)‘ (2005) Harvard Law 
Review, p.2007-2028. 
866 Synthon, para.32. 
867 Ibid. 
868 Ibid. 
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The Supreme Court said the disclosure limb does not necessarily have to enable.
869
 
Disclosure may consist of putting the new information in the public domain; 
enablement only derived from the ordinary workers ability to analyse and synthesize 
it. This then, is seen to actually make the role of the skilled worker more critical as 
they hold the key to the composite enabling disclosure where there is no clear 
disclosure or it is hard to discern the enablement from the disclosure at once.  
 
Thus in cases where there is disclosure, which is not prima facie enabling, the 
Supreme Court gave the skilled worker a critical role to play. What the courts have to 
evaluate is the ability of the skilled worker to work out the disclosed invention from 
the disclosure document and use their common general knowledge to be enabled to 
successfully work it.
870
 This may mean the capability to decide on appropriate 
experimentation. The skilled person uses little or no assistance from the disclosure 
itself to effect the enablement limb. 
 
The sometimes odd and different results or conclusions the skilled worker and the 
courts would reach are a result of the different perspective they each take towards the 
problem. If the skilled worker looks at the end result and thinks he made a different 
product to that described in prior art, it is because his practical obliviousness to the 
two-step approach as the courts. In his position he is hardly concerned with practically 
analysing whether a piece of information discloses or enables. In his mind he is 
concerned with whether or not his labours result in the end product. The court‘s view 
is an objective dual view of the situation. With each piece of information the court 
assesses it on the basis of whether it discloses or enables. The courts will fit every 
aspect of information in the two categories to come up with the conclusion of 
enabling disclosure or not. 
 
The rule under the two-stage enquiry is that once disclosure is established, 
enablement is then assessed. For enablement the question is no longer what the skilled 
worker would understand from the disclosure. The relevant question is then whether 
he would be able to perform the invention the court has held to be disclosed. For 
complex fields such as the pharmaceutical industries, Lord Walker was of the opinion 
                                                             
869 Synthon, para.29 and 42. 
870 Synthon, para.38. 
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that a disclosure may have to be accompanied by vast material to assist the skilled 
worker with enablement.
871
 This is opposite to more mechanical inventions where 
simple disclosure of the invention will probably suffice. Testing the adequacy of the 
enabled disclosure will be against the assumed skill of the relevant worker or team in 
that field of technology. 
 
5.6 Impact on R&D and experimentation 
 
The outcome of the two-stage approach Synthon could be seen to have impact on how 
R&D is conducted. Courts in other jurisdictions have been criticised for unreasonably 
broadening the scope of anticipation, through inherent anticipation, a doctrine stating 
that the result of practising prior art is anticipated regardless of whether the result was 
explicitly disclosed.
872
 The criticism for example is for the broadening of inherent 
anticipation to include chemical structures or subsets that are not ‗measurably 
produced by strict practice of the prior art‘873 as it would have dire consequences for 
the patentability of many simple compound pharmaceuticals structures. The likely 
risky effect of the Supreme Court method of assessing novelty is that undescribed 
reactions, intermediate products and processes or by-products of pharmaceutical 
reactions not directly taught by prior disclosure may be anticipated by the mere fact of 
being stipulated in the disclosure document.
874
 This would allow anticipation of 
reactions solely based upon theoretical predictions or extrapolations of the prior art. 
For example, it could be argued that the mere claim of pharmaceutically active salts is 
a genus claim, which does not necessary encompass all members of the genus, 
especially specific crystalline forms.
875
 The inclination to research more on these 
compounds would, as a result, be limited. 
                                                             
871 Ibid, para.64, per Lord Walker. In accordance with EPO Examination Guidelines: ‗A document 
takes away the novelty of any claimed subject matter derivable directly and unambiguously from that 
document including any features implicit to a person skilled in the art in what is expressly mentioned in 
the document.‘ 
872 Jones B.W. ‗Smithkline v. Apotex: Broadening the scope of inherent anticipation and its impact on 
the patentability of chemical structures‘ (2006) The John Marshal Review of Intellectual Property Law, 
p.456-476. 
873 Loc cit. 
874 Lim A.S.Y. and Christie, A.F. ‗Reach-through claims in biotechnology: an analysis of the 
examination practices of the United States, European and Japanese Patent Offices‘ (2005) Intellectual 
Property Quarterly, p.236-266, p.238-239, define reach through-claims as ‗an attempt to extend the 
boundaries of a patent monopoly…to subsequent and future things that have some relationship to the 
current invention‘ 
875 Jones, fn.872, p.468. 
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The value of experimentation in industry is appreciable and usually accompanies the 
R&D process. The skilled worker in Synthon is allowed to gain insight and learn by 
mistakes. This explains the factual situation in Synthon where the skilled worker had 
to do some experimentation or manipulation to get some results.
876
 Such 
experimentation may include overriding some errors within the patent claim itself, on 
the basis of practical common knowledge. This is safeguarded though, by the fact that 
skilled worker has to work the invention without undue experimentation
877
 of the 
R&D type. In Asahi the experimentation was differentiated by Lord Jauncey saying 
‗Lord Westbury must have meant experiments with the view of discovering 
something not disclosed. He cannot have meant to refer to the ordinary methods of 
trial and error which involve no inventive step and generally are necessary in applying 
any discovery to produce a practical result.‘878 
 
An undesirable consequence of the test is that in industry, a scientist working in R&D, 
cannot have absolute confidence or fully depend on prior art disclosures in 
determining whether an experimentally observed scientific phenomenon could be 
considered new or not. They would first have to really think about the prior art and 
whether it is anticipating or not the seemingly new observation. It would in these 
cases be wise to actually put to test practically the prior art. When getting different 
results, one would not be sure whether they made any mistakes in their experiments or 
they have made an invention of their own that may itself deserves a patent. This is 
because in the pharmaceutical field, there is always an expectation that a formula or 
process developed in the laboratory is identical to the one offered patent protection.
879
 
In Synthon, the enabling disclosure was one that needed ‗a good deal of skilled 
manipulation‘ to get it to work.880 That is to say R&D processes that result in 
unexpected results from the prior disclosure have to be validated and tested. 
 
                                                             
876 Lord Hoffmann emphasised the importance of knowing whether it is disclosure or enablement being 
referred to, in order to judge whether some degree of experimentation is allowed: Synthon, para.30. 
877 Synthon, para.31. 
878 Asahi, p.544. 
879 Kingston, fn.2, p.355. 
880 Synthon, para.15. 
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At the same time we have to be critical of the environment where anticipating prior 
art documents are allowed to be riddled with mistakes and inconsistencies.
881
 The IP 
readings were incorrect and the product was wax instead of crystalline, which are the 
characteristics that scientists use to conclusively identify substances. Lord Irvine 
opined that ‗the very first need of the business community is legal predictability.‘882 
When the validity of what is posed as prior art is doubtful, it seems to defeat the very 
purpose of the patenting system. The patenting system premise is to put new 
information in the public domain. Hitherto, there has never been a reason to qualify 
this expectation with the fact that it has to be the right and correct information. It has 
always been a plausible assumption that novelty destroying prior art is accurate and 
correct at the relevant time. Moreover, with the advance in technology and R&D 
techniques, it would be expected that there would be a pool of refined methodologies 
that point out errors. It would be unfortunate that the court could be seen to allow 
incorrect disclosure information or unworkable processes to be condoned and merely 
blamed on poor choice of basic methodologies, as was the case in Synthon. 
 
It is accepted that the incorrect IR was held a superfluous part of the evidence.
883
 This 
makes sense to legal practitioners. However to the scientist in industry, the IR is 
usually irrefutable proof of the identity of the claimed compound or substance. 
Synthon could have used this technique alone to specify the product, but chose to use 
the other techniques that add nothing else significant to the identity of the product. 
Using the other finger-printing techniques is merely confirmatory to what has already 
been established. Research laboratories equipped with numerous sophisticated 
equipments is typical of large firms which can absorb the extra costs whilst the 
smaller biotechnology firms would not plausibly justify extra equipment which 
performs the same function without improving the efficiency of the pharmaceutical 
discovery. 
 
This industry discomfort can however be justified by the fact that there has to be a 
totality of all the evidence and high requirement of analytical techniques. As such, 
what is not compatible with the rest of the disclosure under examination has to be 
                                                             
881 Nightingale P. ‗Economies of Scale in experimentation: Knowledge and technology in 
pharmaceutical R&D‘ (2000) Industrial and Corporate Change, p.315-359. 
882 Lord Irvine, fn.27, p.334. 
883 Sharples/Curley, fn.753, p.311. 
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properly scrutinised. Requiring a meticulous exploration of prior art by latter 
patentees to the level of spotting out mistakes acts a mechanism that consistently 
keeps the evolving state of art faultless. The laborious exercise of going through the 
prior art can be expected to be a foundation for good R&D and invariably result in 
genuinely good novel inventions. This is kept in check and counter-balanced by the 
appropriate level of skill of the relevant skilled worker in R&D. A lower required 
level of skill would be excused for the inability to spot out many obvious errors. On 
the other hand if it is assumed that the skilled worker has a competent degree of skill 
and experience, it would also be expected he would spot out errors. The problem with 
the Synthon method was the use of an unsuitable solvent, which the skilled worker 
would be expected to able to resolve.
884
 He would also have been able to overcome 
any methodology problems within a reasonable time. 
 
5.7 The principles of the newness test highlighted 
 
It is well established that the concept of enabling disclosure is not a rule about the 
‗inevitable result.‘885 It is argued here that as a matter of principle, the two concepts 
are not and cannot be contrary to each other or mutually exclusive. The main logical 
reason for this is that they are tests that have the same goal, which is to assess whether 
information is new according to the legislation. It therefore comes as no surprise that 
the inevitable result of performing Synthon‘s disclosure is also an enabling disclosure. 
The only discomfort is that on the facts of the case the inevitable result only comes 
after some skilled manipulation of the disclosure in practice. 
 
To reconcile the perspectives of industry and legal practitioners a proposition could be 
made that the anticipation test could be conceptualised at two levels to be satisfied.
886
 
These could be termed the objective and practical considerations. This notion is taken 
from the words of Jacob J., citing Judge Rogge at the eighth Symposium of European 
Patent Judges, where he stated that it may not always be possible to decide cases on 
logical grounds alone, suggesting that novelty assessment of an invention must ‗not 
be restricted to a purely formal comparison with known prior art, but must include the 
                                                             
884 Synthon, para.17. 
885 [2002] EWHC 2573 (Pat), para.86. 
886 Seymore, fn.26, suggests that patent law reforms should be directed to bridging the gap between the 
law and the norms of science. 
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actual information content that which goes beyond the words used.‘887 The objective 
considerations are concerned with the theoretical principles that have to be applied 
and satisfied to prove novelty. It has to do with assessing whether the claimed result is 
achievable. This could be seen to do more with the theory behind whether the 
invention is possible or has been identified.
888
 Through the inevitable result route, 
Jacob J said this tests whether the result is achievable.
889
 Under the enabling 
disclosure route it tests whether the said invention is disclosed or theoretically been 
put in the public domain. 
 
The practical consideration operates on case-by-case basis and may be more 
subjective in nature and includes the ‗actual information content going beyond the 
words used.‘890 This is practical or factual or case-by-case assessment of anticipation. 
This consideration includes information that is intrinsically disclosed or needing no 
explanation. This seeks to test whether the said invention is in fact achievable.
891
 This 
is the practical side of the invention and tests whether the inevitable result is indeed 
inevitable in practice. Under the enabling disclosure route this is whether the 
invention is indeed enabled. Lord Walker said ‗the practical importance of keeping 
the two requirements distinct will vary with the factual situation‘,892 showing the 
influence of the practical consideration in novelty assessment under the enabling 
disclosure route. Some writers
893
 opine that ‗enablement is a factual enquiry.‘ Laddie 
J. in Evans Medical Ltd‟s Patent894 said Lord Jauncey in Asahi ‗was only saying that 
describing a result as being achievable was not enough to prove it to be achievable in 
fact. It is the latter which amounts to enablement.‘ 
 
It becomes clear that under the novelty limb, the patentability of inventions could be 
viewed as dependent on these two considerations; the objective and practical 
elements. Industry players would be well-advised to consider the practical side of 
                                                             
887 [2002] EWHC 2573 (Pat), para.92. 
888 Doble, fn.842, p.515. 
889 [2002] EWHC 2573 (Pat), para.95. 
890 Ibid, para.92. 
891 Ibid, para.95. 
892 Synthon BV v SmithKline Beecham Plc (No.2) [2005] UKHL 59, para.64. 
893 Sharples/Curley, fn.753. 
894 [1998] RPC 517, p.535. 
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inventions before patent application or litigation is pursued. It is then prudent for 
industry to note that the practical elements can certainly be decisive in some cases. 
 
 
South Africa 
 
5.8 Nature of anticipation 
 
Anticipation occurs in three ways; that of making subject matter available to the 
public, matter being contained in an application as subsequently published and from 
inventions used secretly and on a commercial scale within the Republic.
895
 Patents 
Act section 25(5) states: 
‗An invention shall be deemed to be new if it does not form part of the state of 
the art immediately before the priority date of any claim to that invention. 
(6) The state of the art shall comprise all matter (whether a product, a process, 
information about either, or anything else) which has been made available to 
the public (whether in the Republic or elsewhere) by written or oral 
description, by use or in any other way.‘ 
 
The making of subject matter available to the public can be by description (written or 
oral), by use or in any other way. This is a similar situation in the UK. 
 
Secret use still anticipates in South Africa, unlike in the UK where it ended with the 
1949 Act. The Banks Committee concluded that prior secret use by the patentee as a 
ground for invalidating patents could not remain in the statutes if compliance with the 
Strasbourg Convention was to be achieved and recommended the removal of 
s.32(1)(l) and s.32(2) of the 1949 Act and instead replace with prior secret user right 
as found in Patents Act 1977,s.64.
896
 In South Africa, the prior secret use does not 
                                                             
895 Patents Act 1978, s.25(8) provides for invalidation of a patent of subject matter that forms part of 
prior secret use. 
896 Board of Trade, The British Patent System: Report of the Committee to Examine the Patent System 
and Patent Law (1970, Cmnd 4407) (chairman Banks), p.260-261. 
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only absolve an alleged infringer, but the secret subject matter is deemed to form the 
state of the art for novelty purposes only.
897
 
 
In terms of s.61(c) of the Patents Act 1978 a patent may be revoked on the ground that 
the patent is not patentable under section 25. 
 
 
5.9 The Test for Novelty 
 
 
The most authoritative case on novelty is Gentiruco AG v Firestone SA (Pty) Ltd
898
 
which sets out the novelty assessment method for finding of anticipation of an 
invention. This has been formulated and summarised over the years as a three-step 
structured enquiry
899
 wherein the court said that the law of anticipation: 
‗relates to the claims and not the description of the invention in the body of the 
specification. Hence the particular claim must be construed to ascertain its 
essential constituent element or integers. … The prior printed publication or 
patent alleged to be anticipatory is then construed… The two documents are 
then compared to ascertain whether the prior patent was granted for, or the 
prior printed publication ―describes‖, the same process, etc., as that claimed.‘  
 
The different steps of the structured novelty assessment method have been applied 
over the years and will be examined in turn below. 
 
A.  Ascertain the essential elements or integers of the patent claim. 
 
This is a claim construction exercise that seeks to establish the meaning of the patent 
to establish whether the patent has been made available to the public.
900
  
 
                                                             
897 Patents Act, s.25(10) direct that prior secret use forms part of the state of the art for novelty 
purposes only. 
898 1971 BP 58 (A). 
899 Ibid, p.138F-139A. Test also summarised in Netlon Ltd and Another v Pacnet Ltd 1977 BP 87, 
p.108F-109B. 
900 Adam Emil Sierzputowski v Anglo American Corporation of SA Ltd 1972 BP 346 (CP), p.350, the 
court stated that the first task in anticipation assessment is to ascertain the nature of the invention. 
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Each claim stands on its own. Jansen JA in Letraset Ltd v Helios Ltd
901
 postulated 
that: 
 
‗each claim of the complete specification must be considered separately. It is 
not a question of considering all the claims and the body of the specification as 
a totality and thereby determining whether ―the invention was not new‖. Each 
claim must…be taken separately, and if the claims are ambiguous, no 
reference may be made to the body of the specification to enlarge or limit its 
scope (but the body may constitute a dictionary).‘ 
 
 
B. The meaning of the prior art document is ascertained.  
 
This is to say the prior making available to the public of matter or patent alleged to be 
anticipatory is then construed. In this step the court seeks to establish the 
interpretation and import of the anticipatory document.  
 
There are restrictions on the type of prior art documents that can anticipate an 
invention. Disclosures that do not enable do not anticipate the invention. In Letraset 
Ltd v Helios Ltd,
902
 the court stated it this way: 
‗I should have thought independently of authority that no prior description 
ought to invalidate a patent unless you could make the thing from the 
description. I mean unless a person of ordinary skill in the trade could make it 
from the description.‘ 
 
The alleged anticipatory document is construed at the date of making available to the 
public. As such, the construction of the alleged anticipating document, as was the case 
in Gentiruco,
903
 is made ‗to the exclusion of information subsequently discovered.‘ 
This prevents hindsight. The court in Gentiruco warned against the influence of 
                                                             
901 Letraset Ltd v Helios Ltd 1972 BP 243 (A). 
902 (1972) BP 243, p.273G-274A, cited with approval in B-M Group v Beecham Group 1980(4) SA 536 
(A).  
903 Gentiruco, p.139E, approving Ore Concentration Company. (1905)  Ltd v Sulphide Corporation 
Ltd. 31 RPC 206, p.224. 
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hindsight which would unduly increase the anticipatory ability of a prior art 
document. The court said:
904
 
‗If he adopted the process also because of some subsequently acquired 
knowledge or hindsight induced by the patent in suit, which taught him that it 
was worthwhile and effective, the example would not test for anticipation.‘ 
 
C  The anticipatory document and invention or claims in suit must then be 
compared. 
 
In Netlon Ltd and Another v Pacnet (Pty) Ltd
905
 Trollip JA said ‗…the exercise is 
primarily one of construing and comparing the two documents.‘ This comparison is 
done to see to if the anticipatory document was made available to the public through 
describing the same process or product as the patent in suit. Streicher JA in 
Schlumberger Logelco Inc v Coflexip SA
906
 pronounced that the comparison of the 
invention to the prior art description seeks to find out: 
 
‗whether it sets forth or recites at least the latter‘s essential integers in such a 
way that the same or substantially the same process or apparatus is identifiable 
or perceptible and hence made known or the same or substantially the same 
product can be made from that description in the prior publication; if the 
description in the prior document differs, even in a small respect, provided it is 
a real difference, such as the non-recital of a single essential integer, the 
anticipation fails.‘ 
 
The authority on the meaning of ‗describe‘ in South Africa is the dictum of Trollip JA 
in Gentiruco. The learned Judge of Appeal said: 
‗In regard to a prior publication, the ordinary meaning of ‗describe‘ means ‗to 
set forth in words or recite the characteristics of‘. Hence for it to ‗describe‘ the 
invented process, etc., it must set forth or recite at least its essential integers in 
such a way that the same or substantially the same process is identifiable or 
perceptible and hence made known, or the same or substantially the same 
                                                             
904 Ibid, p.143D. 
905 1977 (3) SA 840 (A), p.861H-862B. 
906 Schlumberger Logelco Inc v Coflexip SA 2002 BIP 35, p.44. 
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thing can be made, from that description. ‗Substantially the same‘ means 
practically the same, or, to use Lord Westbury‘s phrase adopted by Wessels, 
J.A. in Veasey‟s case,907 the same ‗for the purposes of practical utility‘, i.e., 
substance and not form must be regarded.‘908 
 
The objective of construing and comparing the prior art document to the invention is 
to establish whether it has been made available to the public, usually by disclosure or 
by use. What is of concern is that the Supreme Court of Appeal in Filta-Matix (Pty) 
Ltd v Carl Freudenberg,
909
 under the 1952 Act, said ‗providing a copy to one person 
hardly amounts to ―publication‖, although it shows a willingness to publish.‘ There 
are provisions for sharing the invention‘s subject matter with those who are involved 
in the R&D or development of a patent document without risking anticipation, but 
disclosure to anyone outside of this circle constitutes making available to the 
public.
910
 The current statute is now clear: the state of the art consists of all matter 
which has been made available to the public by description or use or any other way. 
This is without discrimination or preference of the method of making available to the 
public. Disclosure to one person could be said to be publication or making the 
invention available to the public. 
 
Of interest is how in South Africa the material facts of Merrell Dow could be 
decided, where the fact that volunteers in clinical trials were given terfinadine and 
therefore, unaware, made the acid metabolite in their liver was held to be anticipated 
by disclosure, rather than by use. In South Africa the unique situation is that the 
state of art for novelty is extended by the recognition of prior secret and commercial 
use under s.25(8) as matter that has been made available to the public by virtue of 
s.25(6). Harms JA in McKelvey and others v Deton Engineering (Pty) Ltd and 
another
911
 confirmed that this section ‗extends the state of the art to include use of 
an invention not available to the public, namely secret use on a commercial scale 
within the Republic.‘ Therefore the administration of terfinadine under clinical trials 
                                                             
907 Veasey v Denver Rock Drill and Machinery Co Ltd 1930 AD 243, p.269. 
908 Gentiruco, p.139A-C. 
909 BIP 284 (SCA), p.292D. 
910 Patents Act 1978, s.26(a). 
911 [1997] 3 All SA 569 (A), p.573. 
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conditions would make the terfinadine metabolite to be considered anticipated under 
South African law. 
 
It has been questioned whether the enabling disclosure doctrine applies in South 
African law by academic commentators.
912
 There has been reticence on whether 
foreign law on anticipation should be followed in South Africa, especially that of the 
EPO.
913
 It has been warned that ‗the concept of enabling disclosure should not be 
imported into South African law.‘914 These views do not seem to be supported by case 
law on novelty. 
 
MacArthur J in Elan Transdermal Ltd v Ciba Geigy (pty) Ltd
915
 premised his decision 
on the assumption that enabling disclosure is part of South African law concluding 
that ‗on the assumption that the principle of ―enabling disclosure‖ is part of our law- 
and I bear in mind that Lord Westbury‘s statement about anticipatory documents in 
Hills v Evans was adopted by Veasey‘s case... it is apparent that unless the method of 
putting the earlier document into operation is so self-evident, it will not be treated as 
anticipation.‘ He stated that UK novelty rules ‗for practical purposes… can be 
equated to‘ the South African provision.916 This reasoning seems to be careful about 
legal transplants, wherein the imported rules may not serve the useful purposes served 
in the original jurisdiction or they are applied contrary to the principles for which they 
were designed. The argument advanced by the court in Elan Transdermal therefore 
seem to be well-reasoned and supported by rational novelty principles relative to the 
material facts of the case. 
 
It is unclear though whether the two-staged enabling disclosure method as restated in 
Synthon could be argued as applying in South Africa. In South Africa, after Elan 
Transdermal, the elements of the enabling disclosure method seem to have been 
unsystematically applied and integrated and yet in Synthon the disclosure and 
enablement requirements were held to be distinct elements of the composite 
anticipation limb of patentability. Moreover, doubt as to whether the Synthon method 
                                                             
912 Burrell, p.229. 
913 Burrell, p.229. 
914 Burrell, p.229. 
915 1994 BP (CP) 1, p.23. 
916 Ibid. 
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applies is compounded as the  concept was only raised by the Commissioner of 
Patents in Elan Transdermal but has neither been addressed or approved by the more 
senior Supreme Court of Appeals which has adjudicated novelty issues since Synthon. 
 
This thesis concludes that in the South African case law there does not seem to exist 
separate disclosure and enablement limbs to anticipation. In the novelty assessment 
method, the disclosure and enablement rules tend to be used interchangeably. Merely 
reciting the passages from the UK cases used to develop the doctrine of enabling 
disclosure does not automatically confer its principles onto the South African 
assessment methodology. In the UK once disclosure has been established, enablement 
is then independently assessed and the question is no longer what the person skilled in 
the art would understand from the disclosure, but whether he would be enabled to 
perform it. On the other hand, in South Africa after the integers of the patent and 
interpretation of the prior art disclosure is made, the courts offer little guidance on 
how the comparison or evaluation is to proceed The South African courts therefore 
could be seen as only offering limited guidance on how the disclosure and enablement 
should be approached. 
 
 
5.10 Role of the skilled worker 
 
In the assessment of anticipation, the person skilled in the art also plays a crucial role 
in South Africa as in the UK. Under the previous law, however, the courts were of the 
view that the person skilled in the art played a minimal role. This view was expressed 
in Letraset v Helios,
917
 with Jansen JA saying: 
‗But must the court look at the document through its own eyes, or thorough 
the eyes of ―an ordinary workman skilled in the art‖? It appears to be implicit 
in Genturico that the former is the case:-  
―Again it is emphasised: The opinions of expert witnesses that a document 
does or does not anticipate the patent in suit must be disregarded for that is for 
the courts to decide. ―Again‖ is a reference to the prior discussion of the 
admissibility of evidence to construe a specification, where it appears that the 
                                                             
917 (1972) BP 243, 272E-G, citing Gentiruco, citations omitted. 
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court itself construes the document, and in doing so, has but limited recourse 
to the skilled worker.‖‘ 
 
The interpretation of the ruling in Letraset has evolved, with some arguing that the 
skilled person has more of a role to play in anticipation assessment. Jansen JA in 
Filta-Matrix (Pty) Ltd v Carl Freudenberg
918
 was quoted, citing Lord Reid in C van 
der Lety v Bamfords Ltd 1963 RPC 61, p. 71, as saying: 
‗There is no doubt that, where the matter alleged to amount to anticipation 
consist of written description, the interpretation of that description is, like any 
document, a question for the court assisted where necessary by evidence 
regarding the meaning of technical language. It was argued that the same 
applied to a photograph. I do not think so. Lawyers are expected to be experts 
in the use of the English language, but we are not experts in the reading or 
interpretation of photographs. The question is what the eye of the man skilled 
with appropriate engineering skills and experience would see in the 
photographs, and that appears to me to be a matter for evidence.‘ 
 
The interpretation of the meaning of evidence in pharmaceutical industry is 
sometimes complex. It seems the meaning or significance scientific evidence is more 
appropriately evaluated through the eyes of the person skilled in the art, although the 
court makes the final decision. To this effect the courts have stated that there has to be 
a balance in the contribution that is made by the person skilled in the art in the 
assessment of the novelty.
919
   
 
The focus of the court assessment method seems to be on what the person skilled in 
the art cannot do in the novelty evaluation rather than how they are relevant in the 
assessment. The court‘s emphasis on this non-involvement is seemingly to prevent, 
the court being led by the person skilled in the art into a conclusion.
920
 But this occurs 
at the expense of the court providing more guidance on how the move is made from 
having established the integers of the patent claims and the prior art, into the 
conclusion of whether or not there is anticipation. That is to say, in the quest to exert 
                                                             
918 1997 BIP 264(SCA), 294A-B. 
919 Schlumberger Logelco Inc v Coflexip SA (2002) BIP 35, p.44. 
920 Ibid. 
 216 
authority on the final decision as one to be made by the judiciary rather than the 
scientist, the role of the scientist in judging anticipation is muddled with uncertainty. 
 
 
5.11 Impact on R&D and experimentation 
 
The traditional drug discovery practice proved to be unsatisfactory, whereby research 
started with analysis of the candidate molecules into finding what disease they may 
treat. The more favourable approach is now the rational drug approach whereby 
‗much depends on knowing the nature of the disease and understanding how it affects 
the body‘s chemistry.‘921 South Africa therefore needs to invest in disease studies that 
are prevalent in its population to come up with suitable pharmaceuticals. This is 
because it has been observed that the lack of medicines for diseases prevalent in 
developing countries is due to the lack of therapeutic innovation.
922
 The novelty 
standard should not therefore be a bar in an industry where there is a lot of R&D and 
experimentation that is directed to finding tangible solutions. The anticipation tests 
should recognise that experimentation and trial-and-error is an integral part if the 
process. 
 
The legislature and the courts have been sympathetic to the realities of industry 
wherein it is standard practice that a new invention will come about via 
experimentation. Patents Act 1978 s.26(b) provides that a patent is not invalid by 
reason only of the fact that the invention in respect of which the patent was granted or 
part thereof was disclosed, used or known prior to the priority date of the invention as 
a result of the invention being worked in the Republic by reason of reasonable 
technical trial or experiment by the applicant or patentee. This allows the patentee 
who sustains R&D for some time with the benefit of not being pre-empted by 
experimentation disclosures or uses that may be made in the life cycle of the inventive 
process. 
 
Besides the allowance for the experimentation in coming up with inventions, the law 
allows some limited experimentation in understanding a patent. This, however, does 
                                                             
921 Ballance, et al, fn.766, p.101. 
922 Abbott/Graham, fn.34, p.132. 
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not extend to conducting experiments said to be of the R&D type. In Transdermal Ltd 
v Ciba Geigy (pty) Ltd
923
 the court was of the view that when a person skilled in the 
art has to do further experiments with regard to the alleged anticipating disclosure, the 
invention will not be anticipated and ‗[m]ere suggestions made ex cathedra without 
anything backing them up‘ will not destroy novelty. 
  
The courts seem appreciative of the time and effort that may be put into the R&D and 
experimentation of perfecting inventions that are subsequently released into the public 
domain. They are careful in the admission of alleged anticipatory prior art that with 
the passage of time may appear anticipating. In Lastraset v Transfertech and others
924
 
the court stated that ‗[w]here, as in the present case, there have been considerable 
development in the field in the period of approximately 20 years that has passed since 
the date of the publications, the danger of applying hindsight in the construction of the 
relevant document is considerable, but must be vigorously avoided.‘ However, no 
direction was given on how this could be achieved. 
 
 
UNITED KINGDOM AND SOUTH AFRICA 
 
5.12 Novelty Assessment Suggestions in the UK and South Africa 
 
At the international level, the TRIPS Agreement provided novelty as a minimum 
standard and left what has been called the ‗wiggle room‘925 for countries to define for 
themselves. There have been recommendations that developing countries could 
accommodate the minimum standards into their national development goals by 
adopting relatively stringent novelty standards for instance.
926
 Reform and 
harmonisation instruments like the SPLT was an opportunity to find consensus on 
                                                             
923 1994 BP (CP) 1, p.20. 
924 1981 BP 17 (CP), p.29. 
925 Reichman J.H. ‗From free riders to fair followers: Global competition under the TRIPS Agreement‘ 
(1997) New York University Journal of Intellectual Property Law and Policy, p.11-63, (described 
TRIPS as ‗leav[ing] developing countries ample 'wiggle room' in which to implement national policies 
favouring the public interest in free competition‘). 
926 Reichman J.H. ‗Intellectual property in the twenty-first century: Will developing countries lead or 
follow‘ (2009) Houston Law Review, p.1115-1185, p.1132-1133. 
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what would be held as new and the applicable tests at the international level.
927
 South 
Africa could have influenced how the assessment is to be made.
928
  
 
At domestic level, South Africa has not had a review of the patentability 
requirements. It seems to be a missed opportunity that a review of the UK 
patentability requirements did not include the novelty limb.
929
 The review could have 
also been extended to novelty. Such possible reviews and reforms could include for 
example, a statutory statement of the novelty assessment methods including an 
indicative list of the factors that one should consider when assessing newness. This 
would guarantee clarity to third parties in the certainty and clarity-sensitive 
pharmaceutical and associated industries. Zakos
930
 has suggested that ‗there is a need 
to tailor patent law to accommodate particular industries‘ as patent law is increasingly 
tasked with resolving technology specific issues. Continual reviews and reforms of 
whether the novelty criterion is still compatible with developments in science and 
technology is recommendable.  
 
Novelty has unique implications in South Africa. The blanket and unsubstantiated 
citation of foreign law in South Africa, commonly that of the UK, would not be 
helpful in illuminating the doctrine of anticipation. South Africa is not bound by 
foreign law but international dictates of science would persuade one of the need for 
the judiciary to acknowledge the transnational reach of innovation. There is no reason 
to deviate from international legal norms regulating science for the sake of exerting 
independence at the compromise of accepted or universal scientific principles and 
customs. The judiciary has accepted the similarity of South African novelty statutes to 
that of the UK, therefore it seems desirable that novelty assessment is influenced by 
                                                             
927 Takenaka T. ‗The best patent practice or mere compromise? A review of the current draft of the 
Substantive Patent Law Treaty and a proposal for a ―first-to-invent‖ exception for domestic applicants‘ 
(2003) Texas Intellectual Property Law Journal, p.259-350, p.297-298. 
928 Masungu S.F. ‗International intellectual property standard-setting: A review of the role of Africa in 
shaping the rules for the regulation of the knowledge economy‘ (2004) African Yearbook of 
International Law, p.169-189, p.182-183. 
929 Review of inventiveness in the UK by The Patent Office, ‗The inventive step requirement in the 
United Kingdom patent law and practice‘, 2005, Newport. (available online at www.patent.gov.uk). 
930 Zakos G. ‗Patentability of biotechnology, cloning and nanotechnology‘ (2004) Intellectual Property 
and IT Law. 
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jurisdictions where novelty of the latest technologies have already been 
adjudicated.
931
 
 
 
5.13 Conclusion 
 
At first brush the Synthon case is a straightforward case, which should not have 
reached the Supreme Court.
932
 It is fortunate though that it eventually reached this 
level, as the court got a chance to clarify and simplify how novelty is tested. The court 
stated that the novelty question should be approached in a meticulous, two-stage 
staggered manner, each of which has its own relevant points to consider. In South 
Africa, novelty assessment is also structured into stages, which makes for easier 
analysis of the concept. There however does not seem to be clear guidance or at least 
more detailed rules on how each stage should be approached. A recommendation is 
made that the South African courts make more detailed pronunciations on the 
appropriate elements of the structured approach in carrying out the assessment.   
 
The weakness of the novelty assessment tests in both jurisdictions is that they can 
result in odd results overall or have some subjective elements within them. As 
Soetendorp
933
 observes of corporations that ‗some may prefer to invest in innovation 
that has been protected by trade secret, rather than a weak patent that carries the risk 
of litigation‘ it is imperative that the risk be minimised by a novelty mechanism that 
eliminates the possibility of unpredictable results. A suggestion is made that guidance 
be given by the courts on how to avoid the subjective elements, for instance hindsight, 
rather than mere statements that it should be avoided. The chapter explored how this 
could be achieved, a suggestion directed at making the novelty criteria more 
appreciative of the practice of the science under consideration.  
                                                             
931 Thambisetty fn.158, p.3-4, argues that patent law doctrines and interpretation of patentability 
standards tends to ‗lock-in‘ into particular ones over other viable alternatives with the passage of time. 
932 Sharples/Curley, fn.753, p.311. 
933 Soetendorp, fn.13, p.83. 
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CHAPTER SIX 
  
NON-OBVIOUSNESS 
 
 
6.1 Introduction 
 
It has been said that ‗everything that can be invented has been invented.‘934 This can 
be attributed to and reflects the overwhelming volume of new inventions and the 
cutting-edge advances made in the state of the art at any one period in time that seem 
to be of unsurpassable genius. The reality though is that patents will usually be sought 
for inventions that only have a slight improvement to that which is already state of the 
art.
935
 At the onset of research the potential patentee may intentionally look to making 
a small change in the state of the art. For example, this could be when there is broad 
patent that exist or in niche research activities where a small improvement could lead 
to big rewards. Alternatively patentees may find out during the patenting process that 
there is much prior art that is comparable to what they thought was groundbreaking 
research.
936
  
 
It has been said that it is mostly in the pharmaceutical industry where trivial patents 
are granted and these block access to medicines without enriching the public store of 
knowledge, which is a cost to society.
937
 On the other hand, a situation to be avoided 
is where meticulous research is not able to benefit society as it cannot attain a high 
non-obviousness bar or where genuine inventions are easily invalidated.
938
 The non-
obviousness requirement therefore serves to prevent these extremes from occurring. 
In other words the non-obviousness doctrine is designed to attain the optimal 
equilibrium between the benefits and the costs of the patent system. 
                                                             
934 This quote is attributed, albeit controversially, to US Patent Commissioner Charles H. Duell in a 
letter to US President McKinley in 1899. 
935 Correa C.M. ‗Public health and patent legislation in developing countries‘ (2001) Tulane Journal of 
Technology and Intellectual Property, p.1-53, p.23.  Dutfield/Suthersanen, fn.380, p.379. 
936 It is common in infringement or validity challenges that there be amendments made to the patent 
specification, for instance under Patent Act 1978, s.61(3) in order to avoid an existing patent. 
937 It has been said that the inventiveness criterion is more accurately called the ‗non-triviality‘ 
requirement: Merges R. and Duffy J. Patent Law and Policy, 4th ed (2007) London: LexisNexis 
Butterworths, p.612. 
938 It was said that non-obviousness is difficult to establish when a problem had been sought for many 
years without success: Samuel Parkes & Co. Ltd. v Cocker Bros. Ltd. (1929) 46 RPC 241, p.248. 
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This section will begin with an examination of the statutory definitions of the non-
obviousness criteria in both jurisdictions. The current approach toward patentability 
under the non-obviousness limb will then be analyzed and an evaluation of whether 
the standard is set at the appropriate level will be made. As an ideal standard, the non-
obviousness assessment methods are not to be riddled with loopholes allowing 
hindsight bias that is introduced later on after the priority date or attacks to patent 
validity that are fundamentally based on hindsight and therefore unfair to inventors.
939
 
A non-obviousness assessment improvement will be suggested that seeks to balance 
the competing interests of the opposite extremes of the non-obviousness standard as 
applicable to pharmaceutical inventions that may be new but uncertain as to whether 
they are non-obvious. 
 
 
6.2 The statutory nature of non-obviousness 
 
Non-obviousness is a patentability requirement that was introduced later in the 
development of the patent system than the other limbs to patentability. This 
requirement, because of its function, has been upgraded to being perceived as the 
ultimate standard to patentability.
940
 It was out of the realization that only requiring 
that a patent be new and useful or be of some utility was not enough to provide 
incentives for inventing. There had to be an additional requirement that would guard 
against the obtaining of patents that are simply variants of the state of the art.
941
 In 
new fields of technology where variants are still uncertain, the application of well-
known techniques could involve an inventive step.
942
 However, in Aeomica Inc,
943
 it 
was held that the identification of a human homologue of a previously 
uncharacterized gene from another species using bioinformatics, and therefore 
                                                             
939 British Westinghouse Electric and Manufacturing Co Ltd v Braulik (1910) 27 RPC 209, at p.230. 
940 Witherspoon J. (ed) Nonobviousness- The ultimate condition of patentability (1980) Arlington: 
Bureau of National Affairs. Merges/Duffy, fn.937, p.612. 
941 In the US case Great Atlantic and Pacific Tea Co. v. Supermarket Equip. Co, 340 U.S. 147 (1950) 
at 15, it was framed thus: ‗it is not enough that the invention must be new and useful, it has to be of 
such a quality and distinction that masters of the scientific fields in which it falls will recognize it as an 
advance‘. 
942 Thamisetty, p.187. 
943 BL O/286/05. 
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eliminating the need for wet-lab experiments, was not inventive regardless of the 
method used to identify the homologue. 
 
6.2.1 United Kingdom 
 
Above the requirement of the invention being novel, the Patents Act 1977, s.3
944
 
requires an invention to involve an inventive step. To objectively determine what 
qualifies as inventive deserving of patenting, the legislature introduced the inventive 
step, which is essentially a comparison of the prior art and the claimed invention to 
decide if there is a difference, more than a workshop variation, which warrants a 
patent monopoly. The statute goes on to explain that the inventive step in an invention 
could be identified as ‗not obvious to a person skilled in the art, having regard to any 
matter which forms part of the state of art.‘945  
 
The test of non-obviousness seeks to make an objective and qualitative determination 
of the difference between the closest state of art and the alleged invention.
946
 This 
criteria to patentability is the most difficult to define and apply objectively and 
uniformly in practice.
947
 The criterion
 
of non-obviousness demands creativity on the 
part of the inventor.
948
 It complements the newness requirement by making sure that 
the inventor does not block the public in making obvious modification of the state of 
art. ‗In effect, it excludes from patentability anything which is technically or 
practically derivable or discernible from the available information by someone skilled 
in the relevant art.‘949 Thus the skilled worker must be free to use material that was 
‗lying in the road‘ toward the invention.950 
 
                                                             
944 Formerly it was s32(f), of Patent Acts 1949. An equivalent provision in the EPC is Art.56. 
945 1977 Patents Act, s.2.  
946 Molnlycke, p.112 
947 By the UKIPO‘s own admission, inventiveness is the most difficult to assess. At p.2, para.1.2, and 
p.7 para2.11, The Patent Office, ‗The inventive step requirement in the United Kingdom patent law and 
practice‘, 2005, Newport. Also, Grubb argues that compared to the novelty criteria, the inventiveness 
criteria is subjective and most litigated issue in patent law: Grubb fn.256, p.357. 
948 Willison D.J. and MacLeod S.M. ‗Patenting of genetic material: Are the benefits to society being 
realised?‘(2007) Available http://www.cmaj.ca/cgi/content/full/167/3/259. 
949 Griffiths A. (1999) ‗Windsurfing and the inventive step‘ (1999) Intellectual Property Quarterly, 
p.160-190, p.163. 
950 Genentech Inc‟s Patent [1989] RPC 147. 
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Concerning selection patents, which are common in the pharmaceutical sector,
951
 ‗the 
inventive step in a selection patent lies in the discovery that one or more members of a 
previously known class of products possess some special advantage for a particular 
purpose, which could not be predicted before the discovery was made‘952 For 
pharmaceutical inventions specifically, it has been said that where there are structural 
obviousness inclinations, surprising results or advantages may render the compounds 
non-obvious.
953
 The consideration for the monopoly retained for the selection, is the 
public disclosure of the special advantages that the members of the class possess.
954
 
Thus non-obviousness in selection patents inversely correlates with the degree of 
expectancy of results or unique qualities in the claimed invention. 
 
The inventive step has been declared ‗the largest single cause of uncertainty about the 
validity of patents and hence a frequent inflator of the scales and length of patent 
disputes‘955 This could be perpetuated by the courts if they fail to remedy this 
deficiency with a comprehensive and precise definition of the criteria or elements that 
are to be considered when assessing an invention‘s non-obviousness.956 It is therefore 
important that the approach used by the courts is understood, and will be examined in 
the sections below. 
 
 
6.2.2 South Africa 
 
Similar to the UK, the Patents Act 1978, s.25(1) requires that an invention be granted 
for inventions that involve an inventive step, in addition to being new. Similar to the 
current UK situation, the Patents Act 1978, s.25(10) prescribes that ‗an invention shall 
be deemed to involve an inventive step if it is not obvious to a person skilled in the 
                                                             
951 ‗A ―selection patent‖ is a patent under which a single element or a small segment within a large 
known group is ―selected‖ and independently claimed based on a particular feature not mentioned in 
the large group‘(Correa C.M. ‗Public health and patent legislation in developing countries‘ (2001) 
Tulane Journal of Technology and Intellectual Property, p.1-53) and therefore selection patents are 
useful in making an invention in fields which are generally known (Jeffs J. ‗Selection patents‘ (1988) 
European Intellectual Property Review, p.291-301). 
952 In re I. G. Farbenindustrie A.G.'s Patents (1930) 47 RPC 239 per Maugham J, p.322-323. 
953 Grubb P.W. Patents in chemistry and biotechnology. (1986) London: Clarendon Press, p.231. 
954 Beecham Group Ltd. v Bristol Laboratories International S.A. [1978] RPC 521, p.579. 
955 Cornish W., Llewelyn D. and Aplin T. Intellectual property: Patents, copyright, trademarks and 
allied rights, 7th edn. (2010) London: Sweet and Maxwell, para5-28. 
956 Griffiths, fn.949, p.160. 
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art, having regard to any matter which forms… part of the state of the art.‘ The state 
of the art comprises of matter from ‗immediately before the priority date of the 
invention.‘957 The ‗immediately‘ is superfluous and seems to have been included as an 
unnecessary drafting emphasis delineating the state of the art cut-off day as the day 
before the application is filled. 
 
Concerning selection patents, the rule in South Africa is similar to and draws from the 
UK case law. A class of chemicals that exhibit unique characteristics that are not 
possessed by the group as a whole may be non-obvious in some cases. In The B-M 
Group pty ltd v Beecham Group ltd
958
 the court held that ‗the essence of inventiveness 
of such a patent in our law would be the discovery that ―the selected members‖ all 
have some substantial, special, peculiar advantage over the other, unselected members 
that was not obvious having regard to what was common knowledge at the effective 
date.‘ 
 
Due to their common statutory foundations, it is unsurprising that there is a lot of 
reference to UK decisions in the assessment of non-obviousness in South African 
courts. Similar to the UK, obviousness is in issue in the majority of IP cases that come 
to court.
959
 It is upon the courts, therefore, to develop the law and apply the right 
standard or tests that would not in effect abrogate what the legislature promulgated. 
The thesis now turns to tests that have been applied by the courts in the two 
jurisdictions in interpreting statutory obviousness.  
 
 
6.3 The Structured Approach in Non-obviousness Analysis 
 
6.3.1 United Kingdom 
 
Case law on the concept of the inventive step is framed by the case Windsurfing 
International Inc v Tabur Marine (Great Britain).
960
 The court laid-out an approach 
that has come to be of use the world over, including in South Africa, for assessing 
                                                             
957 Patents Act 1978, s.25(10). 
958 The B-M Group pty Ltd v Beecham Group ltd 1980 BP 343, p.381-382. 
959 Burrell, p.157. 
960 [1985] RPC 59. 
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non-obviousness. It has been said that the Windsurfing test does not aim to clarify the 
meaning of non-obviousness requirements.
961
 Rather it seeks to identify the 
components of the requirement and provide a sequence of steps of what should be 
under consideration when assessment is made. The structured approach identified four 
steps to be taken in assessing non-obviousness. 
 
Some writers insisted that these steps be firmly and separately taken at every 
evaluation.
962
 Other views shy away from placing the judge-made approach on a 
statutory footing as has been suggested at times.
963
 At one time after the decision it 
was even suggested that the steps are wrong and without authority.
964
 The Court, 
mindful of the need to use court-made tools to fill voids in statutes,
965
 cautioned that 
there could be over-analyzation of a court-made approach, leading to results that the 
legislators did not intend.
966
 Ultimately the courts have acknowledged that this 
approach cannot fit each and every case.
967
 
 
The Windsurfing approach first got a rearrangement in Molnlycke AB v Procter & 
Gamble Ltd (No.5)
968
 and further rearranged by Jacob LJ in Pozzoli v BDMO
969
 in a 
quest to clarify the structural approach to be made when assessing obviousness: 
 
„(1) (a) Identify the notional “person skilled in the art” 
      (b) Identify the relevant common general knowledge of that person; 
(2) Identify the inventive concept of the claim in question or if that cannot 
readily be done, construe it; 
                                                             
961 Griffiths, fn.949, p.161. 
962 Garland P. ‗Patents- revocation, infringement, invalidity through obviousness‘ (1997) European 
Intellectual Property Review, p.290-291, p.291. 
963 Grant G. and Gibbins D. ‗―Inventive concept‖-is it a good idea‘ (2005) European Intellectual 
Property Review, p.170-175, p.175, the authors conclude that there are dangers when judicial 
summaries of applicable principles rise to the level of statutory texts, such that tests such as the 
Windsurfing test, actually become a distraction from the compulsory statutory enquiry or questions. 
964 Gratwick S. ‗―Having regard to what was known and used‖-revisited‘ (1999) Law Quarterly 
Review, p.403-414, p.408. 
965 Judges, especially in patent law devise and use some mechanism to bridge the gap between general 
principle and the specific facts of the case, Grant/Gibbins, fn.963, p.170. 
966 Lord Walker, in Kirin-Amgen, para.138-139. 
967 In Ranbaxy UK Ltd v Warner-Lambert Co. [2005] EWHC 2142 (Patents), para.69, Pumfrey J. 
identified two problems with the test and suggested there could be more he was not aware of. 
968 [1992] RPC 21, CA. 
969 Pozzoli v BDMO [2007] EWCA Civ 588, para.2. 
 226 
(3) Identify what, if any, differences exist between the matter cited as forming 
part of the „state of the art‟ and the inventive concept of the claim or the claim 
as construed; 
(4) Viewed without any knowledge of the alleged invention as claimed, do 
those differences constitute steps which would have been obvious to the person 
skilled in the art or do they require any degree of invention?‟ 
  
The modified Windsurfing/Pozzoli approach has been applied by subsequent courts. 
Fysh QC sitting as a High Court judge in Aerotel Ltd v Wavecrest Group Enterprises 
Ltd & Ors
970
 followed the modified Windsurfing/Pozzoli approach. This modified 
approach has the advantage of initially settling facts that are rarely in dispute, as step 
one. That is not to diminish the importance of being careful when judging the identity 
of the person skilled in the art and the prior art. In fact, it makes sense to first settle 
the identity of the skilled man ‗for it is only through the eyes of the skilled man that 
one properly understand what such a man would understand the patentee to have 
meant and thereby set about identifying the concept.‘971 The more complex decision is 
usually the identification and assessment of whether indeed there is the inventive 
concept in an invention under step two. The modified approach therefore motivates 
the initial settling of the more objective, and usually uncontested, facts in the first 
question, after which the more subjective facts in question two to four could be 
decided.  
 
The general approach to obviousness seems to be that the assessment must be 
considered on the facts of each case. In Generics v Lundbeck
972
 the court said ‗the 
court must consider the weight to be attached to any particular factor in the light of all 
the relevant circumstances. These may include such matters as the motive to find a 
solution to the problem the patent addresses, the number and extent of the possible 
avenues of research, the effort involved in pursuing them and the expectation of 
success.‘ Commentators have noted that in Conor, the House of Lords ‗did not want 
                                                             
970 [2008] EWHC 1180 (Pat), para.124 and 12. It has also been followed in Eli Lilly & Company v 
Human Genome Sciences Inc [2008] EWHC 1903 (Pat), para.266 and acknowledged in Symbian, 
para.16. 
971 Pozzoli Spa v BDMO SA & Anor [2007] EWCA Civ 588, para.15. 
972 [2007] RPC 32, para72. 
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to endorse or formulate a particular approach, but instead wanted to stress the 
importance of the facts and circumstances in each case.‘ 
 
The statutory requirements in the assessment of obviousness have two paramount 
considerations that will be considered in more detail in subsequent sections in this 
thesis. First, the notional skilled worker, whose reference point is to be used in the 
evaluation, has to be clearly understood. Secondly, the inventive concept, the gist of 
the non-obviousness requirement, is the aspect that is claimed as an invention, which 
is to be non-obvious to the skilled technician. These considerations have a 
determinant effect on the patentability of inventions. 
 
In evaluating obviousness, tribunals have sometimes used the problem-solution 
approach which is distinct from the UK case law approach.
973
 The EPO‘s problem-
solutions approach is stated thus in the EPO Substantive Examination Manual:
974
 
 
‗(i) determining the ―closest prior art‖, 
(ii) establishing the ―objective technical problem‖ to be solved, and 
(iii) considering whether or not the claimed invention, starting from the closest 
prior art and the objective technical problem, would have been obvious to the 
skilled person.‘ 
 
UK Courts and the UKIPO have not readily followed this approach even though most 
of the disputed patents are European patents with UK designations. The CIPA Guide 
to the Patents Act
975
 attributes this apparent anomaly to the fact that the implementing 
regulations and rules, specifically EPC r.24(1)(c), provide that the description of the 
patent specification shall disclose the invention in such terms that the technical 
problem and its solution can be understood and state the advantageous effect, which is 
not prescribed in section 14 of Patents Act or Patent Rules 1995 or 2007. 
                                                             
973 Ranbaxy UK Ltd v Warner-Lambert Co. [2005] EWHC 1242, para.54, Pumfrey J. in finding the 
patent for atorvastatin, a cholesterol synthesis inhibitor obvious, had to examine both the problem-
solution and Windsurfing as competing approaches in obviousness analysis. England P. and Parker S. 
‗Obviousness in the new European order‘ (2012) Journal of Intellectual Property Law & Practice, 
p.805-815, assert that that the advent of the Unified Patent Court provides an opportunity for truly a 
multi-factorial approach to obviousness. 
974 EPO Substantive Examination Manual, VI, 8.5. 
975 CIPA Guide to the Patents Act, 6th ed, p.78. 
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The problem-solution approach was criticized in Actavis UK Ltd v Merck & Co Inc,
976
 
with Jacob LJ saying, inter alia, the problem it solves is an artificial retrospective 
reformulation of a problem not necessary faced by the person skilled in the art and 
that in any event it is contained in the fourth step of the Windsurfing/Pozzoli. 
 
There are other approaches that have been used by tribunals to assess non-
obviousness. The would-could approach, for instance, seeks to establish whether there 
is any teaching in the prior art that would have prompted the skilled person faced with 
the objective technical problem to arrive at the invention rather than merely that he 
could have arrived at the invention.
977
 There is the obvious-to-try approach which 
assesses non-obviousness on the basis that the skilled person would assess the 
likelihood of success as sufficient to warrant actual trial and the invention will be held 
obvious if it is ‗well worth trying out‘978 although ‗mere possible inclusion of 
something within a research program on the basis you will find out more and 
something might turn up is not enough.‘979 The obvious-to-try is useful only in cases 
where there is a fair expectation of success and how much of an expectation is needed 
depends on particular facts of the case.
980
 
 
The courts have further acknowledged the use of secondary indicia which in certain 
circumstances could be regarded as a sign of inventive step. Commercial success of 
the invention, for instance, has been used as an argument that the invention was non-
obvious. In Haberman v Jackel
981
 the enquiry relied on secondary evidence directed 
at establishing non-obviousness by addressing what has become known as the 
Haberman questions which in summary are: 
(a) What was the problem which the patented development addressed? 
(b) How long had that problem existed? 
(c) How significant was the problem seen to be? 
                                                             
976 [2006] RPC 26, para.34 and 40. 
977 EPO Examination Guidelines, para.5.3. 
978 Johns-Manville Corp‟s Patent  [1967] RPC 479, p.493. 
979 St Gobain v Fusion Provida [2005] EWCA Civ 177. Also, the invention would not be obvious if the 
skilled worker required skills beyond common general knowledge and the amount of trial-and-error 
required of the skilled worker is excessive: Harvard/Fusion proteins OJEPO 1992, 268(T006/890). 
980 Conor, para.42. 
981 [1999] FSR 683. 
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(d) How widely known was the problem and how many were likely to be 
seeking a solution? 
(e) What prior art would have been likely to be known to all or most of those 
who would have been expected to be involved in finding a solution? 
(f) What other solutions were put forward in the period leading up to the 
publication of the patentee‘s development? 
(g) To what extent were there factors which would have held back the 
exploitation of the solution even if it was technically obvious? 
(h) How well has the patentee‘s development been received? 
(i) To what extent can it be shown that the whole or much of the commercial 
success is due to the technical merits of the development? 
 
The Haberman questions were aptly summarized into three categories by Pumfrey J 
in Angiotech Pharmaceuticals Inc‟s Patent,982 saying the first question starts off with 
identifying what the problem was, and then those that address the wider question of 
why the invention was not made earlier and the last three are concerned with 
commercial success. The limitation of these questions is one shared with the problem-
solution approach in that it is premised on the existence of a problem, and one not 
prescribed by law. A further challenge with assessment using the Haberman questions 
was identified by Pumfrey J., saying there is a temptation to turn the indicative list 
into a checklist,
983
 yet Laddie J was clear that these are factors that may be helpful. 
 
In Generics (UK) Ltd & Ors v H Lundbeck A/S
984
 the court warned: 
‗The commercial success may be attributable to factors other than the 
invention, for example effective advertising, better workmanship or more 
attractive presentation. Or it may be that those in the field were not aware of 
the prior art said to render the invention obvious or were unable to exploit any 
developments of it. Careful consideration must be given to all circumstances. 
Many of which were identified by Laddie J in Haberman v Jackel [1999] FSR 
683.‘ 
                                                             
982 [2006] RPC 28. 
983 Angiotech Pharmaceuticals Inc‟s Patent [2006] RPC 28, para.36. 
984 [2007] EWHC 1040 (Pat), para.238-241. Some types of technically advantageous pharmaceuticals 
have had limited market success: Kaufman J and Kalaitzandonakes N ‗The economic potential of 
plant-made pharmaceuticals in the manufacture of biologic pharmaceuticals‘ (2011) Journal of 
Commercial Biotechnology, p.173-182. 
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In using secondary indicia like commercial success in judging non-obviousness, it is 
indeed difficult to identify ‗a mere commercial decision‘ which is ‗matter of business 
judgment.‘985 Concern with secondary indicia is that it has played an increasingly 
primary role in the actual determination of obviousness, even though the courts have 
cautioned that secondary evidence is no more than an aid to assessing primary 
evidence as to obviousness of the difference between the inventive concept and the 
state of the art.
986
 Lemley warns against this trend of judging the patentability of an 
invention using evidence after the invention has been conceived, for instance under 
the justification that further investment in improvement or commercialisation of the 
invention is necessary, in that it is contrary to the ex ante justifications of patents.
987
 
Market considerations of the invention are thus of limited use under a conceptual 
framework which is pivoted on factors at the priority date and the sole statutory 
question being whether there is an inventive step irrespective of the reasons of the 
inventor to pursue the invention.
988
 
 
6.3.2 South Africa 
 
The implementation of the statutory non-obviousness criteria takes on a slightly 
different phraseology in South Africa. Influential academic writers have identified 
three summary questions that Patents Act 1978, s.25 requires of non-obviousness 
assessment:  
 
‗What matter was available to the public immediately before the priority date of the 
patent in suit; secondly, whether the invention claimed was a step forward on the 
                                                             
985 Biogen v. Medeva [1995] RPC 25, 112-114. Indeed the pharmaceutical industry was shown to have 
a large number of non-significant patents, but ‗vigorously protects commercially successful products 
through litigation‘: Bessen/Meuer, fn.1, p.11. 
986 Angiotech Pharmaceuticals Inc‟s Patent [2006] RPC 28, para.82-85. 
987 Lemley M. ‗Ex ante versus ex post justifications for intellectual property‘ (2004) University of 
Chicago Law Review, p.129-149.  
988 The court in Actavis, para.119, acknowledged that ‗obviousness must be determined as of a 
particular date. There is at least one other well-known example showing how an invention which might 
be held obvious on one date, would not be so held at a later date. That is where there has been 
commercial success following a long-felt want. Time can indeed change one's perspective. The 
perspective the court must bring to bear is that of the skilled man at the priority date.‘ Cf. Sichelman T. 
‗Commercializing patents‘ (2010) Stanford Law Review, p.341-413, proposing a conceptual 
patentability framework that is effected only after commercialization of the invention. 
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matter available to the public; and thirdly, whether in the light of the matter available 
to the public the step was inventive, ie not obvious.‘989 
 
This series of questions is a summary of what was initially devised in the first case, 
Roman Roller CC and Another v Seedmark Holdings (Pty) Ltd,
990
 to come before the 
Appeals Court under the new Patents Act. The Court there said: 
 
‗In order to apply the provisions to a particular case it is necessary to first 
determine (i) what the art is to which the invention relates; (ii) what the state 
of the art was at the relevant time and; (iii) who is to be regarded as ‗person 
skilled in the art‘991 
 
‗Secondly one has to answer the question as to whether, in light of the state of 
the art as it was immediately prior to the priority date, the invention claimed in 
the patent constituted a step forward.‘992 
 
‗The next and final question to answer is whether the invention involves an 
inventive step in light of the state of the art at the time and the step forward 
taken by the invention.‘993 
 
The Court of Appeals subsequently made a reformulation of the steps in assessing 
non-obviousness in Ensign-Bickford (South Africa) (Pty) Ltd and Others v AECI 
Explosives and Chemicals Ltd.
994
 Under the reformulation, assessment of non-
obviousness is divided into two broad and structured stages. These are; the 
preliminary assessment and the actual structured assessment of non-obviousness. The 
Court said that the first determination that has to be made is: 
 
‗(i) what the art is to what the invention relates; 
(ii) what the state of the art was at the relevant time and; 
                                                             
989 Burrell, p.154-155. 
990 1996 (1) SA 405 (A); 1995 BP 199. 
991 Ibid, p.210, para.B and  C. 
992 Ibid, p.215. 
993 Ibid, p.219. 
994 Ensign-Bickford (South Africa) (Pty) Ltd and Others v AECI Explosives and Chemicals Ltd (SCA) 
1999 (1) SA 70. 
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(iii) who is to be regarded as ‗person skilled in the art.‘ 
 
This preliminary step of questions was previously stated in Roman Roller CC and 
Another v Seedmark Holdings (Pty) Ltd
995
 and is the link between the statutory 
stipulations and actual assessment. The preliminary stage is helpful as non-
obviousness assessment tends to have many points where subjectivity can be 
introduced. Therefore, the settling of these preliminary points acts as a parameter 
within which the decision maker should make the determination of the non-
obviousness of the invention. It has to be noted that this stage is similar to the UK first 
question of the Windsurfing/Pozzoli approach. 
 
From the preliminary assessment, the enquiry then broadly moves onto the actual 
making of the inventive concept assessment. These were derived from the UK case 
Molnlycke AB v Procter & Gamble Ltd (No.5).
996
 Southwood J, sitting as 
Commissioner of Patents and following Ensign-Bickford said ‗after this step the 
structured enquiry described in the Ensign-Bickford case must be undertaken and the 
four matters referred to in para13 answered.‘997 Southwood J in Ausplow,998 quoting 
Plewman JA in Ensign-Bickford,
999
 said these four steps are: 
 
‗What is the inventive step said to be involved in the patent in suit? 
What was, at the priority date, the state of the art (as statutory defined) 
relevant to that step? 
In what respect does the step go beyond, or differ from, the state of the art? 
Having regard to such development or difference, would the taking of the step 
be obvious to the skilled man?‘ 
 
There seems to be tension between the cases between the two Supreme Court of 
Appeals cases in Roman Roller and Ensign-Bickford. Burrell argues that the earlier 
                                                             
995 Roman Roller, 1996 (1) SA 405 (A), p.413. 
996 [1992] RPC 21, CA, stated in SmithKline Beecham plc v Sandoz AG, Case no: SA Patent no. 
96/3472, p.28. 
997 Ausplow (Pty) Ltd v North Park Trading 3 (Pty) Ltd (formerly Marais Engineering CC) 2007 BIP 1 
(CP), para.57. 
998 Ibid, para.13. 
999  Ensign-Bickford (South Africa) (Pty) Ltd and Others v AECI Explosives and Chemicals Ltd (SCA) 
1999 (1) SA 70, para.24. 
 233 
‗skeletal structure‘ adopted by the courts and used extensively is to be preferred over 
the later ‗more structured enquiry‘. However, the rules of precedent would seem to 
support the later structured enquiry in Ensign-Bickford.
1000
 
 
There was a suggestion that the test or list of questions is non-exhaustive and may be 
taken to conveniently list the inquiries to be made.
1001
 The making of these steps non-
exhaustive is certainly not disallowed by the statute. The point of the second stage 
entails establishing whether an invention has the inventive concept. Since the question 
on the state of the art was settled in the first stage, it may not be necessary to make the 
enquiry again in the second stage. 
 
The Court in Ensign-Bickford gave further assistance on the restrictions to the 
questions one should ask in ultimately deciding obviousness. These are designed to 
take focus away from commercial considerations, as these usually arise after the fact. 
The Court said ‗[f]irstly the question to be determined is whether what is claimed as 
inventive would have been obvious, not whether it would have been commercially 
worthwhile.‘1002 
 
The Court in Ensign-Bickford also said ‗secondly, emphasis must lie on the technical 
features.‘1003 That means overall the structured approach emphasises that the 
inventive concept should be found in the technical features of the invention. As such, 
it could be said that non-obviousness lies in the technical advance made by the 
invention more than just the difference in what is made available to the public and the 
state of the art. 
 
The courts have also emphasised that the assessment is not of the magnitude of the 
non-obviousness but whether the inventive concept does exist at all. The court‘s 
guidance under the structured approach appears to be more in line with the statute as 
it does not emphasise a forward step but only a difference between the inventive 
                                                             
1000 The Supreme Court of Appeals approved the later approach in Cipla Medpro (Pty) Ltd v Aventis 
Pharma SA, Aventis Pharma SA and Others v Cipla Life Sciences (Pty) Ltd and Others [2012] ZASCA 
108. 
1001 Ausplow (Pty) Ltd v North Park Trading 3 (Pty) Ltd (formerly Marais Engineering CC) 2007 BIP 1 
(CP), para.57. 
1002 Ibid, para.58. 
1003 Ibid. 
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concept and the state of the state of the art, a criterion set by the statute. That means 
obviousness is in fact a qualitative test as intended by the statutes.
1004
 It is irrelevant 
that the inventive concept may be small. ‗The law only requires that there be 
inventiveness. It is not a requirement that there be a large step forward.‘1005 This 
position is similar to when the courts, under the former law, would say ‗but if there is 
a real inventive step forward, no matter how small, that is sufficient to give subject-
matter to a patent.‘1006 
 
The structured tests between the two jurisdictions are different in their wording and 
number of stages or questions to be asked but they seem to achieve more or less the 
same result. However, a difference is noticeable in that the UK method takes into 
consideration secondary factors said to be indicative of non-obviousness as 
enunciated in Harbeman for instance, whilst in South Africa emphasis is on non-
deviance from the statutory prescription even though the statute is expressed in 
abstract terms offering no practical guidance on the evaluation. In South Africa 
reliance on these auxiliary considerations would be useful, but limited in terms of 
their use by the inventors or third parties because there is no examination of patent 
applications at the patent office which would gather and evaluate the relevant prior art 
documents in order enable one to make a judgment of whether there is need to engage 
the secondary evidence in the non-obviousness evaluation of each case. The function 
of assessing whether matter is obvious is carried out effectively by patent examiners, 
rather than only being first considered in litigation. Difficulties in making the 
judgment to evoke secondary considerations have been acknowledged. The EPO 
Guidelines for Examination in cases where there is a long-felt need or commercial 
success cautions that ‗where the invention solves a technical problem which workers 
in the art have been attempting to solve for a long time, or otherwise fulfils a long-felt 
need, this may be regarded as an indication of inventive step. Commercial success 
alone is not to be regarded as indicative of inventive step, but evidence of immediate 
commercial success when coupled with evidence of a long-felt want is of relevance 
provided the examiner is satisfied that the success derives from the technical features 
                                                             
1004 As was stated in Molnlycke, p.112, that ‗the statute has laid down what the criterion is to be: it is a 
qualitative not a quantitative test.‘ 
1005 Ausplow, para.59. 
1006 Veasey, p.282. Also in Drummond-Hay v DI Fram & Co Ltd 1963 BP 380 (A), p.388E-F; Herculite 
Products Ltd v Harris 1952 1 SA 627 (W), p.630; Hills v Livingstone-Jackson 1935 NPD 5, p.18; Vine 
and Another v Barratt & Pillans Ltd 1939 WLD 238, p.241. 
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of the invention and not from other influences.‘1007 The Haberman questions would 
therefore have to be used carefully in the South African context. 
 
 
6.4 The notional skilled worker 
 
It is desirable that the assessment of non-obviousness has objective reference points. 
Even though in both jurisdictions the assessment relies on a case-by-case 
assessment,
1008
 it remains important that there are fundamental points that objectively 
anchor the whole assessment methodology. It deserves further investigation therefore 
how the skilled person, who represents an objective view of the state of the art, is 
defined. The primary statutes are silent on the characteristics of the person skilled in 
the art, but case law has established various definitions that continue to evolve and 
play a critical role in the determination of non-obviousness. 
 
6.4.1 United Kingdom 
 
Assessing non-obviousness is based on the mentality or viewpoint of the skilled 
person in the art. It has been said that he is notional addressee of the patent. He is 
labelled by Lord Reid as an ‗unimaginative skilled technician.‘1009 In other words, as 
Aldous L.J. commented in Beloit Technologies
1010
 he has the skill and general 
knowledge of the practitioner of the art, but has no capacity for inventing. ‗He is a 
person with practical knowledge and experience of the kind of work in which the 
invention was intended to be used‘.1011 In other words he reflects the competency that 
would be expected from a real practical worker in the art to which the patent is 
addressed. 
 
                                                             
1007 EPO Examination Guidelines, 11.10.3. In T1212/01(Pyrazolopyrimidinones for the treatment of 
impotence/Pfizer Limited), deciding that neither technical prejudice against the invention nor 
commercial success establishes non-obviousness, the Board identified evidence assessment difficulties 
in resolving contributory factors to inventiveness. 
1008 Kitchin J opined that ‗the question of obviousness must be considered on the facts of each case‘, an 
opinion which was approved by Lord Hoffmann in H Lundbeck A/S v Generics (UK) Ltd [2008] RPC 
19, para.24 and Conor. 
1009 Technograph Printed Circuits Ltd. v Mills & Rockley (Electronics) Ltd. [1972J RPC 346, p.355.   
1010 Beloit Technologies Inc v Valmet Paper Machinery Inc. [1997] RPC 489. 
1011 [2006] EWHC 2686 (Pat), para.75. 
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He is also assumed to have knowledge he would have from learning from existing 
literature in order to provide a solution for a problem at hand.
1012
 It is said he will read 
the literature carefully without a limitation to assimilate the knowledge.
1013
 He obtains 
common general knowledge from standard documents used in industry and 
supplements this with knowledge from documents from industry-specific press, patent 
specifications and relevant scholarly journals.
1014
 In other words, although he is an 
imaginary person, his comprehension and actions reflect those of the typical practical 
worker, which evidently are above those of a layperson. 
 
To decide whether the invention meets the patentability or validity standards of the 
inventive requirement, ‗the court or other tribunal is required to embark on an 
exercise in which they must first ascertain how far, if at all, the invention has 
advanced the state of the art and then evaluate this advance from the perspective of a 
notional person skilled in the relevant art.‘1015 Gratwick points out that he will try 
what is obvious to him which has subjective elements to it,
1016
 while on the other 
hand the courts have maintained that the specified standard is objective.
1017
 
 
Where the skilled worker has a particular problem in mind, it has been said that a 
solution to his problem would usually lead him to an obvious answer, which is not 
inventive as it amounts to no more than an obvious verification.
1018
 On the other hand 
when that result is unexpected, the solution is inventive. In some cases he may not 
have a particular problem in mind, and obtains unexpected results, which entails a 
non-obvious invention. The qualifying criteria seem to be the degree of expectancy in 
the result that entitles one to an invention.
1019
 Moreover, as Griffiths
1020
 opines, the 
‗mental effort which a skilled person would have to reach a patentable invention ….is 
therefore the crucial factor in determining inventiveness and patentability.‘  
                                                             
1012 Cornish/Llewelyn/Aplin, fn.955, para.5-28. 
1013 Jacob L.J. in Rockwater Ltd v Technip SA [2004] WL147665 said this person is a nerd. 
1014 Cornish/Llewelyn/Aplin, fn.955, para.5-37. 
1015 Griffiths, fn.949, p.166. 
1016 Gratwick, fn.949, p.406. 
1017 Molnlycke AB v Procter & Gamble Ltd (No.5) [1992] RPC 21, Sir Donald Nicholls stated that the 
assessment was ‗wholly objective‘. 
1018 Cornish/Llewelyn/Aplin, fn.995, para.5-39. 
1019 In Beecham Group (Amoxycillin) Application [1980] RPC 261, it was held that the invention was 
inventive as the degree of advantage possessed by the Amoxycillin as a therapeutic agent could not 
have been predicted even though the line of research taken in synthesizing it was obvious. 
1020 Griffiths, fn.949, p.169. 
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Authors suggest that there is a need to view the knowledge that comprises the state of 
the art as something which has a potential for further development as reflected in the 
use of the word ‗obvious‘ in specifying the ultimate non-obviousness evaluation.1021 
This implies that the notional skilled person should have some question or aim in 
mind when considering the state of the art. This, nevertheless, does not seem be right, 
at least not in all cases. Accidental discoveries, a common occurrence in the 
pharmaceutical sector, are allowed, in which the skilled worker has no problem in 
mind or was working on a different line of research that results in a solution in 
another area.  
 
The notional skilled person is assumed to have common general knowledge at the 
priority date. Consequently, it has to be emphasised that the notional skilled worker 
uses this knowledge to view the state of the art forward from the priority date. His 
view is not from the invention backward to the prior art, as it has been emphasised 
that hindsight is not allowed.
1022
 Hindsight would raise the patentability bar to levels 
where it would be improbable to have an invention that is considered inventive.
1023
 
Later on in this chapter, attention will be on how hindsight bias could be avoided to 
prevent unduly high non-obviousness standards. Unattended hindsight bias has the 
ability to undermine the case law postulations about the characteristics of the skilled 
person. 
 
In Conor an issue that arose was whether the patentee is mandated to explain why the 
invention works. Commentators are of the view that ‗all he needs to do is to explain 
how it works in a manner which enables persons skilled in the art to perform it 
without themselves inventing anything.‘1024 Against the premise and justification that 
patents perform a public education function, it would at first glance seem this position 
is mistaken. However, the workability of the invention by the person skilled in the art 
is the only burden on the patentee. According to Lord Hoffmann ‗if the claimed 
invention works, it is irrelevant that you arrived at it by accident or on the basis of an 
                                                             
1021 Griffiths, fn.949, p.166. 
1022 Phillips J. and Firth A. Introduction to intellectual property law. 4th edn (2001) Oxford: Oxford 
University Press, p.51. 
1023 Ibid. 
1024 Deepak J.S. ‗The elusive quest for the definition of obviousness- patent law‘s holy grail‘ (2010) 
International Review of Intellectual Property and Competition Law, p.410-427, p.423. 
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altogether mistaken theory.‘1025 The person skilled in the art only has to show that the 
invention works. That is to say the patentee discharges their duty to educate the public 
by showing how the invention works.  
 
 
6.4.2 South Africa 
 
Similar to English law, assessment of non-obviousness in South Africa is based on the 
mind-set of the skilled person in the art. The assessment seeks to establish whether the 
invention was inventive compared to what was available to the public immediately 
before the priority date. In Gentiruco
1026
 the court prescribed that the relevant person 
would be those ‗ordinary skilled or qualified persons engaged in the art or science.‘ 
The Court would, in The B-M Group pty ltd v Beecham Group ltd
1027
 later state that 
the specification addressee would be the notional ‗person skilled in the art or science.‘ 
 
Although, it is rarely in dispute, making the actual identification of the hypothetical 
skilled person has proven difficult in some circumstances. In Heineman Electric (SA) 
Ltd v Switch King Electrical Industries (Pty) Ltd
1028
 the Court acknowledged this 
difficulty and pronounced that ‗it is not always easy to identify the person ‗skilled in 
the art‘ who must be visualised for the purpose of applying that test. His industrial and 
scientific attainments must clearly vary according to the nature of the patent whose 
validity is to be determined. In some of the early patent cases dealing with simple 
devices he has been described as ‗an ordinary workman in the trade‘. At the other end 
of the scale dealing with complex technologies, a very different person may have to 
be visualised, as in Transvaal and O.F.S Chamber of Mines v General Electric 
Company,
1029
 where the invention related to the manufacture of synthetic diamonds 
and where the court expressed itself in these terms:  
                                                             
1025 UCL Institute of Brand and Innovation Law: Conor v Angiotech on Appeal (2011) Skeleton 
argument, para.(d), by Lord Hoffmann in a mock simulation of Conor, 23 November 2011 UCL, 
London. Event proceedings available, at 
www.ucl.ac.uk/laws/ibil/docs/Conor_v_Angiotech/skeleton_Arguments.pdf.  
1026 Gentiruco, p.196D. 
1027 The B-M Group pty ltd v Beecham Group ltd 1978 BP 373 (T), p.398-399. 
1028 1969 BP 297 (CP), p.299-300. 
1029 1966 BP 281 (T). 
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‗It is obvious that there is not a class of synthetic diamond-makers which can 
be looked to establish the common knowledge... Our hypothetical diamond-
maker would be part physicist, part mineralogist and part engineer, part 
chemist and part crystallographer.‘ 
 
This leads to the deduction that this skilled person may sometimes be a group of 
people. It is an amalgamation of different skills which do not exist in reality in one 
person.
1030
 This situation may somehow be seen as not portraying reality and 
introduces weakness in the non-obviousness criteria. In effect, this would mean that 
the patent specification is actually not addressed to anyone in existence. 
 
In Marine Construction and Design Company v Hansen‟s Marine Equipment (Pty) 
Ltd,
1031
 as in the UK, the Court summarised to whom the assessment is relative to and 
actions he would be allowed to take when acting on prior art: 
 
‗The test whether an invention lacks subject-matter and is invalid for 
obviousness, has been authoritatively stated to be whether or not the ordinary 
person skilled in the art could, if faced with the problem solved by the 
invention, and having regard to what was common knowledge in the art at the 
relevant time, and using his intelligence, easily have produced the solution or 
taken the step taken by the patentee.‘  
 
However, it is the court that makes the final decision on what the skilled worker 
would view as obvious. In Miller v Boxes and Shocks (Pty) Ltd
1032
 the court asserted 
that it is was the one that ultimately makes the non-obviousness decision, although ‗it 
is extraordinarily difficult to avoid the evidence of experts from occasionally 
trenching on the province of the court.‘1033  
 
In non-obviousness assessment, hindsight is guarded against but the decision makers 
must be vigilant. This is because its effect would be more severe than in the UK 
                                                             
1030 For instance, in Genentech Inc.‟s Patent [1989] RPC 147, p.278, the court acknowledged that the 
‗successful pursuit of Genentech's research required the deployment of techniques in more than one 
field‘ and no such person existed in reality. 
1031 1971 BP 187, p.198. 
1032 1945 AD 561, p.584. 
1033 Levin v Number Plates and Signs (Pty) Ltd 1942 CPD 412, p.429. 
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because there is no patent application examination carried out in South Africa. The 
first time any person puts themselves in the position of the skilled worker is after the 
patent is sealed or when there is a dispute, which is long after the priority date and by 
which time the knowledge and technology would have advanced and diffused into the 
public domain. What would have been genuinely inventive at the priority date, could 
seem ordinary and mundane at the time of assessment. The role that would be played 
by the examiner at the Patent Office taking the position of the skilled person is thus 
underscored. 
 
 
6.5 The inventive concept 
 
6.5.1 United Kingdom 
 
The objective test of non-obviousness seeks to ascertain significant differences in the 
state of art and what the patentee claims to have invented; the inventive concept. 
Unlike novelty, which is to be assembled from the whole of prior art, non-
obviousness excludes prior specifications that are subsequently published.
1034
 Non-
obviousness assessment may entail the reading of prior art documents in light of each 
other.
1035
 Nevertheless, this does not mean that two pieces of articles could simply be 
placed next to each other without any working inter-relationship.
1036
 
 
There are views that the objective of the evaluation is to measure the development in 
knowledge as advanced by the invention. For example, in Generics (UK) Limited and 
others v H Lundbeck A/S, Lord Walker said there were some discussions of whether 
the inventive concept is the same thing as the technical contribution to the arts.
1037
 
Knowledge has a dynamic nature which may impede proper non-obviousness 
evaluation. It has been said that knowledge ‗should not be viewed at a particular point 
in time in isolation as if it were something static since this would ignore its dynamic 
                                                             
1034 Both Patents Act 1977, s.3 and Patents Act 1978, s.25(10) provide for disregarding of prior 
specifications subsequently published for inventiveness assessment. 
1035 Cornish/Llewelyn/Aplin, fn.995, para.5-40. 
1036 For example, mosaicing- collating material from different sources for comparison with the 
invention- is not allowed and was criticised in Technographic Printed Circuits [1972] RPC 346, p.355. 
1037 Generics (UK) Limited and others v H Lundbeck A/S [2009] UKHL 12, para.29 to 34.  
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quality and provide an inappropriate basis for evaluating change.‘1038 However, in the 
context of non-obviousness assessment, this would not be the correct view to take, as 
the legislation requires one to freeze the state of the art the day before the priority date 
in making assessment of the invention concept. Later developments in knowledge are 
irrelevant as at that time they are not part of the state of art. This would in fact 
introduce hindsight bias. 
 
There have been different approaches to establishing the inventive concept. There is 
the problem and solution approach, favoured in the EPO.
1039
 The Courts and the 
UKIPO, however, have not fully embraced this approach.
1040
 Under this approach, the 
invention is viewed as a solution to a pre-existing problem where the skilled man has 
a particular problem in mind. The inventive concept is viewed as the solution to the 
problem of moving from the closest prior art to the new advantage or solution. This is 
criticised for being impractical though, in the sense that the inventor may not be 
aware of the true closest prior art and the ignoring of other disclosures that may make 
the invention obvious.
1041
 It also suffers from the defect that the problem solved is not 
prescribed by the law and in reality is a fictitious one derived with the benefit of 
hindsight after invention has been developed.
1042
   
 
According to writers,
1043
 the EPO approach is commendable in its emphasis on 
evaluating the inventive concept in terms of knowledge development, which is the 
classical justification foundation of the patenting system. Nevertheless, as with the 
Windsurfing/Pozzolli approach, however, this still leaves open the decisive and 
ultimate evaluation and the question of what quality should be present in new 
knowledge for the invention to be regarded as inventive.
1044
 In fact, in 
Alcan/Aluminium Alloys
1045
 the TBA said that EPC Rule 27(1), the foundation of this 
approach, deals more with formulation of the invention‘s description as opposed to 
non-obviousness assessment under Art.56 EPC. Therefore it could be said that the 
                                                             
1038 Dutfield/Suthersanen, fn.365. 
1039 Cornish/Llewelyn/Aplin, fn.995, para.5-39. 
1040 Cole E. ‗Towards a single pan-European standard- common concepts in UK and ―continental 
Europe‖ patent law: Part 2: Obviousness‘ (2010) European Intellectual Property Review, p.259-267. 
1041 At para 68 and 69, Ranbaxy UK Ltd v Warner-Lambert Company [2006] FSR 14. 
1042 Phillips/Firth, fn.1022, p.51. 
1043 Griffiths, fn.949, p.184. 
1044 Griffiths, fn.949, p.184. 
1045 T465/92 [1995] E.P.O.R 501. 
 242 
current approaches may need some improvement as they do not always make the 
legislatively required assessment of the inventive concept, even though they may 
achieve the appropriate result in most cases. 
 
6.5.2 South Africa 
 
The approach to making the step from the state of the art to the claimed invention is 
easy in theory, but has proven problematic in practice. The approaches suggested over 
the years for evaluating the inventive concept tend to make preparations for making 
this step but do not give clear direction of how to actually take the step, a problem 
similar with the UK as seen above. 
 
In Veasey v Denver Rockdrill and Machinery Company. Ltd
1046
 Wessels JA stated 
that: 
 
‗The difference between the plaintiff‘s invention and prior common 
knowledge must be measured and valued. If there is no difference, there is no 
subject matter; if there is a difference, but it calls for no inventive ingenuity to 
bring it about, there is also no subject-matter; but if there is a real inventive 
step forward, no matter how small, that is sufficient to give subject-matter to a 
patent.‘ 
 
There have been helpful court pronunciations with regards to how the inventive 
concept would be established. One prominent test of conceptualising the inventive 
concept is directed to the attempts that could be made in finding solutions to a 
problem that the person skilled in the art would be faced with: 
 
‗The duty of the judge is, so far as possible, to attempt to gain a full perception 
of the position at the date of the patent, not necessarily of the patentee, but of 
an ordinary skilled person in the art, and to give an answer to the question: ―If 
an ordinary person skilled in the art had set himself to solve the problem 
which the inventor set himself to solve, would he, in the light of the 
                                                             
1046 Veasey v Denver Rockdrill and Machinery Company. Ltd 1930 AD 243, p.282. 
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knowledge which he should have then have had, arrived at this solution 
without difficulty, or would it have required some quantum of invention.‖‘1047 
 
With regard to assuming the inventive concept could be indicated through the skilled 
person trying to solve a problem, it could be said that the South African approach has 
more resemblance to the problem-solution approach used in the EPO. In this respect, 
therefore, the approach to the inventive concept is slightly different to that of the UK 
approach. As such, it bears more the criticisms and strengths of the EPO approach 
than the UK‘s approach. 
 
 
6.7 Reform needs of a structured approach 
 
It is desirable to utilise a structured approach when making non-obviousness 
assessment,
1048
 to assist in attaining and maintaining a consistent level of non-
obviousness. The approach should not be deficient in any of the non-obviousness 
elements required by the statutes. Justice Laddie acknowledged in PCME Ltd v Goyen 
Controls Co UK Ltd
1049
 that Windsurfing „sets out a structured approach to the 
question of obviousness and sometimes simplifies analysis.‘ It is noted that the tests 
are not always applicable or helpful, thus an ideal structured approach that 
systematically integrates all the elements required by the statutes in its steps to ensure 
consistency in all the cases could be suggested.
 
It has come to be expected of an 
approach applying a legislative ‗requirement to be clear, comprehensive and free from 
ambiguity.‘1050 It is on this premise that a reform could be suggested that would 
complement the evaluation of the non-obviousness criteria. 
 
The assessment questions in the tests do not always properly guard against hindsight 
by those attacking a patent. Consistently guarding against hindsight is important 
especially because it is difficult to unlearn what is already known. It has been equated 
to the inventor using much effort completing a word puzzle, with the tests asking the 
                                                             
1047 Levin v Number Plates and Signs (Pty) Ltd 1942 CPD 412, p.424 
1048 Cole P.G. ‗Inventive step: meaning of the EPO problem and solution approach, and implications 
for the United Kingdom: part 1‘ (1998) European Intellectual Property Review, p.214-218, p.214. 
1049 [1999] EWHC 830 (Pat), para.56, emphasis added. 
1050 Griffiths, fn.949, p.170. 
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courts to complete the same puzzle that they already know solutions to.
1051
  Those 
attacking the validity of a patent can easily mosaic, although limitedly,
1052
 taking 
together pieces of prior art that would otherwise not be obvious to make a case of lack 
of non-obviousness.
1053
 To some extent the South African and Windsurfing/Pozzoli 
non-obviousness approaches suffer from this defect. For these reasons suggestions 
could be made for improvement. 
 
 
6.8 Reform proposal 
 
In both jurisdictions, one of the underlying weaknesses of the non-obviousness tests 
used is that they always have the risk of allowing the assessment to be influence by 
‗the brilliance of hindsight.‘1054 It is not possible to unlearn knowledge once acquired 
as observed by Lord Moulton when he said ‗I confess that I view with suspicion 
arguments to the effect that a new combination, bringing with it new and important 
consequences in the shape of practical machines, is not an invention, because, when it 
has once been established, it is easy to show how it might be arrived at by starting 
from something known, and taking a series of apparently easy steps.  This ex post 
facto analysis of invention is unfair to the inventors.‘1055 Judges are well trained in 
carrying out the non-obviousness assessment ex ante.
1056
 Since the evaluation is 
carried out by cognitive beings, the risk is always there.
1057
 To some extent, it then 
depends on the willingness of the evaluator to guard against this bias. If there is a 
coherent structured approach to non-obviousness in place, elimination or at least 
minimization of this hindsight risk seems possible. 
 
 
                                                             
1051 Phillips/Firth, fn.1022, p.51. 
1052 Both South Africa and UK courts guard against mere combinations.  
1053 Daesang Corporation v Ajinomoto Co Inc. [2003] EWHC 973 (Ch), Laddie J, held that in 
obviousness assessment there was a danger of hindsight, as once an invention was made and 
understood, it could be easily arrived at from the prior art by a series of logical and apparently obvious 
steps if not viewed through the eyes of the skilled person in the art at that time. Gratwick, fn.901, 
p.403. 
1054 The court in The B-M Group pty ltd v Beecham Group ltd 1978 BP 373 (T), p.404, warned against 
introducing the unshakable hindsight bias. 
1055 British Westinghouse Electric and Manufacturing Co Ltd v Braulik, (1910) 27 RPC 209, p.230. 
1056 Generally, Guthrie C., Rachlinski, J.J. and Wistrich A.J. ‗Inside the judicial mind‘ (2001) Cornell 
Law Review, p. 777-830. 
1057 Ibid, p.779-780. 
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6.8.1 The skilled person 
 
An approach that continuously approximates reality into the whole obviousness 
analysis is recommended, particularly the typical situation that would have been faced 
by the person skilled in the art. By definition, the skilled person is a legal construct. 
As we have seen, it therefore has no reflection on actual qualities or actions of real 
individuals in all cases. It is proposed that the skilled person should be approximated 
more to real situations.
1058
 This approximation, however, cannot eliminate hindsight 
bias in itself as the person skilled in the art is usually created after the patent is 
challenged or infringed or to assist in resolving particular obviousness issues after the 
priority date. Even examination at the patent office occurs after the fact. That is to say 
the skilled person is identified for making a historical judgment. 
 
6.8.2 The inventive concept 
 
The inventive concept cannot be standardized across all fields of technology. 
Although it is desirable to have certainty and predictability of law, there is also the 
reality that the inventive concept cannot easily, if at all possible, be predetermined. 
This is true even within the same field of technology. This makes it harder to devise a 
methodology that would properly encompass the inventive concept for all cases that 
come to court. 
  
 
6.8.3 The Recommendation  
 
For the attainment of the ideal non-obviousness standard, a two-fold suggestion is 
made. The suggestion is directed at improving assessment and making the 
obviousness decision easier to execute. When making the proposal on an additional 
mechanism of conceptualizing and approaching obviousness assessment, one has to 
                                                             
1058 The use of a hypothetical person to decide what a scientist in the real world would do is seen as 
worrisome: Durie D.J. and Lemley M.A. ‗A realistic approach to the obviousness of inventions‘ (2008) 
William and Mary Law Review, p.989-1020, p.995. In South Africa because of non-examination of 
applications, this is compounded with the passage of time before the inventiveness judgment could be 
made. 
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be mindful of the words of Diplock LJ in Johns-Manville Corporation's Patent
1059
 
that: 
‗The correctness of a decision upon an issue of obviousness does not depend 
upon whether or not the decider has paraphrased the words of the Act in some 
particular verbal formula. I doubt whether there is any verbal formula which is 
appropriate to all classes of claims.‘ 
 
First of all, non-obviousness should be analyzed using a more robust structured 
approach, but one that is not rigid. This assists in properly sorting all evidence to the 
making the non-obviousness decision, emphasizing the pervasive role of the person 
skilled in the art and the identification of the inventive concept. Secondly, the 
framework or mechanism for non-obviousness analysis should prevent or at least 
minimize the infiltration of hindsight bias. It has been suggested that this is attainable 
with the proper use of secondary evidence or considerations.
1060
 
 
To begin with, the robust approach will be considered. When utilizing such a 
structured approach, it is not easy to mix up the division between primary and 
secondary considerations for obviousness. Some technologies rapidly diffuse into the 
public store of knowledge as common knowledge whilst some others remain obscure 
for some time.
1061
 For inventions in sectors where technology is easily integrated into 
the public store of knowledge, it is common that when patents are disputed, facts 
about the invention are easily taken for granted as having been obvious before the 
priority date. A structured approach stimulates the careful consideration of the 
different elements of the invention relative to the prior art. That is to say it enhances 
contextualizing of all the evidence in support or against founding of non-obviousness. 
 
Secondly, it is proposed an analysis that prevents hindsight bias or at least mitigates 
against it. The basis for this assertion is that a ‗proper non-obvious decision must not 
take into account the ex post fact that the invention is actually created.‘1062 This is 
because the non-obviousness analysis should only turn on the ex ante view of the state 
                                                             
1059 [1967] RPC 479. 
1060 Durie/Lemley, fn.1058, p.1006. 
1061 SCP/12/3 Rev, p.33-36. 
1062 Mandel G.N. ‗Patently non-obvious: Empirical demonstration that the hindsight bias renders patent 
decisions irrational‘ (2006) Ohio State Law Journal, p.1391-1463, p.1393. 
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of the art. The statutes in the UK and South Africa prescribe that obviousness should 
be judged against the state of the art at anytime before the priority date and 
immediately before the priority date, respectively. However, the assessment that has 
to be carried out depends heavily on ex post factors. 
 
Mitigating hindsight bias is admittedly complicated, as even with a clear structured ex 
post instruction of evaluation, the hindsight influence does not immediately 
diminish.
1063
 The very knowledge that the invention was attained compels analysis 
toward the invention, an advantage that the patentee did not have when he created the 
invention from the complete sea of prior art.
1064
 Therefore reliance on information 
concerning events after the priority date should be reduced and rarely used as 
‗hindsight research has revealed that individuals tend to overestimate both the 
likelihood a known outcome occurring and the foreseeability of that outcome.‘1065 
Thus, there should be active guarding, in the courts, against the underestimation of the 
inventive concept in disputed inventions as a result of secondary evidence for 
instance.
1066
 Otherwise, there would be obviousness in a lot of inventive concepts that 
indeed advance the state of the art.  
 
In addition, because of hindsight bias, the person skilled in the art is usually assumed 
to have higher skills than they had in actuality.
1067
 This, therefore, can make many 
borderline inventions appear more obvious than they were to a practically existing 
person skilled in the art. There should also be an allowance for the fact that there may 
have been different schools of thought in the technical field under consideration, such 
as in genetic sciences, biotechnology or any of the newer fields like stem cell research 
and nanotechnology, where there may still be no settled accepted unified scientific 
opinions. Courts should therefore not always prescribe or assume one acceptable 
wisdom of the time in the person skilled in the art, but scrutinize for an objective 
range of knowledge.  
 
                                                             
1063 Ibid, p.1395. 
1064 Ibid, p.1403. 
1065 Ibid, p.1404. 
1066 Davis J, in Levin v Number Plates and Signs (Pty) Ltd 1942 CPD 412, p.423-424 warns on 
hindsight taking the opposite extreme of overestimating the inventive concept. 
1067 Mandel, fn.1062, p.1405. 
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The hindsight bias is also high when the result is unexpected.
1068
 This means, for 
instance, that the inventive concept could be judged to be lower than it actually was 
for inventions resulting from routine work with some surprising results. Thus 
preliminary determination of what was achieved by the invention at the priority date 
will be contaminated and judged to be lower than what it was. To diminish the 
influence of hindsight, what is suggested is that the preliminary issues in evidence 
should be settled with the assumption of no invention having occurred or with the 
exclusion of evidence that selectively points towards the existence or attainment of 
the invention. A reason to combine the prior art must come from a specific 
informational sources in existence at the time of the invention -the prior art, general 
knowledge in the art, or the nature of the problem and not be influenced by the 
claimed invention. Then the actual evaluation of the inventive concept will be less 
affected by hindsight bias. The courts are under obligation to determine obviousness, 
a historical judgment, through the eyes of the person skilled in the art in light only of 
the prior art.
1069
  
 
The UK case law pronunciation on obviousness analysis encapsulates the proposal 
that to some degree prevents hindsight: ‗viewed without any knowledge of the alleged 
invention as claimed, do those differences constitute steps which would have been 
obvious to the person skilled in the art or do they require any degree of invention?‘1070 
It is suggested that it should thus be emphasised, more than merely mentioned. In 
South Africa in Ensign-Bickford it was only established that ‗having regard to such 
development or difference, would the taking of the step be obvious to the skilled 
man?‘, without the instruction that such regard should be had with the assumption of 
no invention having occurred. Exercising caution is recommended to prevent 
hindsight bias that occurs from analysis with the knowledge that the invention was 
attained. 
 
 
                                                             
1068 Ibid. 
1069 At the lower end of the expectancy scale when the invention is expected from teachings of prior art, 
there is no inventive concept, see Transvaal and Orange Free State Chamber of Mines v General 
Electric Company 1966 BP 281 (T), p.290. 
1070 Step 4 of Windsurfing/Pozzoli, para.23, emphasis added. 
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6.9 Conclusion 
 
With the advent of international harmonization of the patentability standards, it is 
recommended that the UK and South Africa engage in a continual introspection of 
domestic inventiveness policies. It has been observed that ‗of course, we researchers 
in IP share a professional bias in favour of solving all problems with the law,‘1071 but 
it has to be understood that industry looks for what works practically, to allow 
invention and innovation and to maximise profits. The law should develop to assist 
industry to function efficiently.
1072
 Elements in the non-obviousness assessment 
approach that stifle invention or are impracticable to the industrialist are undesirable. 
Hence, the non-obviousness criteria should appeal to a ‗practical‘ skilled worker in 
the art.
1073
 This is why in law, emphasis should be put on making assessments through 
the eyes of the skilled worker. The identified skilled workers in industry should thus 
be able to analyse for themselves whether their inventions are considered inventive or 
not in law. 
 
It was noted that ‗in our field, legislation keeps increasing in complexity and scope, 
often to no purpose.‘1074 Non-obviousness reforms could however be to simplify the 
case law into a consolidated cohesive instrument rather than the need to wade through 
volumes of case law before identifying which non-obviousness test is to be applied to 
a particular situation. The recommendation made in this chapter has given a two-stage 
approach to non-obviousness, which can meet these needs. It could also serve to bring 
the UK and South Africa assessment methods, of common legal ancestry, closer.  
 
Even though it is generally accepted that those seeking patent protection, do so more 
as a strategic decision, especially in the lucrative fields of pharmaceuticals, the non-
obviousness requirement should carefully guard for technical advancement in the state 
of art and against hindsight. The focus of inventive concept analysis should be on the 
                                                             
1071 Geller P.E. ‗Dissolving intellectual property‘ (2006) European Intellectual Property Review, p.139-
145, p.144. 
1072Lord Irvine, fn.27. England P. ‗Towards a single pan-European standard– common concepts in UK 
and ―continental European‖ patent law: Part 2: obviousness‘ (2010) European Intellectual Property 
Review, p.259-267, p.261-262. 
1073 Szabo G.S.A. ‗The problem and solution approach to the inventive step‘ (1986) European 
Intellectual Property Review, p.293-303, p.300. 
1074 Geller P.E. ‗Dissolving intellectual property‘ (2006) European Intellectual Property Review, p.139-
145. 
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provision of new technical solutions which are not simple variants of the state of the 
art, which in this chapter has been recommended as a conceptual framework for 
making non-obviousness assessments. 
 251 
CHAPTER SEVEN 
 
INDUSTRIAL APPLICATION 
 
7.1 Introduction 
 
One of the four routes identified in chapter one of this thesis by which pharmaceutical 
discovery occurs is through the study of disease pathway and identifying the target 
that is involved in the disease, a process that increasingly relies on biotechnology and 
genomic technologies. The science of genomics, in particular, correlates genetic 
information with biochemical pathways and disease mechanisms with the 
consequence, for instance, that in a particular disease, if a gene is under- or over 
expressed, then the protein for that gene may be a target for pharmaceutical molecule 
intervention that interferes with its function commonly through the blocking of the 
receptor for that protein.
1075
 Such biomedical technological interventions are usually 
seen as helpful in the carrying out of research that result in pharmaceutical treatment 
of disease, but questions have been raised on the desirability of their inclusion in the 
ambit of patent protection. 
 
As a result, at one end, there is great interest in the patenting of inventions of the 
frontier and emerging fields of biomedical technology. This is the case in the 
biotechnological and genomic fields which have been heralded as opening new 
avenues of treatment and providing the pioneering research tools in the fight against 
disease. On the other hand, there is concern that allowing the patenting of what could 
essentially be considered research tools in these fields or the products resulting 
thereof, would hinder further research and advance of the technology if the patenting 
is allowed before tangible results are observed or the science is fully understood.
1076
 
The requirement that an invention must be capable of industrial application is 
positioned in the middle of this debate and is usually cited as bringing equilibrium 
between the two extreme views. The germinate sciences and field of technologies will 
                                                             
1075 Grubb, fn.256, p.294. 
1076 Eisenberg R.S. and Merges R.P. ‗Opinion letter as to the patentability of certain inventions 
associated with the identification of partial cDNA sequence (1995) American Intellectual Property Law 
Association Quarterly Journal, p. 6.  
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therefore be used in this chapter for an expository analysis of the interpretation of the 
industrial application criteria. 
 
In this chapter, the thesis turns to analyse how the criteria of industrial applicability or 
use has been applied in the two jurisdictions. Satisfying the industrial application 
criteria for the pharmaceutical molecules or processes is not considerably 
controversial. Thus, particular focus will be on the approach that is taken in applying 
this criterion in the research technologies that precede and enable the development of 
the medical and pharmaceutical products. That is to say particular focus will be on the 
‗transforming and enabling technologies.‘1077 It should also be noted that since these 
are frontier technologies, their application is usually not restricted to one field of 
technology, but has impact on other diverse fields besides health related ones.
1078
 
 
The chapter will briefly trace the purpose of the industrial application criteria in the 
patentability of inventions discourse to begin with. Then the statutory nature of the 
criteria in the two jurisdictions will be examined and analysis of how the tests have 
been applied by the courts will be made. There will also be an examination of how the 
two jurisdictions have, by using the industrial application criteria, sought to put a 
balance between the unpatentability of medical treatment methods whilst allowing the 
patenting of the compounds of those treatments. 
 
 
7.2 The purpose of the industrial application criteria 
 
The industrial application limb to patentability is one that has rarely received attention 
from the courts or commentators as there have not been significant challenges to 
granted patents on this ground. In the UK, Chiron Corporation and Others v Murex 
Diagnostics Ltd. and Others,
1079
 is one case that looked into the industrial 
applicability requirement, albeit briefly. However, this trend recently changed as in 
                                                             
1077 ‗A framework for biotechnology statistics‘ (2005) Organisation for Economic Co-operation and 
Development, OECD Secretariat, p.12. 
1078 Johnson D.K.N., ‗Biotechnology Inventions: What Can We Learn from Patents?‘ (1999). Wellesley 
College Working Paper, http://dx.doi.org/10.2139/ssrn.181009. 
1079 [1996] RPC 535. 
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Human Genome Sciences Inc v Eli Lilly,
1080
 (HGS) the assessment of the requirement 
reached the Supreme Court. In South Africa, the question of the assessment of the 
criteria has not been directly addressed by the courts. 
 
The criteria works in tandem with the other patentability criteria in ensuring that 
practical technical advances and advantages are disclosed by the patent.
1081
 Authors 
state that ‗[t]his requirement emphasises the importance of practical application to the 
patent system.‘1082  For instance, the patent application is expected to disclose or it is 
generally implicit from specification what the practical advantage of the invention is 
or for biotechnology inventions the requirement to disclose at least one practical use 
of the invention is testament to the fact that practical technical advances are 
considered important to the system.
1083
 This function comports with the justification 
of the patent system that the patent is regarded as a system of disclosing advances in 
the state of the art in practicable ways. 
 
The need to highlight the practical advantage of inventions is perhaps more significant 
in the biotechnological and genomic industries which have been shown to be vital for 
modern pharmaceutical industries. These inventions are in many cases radical and 
geminate such that their practical application in most cases is not yet fully understood 
or appreciated. Nonetheless, the patentees are given a monopoly with the view that 
they will put the invention into practice.
1084
 Therefore, the purpose of the criteria 
emphasises practical application. 
 
The current focus of the application of the criterion could be viewed as different to 
when the criterion was at its infancy. At that time, there was to a large extent a clear 
demarcation between different fields of technology and most inventions could be seen 
as to what they were intended to serve. Discerning the function of the invention was 
relatively straightforward. The emergence of new and complex technologies has 
                                                             
1080 [2011] UKSC 51. 
1081 It has to be noted that the criterion is separate to related patentability criteria. The UKIPO for 
instance notes that an invention that is challenged on this ground would usually fail the excluded 
subject matter limb to patentability, para. 4.03: http://www.ipo.gov.uk/practice-sec-004.pdf. In Aerotel 
[9](v), Jacob L.J. observed that the criteria may overlap with patentability exclusions. 
1082 Phillips/Firth, fn.1022, p.57. 
1083 Biotechnology Directive, Art.5.3 requiring sequence or partial sequence of genes to be disclosed. 
1084 Lord Sydney Templeman ‗Intellectual property‘ (1998) Journal of International Economic Law, 
1998, p.603-606, p.606. 
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changed not only the ease of making judgment of the function of an ensuing invention 
in R&D, but making the distinction between research tools themselves and the 
resultant invention from that activity.
1085
 
 
Another purpose of the industrial application criterion developed as a legislative 
fiction to exclude the patenting of medical treatment methods or diagnosis on the 
ground of their not being capable of industrial application. This has subsequently 
changed in the UK as the rejection from patentability of medical treatment methods is 
now made as a policy exclusion. In South Africa, it remains as a bar to patentable 
invention under the concept that medical methods of treatment are not capable of 
industrial application. Although the position has changed in the UK, there will be a 
discussion of medical methods unpatentability and a comparison between the two 
jurisdictions highlighted for lessons to be had from the reasoning under this rule. 
 
 
7.3 United Kingdom 
 
7.3.1 The statutory nature of the industrial application criteria 
 
The industrial applicability requirement is governed by the Patents Act 1977 section 
4. Section 1(1)(c) provides that one of the conditions for patentability of an invention 
is that it must be capable of industrial application and then section 4(1) elucidates this 
by providing that ‗an invention shall be taken to be capable of industrial application if 
it can be made or used in any kind of industry, including agriculture.‘ This comports 
with EPC Art.57, which states that ‗an invention shall be considered as susceptible of 
industrial application if it can be made or used in any kind of industry, including 
agriculture.‘ The words ‗capable‘ and ‗susceptible‘ seem to be used synonymously as 
the courts adopted an interpretation approach which accepts the two as synonymous 
and used Art.57 to interpret whether or not an invention is capable of industrial 
application.
1086
 
                                                             
1085 Commentators claiming that the recent trend in gene-related inventions has been the patenting of 
research tools blurring the line between R&D output and the indispensible research tools; Sumikura K. 
‗Intellectual property rights policy for gene related inventions- toward optimum balance between 
public and private ownership‘, in Castle, fn.40, p.77-78. 
1086 HGS, para.28. 
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To discern the appropriate interpretation and application of this criterion, the history 
of the provision is instructive. During the negotiations for the EPC, there was a 
suggestion made that the industrial application criterion in the original draft 
instrument be dispensed with, but it was decided that the criterion was necessary ‗to 
avoid any restrictive nature of patentable inventions.‘1087 The broad meaning of the 
word ‗industry‘ was emphasised and also said to include the army and the 
professions.
1088
 The intention was to extend the patentability of inventions to cover 
fields that could not be contemplated at that time. Interpretation was intended to be 
liberal and inclusive of fields that may not be readily considered to be industry. 
 
At that time, when the industrial applicability article was under consideration in the 
negotiations, particular attention was also directed to holding agriculture as an 
industry. The express reference to agriculture in the definition was included because 
in the EPC negotiations the Netherland‘s delegation raised reservations about 
technical processes applying to agriculture, to which the chairman pointed out that it 
would be difficult to exclude agricultural inventions from patentability because of a 
single member.
1089
 That is one reason why the criterion in the statute specifies 
agriculture. 
 
Economies and industries have advanced since that period and there is now usually 
the need to ascertain the industrial application of inventions in new and complex 
fields of technology. The interpretation of industrial applicability in the UK has been 
further influenced by Community law in subsequent Directives, designed to clarify 
the patenting of some new fields of technology, that have to be taken into account 
when interpreting this criterion, for instance in biotechnological inventions. This 
renders the assessment of industrial application of some inventions to further 
conditions, for instance that ‗the industrial application of a sequence or a partial 
sequence of a gene must be disclosed in the patent application.‘1090 Furthermore, the 
                                                             
1087 Document IV/2767/61-E, Draft Article 13, 14 March 1961, p.11. 
1088 Document 9081/IV/63-E-Final, p.74. ‗Professions‘ appear to be directed to professional fields for 
instance doctors. 
1089 Document IV/2767/61-E, Discussion of Article 13 of the Preliminary Draft of 14 March 1961, 
p.10. 
1090 Rule 29(3) EPC; This rule is a result of the implementation of European Parliament and Council 
Directive 98/44, the Biotechnology Directive. 
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EPC has also had revisions which have to be taken into account when evaluating 
industrial applicability.
1091
 With this statutory framework in mind, the thesis turns to 
analyse how the criteria has been applied in court. 
 
 
7.3.1.1 The test in court 
 
Domestically, the test for industrial applicability has been authoritatively clarified by 
the Supreme Court in Human Genome Sciences (HGS), in an assessment which to a 
large extent referred to the decision of the EPO deciding on the same subject 
matter.
1092
 The case centred on a genes-related invention, which are increasingly 
useful for pharmaceutical discovery, with the genomics industry, for instance, 
working with and patenting at least three types of genes: those encoding therapeutic 
proteins, sequences with diagnostic information and receptors useful in high 
throughput drug discovery screenings.
1093
 The case concerned an invention by Human 
Genome Sciences, which describes an encoding nucleotide, amino acid nucleotide, 
certain antibodies and a novel human protein Neutrokine-alpha which is a member of 
the tumour necrosis factor (TNF) group ligand superfamily of cytokines, which are 
proteins that act as inter-cellular mediators in inflammation and other immune 
responses.
1094
 This is important to drug discovery because it is through understanding 
the pathway of disease that there can be the creation of new compounds that will act 
in desirable ways within this pathway. Indeed, the claimed Neutrokine-alpha was 
shown to be expressed in inflammation and in the fight against infection in a variety 
of diseases.
1095
  
 
The court said the methodology of assessing industrial applicability needed to be case 
sensitive, as there is the likelihood that inventions that are challenged on this ground 
                                                             
1091 The revised EPC, EPC (2000). 
1092 The Supreme Court saw it fit to differ from the lower courts in preference to EPO, with the Lords 
stating reluctance in overturning a decision by highly experienced IP judges in the courts below: HGS, 
para.166, 168 and 172. 
1093 Ebersole T.J., Guthrie M.C. and Goldstein J.A. ‗Patent pools as a solution to the licensing of 
diagnostic genetics‘ (2005) Intellectual Property and Technology Law Journal, p.1-5, p.5. 
1094 HGS [2011] UKSC 51, para.7 and 10. For instance the TNF superfamily consist of molecules that 
have characteristics that make them important in the treatment of acquired and genetic diseases: 
Bodmer J., Schneider P. and Tschopp J. ‗The molecular architecture of the TNF superfamily‘ (2010) 
Trends in Biochemical Sciences, p.19-26. 
1095 [2011] UKSC 51, para.8. 
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are in a new field of technology where there is still a lot unknown about them.
1096
 
Hence, the court stated that it was preferable that caution be exercised in approaching 
the evaluation so as to balance interests of the inventor and public by not hindering 
subsequent research in this field.
1097
 At the same time, in allowing the appeal, the 
court emphasised the need for consistency in arriving at results as demonstrated by 
the EPO.
1098
 This suggests that the case-by-case sensitivity of the approach in 
deciding industrial applicability is to be balanced out by approaching each 
patentability analysis in a consistent manner. That is to say deciding on a case-by-case 
basis does not encroach on and derogate the need for consistency of methodology 
even though the fields of technology may still be new and uncertain. 
 
The court outlined three groupings of conditions that would have to be fulfilled in 
establishing industrial applicability, especially for patents involving biological 
material. The first and general consideration stated by the court was that to satisfy 
EPC Article 57, the patent must specify a practical advantage and a concrete benefit 
and that merely speculative use will not suffice and that the patent and the common 
general knowledge must enable the person skilled in the art exploit and use the 
claimed invention.
1099
 Secondly, more specifically where the patent discloses a new 
protein with its encoding gene, a real as opposed to a purely theoretical possibility of 
exploitation is needed; not attributing a clear function of the protein structure will not 
suffice. The absence of wet lab or experimental evidence will not be adverse to the 
attainment of industrial applicability and a plausible or reasonably credible claimed 
use or ‗educated guess‘ can suffice in meeting the criteria, moreover this plausibility 
can be assisted by later evidence even though the later evidence on its own will not 
suffice.
1100
 The court emphasised that the requirements of plausibility and specific 
possibility of exploitation can be at any of three levels; namely the biochemical, 
cellular or biological levels and this was found to be one of the reasons the lower 
courts conclusion differed from that of the EPO.
1101
 Thirdly, in cases where the novel 
protein is claimed to be a member of a family or superfamily, the court added that if 
                                                             
1096 HGS, para.2. 
1097 HGS, para.99. 
1098 Needle J. ‗Patents: Industrial application‘ (2011) Chartered Institute of Patent Agents Journal, 
p.768-769. 
1099 HGS, para.107. 
1100 Ibid. 
1101 Ibid. 
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all the known members have a particular role to play in the disease pathway, 
assigning a similar role to the novel protein may be adequate and the problem to be 
solved in such a case would be in the disclosure of isolating a further member of the 
family.
1102
 As ‗the disclosure is ―important to the pharmaceutical industry‖, the 
disclosure of the sequence of the protein and its gene may suffice.‘1103  This, however, 
may not hold true if there is contradictory evidence as to such membership to the 
group or if the members of the group have different activities, although it is 
acceptable if the majority have a common role.
1104
 
 
Noteworthy in this case is that the court was of the view that the courts below 
identified the appropriate facts but then made an incorrect conclusion in applying 
those facts.
1105
 This highlights the importance of assessment methods that will take 
one from sifting through the relevant facts in the evidence of the case to actually 
making the appropriate conclusion of whether the invention meets the industrial 
applicability benchmark. Lord Hope did not accept the view by Jacob L.J. in the 
Court of Appeal that the reason the decision of the trial judge differed from that of the 
TBA was because they were using different evidence and procedure.
1106
 In essence, 
the court was saying that the patentability evaluation carried out for identical 
inventions has to result in the same result. 
 
The industrial applicability contention by HGS was that the standard was set too high 
by the courts below, with regards to patents for biological matter.
1107
 The court below 
had concluded that the patent‘s Neutrokine-alpha function ‗at best, were a matter of 
expectation and then far too high a level of generality to constitute a sound or 
concrete for anything except a research project.‘1108 Prior to this case, commentators 
had acknowledged that requiring specific uses of a molecule of the invention was a 
high standard for the industrial application criterion, which would exclude some raw 
biological information from patenting and, unless interpreted very narrowly, would 
not exclude structural genomics inventions from patenting because the gene and 
                                                             
1102 Ibid. 
1103 Ibid. 
1104 Ibid. 
1105 Ibid, per Lord Neuberger, para.104, 165. 
1106 Ibid, para.165, per Lord Hope. 
1107 Ibid, para.33. 
1108 [2008] RPC 29, para.234. 
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protein sequences and structure will in most cases be associated with function.
1109
 As 
a result in this case, some commentators have stated that the standard for industrial 
application has been lowered by the Supreme Court.
1110
  
 
Of particular impact to researchers in the field of pharmaceutical discovery is perhaps 
the fact that the assessment method allows industrial applicability to be established 
without tests to support the data. The BioIndustry Association made submissions to 
the effect that early patenting is favourable for the ability to attract funding.
1111
 
However it is suggested that early patenting by one individual cannot override the 
public benefit argument that subsequent researchers must not be prevented in carrying 
out further desirable advances to the technology. It had been asserted before this case 
that the assessment has to take into consideration that mere speculations that have not 
been practically tested are not accepted as meeting the industrial application 
criteria.
1112
 This proposition is premised on the fact that the appropriate benchmark is 
one where the public is taught something and that teaching must be of something 
valuable and practicable.  
 
The court addressed attainment of this delicate equilibrium by stating that caution 
must be exercised when the decision is made and proper weight be given to the 
research process of figuring out the possible use of the compounds under study.  In 
particular, it saw it appropriate that the assessment revolve around whether the 
prediction could be considered plausible. The lower courts were of the view that the 
disclosed use was no more than speculative and did not arise to the level of showing 
an ‗immediate concrete benefit.‘1113 Nonetheless, the Supreme Court was of the view 
that concrete prediction was allowed,
1114
 as it is an unavoidable step in knowledge 
generation. The root issue in Conor revolved on whether the inventor was mandated 
                                                             
1109 Barman H.M. and Dreyfuss R.C. ‗Reflections on the science and the law of structural biology, 
genomics and drug development‘ (2006) UCLA Law Review, p.871-908, p.893. 
1110 Sharples A. ‗Industrial applicability, patents and the Supreme Court: Human Genome Sciences Inc 
v Eli Lilly and Co‘ (2012) European Intellectual Property Review, p.284-286, p.286. 
1111 BioIndustry Association intervened in these proceedings, HGS, para.100 and 101. 
1112 Thambisetty S ‗Legal transplant in patent law: Why ―utility‖ is the new ―industrial applicability‖‘ 
(2009) Jurimetrics, p.155-201, p.182. 
1113 HGS, para.129, 120. 
1114 HGS, para.120, 121. A concrete prediction should be plausible, para.122, and is indeed difficult to 
discern: para.126 and 127. 
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to explain why the invention works and it was settled that he was only required to 
explain how it works in a manner that enables the skilled person to carry it out.
1115
 
 
Other factors considered important were the notional addressee and his view of the 
‗common general knowledge‘ which was used to assess the invention‘s susceptibility 
of industrial application.
1116
 Accordingly, these have a significant role to play in 
reaching the conclusion which the Supreme Court identified as attributable to the 
difference between the lower courts and the EBA. The court said: 
„There is a very obvious difference of view as to the test that the invention had 
to satisfy to be susceptible of industrial application. For the TBA, the question 
was whether, taking the common general knowledge into account, it had been 
plausibly shown that the molecule was usable. It was not necessary for a 
skilled person to undertake a research programme to conclude that the 
presence of Neutrokine-α in B cell and T cell lymphomas might be used to 
develop appropriate means and methods for their diagnosis and treatment... 
For the judge, this did not go far enough. For him the critical point was that 
neither the Patent nor the common general knowledge identified any disease 
or condition which Neutrokine-α could be used to diagnose or treat.‟1117  
 
Assessment of the patentability standard in the UK considers judgements that do not 
emanate in the local authority alone; the EPO decisions being the most common relied 
on.
1118
 In addition, the influence of other jurisdictions has been accepted by the 
courts.
1119
 Under such customs, commentators have suggested that similar foreign 
rules that are not statutorily sanctioned in the UK could infiltrate case law and 
practice in UK tribunals.
1120
 However, the Supreme Court was clear that there has to 
be caution in transplanting apparently similar concepts and was not persuaded by US 
utility standard although its benefits were acknowledged.
1121
 It is notable that the 
                                                             
1115 Deepak J.S. ‗The elusive quest for the definition of obviousness- patent law‘s holy grail‘ (2010) 
International Review of Intellectual Property and Competition Law, p.410-427, p.423. 
1116 HGS, para.31. 
1117 HGS, para.161. 
1118 For instance Lord Neuberger said‗[h]owever, on further reflection, like Lord Hope, I have come to 
the conclusion that the basis upon which the Judge decided the issue was not consistent with the 
approach adopted by the Board...‘, HGS, para.106. 
1119 Lower courts used and made comparisons with the American utility standard. 
1120 Thambisetty, fn.158. 
1121 HGS, para.40. 
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industrial applicability in HGS had two sources of external persuasive influence, one 
from the US and the other from the TBA and the court preferred the TBA 
jurisprudence in overturning the lower courts. That is to say the court was at liberty to 
flexibly choose external law deemed more effective for appropriate legal 
development, a contrast to a situation where there is an obligation to follow external 
law historically prevalent in developing countries. Writers have said ‗where law 
develops internally through a process of trial and error, innovation and 
correction,…legal institutions tend to be highly effective. By contrast, where foreign 
law is imposed and legal evolution is external rather than internal, legal institutions 
tend to be much weaker.‘1122  
 
 
7.4 South Africa 
 
7.4.1 The statutory nature of the industrial application criteria 
 
The Patents Act s.25(1) inter alia, provides that a patent may be granted for an 
invention ‗which is capable of being used or applied in trade or industry or 
agriculture.‘ This is unlike the UK Act, which initially prescribes that the invention 
must be capable of industrial application in one section and then defines that 
capability as subsisting if the invention ‗can be made or used in any kind of industry, 
including agriculture‘ in another section. This seems to be a superfluous difference in 
statute drafting and would result in identical outcomes in terms of the statutory 
requirements for industrial application. 
 
There is not much substantive discussion on the criteria in South Africa. Academic 
authors in South Africa have sought to resolve the difference between the words ‗used 
or applied‘ in defining industrial applicability under the current law. The previous 
South African Patents Act provided protection for ‗any useful...composition of matter 
capable of being used or applied in trade or industry‘, but omitted the word ‗used‘ 
from the grounds of opposition, revocation and defence for infringement under this 
                                                             
1122 Berkowitz D., Pistor K and Richard J.F ‗The Transplant Effect‘ (2003) American Journal of 
Comparative Law, p.164-204, p.189. 
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limb.
1123
 On one end, authors have stated that the inclusion of both words in the 
current Act is ex abundante cautela while on the other end there are those who favour 
the retention of both.
1124
 In practice, this seems unlikely to result in significant 
differences in applying the criterion. At the same time, one could suggest that this is 
in line with the expansive interpretation for industrial application that was intended in 
the negotiations of the EPC and Strasbourg Conventions. Moreover, in South Africa, 
the statute explicitly refers to trade, in addition to industry and agriculture as found in 
the UK statute. This is indicative of an intention for an even wider ambit of the statute 
by the legislature compared to the UK. 
 
 
7.4.2 Test in court 
 
The test has not been applied by the courts. Some parallels could be drawn with the 
test as applied in the UK. Flowing from the statutory framework discussed above for 
the UK, the interpretation could be said to be similar. This is based not only on the 
fact that South Africa and UK have common sources of the criterion, but because of 
the reliance on EPO and UKIPO guidance documents when South African courts 
assess patentability generally. 
 
Significant difference between the two jurisdictions is perhaps in the area of 
biological inventions. In the UK, reliance has had to be placed on the Biotechnology 
Directive, stating that the industrial application must be disclosed in the 
application.
1125
 South Africa does not have to follow this instrument. At the same 
time, there is no local instrument that addresses these, yet the technologies have 
advanced since the current Patents Act came into force. Commentators have asserted 
that the policy makers or tribunals that interpret a particular concept before others 
gain a position of influencing over other jurisdictions later on when they encounter 
similar situations.
1126
 The South African jurisdiction is likely to follow the position in 
UK on the strength of the commonality of the origins and foundations of the industrial 
                                                             
1123 Patents Act 1952, s.23(1)(c), s.43(1), s.53(a). 
1124 Gerntholtz R.O.P. ‗Are medical methods patentable?‘ (1969) Tydskrif vir Hedendaagse Romeins-
Hollandse Reg,  p.242-262, p.254; Burrell, p.42. 
1125 Art.5. 
1126 Thambisetty, fn.1112, p.155-156. 
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provisions and also the influence of the jurisdiction and seniority of the court that has 
already decided this issue. However, this could not be assumed as certain. 
 
7.5 United Kingdom and South Africa 
 
7.5.1 Summary of the industrial application criteria 
 
There appears to be a similarity in the statutory framework that requires the invention 
to be capable of industrial application between the UK and South Africa. Even though 
the UK has the elaboration of how industrial application is defined in another section 
of the statute, there is internal consistency that makes it similar to the South African 
statute.
1127
 
 
The major difference between the UK and South Africa is in how the statutory 
framework has been adapted to the patenting of the new fields of technology, 
especially biosciences, which carry the potential to alleviate some of the burdens of 
disease which cannot easy be dealt with under the traditional pharmaceutical 
interventions. In the UK, there is the additional requirement, for instance, that the 
‗industrial application of a sequence or partial sequence of a gene must be disclosed in 
the patent application as filed‘1128 for the specification to be considered to have 
attained the requisite patentability benchmark. Essentially, the requirement prevents 
speculative claiming in new fields, where patentees usually seek to cover a wide 
scope for the invention for possible harnessing of future developments in the field.
1129
 
In South Africa, the law is silent on this point and there is no guidance on how 
genomic related inventions would be assessed for industrial applicability. 
 
 
  
                                                             
1127 The UKIPO was of the view that since the requisite changes to the Patents Acts due to the EPC 
2000 were to be made through an amendment, it was not possible to the completely re-arrange the 
existing structure and text of the legislation: para.20, http://www.ipo.gov.uk/patact-response.pdf.  
1128 Patents Act 1977 c.37, Schedule A2 Biotechnological Inventions, added by Patents Regulations 
2000/2037 Sch.2 para.1 (July 28, 2000). 
1129 HGS, para.56, 58. 
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7.6 United Kingdom 
 
7.6.1 Methods of treatment and diagnosis 
 
Before the commencement of the Patents Act 1977, the Court of Appeal was of the 
view that medical treatment methods were not within the ambit of patent law, 
although the precise grounds were not entirely clear. One view was as articulated by 
Russell L.J. in Upjohn Co. (Robert's) Application
1130
 that ‗it had always been the view 
of those professionally concerned with patent law that a method of medical treatment 
of a human being is not within the definition of invention as meaning ‗any manner of 
new manufacture‘ within s.6 of the Statute of Monopolies.‘  
 
After the 1977 statute came into force, these medical inventions were statutorily 
explicitly excluded from patentability on a more clear ground. Methods of treatment 
or diagnosis of the human and animal body were prevented from being the subject 
matter of a patent by the expedient of stating that they were not capable of industrial 
application under the Patents Act 1977, s.4(2): 
‗An invention of a method of treatment of the human or animal body by 
surgery or therapy or of diagnosis practised on the human or animal body shall 
not be taken to be capable of industrial application.‘ 
 
This exclusion was so designed to prevent veterinarians and doctors from being sued 
directly for treating their patients using patented medication
1131
 but this did not 
prevent the patenting of the medication itself. In other words this did not prevent the 
patenting of a product consisting of a substance or compound for use in any such 
method as:  
                                                             
1130 [1977] RPC 94, p.96. 
1131 Department of Trade and Industry (DTI) Consultation Paper on the Proposed Patents Amendment 
Bill, issued 29 November 2002, p.9. Also, it has been said that ‗the policy behind the exclusion of such 
methods is clearly to ensure that those who carry out such methods as part of the medical treatment of 
humans or the veterinary treatment of animals should not be inhibited by patents.‘ Decision of TBA: T 
964/99-3.4.1, Device and Method for Sampling of Substances using Alternating Polarity/CYGNUS, 
Inc., [2002] O.J.E.P.O 4, 10 (point 3.7 of the Reasons). 
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‗Subsection (2) above shall not prevent a product consisting of a substance or 
composition being treated as capable of industrial application merely because 
it is invented for use in any such method.‘1132  
 
These instruments indicated that medical treatment methods may actually constitute 
an ‗invention‘ but due to arbitrary legal creation they are to be regarded as incapable 
of industrial application even if they were.
1133
 This legal fiction was said to be 
directed toward preserving public policy, although there were criticisms of whether it 
was justified or even logical.
1134
 Others opine that when the EPC was drafted, the 
medical profession was not regarded as a trade, a contrast to current prevailing 
opinion.
1135
 It is difficult to envisage a justifiable situation where the performance of a 
medical method is reserved for a select few practitioners as a result of the existence of 
a patent. In Wellcome /Pigs,
1136
 the Board was of the view that policy should prevent 
the reach of patents into the treatment of humans or animals. Nonetheless, promoting 
this point under the notion of the underlying invention not being capable of industrial 
application remained unconvincing. 
 
The basis of holding methods of treatment as not capable of industrial application 
whilst holding that the compounds are patentable also caused difficulties in the way 
the inventions could be claimed.
1137
 The then DTI issued a Consultation Paper
1138
 to 
clarify the position on the patentability of medicaments. Subsequently, on 15 January 
2004 the Patents Bill was introduced in the House of Lords, which inserted a new 
section 4A provision to the 1977 Act to emphasise that although methods of treatment 
or diagnosis are not patentable, the substances or compounds used in such methods 
                                                             
1132 1977 Patents Act, s.4(3). 
1133 Paterson, fn.464, p.421. 
1134 Pila J. ‗Methods of Medical Treatment in Australian and United Kingdom Patents Law‘ (2001) 
University of New South Wales Law Journal, p.421-444, p.422. 
1135 Bostyn S.J.R. ‗No cure without pay? Referral to the Enlarged Board of Appeal concerning the 
patentability of diagnostic methods‘ (2005) European International Property Review, p.412-419, p.413 
1136 T116/85 Wellcome/Pigs I O.J. EPO 1989 13. 
1137 This had impact not only in the claiming of compounds used in medical treatment, but also in 
second medical use. For instance see Ventose E.D. ‗Patent protection for second and further medical 
uses under the European Patent Convention‘ (2009) Scripted, p.57-74.  DOI:10.2966/scrip.060109.57. 
1138 Department of Trade and Industry Consultation Paper on the Proposed Patents (Amendment) Bill 
on 29 November 2002.  ‗The primary reason for the consultation was to set out proposals for amending 
the Patents Act 1977 in order to give effect to the revised EPC, which was agreed in November 2000. 
The consultation aimed to inform the public of the effect of EPC 2000 on the Act, and to seek views on 
the proposed changes which followed from that effect: para.2, http://www.ipo.gov.uk/patact-
response.pdf. 
 266 
are patentable, regardless of form of the claim. Traditionally, only ‗Swiss‘ type claims 
were generally accepted for claims to new use of known compositions or substances, 
for example in the form; the use of compound X for the manufacture of medicament 
to treat Y. The resulting Patents Act, s4A(4)
1139
 had the effect of removing the 
requirement of Swiss type claims, thus pharmaceutical substances can now be claimed 
as: substance X for use in treatment of disease Y. 
 
The reasoning preventing the patenting of medicament has consequently also now 
changed from lack of industrial application to an exception.
1140
 This is the major point 
of difference between the UK and South Africa, whereby the UK has moved into 
preventing patentability of methods of treatment as an exception whilst in South 
Africa it is done on the industrial applicability ground. Authors, doubting the wisdom 
of the change, have said ‗removing the lack of industrial applicability language from 
Section 4 removes the ethical or public policy dimension of this criterion in the only 
statutory instance where it was used to represent such interests, however poorly 
interpreted‘1141 and this undermines the criterion as a ‗gate-keeper‘ criterion and 
weakens the public policy principles which the previous law sought to address. 
However, in a closer examination of the EPC travaux preparatoires this does not 
seem to have been the intended direct function of the criterion. For example, when 
delegations enquired whether earlier versions of the industrial application criterion 
would be wide enough to cover all possible applications, the Chairman, supported by 
other delegations, explained that the subject matter of an invention could even be a 
new application of a known substance obtained by a process already known, with the 
practical implementation of a new application constituting a new use of the subject 
matter of an invention.
1142
 The industrial application was intended to allow for the 
widest possible interpretation and to cover wide industrial activity within the ambit of 
this criterion and no ethical obligations were imposed.  
                                                             
1139 Inserted by s.1 of Patents Act 2004. 
1140 The Patents Act 1977, Ch. 37, Section 4A(1) (2007), reflecting EPC, Art.53(c) (2000).  The 
UKIPO is of the view that this did not result in a significant change in practice: UKIPO, Examination 
guidelines for applications relating to medical inventions in the UKIPO, 
http://www.ipo.gov.uk/medicalguidelines.pdf (9 January 2012) para.4. Also, indeed TRIPS Art 27.3(a) 
provides that ‗medical treatment and diagnostic techniques for humans and animals can be exempted 
from patentable subject material.‘ 
1141 Thambisetty, fn.1044, p.166. 
1142 Document IV/2767/61-E, p.46. This is particularly significant for further or second medical use 
claims. 
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The assertion that industrial application is not intended to directly deal with public 
interest as a gate-keeper further finds support in that when the industrial application 
was discussed expressly with regards to pharmaceutical products, the Working Party 
concluded that each member state ‗could cause compulsory licences to be granted for 
a European patent protecting such a product if public interest so required.‘1143 The 
framers of the EPC sought to remove public policy considerations from the industrial 
applicability of pharmaceutical products patentability. Even in the Strasbourg 
Convention, which was frequently referred to in the EPC negotiations, under the 
article dealing with industrial character, it was agreed that ‗―susceptible of industrial 
application‖ shall be understood in the widest sense‘ and exclusions and exceptions to 
patentability were only made optional for members and not on an incapable of 
industrial application grounding.
1144
 There was a question as to whether therapeutic 
methods should be regarded as inventions, and, after some discussion, it was agreed 
that they were not patentable under the laws of six members and none of the Working 
Party delegations wanted to depart from that principle.
1145
 That is to say, the framers 
preferred not discussing the reasoning and basis of their exclusion from patentability 
nor whether they were inventions.
1146
 
 
Even currently, the EPC 2000 changes indirectly acknowledges that the industrial 
application criteria was not designed to act as a direct public policy gate-keeper 
preventing the patentability of medical inventions, but rather serving the public 
interest by encouraging patenting of the widest array of invention types. Proposals for 
the change stated that: 
‗While these surgical or therapeutic methods constitute inventions, they have 
been excluded from patentability by the fiction of their lack of industrial 
applicability. It is undesirable to uphold this fiction since methods of treatment 
and diagnostic methods are excluded from patentability in the interests of 
public health. It is therefore preferable to include these inventions in the 
                                                             
1143 Document 3076/IV/62-E, 22 May 1962, p.138. 
1144 Document EXP/Brov (61)2 Revised, Preliminary Draft Convention on the Unification of Certain 
Points of Substantive Law on Patents, 8 May 1961, Appendix v, p.26. 
1145 Document 2632/IV/64-E-Final, Proceedings of the 12th meeting of the Patents Working Party held 
at Brussels from 26 March to 6 March 1964, Minutes, p.22. 
1146 Ventose E.D. ‗In the footsteps of the framers of the European Patent Convention: examining the 
travaux preparatoires‟ (2009) European Intellectual Property Review, p.353-363, p.354. 
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exceptions to patentability in order to group the three categories of exceptions 
to patentability together in Article 53(a), (b) and (c) EPC.‘1147 
 
The reclassification of the patentability of the medical treatment methods was said to 
be a cosmetic exercise and did not change the substance of the law.
1148
 The switch 
does not seem to diminish the argument by pharmaceutical firms that patents provide 
the incentive to invest in finding new or improved treatment. Court judges questioned 
the logic in excluding methods of medical treatment, saying  ‗[t]he thinking behind 
the exception is not particularly rational: if one accepts that a patent monopoly is a 
fair price to pay for the extra research incentive, then there is no reason to suppose 
that that would not apply also to methods of medical treatment.‘1149 In many cases, it 
is difficult to differentiate between the methods of treatment per se and a treatment 
course utilising a specific sequence of treatment compounds. 
 
 
7.7 South Africa 
 
7.7.1 Methods of treatment and diagnosis  
 
Patents Act 1978, s.25(11) prevents the patenting of human and animal treatment 
methods. It states ‗an invention of method of treatment of the human or animal body 
by surgery or therapy or diagnosis practiced on the human body or animal body shall 
be deemed not to be capable of being used or applied in trade or industry or 
agriculture.‘  This however ‗shall not prevent a product consisting of a substance or 
composition being deemed to be capable of being used or applied in trade or industry 
or agriculture merely because it is invented for use in any such method.‘1150 This is a 
position similar to the UK before the amendment of 2004. The statute is unsurprising, 
                                                             
1147 The Basic Proposal for the Revision of the European Patent Convention, October 13, 2000, 
Explanatory Remarks, Art.53, para.3. 
1148 It was stated that the change was ‗a purely editorial change‘, Opinion of the EBA: Diagnostic 
methods G1/04, p.359. 
1149 Bristol Myers Squibb Co. v. Baker Norton Pharm. Inc. [1999] RPC 253, p.274. In Eli Lilly & Co.'s 
Application [1975] RPC 438, p.438, the Justices referred to the exclusion as an exception ‗based in 
ethics rather than logic.‘ 
1150 Patents Act 1978, s.25(12). 
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given that the rider for the industrial applicability for methods of treatment as stated in 
s.25(11) and (12) is derived from the EPC.
1151
  
 
The difference now in the South African statute from the UK legislation lies in the 
fact that although methods of medical treatment are expressly recognised as 
inventions in both jurisdictions, in South Africa, the unpatentabilty lies in holding 
these inventions as incapable of industrial application. This is expected given the fact 
that during the EPC negotiations, the negotiations focused on the drafting of the 
provision fitting the prevailing conditions in some of the member states, rather than 
any significant debate on the property or characteristics of making treatment methods 
an exclusion.
1152
 When the question of whether a therapeutic method should be 
regarded as an invention, the Chairman of the Working Party stated that six of the 
Member States did not consider it so and none of the delegates wanted to depart from 
that principle.
1153
 South Africa adopted the text into the 1978 Act and this has 
remained the law without much discussion by the law makers or policy makers on the 
desirability of its qualities in this regard. 
 
However, the opinion of academics has been to question the desirability of the current 
statutory position. They have pointed that when the Minister of Economic Affairs 
introduced the Patents Bill for the second reading in Parliament he stated that ‗...the 
principle of this Bill...(is) that all inventions are clearly in the public interest‘1154 and 
therefore have asserted that ‗there can be no doubt that it was the intention of the 
legislature, when passing the Patents Act, to grant the privileges of patent rights to all 
types of practical inventions‘ thus ‗why should there be no ―inventions‖ in the field of 
medical science?...why should patentable invention only include medicines and 
curative devices and exclude medical methods?‘1155 Viewing methods of treatment as 
not capable of industrial application has been shown to be illogical, a lesson that 
could be learnt from the UK case law. Nevertheless, the fact remains that the South 
African statute does provide for their exclusion from patentability on the industrial 
                                                             
1151 Domanski, fn.544, p.316. 
1152 Ventose, fn.1146, p.354. 
1153 Ibid. 
1154 South African Parliament, Assembly Debates 1952, 3007. 
1155 Gerntholtz, fn.190, p.258. 
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applicability ground. Since this has not been tested in court, the desirability of the 
provision has not been convincingly or authoritatively critiqued.  
 
 
7.8 United Kingdom and South Africa 
 
7.8.1 Summary of the methods of treatment diagnosis 
 
The practical interpretation of patentability of an invention under the industrial 
application limb is intended to be wide, whilst exclusions from patentability are said 
to be approached in a balanced fashion. This puts South Africa and the UK on 
opposite ends in current statutory terms dealing with the regulation of the patenting of 
methods of treatment. It is perhaps difficult to accept the reasoning by some authors 
that the patentability of methods of treatment should have continued to be under the 
industrial application criteria.
1156
 This assertion is based on the fact that generally, 
industrial application is interpreted widely and yet an exception is construed in a more 
balanced approach. The difference in approach between the two positions is 
irreconcilable to the opposing functions of these two levers. Jacob J rejecting a 
challenge that a claim was to method of treatment rather than method of manufacture, 
stated that: 
 
‗I am reinforced in that view by the consideration that the Article 52(4) 
provision about methods of treatment is an exception to patentability and as an 
exception should be construed narrowly.... There is also the limited purpose of 
the exception to be considered. It is not so broad as to stop doctors using 
whatever they feel they need to treat patients. If that were the purpose then one 
would not allow patents for medicines or medical implements at all. The 
purpose of the limitation is much narrower, merely to keep patent law from 
interfering directly with what the doctor actually does to the patient.‘1157 
 
Conflation of the reasoning behind the industrial application criterion with purely 
public policy consideration under exceptions can lead to erroneous conclusions. This 
                                                             
1156 Thambisetty, fn.1044, p.167. 
1157 Bristol-Myers Squibb Co. v Baker Norton Pharmaceuticals Inc. [1999] RPC 253, para.50-51. 
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could also possibly open up the introduction of emotive interpretation and assessment 
of the patentability limb under industrial applicability. Making an exception for 
methods of treatment is allowed and recommendable. However, doing so under the 
industrial application seems to be a strained approach. 
 
 
7.9 Discussion of the overall industrial criteria for the UK and South Africa 
 
The first time significant discussions between countries on the industrial application 
criterion were carried out, the main focus was on whether or not there should be 
inclusion of agriculture within the patent system and also resulted in artificially 
holding that methods of treatment were not capable of industrial application. The 
susceptibility of industrial application of the typical invention then was not very 
contentious. There are now concerns that the patent standards may no longer be 
responsive to the technologies that have developed and advanced since then.
1158
 For 
example, the main concern is that the industrial application when assessed, should be 
considered established only downstream at the R&D stage when there is discernible 
or tangible conversion of genomic and proteomic information into practical and 
feasible outcomes rather than far upstream where the researcher at the forefront of the 
knowledge would be granted a patent that prevents further engagement in the field by 
subsequent scientists.
1159
 It is argued, though, that the criteria serves its purpose of 
evaluating whether an invention is capable of industrial application through its 
practical implementation; the result that the public interest is served by the prevention 
of patenting of germinate technologies is served as a separate and perhaps derivative 
purpose. Focusing on the susceptibility of the practical manifestation of the claimed 
invention confers objectivity in the assessment method, without the need for bringing 
other considerations into the criteria that are better served by other patentability 
requirements. 
 
                                                             
1158 Berman H.M. and Dryfuss R.C. ‗Reflections on the science and law of structural biology, genomics 
and drug development‘ (2005) UCLA Law Review, p.871-908. Also, Prais R. ‗Blacklight, or the 
patentability of wrong inventions‘ (2009) European Intellectual property Review, p.269-272. 
1159 Eisenberg/Merges, fn.1076, p.6, claiming the criteria serves a timing function, leaving basic 
research discoveries in the public domain until they have yielded tangible benefits and have thereby left 
‗the realm of philosophy‘ and entered ‗the world of commerce‖‘. 
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The use of history in benchmarking the application of a principle over time or to 
extract principles to be learnt for current frameworks is useful but delicate as was 
suggested in chapter two. If caution is not exercised, we extract from it meaning of 
what we may erroneously assume the criteria represented historically and misapply it 
to our contemporary situation. It is advisable that we do not overstretch some 
concepts into what we perceive to be the truth or the reality from the perspective of 
our current environment or conditions. It is indeed important to protect public health; 
however, to do it directly under industrial applicability limb could be illogical and 
inconsistent as shown in this chapter. The reform to remove the non-industrial 
applicability of medical methods of treatment is one way the legislature recalibrated 
the criteria in the UK. For South Africa, it could be suggested that it may be untenable 
to hold that methods of treatment are incapable of industrial application, and rather 
that this be made a proper exclusion on policy grounds. With this framework in place, 
it becomes easier to make an assessment of whether a purported invention is capable 
of industrial application rather than trying to artificially fit the evaluation into illogical 
historical models. 
 
 
7.10 Conclusion 
 
The continued relevance of the industrial application requirement has been analysed 
in this chapter. The criterion has shifted from its focus on whether inventions in 
agriculture are to be considered capable of industrial application, wherein the 
transition abandoning the ‗manner of manufacture‘ in defining the invention was 
made. Inventions relating to health have come under the spotlight when this criterion 
is discussed. The limb has become a benchmark that brings about balance as to when 
the research output in some of the radical fields leading to health related inventions 
should be patentable with due regard for space for subsequent improvement by the 
competitors or third parties who may have already spent a considerable amount of 
resources and time working towards the solution in the yet to be fully understood or 
immature industries. The tests that the tribunals tasked with assessing the patentability 
of these are therefore crucial to a vibrant research clusters resulting in inventions that 
meet medical and pharmaceutical needs. 
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Industry conditions have significantly changed since the initial introduction of the 
criteria. Interpretation that attempts to retrieve from history what the intention of the 
framers of the original instruments was is difficult to achieve. Focus would rather 
shift into what the policy makers and legislatures now intend to do to in adjusting the 
system to fit with evolving technology. In the UK, there have been legislative 
interventions which clarify the positions with regard to the criteria whilst, in South 
Africa, there has not been statutory activity dealing with this concept. It is possible to 
extend this reform movement to South Africa, but without appropriate modifications 
in light of prevailing domestic constitutional or legal frameworks, the extension 
would lead to a flawed model. Therefore it is recommended that it is imperative for 
the South African legislature to consider statutory reforms of this patentability limb to 
align it with technological developments. 
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CHAPTER EIGHT 
 
CONCLUSION 
 
8.1 Introduction 
 
The objective of this concluding chapter is to integrate and streamline the conclusions 
and suggestions made throughout the thesis. Each chapter of the thesis addressed 
specific aspects relating to the patentability standards as applied to pharmaceutical 
inventions in the UK and South Africa. In so doing, each chapter analysed a 
dimension that impacts on the overall patentability of inventions in the two 
jurisdictions. This chapter seeks to make a concluding reflection, at a holistic level, on 
the principles established throughout the thesis regarding the patentability standards 
and whether the methods used for assessing them achieve their intended purpose.  
 
8.2 The thesis outlook 
 
The research carried out in this thesis sought to compare the patentability of 
inventions as applied in the UK and South Africa. The comparison was done at 
various levels and from different viewpoints that impact upon the patentability 
standard, with the statute as existing in the two countries being central to the analysis. 
The influence of policy, the international instruments and debates thereof, the opinion 
of various and diverse stakeholders of economic or technical nature, as well as the 
critique of academic commentators informing the patentability setting and assessment 
were critically analysed. However, the statute maintained primacy as it is the final 
determinant of which inventions will be considered legitimately patented in reality. 
 
The thesis, being on the patentability of pharmaceutical inventions, inherently attracts 
controversy. These range from opponents of the system who tend to deploy rhetoric 
portraying patents in bad light, to the misconception about the pharmaceutical patent 
that occurs within discussions and debates on the system, sometimes with inadequate 
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understanding of the features of the system.
1160
 This is understandable, as the thesis 
acknowledged that the system has a wide array of stakeholders due to the impact of 
pharmaceutical patenting on society at large. The recent trend has indeed been the 
inclusion of more non-technically inclined participants within the patentability 
discourse and the awakening, especially of developing country policy-makers, to the 
impact of patents for pharmaceuticals.
1161
 Nonetheless, the need for specialist or 
technical knowledge of the regime cannot be avoided because whatever inclusive 
patentability instrument is developed and agreed upon, it will have to be interpreted in 
specific terms and the subject matter that is usually contested in court is in most cases 
of a technical nature. The value of the thesis therefore manifests itself in those 
complex circumstances where the assessment to establish patentability is carried out 
and the question of whether the appropriate equilibrium sought by the policy and the 
law is attained. 
 
A theme throughout the thesis has been to ground the discussion of the law of 
patentability on the science at issue. As a matter of observation, the science and 
technology is increasingly becoming more complex and there are constantly new 
derivative fields of knowledge and technology. A point that has been emphasised 
throughout the thesis is that pharmaceutical inventions have multiple sources and the 
misunderstanding of what the typical invention in this field is assumed to be were 
highlighted, pointing out that carrying out pharmaceutical R&D is not such a 
straightforward venture. Each of the four general sources of pharmaceuticals were 
highlighted in relation to the different limbs to patentability and the associated and 
underlying technologies that have become integral to the industry. 
 
This research has been a comparative enterprise and, as such, had to conform to some 
general rules for a systematic analysis as dictated in the first chapter. However, even 
with those boundaries in place, there were some hurdles to overcome as some 
patentability issues in one jurisdiction would not necessarily have corresponding 
features in the other or there being other variables that could not be identically 
assessed in the other jurisdiction, such as further internal rules that have an impact in 
                                                             
1160 Deere C. The implementation game: The TRIPS Agreement and the global politics of intellectual 
property reform in developing countries (2009) Oxford: Oxford University Press, p.118-120. 
1161 Drahos P. ‗Developing countries and international intellectual property standard-setting‘ (2002) 
The Journal of World Intellectual Property, p.765-789.  
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only one of the jurisdiction under study. The Biotechnology Directive or the origin 
disclosure rules for all South Africa patent applications are illustrations of these 
unique features which complicated the analysis. Moreover, the comparative analysis 
could be significantly affected when equivalent rules in the patentability statutes are 
compromised by whether or not they have actually been applied at all in reality and 
also how they have been applied in reality. One theme that emerged in this regard is 
that in South Africa, for some of the patentability limbs although stated in the statutes 
book, there were no corresponding cases in practice, which would have given a more 
detailed illustrated guidance on how the courts have dealt with the various limbs to 
patentability.
1162
 
 
As a result, where there was no application of the law in practice or in the courts, 
there are lessons to be learnt from a comparable foreign authority where a particular 
issue has been comprehensively addressed. Since this is a comparative study premised 
on careful learning of legal principles from other jurisdictions but without blind legal 
transplant, a suggestion could be made to address this shortage in case law. A 
recommendation is made that the South African Patent Office could produce a manual 
that would clarify the deficient legislative framework from the suggestions made from 
the comparative enterprise in this thesis for the different limbs. This would also 
compensate for the lack of examination and consolidate the law of patentability into 
one source. The finding in this thesis is that the lack of the law in practice has been 
manifested in the criteria for excluded subject matter and industrial application limbs, 
which nevertheless attracted public pronunciations by policy makers on the criteria 
without any corresponding law to supporting those assertions.
1163
 
 
  
                                                             
1162 Commentators assert that a broad judge made rule will require a series of judicial decisions before 
inference could be made to similar situations; therefore it was difficult to definitively discern the ratio 
decidendi of some the limited number of litigated South African cases: Landes W.M. and Posner R.A 
‗Legal precedent: A theoretical and empirical analysis‘ (1976) NBER Working Paper Series, p.2. 
1163 Justice Harms condemns those pronunciations which have no legal basis and the tendency to 
oppose concerns by pharmaceutical firms and any IP law reforms advanced at international stage: 
Harms, fn.504. cf Regarding negotiations at WTO or WIPO it has been said that ‗the key to getting 
agreement is getting the right mix of issues on the table, even if they are previously unrelated, so that 
they can be linked for bargaining purposes‘,  Ryan M.P. Knowledge diplomacy: Global competition 
and the politics of intellectual property (1998) Washington: The Brookings Institution, p.92. 
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8.3 The thesis foundation 
 
As it has already been alluded to, the view-point adopted in this thesis finds 
grounding in the law. The thesis is anchored on the notion that even though the 
legislature is notionally free to prescribe the domestic patentability frameworks, it is 
helpful to do so mindful of the lessons to be learnt from the historical models of the 
system or from foreign jurisdictions. As the system does not exist in isolation immune 
from external influences, the historical models of patent justifications present a 
valuable source of instructive discourse on how to refine the patentability standards to 
attain particular ends. It was shown that the UK has a wealth of history in setting 
various patentability levels and these are helpful in adjusting present and future 
standards. Prudence was stressed in doing so, as there are outcomes of legislative 
interventions that are not automatically repeatable, predictable or even applicable to 
later situations.
1164
 
 
Historically, South Africa followed the UK in most of the historical statutory 
promulgations. It was observed in this thesis that some of these statute imports 
seemed to be unconsidered and no clearly formulated basis for their adoption was 
discernible. The thesis then suggested that from this history, South Africa could in 
some instances extract the principles to be mindful of when appropriately formulating 
reforms and that these are to be directed to particular internal needs. The patentability 
standard must serve a clear domestic need. The argument advanced by this thesis is 
that the lessons are derivable from the historical and classical justifications of the 
system and its evolution. 
 
A limitation to the recasting of patentability standards from any historical or foreign 
source is that the UK and South Africa are bound or at least persuaded by external 
obligations that impact on how they could manoeuvre their domestic models of 
patentability. The TRIPS Agreement has affected the extent of how both jurisdictions 
could adjust their laws.
1165
 For both countries, the influence of external forces is from 
both international and regional centres and increasingly plays a role in the setting of 
                                                             
1164 As pertinently stated by Mustill LJ in Genentech Inc's Patent (Human Growth Hormone) [1989] 
RPC 147, p.258-259. 
1165 Reichman J.H. ‗The TRIPS Agreement comes of age: Conflict or cooperation with developing 
countries‘ (2000) Case Western Reserve Journal of International Law, p.441-470. 
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the patentability standard. More crucial is that interpretation and assessment of the 
patentability limbs can rely on external authority for both jurisdictions. For example, 
the UK takes note of patentability interpretation in the EPO, a point illustrated by the 
Supreme Court in HGS overturning the domestic lower courts because the approach 
they used was different to that used by the TBA.
1166
 South Africa‘s influence by 
foreign jurisdictions is demonstrated by the constant use of EPO and UKIPO 
examination manuals for deciding patentability cases.    
 
In respect of the dynamics within the international forum, the UK and South Africa 
were noted to differ in their relative positions at the international arena. The UK is 
one of the members of what can be called the powerful or influential grouping that 
persuades the direction of patentability discourse and general IP law. Not only is it 
through the wealth of patentability case law that other jurisdictions rely on or at least 
tend to refer to, but also in making reasoned and often strategic contribution at this 
level.
1167
 South Africa is usually seen to be amongst the group that has traditionally 
been considered the recipients of the laws from the international arena or foreign 
sources. However, in this thesis it was shown that on the provisions that deal with 
patentability, South Africa already had statutory patentability standards similar to 
those that were prescribed by the TRIPS Agreement.
1168
   
 
The thesis proposed that even though the conditions or other variables that can impact 
on pharmaceutical patentability may exist, the patentability at the international level 
could advisably be approximated to a universal standard. This is grounded on the 
basis that science is universal and there is an increase in cross-jurisdictional use or 
flow of scientific knowledge. An argument was put forward that there is benefit to be 
had in setting the patentability standard at globalised levels based on the universality 
of knowledge.
1169
 There certainly are differences in knowledge systems and 
economies between the developed and developing countries, but the scientist to whom 
                                                             
1166 HGS, para.129 and 171. 
1167 Helfer, fn.169. 
1168 In South Africa the patentability limbs were introduced in colonial times and tended to readily 
follow UK statutory changes. In addition, the patenting of pharmaceutical products, a controversial 
TRIPS provision, had been allowed previously. 
1169 Youde notes that ‗it is not scientific knowledge on its own that influences policy: it is the 
interaction between knowledge and broader cultural contexts in which that knowledge exist‘, Youde 
J.R. AIDS, South Africa and the politics of knowledge (2007) Hampshire: Ashgate Publishing Limited, 
p.30. 
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the specification is addressed is universal. A patentability assessment that would 
require consideration of the personal and subjective circumstances of the researcher is 
rejected. 
 
8.4 The model building 
 
The four justifications developed from the history of the patent were useful for 
deployment into how each of the patentability limbs is set or evaluated. The thesis 
suggested that the tests designed for the assessment of each of the limbs should reflect 
this. It is also important to verify whether the tests that are utilised in court are attuned 
to the purpose of the patent system.
1170
 
 
In chapter one, the four justifications were relied on to build what was laid out as an 
optimal standard. The justifications are that there must be recognition of the 
inventor‘s right to the invention, the patent is a monopoly reward, the patent is an 
incentive to invent and innovate and the patent performs an information function and 
therefore the patentability assessor has to be mindful of these. The justifications all 
have a vital contribution to make in setting the appropriate patentability standards. 
Thus, it was proposed that when setting policy or making assessment of whether an 
invention meets the patentability standards, regard should be taken of all of them as 
they affect how far the balance between private interest and the public is struck. 
 
In chapter four, it was shown that the limb of excluded subject matter not only 
provides a lever for balancing between the private and public interests, but it also 
provides a systematic mechanism of deciding whether subject matter falls within the 
realm of categories the legislature deem unsuitable for patenting. 
 
Building particularly on the classical justification that the patent acts as an 
information source, the assessment under the novelty limb sought to evaluate whether 
inventions disclose anything that was not available to the public before. Overall the 
evaluation methods were found to identify objective integers to use in the assessment. 
                                                             
1170 As suggested in the thesis, in order to improve on fact-specific patentability judgments, policy-
based decision-making has been identified as a viable approach: Rai A.K ‗Engaging facts and policy: A 
multi-institutional approach to patent system reform‘ (2003) Columbia Law Review, p.1035-1135 
generally and particularly, p.1101-1103. 
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However, there are some aspects that have the potential of introducing some 
subjectivity, such as relying on the common general knowledge which can be 
subjective or the enablement concept which can sometimes allow experimentation by 
the skilled person. 
 
The sixth chapter is largely grounded on the premise that patents provide an incentive 
to invent and innovate resulting in an improvement in the state of the art in non-
obvious ways. The thesis found that the patentability assessment methods could be 
carried out in a way that prevents hindsight, a factor that increases with passage of 
time from the point of invention or absorption of the invention into general use. 
 
The industrial application criteria was seen as one that is important for safeguarding 
that claimed inventions for which a patent is granted are practical. It was emphasised 
that it seems unnecessary to add other obligations on this criteria, for instance ones 
that are directed toward ethical or public policy considerations. 
 
8.5 Recommendations 
 
In addition to suggestions made throughout the thesis, this section seeks to combine 
principles applicable on a general level to the patentability limbs into a unified 
proposal. 
A 
The patentability limbs are distinct and separate, however, they often have 
overlapping elements. For instance, for the industrial application and excluded subject 
matter limbs it was observed that a purported invention that is caught out by one limb 
is likely to be caught out by the other
1171
 or the fact that a court challenge on non-
obviousness usually accompanies novelty.
1172
 Thus, in order to maintain the 
distinction between the patentability limbs and the principles applicable thereof, it is 
necessary for commentators and courts to remain vigilant when testing under each 
separate limb. 
 
                                                             
1171 Melia‟s Application, UK Patent No. BL O/153/92. 
1172 For instance in Synthon. 
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This builds onto another premise, that the assessment test must make it clear as to 
which evidence is to be captured for evaluation. For example, non-obviousness must 
be forward looking from the priority date without allowing hindsight or accounting 
for development after the priority date. This maintains objectivity in the assessment. 
Understanding this is not only useful for courts, which were found to be mindful of 
this, but perhaps more crucially for policy makers. Patent policy discussions 
especially at the international level can sometimes be rather charged and the 
advancing of stakeholder positions and interests is usually accomplished by tactical 
negotiation means. In the end, the assertions that are made at these political forums 
may be of limited use for the inventors in the domestic regimes wherein it becomes 
difficult to establish the accurate applicable standard. 
 
For instance, South Africa has pursued the agenda on origin disclosure in multiple 
international forums for some time now in the quest to protect its resources.
1173
 
However, this agenda has now been superimposed in undesirable ways on the 
domestic patentability requirement that patent practitioners and judges alike have 
lamented.
1174
 The domestic discourse is increasingly being informed and governed by 
the discourse from the international arena, which seems to be mainly directed at 
warning on the disadvantages of the patent. As a result, internally, the question of 
what constitutes prior art has become uncertain and eroded such that it is becoming 
increasingly difficult to properly judge prior art for patentability assessments. 
 
The overarching theme and recommendation is that the assessment methods 
must be clear and accurately identify the appropriate elements for assessment 
under each limb without undue influence from third parties. 
 
B 
The premise in this thesis is that the optimal patentability standard is one that has 
characteristics that are compatible with both the needs of industry and the dictates of 
public interest. These needs are difficult to ascertain objectively and are subjective to 
the opinion of the participant concerned. The views of industry players on what 
                                                             
1173 Visser C. ‗Some thoughts on making intellectual property work for traditional Knowledge‘ (2002) 
South African Mercantile Law Journal, p.656-687. 
1174 Harms L.T.C ‗A few negative trends in the field of intellectual property rights‘ (2009) THRHR, 
p.175-191. 
 282 
should be patentable are varied, but perhaps can be encapsulated by what the 
president of the EPO said; that the interests of patentees or their competitors or third 
parties is best served when the patent application is treated consistently and 
independently of who in one occasion is the applicant, such that even when they are 
third parties they equally benefit.
1175
  
 
The assessment methods used in courts can be said to achieve this benchmark of 
objectivity or at least approximate it and are independent of subjectivity that could 
otherwise be introduced by looking into the identity or circumstances of the patentee 
rather than the claimed invention. Lord Hoffmann has aptly summed up that the 
claimed invention must be judged according to what the patentee claims ‗and not to 
some vague paraphrase based upon the extent of his disclosure in the description‘.1176 
In doing so, he has allowed patentees to be held only to their claims and not any other 
perceptions outside of the claims under scrutiny.  
 
The interest of the public was found to be served in this equation through the benefit 
of the disclosed information accruing to the public, the patentee exploiting their 
patented invention and through third parties either being clear on how to invent 
around the patent or use the invention at the expiry of the patent. The success of 
serving the public interest is dependent on the repeatability of the tests used by the 
courts and the enabling of third parties to predict how they could legitimately work 
around the invention without infringing. 
 
Ultimately, robust patentability assessment methods are necessary to achieve the 
goal of objective and consistent analysis of the claimed invention. 
 
A future outlook from this research is that patentability standards can and do evolve 
and their refining to allow adaptation to new technologies. As new technology comes 
about and the debate on truly global patent regime rages on, the law-makers have a 
difficult task whereby they have to make decisions on how the standards have to be 
                                                             
1175 Referring to the Patents Office‘s task of always striking an equilibrium in the examination of patent 
applications for its multiple stakeholders: EPO President Benoît Battistelli ‗How Can Europe Be a Key 
Player at Global Level in the Patent Field? What is the Role of the EPO?‘, 8November, London: UCL. 
1176 Conor, para.19, Lord Hoffmann, allowing the claim for invention which only had limited 
experimental data. 
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structured such that pharmaceutical research is not hindered. Whatever legislative 
framework they adopt, it would have to be one that applies equally amongst the users 
of the system and provides safeguards that the framework chosen meets its intended 
purpose. 
 
 
8.6 Conclusion 
 
In conclusion, it is important that the patentability standards are attuned to their 
designed purpose. The veracity of standards as set by the statutes is vindicated only if 
it also applies in reality. This is important because there is little point in having a 
patent that will, in all likelihood, be invalidated in practice. Admittedly, there is a case 
to be made for patents that are completely adjusted for local circumstances, as 
currently litigation and patentability assessment is made territorially. Nonetheless, if 
the patent offers no protection beyond the jurisdictional borders, it will be of less 
value in more globalised knowledge economies. 
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